WO2018136265A1 - Bicyclic compounds as allosteric shp2 inhibitors - Google Patents

Bicyclic compounds as allosteric shp2 inhibitors Download PDF

Info

Publication number
WO2018136265A1
WO2018136265A1 PCT/US2018/013023 US2018013023W WO2018136265A1 WO 2018136265 A1 WO2018136265 A1 WO 2018136265A1 US 2018013023 W US2018013023 W US 2018013023W WO 2018136265 A1 WO2018136265 A1 WO 2018136265A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
optionally substituted
compound
heterocycle
membered
Prior art date
Application number
PCT/US2018/013023
Other languages
French (fr)
Inventor
Brian R. BLANK
Jennifer PITZEN
Gang Wang
Walter S. Won
Christos TZITZILONIS
Jie Jack Li
Elena S. Koltun
Naing Aay
Andreas BUCKL
Kevin MELLEM
Christopher Semko
Ash JOGALEKAR
Gert KISS
Adrian Gill
Original Assignee
Revolution Medicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL296456A priority Critical patent/IL296456A/en
Priority to SG11201906209SA priority patent/SG11201906209SA/en
Application filed by Revolution Medicines, Inc. filed Critical Revolution Medicines, Inc.
Priority to MX2019008695A priority patent/MX2019008695A/en
Priority to RU2019126456A priority patent/RU2776846C2/en
Priority to BR112019015075-7A priority patent/BR112019015075A2/en
Priority to CN201880018606.4A priority patent/CN110446709B/en
Priority to CN202311080113.2A priority patent/CN117327075A/en
Priority to KR1020197024604A priority patent/KR102665763B1/en
Priority to EP18701883.3A priority patent/EP3571199A1/en
Priority to CA3051206A priority patent/CA3051206A1/en
Priority to AU2018210770A priority patent/AU2018210770B2/en
Priority to JP2019539774A priority patent/JP7240319B2/en
Publication of WO2018136265A1 publication Critical patent/WO2018136265A1/en
Priority to IL268030A priority patent/IL268030B2/en
Priority to US16/518,798 priority patent/US11739093B2/en
Priority to AU2022204275A priority patent/AU2022204275A1/en
Priority to JP2022187881A priority patent/JP2023018095A/en
Priority to US18/220,196 priority patent/US20240199616A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present disclosure relates to inhibitors of protein tyrosine phosphatase SHP2 useful in the treatment of diseases or disorders. Specifically, this disclosure is concerned with compounds and compositions inhibiting SHP2, methods of treating diseases associated with SHP2, and methods of synthesizing these compounds.
  • SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3- kinase- AKT pathways.
  • SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail.
  • the two SH2 domains control the subcellular localization and functional regulation of SHP2.
  • the molecule exists in an inactive, self- inhibited conformation stabilized by a binding network involving residues from both the N- SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
  • the present disclosure relates to compounds capable of inhibiting the activity of SHP2.
  • the disclosure further provides a process for the preparation of compounds disclosed herein, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
  • One aspect of the disclosure relates to compounds of Formula ⁇ :
  • A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -Ci-Cealkynyl, -C 3 -C 8 cycloalkyl, -OH, halogen, -NO2, -CN, - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0)NR 5 R 6 , - R 5 S(0)R 6 , -C(0)R 5 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted
  • X 1 is N or C;
  • X 2 is N or CH
  • B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
  • R 2 is -H, -OR b , -NR 5 R 6 ,-CN, -Ci-Cealkyl, -C 2 -C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -NH 2 , halogen, -C(0)OR b , -C 3 -C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , - R 5 R
  • Y 2 is - R a - -(CR3 ⁇ 4)m- -C(O)-, -C(R a ) 2 NH- -(CR a 2 )mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C 3 -C 8 cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more - H 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C3-C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R 3 is -H, -C i-C 6 alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C 3 -C 8 cycloalkyl, or -(CH 2 )n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , -NHR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, -NH 2 , heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -COOR b , -CONHR b , -CONH(CH 2 )nCOOR b ,
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN; R and R are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycl
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, -OH, halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is
  • X 1 is N or C;
  • X 2 is N or CH
  • B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
  • R 2 is -H, -OR b , -NR 5 R 6 ,-CN, -Ci-Cealkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -NH2, halogen, -C(0)OR b , -C 3 -C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , - R 5 R 6 ,
  • Y 2 is - R a - -(CR3 ⁇ 4)m- -C(O)-, -C(R a ) 2 NH- -(CR a 2 )mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C 3 -C 8 cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more - H 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C3-C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R 3 is -H, -Ci-C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, -C 3 -C 8 cycloalkyl, or -(CH 2 )n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , -NHR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, -NH 2 , heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -COOR b , -CONHR b , -CONH(CH 2 )nCOOR b ,
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, -OH, halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is
  • X 1 is N or C
  • X 2 is N or CH
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
  • R 2 is -H, -OR b , - R 5 R 6 ,-CN, -Ci-Cealkyl, -Ci-Cealkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, - H2, halogen, -C(0)OR b , -C3-C 8 cycloalkyl, aryl, heterocyclyl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, wherein each alkyl, alkeny
  • Y 2 is - R a - -(CR a 2)m- -C(O)-, -C(R a ) 2 H-, -(CR a 2 )mO- -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C3-C 8 cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C3-C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R 3 is, at each occurrence, selected from the group consisting of -H, -Ci-C 6 alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, C 3 -C 8 cycloalkyl, or -(CH2)n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR b , -NHR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -COOR b , -CONHR b , -CONH(CH 2 )nCOOR b ,
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, -OH, halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is
  • X 1 is N or C
  • X 2 is N or CH
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
  • R 2 is -H, -OR b , - R 5 R 6 ,-CN, -Ci-Cealkyl, -Ci-Cealkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, - H2, halogen, -C(0)OR b , -C3-C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is
  • Y 2 is - R a - -(CR3 ⁇ 4)m-, -C(O)-, -C(R a ) 2 H-, -(CR a 2 )mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C3-C 8 cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C3-C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R 3 is -H, -Ci-C 6 alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C 3 -C 8 cycloalkyl, or -(CH2)n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR b , -NHR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -COOR b , -CONHR b , -CONH(CH 2 )nCOOR b ,
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C3-C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • A is a 5- to 12-membered monocyclic or olycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 5 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or
  • X 1 is N or C;
  • X 2 is N or CH
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
  • -Ci-Cealkyl -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F;
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-Cealkyl, -C 2 -C 6 alkenyl, -C 4 -C 8 cycloalkenyl,
  • each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0) 2 R 5 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0)R 6 , heterocycle, aryl, or heteroaryl;
  • Y 2 is - R a - -(CR3 ⁇ 4)m- -C(O)-, -C(R a ) 2 H-, -(CR a 2 )mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C 3 -C 8 cycloalkyl, or -Ci- C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C 3 -C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R 3 is -H, -Ci-C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, -C 3 -C 8 cycloalkyl, or -(CH 2 )n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , - HR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F, provided that the heterocycle formed by the combination of R 3 and R a is not an optionally substituted piperazinyl;
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • One aspect of the disclosure relates to compounds of Formula IV that are compounds of Formula IV-Q:
  • A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl, provided that R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 ;
  • Y 1 is -S- or a direct bond
  • X 1 is N or C
  • X 2 is N or CH
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
  • -Ci-Cealkyl -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F;
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-Cealkyl, or - H 2 ; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 ;
  • Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ;
  • R 3 is combined with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F, provided that the heterocycle formed by the combination of R 3 and R a is not an optionally substituted piperazinyl;
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl
  • n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • compounds disclosed herein e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • Another aspect of the disclosure relates to methods of inhibiting SHP2.
  • the method comprises administering to a patient in need thereof, an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • Another aspect of the disclosure is directed to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof) and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier can further comprise an excipient, diluent, or surfactant.
  • composition can be effective for treating a disease associated with SHP2 modulation in a subject in need thereof.
  • Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • Another aspect of the disclosure relates to methods of inhibiting SHP2 comprising administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use in treating or preventing a disease associated with SHP2 modulation.
  • One aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, for use in treating of preventing a disease associated with SHP2 modulation.
  • Another aspect of the disclosure relates to the use of one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • compounds disclosed herein e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof
  • Another aspect of the disclosure relates to the use of pharmaceutical
  • compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • compounds disclosed herein e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof
  • a pharmaceutically acceptable carrier in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • Another aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • the medicament is used for treating or preventing a disease associated with SHP2 modulation.
  • the present disclosure also provides compounds and pharmaceutical compositions that are useful in inhibiting SHP2.
  • an alkyl group that is optionally substituted may be a fully saturated alkyl chain (i.e. a pure hydrocarbon).
  • the same optionally substituted alkyl group may have substituents different from hydrogen. For instance, it can, at any point along the chain be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein.
  • aryl may refer to cyclic, aromatic hydrocarbon groups that have 1 to 2 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl).
  • the aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H,
  • heteroaryl may mean a monovalent or multivalent monocyclic aromatic radical or a polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from N, S, P, and O, the remaining ring atoms being C.
  • Heteroaryl as herein defined also may mean a bicyclic heteroaromatic group wherein the heteroatom is selected from N, S, P, and O.
  • the term may also include multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below.
  • the term may also include multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, can be condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycles, (to form for example a 1, 2, 3, 4-tetrahydronaphthyridinyl such as 1, 2, 3, 4-tetrahydro- 1,8- naphthyridinyl), carbocycles (to form for example 5,6,7, 8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system.
  • heteroaryls to form for example a naphthyridinyl such as 1,8-naphthyridinyl
  • heterocycles to form for example a 1, 2, 3, 4-tetrahydronaphthyrid
  • the rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system and at any suitable atom of the multiple condensed ring system including a carbon atom and heteroatom (e.g., a nitrogen).
  • the heteroaromatic radical may by optionally substituted independently with one or more substituents described herein.
  • substituents include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazolyl, benzimidazolyl, thieno[3,2- b] thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[l,2- a] pyridinyl, imidazo[l,5-a]pyrazinyl, indazolyl
  • Alkyl may refer to a straight or branched chain saturated hydrocarbon.
  • Ci- C 6 alkyl groups contain 1 to 6 carbon atoms. Examples of a Ci-C 6 alkyl group may include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
  • alkenyl may mean an aliphatic hydrocarbon group containing a carbon— carbon double bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups may have about 2 to about 4 carbon atoms in the chain. Branched may mean that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkenyl chain. Exemplary alkenyl groups may include, but are not limited to, ethenyl, propenyl, n-butenyl, and i-butenyl.
  • a C2-C6 alkenyl group is an alkenyl group containing between 2 and 6 carbon atoms.
  • alkynyl may mean an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups may have about 2 to about 4 carbon atoms in the chain. Branched may mean that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups may include, but are not limited to, ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, and n-pentynyl.
  • a C2-C6 alkynyl group is an alkynyl group containing between 2 and 6 carbon atoms.
  • cycloalkyl may mean monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms.
  • Examples of cycloalkyl groups may include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl.
  • a C3-C8 cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms.
  • a cycloalkyl group may be fused (e.g., decalin) or bridged (e.g., norbornane).
  • cycloalkenyl may mean monocyclic, non-aromatic unsaturated carbon rings containing 4-18 carbon atoms.
  • Examples of cycloalkenyl groups may include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl.
  • a C 4 - C 8 cycloalkenyl is a cycloalkenyl group containing between 4 and 8 carbon atoms.
  • heterocyclyl or “heterocycloalkyl” or
  • heterocycle may refer to monocyclic or polycyclic 3 to 24-membered rings containing carbon and heteroatoms selected from oxygen, phosphorus, nitrogen, and sulfur and wherein there are no delocalized ⁇ electrons (aromaticity) shared among the ring carbon or
  • Heterocyclyl rings may include, but are not limited to, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl.
  • a heteroycyclyl or heterocycloalkyl ring may also be fused or bridged, e.g., can be a bicyclic ring.
  • heterocyclyl or “heterocycloalkyl” or “heterocycle” may be a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-24 atoms of which at least one atom is chosen from nitrogen, sulfur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulfur atom may be optionally oxidised to form the S-oxides.
  • Heterocyclyl may be a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulfur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulfur atom may be optionally oxidised to form S-oxide(s).
  • heterocyclyl may include thiazolidinyl, pyrrolidinyl, pyrrolidin-2-one, pyrrolinyl, 2-pyrrolidonyl, 2,5- dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydro thienyl, 2,4-dioxoimidazolidinyl, 2-oxo-l,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydro uracilyl, 1,3-benzodioxolyl, 1,2,4- oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothien
  • Spirocycle or “spirocyclic” may mean carbogenic bicyclic ring systems with both rings connected through a single atom.
  • the ring can be different in size and nature, or identical in size and nature. Examples may include, but are not limited to, spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane.
  • One or both of the rings in a spirocycle can be fused to another carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
  • a C5-C12 spirocycle is a spirocycle containing between 5 and 12 carbon atoms.
  • One or more of the carbon atoms can be substituted with a heteroatom.
  • the term "spirocyclic heterocycle,” “spiroheterocyclyl,” or “spiroheterocycle” is understood to possibly mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl).
  • a spirocyclic heterocycle can contain between 5 and 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
  • compositions comprising an effective amount of one or more disclosed compounds and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier, diluent or excipient may include without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier that has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • the disclosure may include pharmaceutically acceptable salts of the compounds disclosed herein.
  • pharmaceutically acceptable salts may include, e.g., water- soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2- disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide,
  • “Pharmaceutically acceptable salt” also includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” may refer to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which may be formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-l,2-d
  • “Pharmaceutically acceptable base addition salt” may refer to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases may include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. For example, inorganic salts may include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases may include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine,
  • tromethamine purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • tautomers may refer to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another.
  • a "tautomer” is a single member of this set of compounds. Typically a single tautomer is drawn but it may be understood that this single structure may represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it may be understood that both the enol and ketone forms are part of the disclosure.
  • compounds of the Present disclosure can exist in tautomeric form.
  • R 2 can be -OH and tautomers of the compounds can exist in equilibrium:
  • the disclosure may include prodrugs of the compounds described herein.
  • prodrug as used in this disclosure, may mean a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.
  • a prodrug may be a drug which is inactive in the body, but may be transformed in the body typically either during absorption or after absorption from the gastrointestinal tract into the active compound. The conversion of the prodrug into the active compound in the body may be done chemically or biologically (i.e., using an enzyme).
  • the disclosure may include solvates of the compounds described herein.
  • solvate may refer to a complex of variable stoichiometry formed by a solute and solvent.
  • solvents for the purpose of the disclosure may not interfere with the biological activity of the solute.
  • suitable solvents may include, but are not limited to, water, MeOH, EtOH, and AcOH.
  • Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates may include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
  • the disclosure may include isomers of the compounds described herein.
  • the term "isomer” may refer to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of present disclosure may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. [0054] The disclosure may include stereoisomers of the compounds described herein.
  • stereoisomers may refer to the set of compounds which have the same number and type of atoms and share the same bond connectivity between those atoms, but differ in three dimensional structure.
  • stereoisomer may refer to any member of this set of compounds. For instance, a stereoisomer may be an enantiomer or a diastereomer.
  • the present disclosure may embrace all geometric and positional isomers.
  • a compound of the present disclosure incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure.
  • the substituent may be in the E or Z configuration.
  • the cycloalkyl substituent may have a cis or trans configuration.
  • the term “enantiomers” may refer to a pair of stereoisomers which are non- superimposable mirror images of one another.
  • the term “enantiomer” may refer to a single member of this pair of stereoisomers.
  • the term “racemic” may refer to a 1 : 1 mixture of a pair of enantiomers.
  • the disclosure may include enantiomers of the compounds described herein. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound.
  • the compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry.
  • the compounds may be the ( ⁇ -enantiomer.
  • the compounds may be the (R)-enantiomer.
  • the compounds may be the (+) or (-) enantiomers.
  • compounds and compositions of the disclosure may be enriched to provide predominantly one enantiomer of a compound described herein.
  • An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.5 or even 100 mol percent.
  • the compound described herein enriched in one enantiomer may be substantially free of the other enantiomer, wherein substantially free may mean that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture.
  • substantially free may mean that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture.
  • a composition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2 mol percent of the second enantiomer.
  • diastereomers may refer to the set of stereoisomers which cannot be made superimposable by rotation around single bonds. For example, cis- and trans- double bonds, endo- and exo- substitution on bicyclic ring systems, and compounds containing multiple stereogenic centers with different relative configurations may be considered to be diastereomers.
  • the term "diastereomer” may refer to any member of this set of compounds.
  • the synthetic route may produce a single diastereomer or a mixture of diastereomers.
  • the disclosure may include diastereomers of the compounds described herein.
  • the compounds and compositions of the disclosure may be enriched to provide predominantly one diastereomer of a compound disclosed herein.
  • a diastereomerically enriched mixture may comprise, for example, at least 60 mol percent of one diastereomer, or more preferably at least 75, 99, 95, 96, 97, 98, 99, or even 100 mol percent.
  • the compounds described herein further include all pharmaceutically acceptable isotopically labeled compounds.
  • An “isotopically” or “radio-labeled” compound may be a compound where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • hydrogen atoms are replaced or substituted by one or more deuterium or tritium.
  • Certain isotopically labeled compounds of this disclosure for example, those incorporating a radioactive isotope, may be useful in drug and/or substrate tissue distribution studies.
  • radioactive isotopes tritium, i.e., 3 H, and carbon 14, i.e., 14 C may be particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Suitable isotopes that may be incorporated in compounds described herein include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), U C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1 , 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I, and 131 I.
  • an "effective amount" when used in connection with a compound may be an amount effective for treating or preventing a disease in a subject as described herein.
  • carrier as used in this disclosure, may encompass carriers, excipients, and diluents and may mean a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
  • treating with regard to a subject, may refer to improving at least one symptom of the subject's disorder. Treating may include curing, improving, or at least partially ameliorating the disorder.
  • prevent or "preventing” with regard to a subject may refer to keeping a disease or disorder from afflicting the subject. Preventing may include prophylactic treatment. For instance, preventing can include administering to the subject one or more compounds disclosed herein before a subject is afflicted with a disease and the administration will keep the subject from being afflicted with the disease.
  • disorder is used in this disclosure and may be used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
  • administer refers to either directly administering one or more disclosed compounds or a pharmaceutically acceptable salt of the one or more disclosed compounds or a composition comprising one or more disclosed compounds to a subject, or administering a prodrug derivative or analog of the one or more disclosed compounds or pharmaceutically acceptable salts of the one or more disclosed compounds or compositions to the subject, which may form an equivalent amount of active compound within the subject's body.
  • a "patient” or “subject” may be a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
  • Compounds of the disclosure include compounds of Formula ⁇ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers of any of the foregoing.
  • the compound is of the Formula I-A:
  • A is aryl
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -Ci-Cealkynyl, -C 3 -C 8 cycloalkyl, -OH, halogen, -NO2, -CN, - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 5 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , -NR 5 S(0) R 5 R 6 , - R 5 S(0)R 6 , -C(0)R 5 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally
  • X 1 is N or C;
  • X 2 is N or CH
  • B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
  • R 2 is -H, -OR b , -NR 5 R 6 , -CN, -Ci-Cealkyl, -C 2 -C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -NH 2 , halogen, -C(0)OR b , -C 3 -C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5
  • R a is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more - H 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C 3 -C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , -S(0)R 5 ,
  • R 3 is -H, -Ci-C 6 alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C 3 -C 8 cycloalkyl, or -(CH 2 )n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , - HR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -COOR b , -CO HR b , -CO H(CH 2 )nCOOR b ,
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • A is heteroaryl
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -Ci-Cealkynyl, -Cs-Cscycloalkyl, -OH, halogen, -NO2, -CN, - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0)NR 5 R 6 , - R 5 S(0)R 6 , -C(0)R 5 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one
  • X 1 is N or C;
  • X 2 is N or CH
  • B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
  • R 2 is -H, -OR b , -NR 5 R 6 , -CN, -Ci-Cealkyl, -C 2 -C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -C2-C 6 alkynyl, -NH 2 , halogen, -C(0)OR b , -C3-C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R
  • Y 2 is -NR a -, -(CR3 ⁇ 4)m-, -C(O)-, -C(R a ) 2 H-, -(CR3 ⁇ 4)mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or -Ci- C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C 3 -C 8 cycloalkyl, -C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , -S(0)R 5 ,
  • R 3 is -H, -Ci-C 6 alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C 3 -C 8 cycloalkyl, or -(CH 2 )n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , - HR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -COOR b , -CO HR b , -CO H(CH 2 )nCOOR b ,
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the compound is of the Formula II- A:
  • the compound is of the Formula II-A1 :
  • C forms a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12- membered spiroheterocycle along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, or - H 2 .
  • the compound is of the Formula II- A2:
  • the compound is of the Formula II- A3 :
  • the compound is the Formula II-B:
  • the compound is of the Formula II-B 1 :
  • C forms a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12- membered spiroheterocycle along with the carbon atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH,
  • the compound is of the Formula II-B2:
  • the compound is of the Formula II-B3 :
  • the compound is of the Formula II-B4:
  • the compound is of the Formula II-B 5:
  • the compound is of the Formula II-B6:
  • ⁇ - ⁇ 6 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • the compound is the Formula II-C:
  • C forms a 3- to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, or - H 2
  • the compound is of the Formula II-C 1 :
  • the compound is the Formula II-D:
  • C forms a 3- to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, or - H 2
  • the compound is of the Formula II-D 1 :
  • the compound is the Formula II-E:
  • the compound is the Formula II-F:
  • the compound is the Formula II-G:
  • R 2 is an aryl or heteroaryl.
  • the compound is of the Formula III- A:
  • the compound is of the Formula III-A 1 :
  • C forms a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12- membered spiroheterocycle along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH,
  • the compound is of the Formula III- A2:
  • the compound is of the Formula III- A3 :
  • III-A3 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • the compounds of the disclosure are compounds of Formula IV:
  • A is a 5- to 12-membered monocyclic or olycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl,
  • each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , halogen, -NO2, -CN, - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0) R 5 R 6 , -C(0)R 5 , or -C0 2 R 5 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN,
  • X 1 is N or C;
  • X 2 is N or CH
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more -Ci- Cealkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F;
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-Cealkyl, -C 2 -C 6 alkenyl, -C 4 -C 8 cycloalkenyl,
  • each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0) 2 R 5 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0)R 6 , heterocycle, aryl, or heteroaryl;
  • Y 2 is - R a - -(CR3 ⁇ 4)m- -C(O)-, -C(R a ) 2 H-, -(CR a 2 )mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C 3 -C 8 cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more - H 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C 3 -C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , - HR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F, provided that the heterocycle formed by the combination of R 3 and R a is not an optionally substituted piperazinyl;
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, - H2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • R 4 is H.
  • R 4 is .
  • Y 1 is -S- or a direct bond.
  • Y 1 is -S-.
  • Y 1 is a direct bond.
  • Y 2 is -(CR a 2 )m- In one or more embodiments of the compounds of Formula IV, Y 2 is -NR a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV, A is phenyl. In one or more embodiments of Formula IV, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV, A is pyridinyl. In one or more embodiments of Formula IV, A is indazolyl. In one or more embodiments of Formula IV, A is a 5- to 12-membered monocyclic or poly cyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 . In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 . In certain such embodiments, R 5 and R 6 are both -H. In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or -NFh. In one or more embodiments of Formula IV, R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H.
  • R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In one or more embodiments of Formula IV, R 2 is -OH. In one or more embodiments of Formula IV, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV, R 2
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula IV, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV, R 3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12- membered polycyclic heterocycle, which is optionally substituted with one or more
  • -Ci-Cealkyl -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or - H2.
  • n is 1.
  • R and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV, X 1 is C and X 2 is N. In one or more embodiments of Formula IV, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heterocycle. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl. [00112] In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above.
  • the rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV, B is substituted with one or more -Ci-Cealkyl, -OH, - Fh, oxo, -(CH2)n H2,
  • B is substituted with one or more oxo. In one or more embodiments of Formula IV, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV, B is substituted with one or more -OH. In one or more embodiments of Formula IV, B is substituted with one or more - H2. In one or more embodiments of Formula IV, B is substituted with one or more -CF3. In one or more embodiments of Formula IV, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F; d) R 2 is -H, -Ci-Cealkyl, or - H2; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is H; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • A is a monocyclic or polycyclic aryl or pyridinyl
  • X 1 is C and X 2 is CH;
  • B including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ; f) R is combined with R a to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H2; e) Y 2 is - R a -, wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • A is a monocyclic or polycyclic aryl or pyridinyl
  • X 1 is N and X 2 is CH;
  • B including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ; f) R 3 is combined with R a to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optional
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • A is a monocyclic or polycyclic aryl or pyridinyl
  • X 1 is N and X 2 is N;
  • B including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ; f) R 3 is combined with R a to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or -
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H2; e) Y 2 is - R a -, wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • A is a monocyclic or polycyclic aryl or pyridinyl
  • X 1 is C and X 2 is CH;
  • B including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ; f) R 3 is combined with R a to form a 5- to 12-membered spiroheterocycle, wherein
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • A is a monocyclic or polycyclic aryl or pyridinyl
  • X 1 is C and X 2 is N;
  • B including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ; f) R 3 is combined with R a to form a 5- to 12-membered spiroheterocycle, wherein
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is -S-; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or -
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H2; e) Y 2 is - R a -, wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn,
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features: a) R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl,
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H2; e) Y 2 is - R a -, wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is C and X 2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof have one, two, or three or more of the following features:
  • R 4 is , A is a monocyclic or polycyclic aryl or pyridinyl, and Y 1 is a direct bond; b) X 1 is N and X 2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F; d) R 2 is -H, -Ci-Cealkyl, or - H 2 ; e) Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn
  • the compound is of Formula IV-A:
  • X B1 is N, R 9 , CR 9 , S, or O
  • X B2 is N, R 9 , CR 9 , S, or O
  • X B3 is N, NR 9 , CR 9 , S, or O
  • R 9 is independently, at each occurrence, -H, -Ci-C 6 alkyl, -OH, -NH 2 , heteroaryl, heterocyclyl, -(CH 2 ) n NH 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F, provided that if X 1 is C, at least one of X B1 , X B2 , and X B3 is not CR 9 , or provided that if each of X B1 , X B2 , and X B3 are
  • X B1 is N or NR 9 .
  • X B1 is CR 9 . In certain embodiments of Formula IV-A, X B1 is S. In certain embodiments of Formula IV-A, X B1 is O. In certain embodiments of Formula IV-A, X B2 is N or NR 9 . In certain embodiments of Formula IV-A, X B2 is CR 9 . In certain embodiments of Formula IV-A, X B2 is S. In certain embodiments of Formula IV-A, X B2 is O. In certain embodiments of Formula IV-A, X B3 is N or NR 9 . In certain embodiments of Formula IV-A, X B3 is CR 9 . In certain embodiments of Formula IV-A, X B3 is S.
  • X B3 is O.
  • X B1 is N, NR 9 , or CR 9 ;
  • X B2 is N, R 9 , or CR 9 ; and
  • X B3 is N, NR 9 , or CR 9 .
  • X B1 is N or NR 9 .
  • X B1 is CR 9 .
  • X B2 is N or NR 9 .
  • X B2 is CR 9 .
  • X B3 is N or NR 9 .
  • X B3 is CR 9 .
  • R 9 is -( ⁇ 3 ⁇ 4) ⁇ 0 ⁇ and n is 1. In some embodiments of Formula IV-A, R 9 is H.
  • R 4 is H.
  • R 4 is In certain such embodiments, Y 1 is -S- or a direct bond. In one or more embodiments of Formula IV-A, Y 1 is -S-. In one or more embodiments of Formula IV-A, Y 1 is a direct bond.
  • Y 2 is
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-A, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-A, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-A, A is phenyl. In one or more embodiments of Formula IV-A, A is a monocyclic or polycyclic heteroaryl.
  • A is pyridinyl. In one or more embodiments of Formula IV- A, A is indazolyl. In one or more embodiments of Formula IV-A, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-A, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-A, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-A, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-A, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-A, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-A, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl. In one or more embodiments of Formula IV-A, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- A, R 5 and R 6 are independently, at each occurrence, -Ci-C 6 alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-A, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-A, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV- A, R 2 is -OH. In one or more embodiments of Formula IV- A, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-A, R 2 is - H2.
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-A, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-A, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-A, R 3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, [00179]
  • R and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NFh, -OH, -(CFh ⁇ Fh, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 is optionally substituted with one or more -Ci-Cealkyl, -NFh, -OH, -(CFh ⁇
  • spiroheterocycle which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NFh.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV- A, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV- A, X 1 is C and X 2 is N. In one or more embodiments of Formula IV- A, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-B:
  • IV-B and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof wherein X B4 is N or CR 9 ; X B5 is N or CR 9 ; X B6 is N or CR 9 ; and X B7 is N or CR 9 , wherein R 9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, - H 2 , heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F, provided that if X 1 is C, at least one of X B4 , X B5 , X B6 , and X B7 is not CR 9 , or provided that if each of X B4 , X B5 , X B6 , and X B7 are CR 9 , where
  • X B4 is N. In certain embodiments of Formula IV-B, X B4 is CR 9 . In certain embodiments of Formula IV-B, X B5 is N. In certain embodiments of Formula IV-B, X B5 is CR 9 . In certain embodiments of Formula IV-B, X B6 is N. In certain embodiments of Formula IV-B, X B6 is CR 9 . In certain embodiments of
  • Formula IV-B, X B7 is N. In certain embodiments of Formula IV-B, X B7 is CR 9 . In certain embodiments of Formula IV-B, X B4 is N, X B5 is CR 9 , X B6 is N, and X B7 is CR 9 . In certain such embodiments, R 9 is independently, at each occurrence, -H.
  • R 9 is -(CH 2 ) n OH and n is 1. In some embodiments of Formula IV-B, R 9 is H.
  • R 4 is H.
  • R 4 is In certain such embodiments, Y 1 is -S- or a direct bond. In one or more embodiments of Formula IV-B, Y 1 is -S-. In one or more embodiments of Formula IV-B, Y 1 is a direct bond.
  • Y 2 is -(CR3 ⁇ 4)m-. In one or more embodiments of the compounds of Formula IV-B, Y 2 is - R a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-B, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-B, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-B, A is phenyl. In one or more embodiments of Formula IV-B, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-B, A is pyridinyl. In one or more embodiments of Formula IV- B, A is indazolyl.
  • A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3.
  • n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-B, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-B, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-B, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-B, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-B, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-B, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- B, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-B, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-B, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In one or more embodiments of Formula IV-B, R 2 is -OH. In one or more embodiments of Formula IV-B, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV-B, R 2 is -NH2.
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula IV-B, R 3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle. In one or more embodiments of Formula IV-B, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-B, R is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH 2 ) n NH 2 , or - H 2 .
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-B, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-B, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-B, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-C:
  • IV-C and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
  • R 4 is H.
  • R 4 is .
  • Y 1 is -S- or a direct bond.
  • Y 1 is -S-.
  • Y 1 is a direct bond.
  • A is a monocyclic or poly cyclic cycloalkyl.
  • A is a monocyclic or poly cyclic heterocycloalkyl.
  • A is a monocyclic or polycyclic aryl.
  • A is phenyl. In one or more embodiments of Formula IV-C, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-C, A is pyridinyl. In one or more embodiments of Formula IV- C, A is indazolyl. In one or more embodiments of Formula IV-C, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-C, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-C, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-C, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-C, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-C, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-C, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl. In one or more embodiments of Formula IV-C, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- C, R 5 and R 6 are independently, at each occurrence, -Ci-C 6 alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-C, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-C, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-C, R 2 is -OH. In one or more embodiments of Formula IV-C, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-C, R 2 is -NHz.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NHz, oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or -NH2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or -NH2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C6alkyl, -(CH 2 ) n NH 2 , or - H 2 .
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-C, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-C, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-C, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl. [00216] In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above.
  • the rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-C, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-C, B is substituted with one or more oxo. In one or more embodiments of Formula IV-C, B is substituted with one or more -Ci-C6alkyl.
  • B is substituted with one or more -OH. In one or more embodiments of Formula IV-C, B is substituted with one or more - H2. In one or more embodiments of Formula IV-C, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-C, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-C, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-C, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-D:
  • IV-D and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
  • C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CFIF2, or -CH2F.
  • the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH 2 )n H2, -(CH 2 )nOH, -CF3, -CHF2, or -CH2F.
  • n is 1.
  • the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1.
  • the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3- to 12-membered monocyclic
  • the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3-to 12-membered polycyclic heterocycle.
  • the nitrogen atom to which it is attached is an optionally substituted 5- to 12-membered spiroheterocycle.
  • Formula IV-D C ring, along with the nitrogen atom to which it is attached, is an optionally substituted — .
  • the nitrogen atom to which it is attached is an optionally substituted — .
  • R 4 is H.
  • R 4 is .
  • Y 1 is -S- or a direct bond.
  • Y 1 is -S-.
  • Y 1 is a direct bond.
  • A is a monocyclic or polycyclic cycloalkyl. In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic heterocycloalkyl. In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-D, A is phenyl. In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-D, A is pyridinyl. In one or more embodiments of Formula IV- D, A is indazolyl. In one or more embodiments of Formula IV-D, A is a 5- to 12-membered monocyclic or poly cyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-D, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-D, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-D, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-D, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-D, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-D, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-D, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- D, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-D, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-D, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In one or more embodiments of Formula IV-D, R 2 is -OH. In one or more embodiments of Formula IV-D, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV-D, R 2 is -NH2.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-D, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-D, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-D, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-D, B is substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , oxo,
  • B is substituted with one or more oxo. In one or more embodiments of Formula IV-D, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-D, B is substituted with one or more -OH. In one or more embodiments of Formula IV-D, B is substituted with one or more - H2. In one or more embodiments of Formula IV-D, B is substituted with one or more -CF 3 . In one or more embodiments of Formula IV-D, B is substituted with one or more -CHF2.
  • B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-D, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-E:
  • IV-E and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein X B1 is N, NR 9 , CR 9 , S, or O; X B2 is N, R 9 , CR 9 , S, or O; and X B3 is N, NR 9 , CR 9 , S, or O, wherein R 9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH 2 )nNH2, -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F, provided that if X 1 is C, at least one of X B1 , X B2 , and X B3 is not CR 9 , or provided that if each of X B1 , X B2 , and X B3 are CR 9 , X 1
  • X B1 is N or NR 9 .
  • X B1 is CR 9 . In certain embodiments of Formula IV-E, X B1 is S. In certain embodiments of Formula IV-E, X B1 is O. In certain embodiments of Formula IV-E, X B2 is N or NR 9 . In certain embodiments of Formula IV-E, X B2 is CR 9 . In certain embodiments of Formula IV-E, X B2 is S. In certain embodiments of Formula IV-E, X B2 is O. In certain embodiments of Formula IV-E, X B3 is N or NR 9 . In certain embodiments of Formula IV-E, X B3 is CR 9 . In certain embodiments of Formula IV-E, X B3 is S. In certain embodiments of Formula IV-E, X B3 is O.
  • X B1 is N or NR 9 .
  • X B1 is CR 9 .
  • X B2 is N or NR 9 .
  • X B2 is CR 9 .
  • X B3 is N or NR 9 .
  • X B3 is CR 9 .
  • R 9 is -( ⁇ 3 ⁇ 4) ⁇ 0 ⁇ and n is 1.
  • R 9 is H.
  • Y 2 is -(CR3 ⁇ 4)m-. In one or more embodiments of the compounds of Formula IV-E, Y 2 is - R a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-E, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-E, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-E, A is phenyl. In one or more embodiments of Formula IV-E, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-E, A is pyridinyl. In one or more embodiments of Formula IV- E, A is indazolyl. In one or more embodiments of Formula IV-E, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-E, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-E, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-E, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-E, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-E, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-E, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-E, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-E, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-E, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally
  • R 2 is methyl.
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-C 6 alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 .
  • R 2 is -OH.
  • R 2 is - R 5 R 6 .
  • R 2 is - H2.
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula IV-E, R 3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle. In one or more embodiments of Formula IV-E, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-E, R 3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H2, -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-E, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-E, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-E, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-F:
  • IV-F and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof wherein X B4 is N or CR 9 ; X B5 is N or CR 9 ; X B6 is N or CR 9 ; and X B7 is N or CR 9 , wherein R 9 is independently, at each occurrence, -H, -Ci-C 6 alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F, provided that if X 1 is C, at least one of X B4 , X B5 , X B6 , and X B7 is not CR 9 , or provided that if each of X B4 , X B5 , X B6 , and X B7 are CR 9 , X 1 must be N.
  • X B4 is N. In certain embodiments of Formula IV-F, X B4 is CR 9 . In certain embodiments of Formula IV-F, X B5 is N. In certain embodiments of Formula IV-F, X B5 is CR 9 . In certain embodiments of Formula IV-F, X B6 is N. In certain embodiments of Formula IV-F, X B6 is CR 9 . In certain embodiments of Formula IV-F, X B7 is N. In certain embodiments of Formula IV-F, X B7 is CR 9 . In certain
  • X B4 is N
  • X B5 is CR 9
  • X B6 is N
  • X B7 is CR 9 .
  • R 9 is independently, at each occurrence, -H.
  • R 9 is -( ⁇ 3 ⁇ 4) ⁇ 0 ⁇ and n is 1.
  • R 9 is H.
  • Y 2 is -(CR3 ⁇ 4)m-. In one or more embodiments of the compounds of Formula IV-F, Y 2 is -NR a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-F, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-F, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-F, A is phenyl. In one or more embodiments of Formula IV-F, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-F, A is pyridinyl. In one or more embodiments of Formula IV- F, A is indazolyl. In one or more embodiments of Formula IV-F, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-F, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-F, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-F, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-F, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-F, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-F, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or -NR 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl. In one or more embodiments of Formula IV-F, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-F, R 5 and R 6 are independently, at each occurrence, -Ci-C 6 alkyl. [00260] In one or more embodiments of Formula IV-F, R 2 is -H.
  • R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-F, R 2 is -H, -OH, - R 5 R 6 , -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-F, R 2 is -OH. In one or more embodiments of Formula IV-F, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV-
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula IV-F, R 3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle. In one or more embodiments of Formula IV-F, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-F, R 3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-F, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-F, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-F, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-G:
  • IV-G and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-G, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-G, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-G, A is phenyl. In one or more embodiments of Formula IV-G, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-G, A is pyridinyl. In one or more embodiments of Formula IV- G, A is indazolyl. In one or more embodiments of Formula IV-G, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-G, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-G, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-G, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-G, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-G, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-G, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-G, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- G, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-G, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-G, R 2 is -H, -OH, - R 5 R 6 , -Ci-C 6 alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-G, R 2 is -OH. In one or more embodiments of Formula IV-G, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-G, R 2 is - H2.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-G, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-G, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-G, X 1 is N and X 2 is CH.
  • Formula IV-G is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle. [00280] In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-G, the heterocyclyl ring is bridged.
  • Formula IV-G B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-G, B is substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F. In one or more embodiments of Formula IV-G, B is substituted with one or more oxo. In one or more embodiments of Formula IV-G, B is substituted with one or more -Ci-C6alkyl.
  • B is substituted with one or more -OH. In one or more embodiments of Formula IV-G, B is substituted with one or more - H2. In one or more embodiments of Formula IV-G, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-G, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-G, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-G, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-H:
  • IV-H and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
  • C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH 2 )n H2, -(CH 2 )nOH, -CF3, -CHF2, or -CH2F.
  • n is 1.
  • the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1.
  • the C ring, along with the nitrogen atom to which it is attached is an optionally substituted 3- to 12-membered monocyclic heterocycle.
  • the C ring, along with the nitrogen atom to which it is attached is an optionally substituted 3-to 12-membered polycyclic heterocycle.
  • the nitrogen atom to which it is attached is an optionally substituted 5- to 12-membered spiroheterocycle.
  • nitrogen atom to which it is attached is an optionally sub
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-H, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-H, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-H, A is phenyl. In one or more embodiments of Formula IV-H, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-H, A is pyridinyl. In one or more embodiments of Formula IV- H, A is indazolyl. In one or more embodiments of Formula IV-H, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-H, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-H, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-H, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-H, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-H, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-H, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl. In one or more embodiments of Formula IV-H, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- H, R 5 and R 6 are independently, at each occurrence, -Ci-C 6 alkyl. [00291] In one or more embodiments of Formula IV-H, R 2 is -H.
  • R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-H, R 2 is -H, -OH, - R 5 R 6 , -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-H, R 2 is -OH. In one or more embodiments of Formula IV-H, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-H, R 2 is - H2.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-H, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-H, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-H, X 1 is N and X 2 is CH.
  • Formula IV-H is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • Formula IV-H is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-H, B is substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH2)n H2,
  • B is substituted with one or more oxo. In one or more embodiments of Formula IV-H, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-H, B is substituted with one or more -OH. In one or more embodiments of Formula IV-H, B is substituted with one or more - H2. In one or more embodiments of Formula IV-H, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-H, B is substituted with one or more -CHF2.
  • B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-H, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-I:
  • X B1 is N, NR 9 , CR 9 , S, or O
  • X B2 is N, R 9 , CR 9 , S, or O
  • X B3 is N, NR 9 , CR 9 , S, or O
  • R 9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F, provided that if X 1 is C, at least one of X B1 , X B2 , and X B3 is not CR 9 , or provided that if each of X B1 , X B2 , and X B3 are CR 9 , X
  • X B1 is N or NR 9 . In certain embodiments of Formula IV-I, X B1 is CR 9 . In certain embodiments of Formula IV-I, X B1 is S. In certain embodiments of Formula IV-I, X B1 is O. In certain embodiments of Formula IV-I, X B2 is N or NR 9 . In certain embodiments of Formula IV-I, X B2 is CR 9 . In certain embodiments of Formula IV-I, X is S. In certain embodiments of Formula IV-I, X is O. In certain embodiments of Formula IV-I, X B3 is N or R 9 . In certain embodiments of Formula IV-I, X B3 is CR 9 . In certain embodiments of Formula IV-I, X B3 is S. In certain embodiments of Formula IV-I, X B3 is O.
  • X B1 is N or NR 9 .
  • X B1 is CR 9 .
  • X B2 is N or NR 9 .
  • X B2 is CR 9 .
  • X B3 is N or NR 9 .
  • X B3 is CR 9 .
  • R 9 is -( ⁇ 3 ⁇ 4) ⁇ 0 ⁇ and n is 1. In some embodiments of Formula IV-I, R 9 is H.
  • Y 2 is -(CR3 ⁇ 4)m In one or more embodiments of the compounds of Formula IV-I, Y 2 is -NR a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-I, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-I, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-I, A is phenyl. In one or more embodiments of Formula IV-I, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-I, A is pyridinyl. In one or more embodiments of Formula IV-I, A is indazolyl. In one or more embodiments of Formula IV-I, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-I, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-I, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-I, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-I, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-I, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-I, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-I, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-I, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-I, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-I, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 .
  • R 2 is -OH. In one or more embodiments of Formula IV-I, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV-I, [00309] In one or more embodiments of Formula IV-I, R a is -H.
  • R 3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-I, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-I, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-I, R 3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H2, -(CH 2 )nOH, -CF 3 , -CHF2, or -CFI2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-I, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-I, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-I, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-J:
  • X B4 is N or CR 9 ;
  • X B5 is N or CR 9 ;
  • X B6 is N or CR 9 ;
  • X B7 is N or CR 9 , wherein R 9 is independently, at each occurrence, -H, -Ci-C 6 alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F, provided that if X 1 is C, at least one of X B4 , X B5 , X B6 , and X B7 is not CR 9 , or provided that if each of X B4 , X B5 , X B6 , and X B7 are CR 9 , X 1
  • X B4 is N. In certain embodiments of Formula IV-J, X B4 is CR 9 . In certain embodiments of Formula IV-J, X B5 is N. In certain embodiments of Formula IV-J, X B5 is CR 9 . In certain embodiments of Formula IV-J, X B6 is N. In certain embodiments of Formula IV-J, X B6 is CR 9 . In certain embodiments of Formula IV-J, X B7 is N. In certain embodiments of Formula IV-J, X B7 is CR 9 . In certain
  • X B4 is N
  • X B5 is CR 9
  • X B6 is N
  • X B7 is CR 9
  • R 9 is independently, at each occurrence, -H.
  • R 9 is -(CH 2 ) n OH and n is 1. In some embodiments of Formula IV-J, R 9 is H.
  • Y 2 is -(CR3 ⁇ 4)m-. In one or more embodiments of the compounds of Formula IV-J, Y 2 is - R a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-J, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-J, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-J, A is phenyl. In one or more embodiments of Formula IV-J, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-J, A is pyridinyl. In one or more embodiments of Formula IV-J, A is indazolyl. In one or more embodiments of Formula IV-J, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-J, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-J, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-J, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-J, R 1 is independently, at each occurrence, -H or halogen.
  • R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-J, R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 . In one or more embodiments of Formula IV- J, R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 . In certain such embodiments, R 5 and R 6 are both -H. In one or more embodiments of Formula IV- J, R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV- J, R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV- J, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- J, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV- J, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV- J, R 2 is -H, -OH, - R 5 R 6 , -Ci-C 6 alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV- J, R 2 is -OH. In one or more embodiments of Formula IV- J, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV- J,
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula IV- J, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-J, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-J, R 3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 )nOH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH 2 )n H 2 , or - H 2 .
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH 2 ) n NH 2 , or - H 2 .
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH 2 ) n NH 2 , or - H 2 .
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV- J, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV- J, X 1 is C and X 2 is N. In one or more embodiments of Formula IV- J, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-K:
  • IV-K and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-K, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-K, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-K, A is phenyl. In one or more embodiments of Formula IV-K, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-K, A is pyridinyl. In one or more embodiments of Formula IV- K, A is indazolyl. In one or more embodiments of Formula IV-K, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-K, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C 6 alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-K, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-K, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-K, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-K, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-K, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-K, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- K, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-K, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-K, R 2 is -H, -OH, - R 5 R 6 , -Ci-C 6 alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-K, R 2 is -OH. In one or more embodiments of Formula IV-K, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-K, R 2 is - H2.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CFIF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • spiroheterocycle which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-K, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-K, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-K, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-K, B is substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH2)n H2,
  • B is substituted with one or more oxo. In one or more embodiments of Formula IV-K, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-K, B is substituted with one or more -OH. In one or more embodiments of Formula IV-K, B is substituted with one or more - H2. In one or more embodiments of Formula IV-K, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-K, B is substituted with one or more -CHF2.
  • B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-K, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-L:
  • IV-L and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
  • C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered poly cyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(C h Fh, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH 2 )n H2, -(CH 2 )nOH, -CF3, -CHF2, or -CH2F.
  • n is 1.
  • the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1.
  • the C ring, along with the nitrogen atom to which it is attached is an optionally substituted 3- to 12-membered monocyclic heterocycle.
  • the C ring, along with the nitrogen atom to which it is attached is an optionally substituted 3-to 12-membered polycyclic heterocycle.
  • the nitrogen atom to which it is attached is an optionally substituted 5- to 12-membered spiroheterocycle.
  • nitrogen atom to which it is attached is an optionally sub
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-L, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-L, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-L, A is phenyl. In one or more embodiments of Formula IV-L, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-L, A is pyridinyl. In one or more embodiments of Formula IV- L, A is indazolyl. In one or more embodiments of Formula IV-L, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-L, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula IV-L, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-L, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV-L, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-L, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-L, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl. In one or more embodiments of Formula IV-L, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-L, R 5 and R 6 are independently, at each occurrence, -Ci-C 6 alkyl. [00355] In one or more embodiments of Formula IV-L, R 2 is -H.
  • R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl.
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 .
  • R 2 is -OH.
  • R 2 is - R 5 R 6 .
  • R 2 is - H2.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-L, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-L, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-L, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-L, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)nNH2,
  • B is substituted with one or more oxo. In one or more embodiments of Formula IV-L, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-L, B is substituted with one or more -OH. In one or more embodiments of Formula IV-L, B is substituted with one or more - H2. In one or more embodiments of Formula IV-L, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-L, B is substituted with one or more -CHF2.
  • B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-L, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-M:
  • IV-M and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof wherein X B1 is N, NR 9 , CR 9 , S, or O; X B2 is N, R 9 , CR 9 , S, or O; and X B3 is N, NR 9 , CR 9 , S, or O, wherein R 9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F, provided that if X 1 is C, at least one of X B1 , X B2 , and X B3 is not CR 9 , or provided that if each of X B1 , X B2 , and X B3 are CR 9 , X
  • X B1 is N or NR 9 .
  • X B1 is CR 9 . In certain embodiments of Formula IV-M, X B1 is S. In certain embodiments of Formula IV-M, X B1 is O. In certain embodiments of Formula IV-M, X B2 is N or NR 9 . In certain embodiments of Formula IV-M, X B2 is CR 9 . In certain embodiments of Formula IV-M, X is S. In certain embodiments of Formula IV-M, X B2 is O. In certain embodiments of Formula IV-M, X B3 is N or R 9 . In certain
  • X B3 is CR 9 . In certain embodiments of Formula IV-M, X B3 is S. In certain embodiments of Formula IV-M, X B3 is O.
  • X B1 is N or NR 9 .
  • X B1 is CR 9 .
  • X B2 is N or NR 9 .
  • X B2 is CR 9 .
  • X B3 is N or NR 9 .
  • X B3 is CR 9 .
  • R 9 is -( ⁇ 3 ⁇ 4) ⁇ 0 ⁇ and n is 1. In some embodiments of Formula IV-M, R 9 is H.
  • Y 2 is
  • Y 2 is -NR a -
  • R 2 is -H. In one or more embodiments of Formula IV-M, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-M, R 2 is -H, -OH, - R 5 R 6 , -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-M, R 2 is -OH. In one or more embodiments of Formula IV-M, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-M, R 2 is - H2.
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-M, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-M, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-M, R 3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-M, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-M, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-M, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-N:
  • X B4 is N or CR 9 ;
  • X B5 is N or CR 9 ;
  • X B6 is N or CR 9 ;
  • X B7 is N or CR 9 , wherein R 9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH 2 , heteroaryl, heterocyclyl, -(CH 2 )nNH2, -(CH 2 )nOH, -CF 3 , -CHF 2 , or -CH 2 F, provided that if X 1 is C, at least one of X B4 , X B5 , X B6 , and X B7 is not CR 9 , or provided that if each of X B4 , X B5 , X B6 , and X B7 are CR 9 , X 1 must be
  • X B4 is N. In certain embodiments of Formula IV-N, X B4 is CR 9 . In certain embodiments of Formula IV-N, X B5 is N. In certain embodiments of Formula IV-N, X B5 is CR 9 . In certain embodiments of Formula IV-N, X B6 is N. In certain embodiments of Formula IV-N, X B6 is CR 9 . In certain embodiments of Formula IV-N, X B7 is N. In certain embodiments of Formula IV-N, X B7 is CR 9 .
  • X B4 is N
  • X B5 is CR 9
  • X B6 is N
  • X B7 is CR 9
  • R 9 is independently, at each occurrence, -H.
  • R 9 is -(CH 2 )nOH and n is 1. In some embodiments of Formula IV-N, R 9 is H.
  • Y 2 is
  • Y 2 is -NR a -
  • R 2 is -H. In one or more embodiments of Formula IV-N, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-N, R 2 is -H, -OH, -NR 5 R 6 ,
  • R 2 is -OH. In one or more embodiments of Formula IV-N, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV-N, R 2 is -NH 2 . [00381] In one or more embodiments of Formula IV-N, R a is -H.
  • R 3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-N, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-N, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-N, R 3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -NFh, -OH, -(CH2)nNH2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NFh.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)nNH2, or -NH2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF 3 , -CHF 2 , or -CH2F.
  • R and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-N, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-N, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-N, X 1 is N and X 2 is CH.
  • the compound is of Formula IV-O:
  • R 2 is -H.
  • R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl.
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 .
  • R 2 is -OH.
  • R 2 is - R 5 R 6 .
  • R 2 is - H2.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF 2 , or -CH2F.
  • R and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H2, -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-O, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-O, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-O, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B, including the atoms at the points of attachment is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl.
  • B, including the atoms at the points of attachment is an optionally substituted monocyclic 5 to 6-membered heteroaryl.
  • B, including the atoms at the points of attachment is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-O, B is substituted with one or more -Ci-Cealkyl, -OH, - H 2 , oxo, -(CH2)n H2, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F. In one or more embodiments of Formula IV-O, B is substituted with one or more oxo. In one or more embodiments of Formula IV-O, B is substituted with one or more -Ci-C6alkyl.
  • B is substituted with one or more -OH. In one or more embodiments of Formula IV-O, B is substituted with one or more - H2. In one or more embodiments of Formula IV-O, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-O, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-O, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-O, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-P:
  • IV-P and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
  • C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(03 ⁇ 4) ⁇ ⁇ 2, -( ⁇ 3 ⁇ 4) ⁇ 0 ⁇ , -CF 3 , -CHF2, or -CH2F.
  • the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH 2 )n H2, -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F.
  • n is 1.
  • the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1.
  • the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3- to 12-membered monocyclic
  • the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3-to 12-membered polycyclic heterocycle.
  • the nitrogen atom to which it is attached is an optionally substituted 5- to 12-membered spiroheterocycle.
  • Formula I -P, C ring, along with the nitrogen atom to which it is attached, is an optionally substituted in certain embodiments of Formula IV-P, C ring, along with the
  • nitrogen atom to which it is attached is an optionally substituted
  • R 2 is -H. In one or more embodiments of Formula IV-P, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-P, R 2 is -H, -OH, - R 5 R 6 , -Ci-C 6 alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula IV-P, R 2 is -OH. In one or more embodiments of Formula IV-P, R 2 is -NR 5 R 6 . In one or more embodiments of Formula IV- P, R 2 is -NHz.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-P, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-P, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-P, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-P, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H2, -(CH2)nOH, -CF 3 , -CFIF2, or -CH2F. In one or more embodiments of Formula IV-P, B is substituted with one or more oxo. In one or more embodiments of Formula IV-P, B is substituted with one or more -Ci-C6alkyl.
  • B is substituted with one or more -OH. In one or more embodiments of Formula IV-P, B is substituted with one or more - H2. In one or more embodiments of Formula IV-P, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-P, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-P, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-P, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • the compound is of Formula IV-Q:
  • A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl, provided that
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 ;
  • Y 1 is -S- or a direct bond
  • X 1 is N or C
  • X 2 is N or CH
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
  • R 2 is -H, -OH, - R 5 R 6 , -Ci-Cealkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 ;
  • Y 2 is - R a - wherein the bond on the left side of Y 2 , as drawn, is bound to the ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ;
  • R 3 is combined with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, -CHF 2 , or -CH 2 F, provided that the heterocycle formed by the combination of R 3 and R a is not an optionally substituted piperazinyl;
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl
  • n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Y 1 is -S-. In one or more embodiments of Formula IV-Q, Y 1 is a direct bond.
  • A is a monocyclic or poly cyclic aryl. In one or more embodiments of Formula IV-Q, A is phenyl. In one or more
  • A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-Q, A is pyridinyl. In one or more embodiments of Formula IV- Q, A is indazolyl.
  • n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-Q, n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula IV-Q, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula IV- Q, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-Q, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula IV-Q, R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or -NR 5 R 6 . In certain such embodiments, R 5 and R 6 are both -H. In one or more embodiments of Formula IV-Q, R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-Q, R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-Q, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula IV-Q, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula IV-Q, R 2 is -OH. In one or more embodiments of Formula IV-Q, R 2 is - R 5 R 6 . In one or more embodiments of Formula IV-
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NFh, -OH, -(CFh ⁇ Fh, -(CH2)nOH, -CF 3 , -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • n 1
  • X 1 is N and X 2 is N. In one or more embodiments of Formula IV-Q, X 1 is C and X 2 is CH. In one or more embodiments of Formula IV-Q, X 1 is C and X 2 is N. In one or more embodiments of Formula IV-Q, X 1 is N and X 2 is CH.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-Q, B is substituted with one or more oxo. In one or more embodiments of Formula IV-Q, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV- Q, B is substituted with one or more -OH. In one or more embodiments of Formula IV-Q, B is substituted with one or more - H 2 . In one or more embodiments of Formula IV-Q, B is substituted with one or more -CF 3 .
  • B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-Q, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-Q, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
  • a compound of the present disclosure e.g., a compound of Formula ⁇ , I, II, III, or IV
  • a compound of Formula ⁇ , I, II, III, or IV can be selected from:
  • the compounds of the disclosure are compounds of Formula V:
  • A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C 8 cycloalkenyl, -Ci-Cealkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 5 , halogen, -NO2, -CN, - R 5 R 6 , -SR 5 , -S(0) 2 R 5 R 6 , -S(0) 2 R 5 , - R 5 S(0) 2 R 5 R 6 , - R 5 S(0) 2 R 6 , -S(0) R 5 R 6 , -S(0)R 5 , - R 5 S(0)R 6 , -C 5 S(0)R 6 , -C
  • B is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more -Ci- Cealkyl, -OH, -NH 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or
  • R 2 is -H, -OH, -NR 5 R 6 , -Ci-Cealkyl, -C 2 -C 6 alkenyl, -C 4 -C 8 cycloalkenyl,
  • Y 2 is -NR a - -(CR3 ⁇ 4)m- -C(O)-, -C(R a ) 2 NH-, -(CR a 2 )mO-, -C(0)N(R a )-,
  • R a is independently, at each occurrence, -H, -D, -OH, -C 3 -C 8 cycloalkyl, or
  • each alkyl or cycloalkyl is optionally substituted with one or more -NH2, wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
  • R b is independently, at each occurrence, -H, -D,-Ci-C 6 alkyl, -C 3 -C 8 cycloalkyl, -C2-C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 ,
  • R 3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C 3 -C8cycloalkyl, or -(CH 2 )n-R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR b , -NHR b , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R a to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C 6 alkyl, -OH, -NH 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -CF 3 , -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R 3 and R a is not an optionally substituted piperazinyl;
  • R 5 and R 6 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, or -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C 6 alkyl, -C2-C 6 alkenyl, -C4-C 8 cycloalkenyl, -C2-C 6 alkynyl, -C 3 -C 8 cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R 10 is -H or -Ci-Cealkyl
  • n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
  • n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • R 4 is H.
  • R 4 is .
  • Y 1 is -S- or a direct bond.
  • Y 1 is -S-.
  • Y 1 is a direct bond.
  • Y 2 is -(CR3 ⁇ 4)m-. In one or more embodiments of the compounds of Formula V, Y 2 is -NR a - [00432] In one or more embodiments of the compounds of Formula V, R is -H. In one or more embodiments of the compounds of Formula V, R 10 is -Ci-C6alkyl.
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula V, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula V, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula V, A is phenyl. In one or more embodiments of Formula V, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula V, A is pyridinyl. In one or more embodiments of Formula V, A is indazolyl. In one or more embodiments of Formula V, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each
  • n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C 6 alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula V, R 1 is independently, at each occurrence, -OR 5 or halogen. In one or more embodiments of Formula V, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula V, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula V, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula V, R 1 is independently, at each
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 . In certain such embodiments, R 5 and R 6 are both -H. In one or more embodiments of Formula V, R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or -NFh. In one or more embodiments of Formula V, R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C 6 alkyl. In one or more embodiments of Formula V, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula V, R 5 and R 6 are independently, at each occurrence, -Ci-C 6 alkyl.
  • R 2 is -H.
  • R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula V, R 2 is -H, -OH, - R 5 R 6 , -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula V, R 2 is -OH. In one or more
  • R 2 is - R 5 R 6 . In one or more embodiments of Formula V, R 2 is
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula V, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula V, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula V, R 3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12- membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF3, -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • B including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heterocycle. In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
  • B including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • B, including the atoms at the points of attachment is an optionally substituted monocyclic or polycyclic 5- to 12-membered heteroaryl.
  • B, including the atoms at the points of attachment is an optionally substituted monocyclic 5 to 6-membered heteroaryl.
  • B, including the atoms at the points of attachment is a monocyclic 7- to 12-membered heteroaryl.
  • B is an optionally substituted polycyclic 5- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula V, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH 2 )n H2, -(CH 2 )nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V, B is substituted with one or more oxo. In one or more embodiments of Formula V, B is substituted with one or more -Ci-C6alkyl.
  • B is substituted with one or more -OH. In one or more embodiments of Formula V, B is substituted with one or more - H2. In one or more embodiments of Formula V, B is substituted with one or more -CF3. In one or more embodiments of Formula V, B is substituted with one or more -CHF2. In one or more embodiments of Formula V, B is substituted with one or more -CH2F. In one or more embodiments of Formula V, B is substituted with one or more -(CH 2 )nNH 2 . In certain such embodiments, n is 1.
  • the compound is of Formula V-A:
  • V-A and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof wherein X B4 is N or CR 9 ; X B5 is N or CR 9 ; X B6 is N or CR 9 ; and X B7 is N or CR 9 , wherein R 9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, - H 2 , heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • X B4 is N. In certain embodiments of Formula V-A, X B4 is CR 9 . In certain embodiments of Formula V-A, X B5 is N. In certain embodiments of Formula V-A, X B5 is CR 9 . In certain embodiments of Formula V-A, X B6 is N. In certain embodiments of Formula V-A, X B6 is CR 9 . In certain embodiments of Formula V-A, X B7 is N. In certain embodiments of Formula V-A, X B7 is CR 9 .
  • R 9 is -(CH 2 ) n OH and n is 1. In some embodiments of Formula V-A, R 9 is H.
  • R 10 is -H. In one or more embodiments of the compounds of Formula V-A, R 10 is -Ci-C6alkyl.
  • R 4 is H.
  • R 4 is In certain such embodiments, Y 1 is -S- or a direct bond. In one or more embodiments of Formula V-A, Y 1 is -S-. In one or more embodiments of Formula V-A, Y 1 is a direct bond.
  • Y 2 is -(CR3 ⁇ 4)m-. In one or more embodiments of the compounds of Formula V-A, Y 2 is - R a -
  • A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula V-A, A is a monocyclic or polycyclic heterocycloalkyl. In one or more embodiments of Formula V-A, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula V-A, A is phenyl. In one or more embodiments of Formula V-A, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula V-A, A is pyridinyl. In one or more embodiments of Formula V-A, A is indazolyl.
  • A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
  • n is independently, at each occurrence, 0, 1, 2, or 3.
  • n is independently, at each occurrence, 1 or 2.
  • R 1 is independently, at each occurrence, -H, -OR 5 , halogen, -Ci-C6alkyl, -CN, or - R 5 R 6 . In one or more embodiments of Formula V-A, R 1 is independently, at each occurrence, -H, -OR 5 or halogen. In one or more embodiments of Formula V-A, R 1 is independently, at each occurrence, -H or -OR 5 . In one or more embodiments of Formula V-A, R 1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula V-A, R 1 is independently, at each occurrence, -H or - R 5 R 6 . In one or more embodiments of Formula V-A, R 1 is
  • R 1 is independently, at each occurrence, -H, -OR 5 or - R 5 R 6 .
  • R 1 is independently, at each occurrence, -H, halogen or - R 5 R 6 .
  • R 5 and R 6 are both -H.
  • R 1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
  • R 1 is independently, at each occurrence, -H, -CN or halogen.
  • R 5 and R 6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula V-A, R 5 and R 6 are independently, at each occurrence, -H. In one or more embodiments of Formula V-A, R 5 and R 6 are independently, at each occurrence, -Ci-C6alkyl.
  • R 2 is -H. In one or more embodiments of Formula V-A, R 2 is -Ci-C 6 alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In certain such embodiments, R 2 is methyl. In one or more embodiments of Formula V-A, R 2 is -H, -OH, -NR 5 R 6 , -Ci-C 6 alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or -NR 5 R 6 . In one or more embodiments of Formula V-A, R 2 is -OH. In one or more embodiments of Formula V-A, R 2 is -NR 5 R 6 . In one or more embodiments of Formula V-A,
  • R a is -H.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula V-A, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula V-A, R 3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula V-A, R is an optionally substituted 5- to 12- membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF 2 , or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -(CH2)n H2, or - H2.
  • n is 1.
  • R 3 and R a together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 )nOH, -CF3,
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH 2 )n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH 2 , -OH, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12-membered
  • R 3 and R a together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C 6 alkyl, -OH, - H 2 , oxo, heteroaryl, heterocyclyl, -(CH 2 ) n H 2 , -(CH 2 ) n OH, -CF 3 , -CHF 2 , or -CH 2 F.
  • R 4 is H.
  • R 4 is
  • A is a 5- to 12- membered monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, A is a monocyclic or polycyclic heterocycloalkyl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, A is a monocyclic or polycyclic heteroaryl.
  • Y 1 is -S-. In one or more embodiments of Formula ⁇ , I, IV, or V, Y 1 is a direct bond.
  • Y 2 is - R a - In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, Y 2 is -(CR a 2 ) m - In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, Y 2 is -C(O)-. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, Y 2 is -C(R a ) 2 H- or -(CR3 ⁇ 4)mO-. In one or more
  • Y 2 is -C(0)N(R a )-, -N(R a )C(0)-,
  • Y 2 is -N(R a )C(0)N(R a )-, -N(R a )C(S)N(R a )-, -OC(0)N(R a )-, -N(R a )C(0)0-, or -C(0)N(R a )0-.
  • Y 2 is -C(0)0- -OC(O)-, or -OC(0)0-.
  • R 2 is -OH. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR 5 , or - R 5 R 6 . In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 2 is an optionally substituted -C2-C6alkenyl.
  • R 2 is an optionally substituted -C4-C8cycloalkenyl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 2 is an optionally substituted -C2-C 6 alkynyl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 2 is an optionally substituted -C3-C8cycloalkyl.
  • R 2 is an optionally substituted monocyclic or poly cyclic heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
  • R a is -H. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R a is -OH. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R a is an optionally substituted -C3-C8cycloalkyl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R a is an optionally substituted
  • R b is H. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R b is an optionally substituted
  • R b is an optionally substituted -C3-C8cycloalkyl.
  • R is an optionally substituted -C2-C 6 alkenyl.
  • R b is an optionally substituted monocyclic or polycyclic heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
  • R 3 is an optionally substituted -Ci-C 6 alkyl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 3 is an optionally substituted 3- to 12- membered monocyclic heterocycle. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, R 3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
  • R 3 and R a together with the atom to which they are attached combine to form an optionally substituted 3- to 12- membered monocyclic heterocycle.
  • R 3 and R a together with the atoms to which they are attached combine to form an optionally substituted 3- to 12-membered polycyclic heterocycle.
  • X 1 is N. In one or more embodiments of Formula ⁇ , I, II, III, or IV, X 1 is C.
  • X 2 is N. In one or more embodiments of Formula ⁇ , I, II, III, or IV, X 2 is CH.
  • X 1 is N and X 2 is N. In one or more embodiments of Formula ⁇ , I, II, III, or IV, X 1 is N and X 2 is CH. In one or more embodiments of Formula ⁇ , I, II, III, or IV, X 1 is C and X 2 is N. In one or more embodiments of Formula ⁇ , I, II, III, or IV, X 1 is C and X 2 is CH.
  • Formula ⁇ , I, II, III, IV, or V, B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heterocycle.
  • Formula ⁇ , I, II, III, IV, or V, B including the atoms at the points of attachment, is a polycyclic 5- to 12-membered heterocyclyl.
  • the heteroycyclyl ring is fused.
  • the heterocyclyl ring is bridged.
  • Formula ⁇ , I, II, III, IV, or V, B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula ⁇ , I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
  • the polycyclic heteroaryl is a multiple condensed ring as described above.
  • the rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • R 2 is an optionally substituted -Ci-C6alkyl and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl.
  • R 2 is an optionally substituted -Ci-C6alkyl and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5-membered heteroaryl.
  • R 2 is an optionally substituted -Ci-C 6 alkyl and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 6- membered heteroaryl.
  • R 2 is -OH and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl.
  • R 2 is -OH and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5-membered heteroaryl.
  • R 2 is -OH and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 6-membered heteroaryl.
  • Y 1 is -S- and A is an optionally substituted 5- to 12-membered monocyclic or polycyclic cycloalkyl.
  • Y 1 is -S- and A is an optionally substituted monocyclic or polycyclic heterocycloalkyl.
  • Y 1 is -S- and A is an optionally substituted monocyclic or polycyclic aryl.
  • Y 1 is S and A is an optionally substituted monocyclic or polycyclic heteroaryl.
  • Y 1 is a direct bond and A is an optionally substituted 5- to 12-membered monocyclic or polycyclic cycloalkyl.
  • Y 1 is a direct bond and A is an optionally substituted monocyclic or polycyclic heterocycloalkyl.
  • Y 1 is a direct bond and A is an optionally substituted monocyclic or polycyclic aryl.
  • Y 1 is a direct bond and A is an optionally substituted monocyclic or polycyclic heteroaryl.
  • the compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the schemes given below.
  • the compounds of any of the formulae described herein may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes and examples.
  • protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry.
  • Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
  • the selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of the present disclosure.
  • the present disclosure may include both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well.
  • a compound When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994).
  • the compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
  • the compounds of the present disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis.
  • compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. These methods include but are not limited to those methods described below.
  • the resulting intermediate can be coupled to a substituted aryl- or heteroaryl-thiol in the presence of a copper catalyst (e.g., Cul) or under SNAr conditions, alternatively, the resulting intermediate can be coupled to an appropriately substituted aryl or heteroaryl boronic acid in the presence of Pd catalyst. Additional deprotection and/or functionalization steps can be required to produce the final compound.
  • Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof.
  • the methods may involve administering to a patient in need of treatment for diseases or disorders associated with SHP2 modulation an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula ⁇ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical compositions of the present disclosure.
  • compounds of the present disclosure e.g., compounds of Formula ⁇ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • the disease can be, but is not limited to Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R).
  • PDGF-R platelet-derived growth factor
  • FGF-R fibroblast growth factor
  • EGF-R epidermal growth factor
  • SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer.
  • MAP mitogen activated protein
  • SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers.
  • SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
  • SHP2 plays a role in transducing signals originating from immune checkpoint molecules, including but not limited to programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • CTL-4 cytotoxic T-lymphocyte-associated protein 4
  • modulation of SHP2 function can lead to immune activation, specifically anti-cancer immune responses.
  • Another aspect of the disclosure is directed to a method of inhibiting SHP2.
  • the method involves administering to a patient in need thereof an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula ⁇ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical compositions of the present disclosure.
  • the present disclosure relates to compounds or compositions disclosed herein that are capable of modulating the activity of (e.g., inhibiting) SHP2.
  • the present disclosure also relates to the therapeutic use of such compounds and compositions.
  • One or more disclosed compounds or compositions can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects.
  • SHP2 is inhibited after treatment with less than 1000 nM of a compound of the disclosure.
  • SHP2 is inhibited after treatment with about 1 nM to about 10 nM of a compound of the disclosure.
  • SHP2 is inhibited after treatment with less than about 1 nM of a compound of the disclosure.
  • SHP2 is inhibited after treatment with about 10 nM to about 100 nM of a compound of the disclosure.
  • SHP2 is inhibited after treatment with about 100 nM to about 10 ⁇ of a compound of the disclosure.
  • Another aspect of the present disclosure relates to a one or more compounds of the present disclosure (e.g., compounds of Formula ⁇ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or one or more compositions of the present disclosure, for use in treating or preventing a disease associated with SHP2 modulation.
  • the disease is Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R).
  • SFIP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SFIP2 significantly inhibited cell growth of lung cancer cell lines with SFIP2 mutation or
  • EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers.
  • SFIP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
  • the present disclosure relates to the use of one or more compounds of the present disclosure (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease.
  • the disease is associated with SHP2 modulation.
  • the present disclosure relates to one or more compounds of the present disclosure (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • the medicament is used for treating or preventing a disease associated with SHP2 modulation.
  • the present disclosure relates to one or more compositions comprising one or more compounds of the present disclosure (e.g., compounds of Formula ⁇ , I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • the medicament is used for treating or preventing a disease associated with SHP2 modulation.
  • compositions comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier can further include an excipient, diluent, or surfactant.
  • compositions of the disclosure can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20%) of one or more of the disclosed compounds by weight or volume.
  • modes may include systemic or local administration such as oral, nasal, parenteral, intravenous, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
  • the disclosed compounds or pharmaceutical compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be
  • Illustrative pharmaceutical compositions may include tablets and gelatin capsules comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier, such as, but not limited to, a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/
  • polyvinylpyrrolidone if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, algiic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl- cyclodextrin, PEG400, PEG200.
  • a disintegrant e.g., starches, agar, methyl cellulose, bentonite
  • Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc.
  • one or more of the disclosed compounds are dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
  • a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like.
  • Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
  • One or more of the disclosed compounds or compositions can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
  • One or more disclosed compounds or compositions can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • liposomes can be formed from a variety of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of
  • phospholipids containing cholesterol, stearylamine or phosphatidylcholines.
  • a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described for instance in U.S. Pat. No. 5,262,564, the contents of which are hereby incorporated by reference.
  • One or more disclosed compounds or compositions can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
  • the disclosed compounds can also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer,
  • the one or more disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

Description

BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
[0001] This application claims the benefit of U.S. Provisional Application No.
62/449,530, filed January 23, 2017, the contents of which are incorporated herein by reference in its entirety.
Field of the Disclosure
[0002] The present disclosure relates to inhibitors of protein tyrosine phosphatase SHP2 useful in the treatment of diseases or disorders. Specifically, this disclosure is concerned with compounds and compositions inhibiting SHP2, methods of treating diseases associated with SHP2, and methods of synthesizing these compounds.
Background of the Disclosure
[0003] SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3- kinase- AKT pathways.
[0004] SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive, self- inhibited conformation stabilized by a binding network involving residues from both the N- SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
[0005] Mutations in the PTPN11 gene and subsequently in SHP2 have been identified in several human diseases, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2, therefore, represents a highly attractive target for the development of novel therapies for the treatment of various diseases. The compounds of the present disclosure fulfill the need for small molecules to that inhibit the activity of SHP2.
Summary of the Disclosure
[0006] The present disclosure relates to compounds capable of inhibiting the activity of SHP2. The disclosure further provides a process for the preparation of compounds disclosed herein, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
[0007] One aspect of the disclosure relates to compounds of Formula Γ :
Figure imgf000003_0001
Γ and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof wherein:
Figure imgf000003_0002
A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -C3-C8cycloalkyl, -OH, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0)NR5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
R2 is -H, -ORb, -NR5R6,-CN, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -NH2, halogen, -C(0)ORb, -C3-C8cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m- -C(O)-, -C(Ra)2NH- -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-,
-C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000004_0001
R3 is -H, -C i-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -COORb, -CONHRb, -CONH(CH2)nCOORb,
-NHCOORb, -CF3, -CHF2, or -CH2F;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN; R and R are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, - H2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0008] Another aspect of the disclosure relates to compounds of Formula I:
Figure imgf000005_0001
I and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
R2 is -H, -ORb, -NR5R6,-CN, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -NH2, halogen, -C(0)ORb, -C3-C8cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m- -C(O)-, -C(Ra)2NH- -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000006_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -COORb, -CONHRb, -CONH(CH2)nCOORb,
-NHCOORb, -CF3, -CHF2, or -CH2F; R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0009] Another aspect of the disclosure relates to compounds of Formula II:
Figure imgf000007_0001
II
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl; R2 is -H, -ORb, - R5R6 ,-CN, -Ci-Cealkyl, -Ci-Cealkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, - H2, halogen, -C(0)ORb, -C3-C8cycloalkyl, aryl, heterocyclyl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5,
- R5S(0)NR5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom;
Y2 is - Ra- -(CRa2)m- -C(O)-, -C(Ra)2 H-, -(CRa 2)mO- -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0- -C(0)N(Ra)0-, -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000008_0001
R3 is, at each occurrence, selected from the group consisting of -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -COORb, -CONHRb, -CONH(CH2)nCOORb,
-NHCOORb, -CF3, -CHF2, or -CH2F; R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0010] Another aspect of the disclosure relates to compounds of Formula III:
Figure imgf000009_0001
III
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl; R2 is -H, -ORb, - R5R6 ,-CN, -Ci-Cealkyl, -Ci-Cealkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, - H2, halogen, -C(0)ORb, -C3-C8cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m-, -C(O)-, -C(Ra)2 H-, -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0- -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000010_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -COORb, -CONHRb, -CONH(CH2)nCOORb,
-NHCOORb, -CF3, -CHF2, or -CH2F; R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0011] One aspect of the disclosure relates to compounds of Formula IV:
Figure imgf000011_0001
IV and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof wherein:
Figure imgf000011_0002
A is a 5- to 12-membered monocyclic or olycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
Figure imgf000011_0003
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR5, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F;
R2 is -H, -OH, - R5R6, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl,
-C2-C6alkynyl, - H2, halogen, -C3-C8cycloalkyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m- -C(O)-, -C(Ra)2 H-, -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0- -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or -Ci- C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000012_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, - HRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0012] One aspect of the disclosure relates to compounds of Formula IV that are compounds of Formula IV-Q:
Figure imgf000013_0001
IV-Q
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof wherein:
Figure imgf000013_0002
A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl, provided that
Figure imgf000013_0003
R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6;
Y1 is -S- or a direct bond;
X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F;
R2 is -H, -OH, - R5R6, -Ci-Cealkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6;
Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
R3 is combined with Ra to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl;
m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0013] Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
[0014] Another aspect of the disclosure relates to methods of inhibiting SHP2. The method comprises administering to a patient in need thereof, an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof). [0015] Another aspect of the disclosure is directed to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof) and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can further comprise an excipient, diluent, or surfactant. The
pharmaceutical composition can be effective for treating a disease associated with SHP2 modulation in a subject in need thereof.
[0016] Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
[0017] Another aspect of the disclosure relates to methods of inhibiting SHP2 comprising administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
[0018] Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use in treating or preventing a disease associated with SHP2 modulation. One aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, for use in treating of preventing a disease associated with SHP2 modulation.
[0019] Another aspect of the disclosure relates to the use of one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation. Another aspect of the disclosure relates to the use of pharmaceutical
compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[0020] Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. Another aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. In some embodiments, the medicament is used for treating or preventing a disease associated with SHP2 modulation.
[0021] The present disclosure also provides compounds and pharmaceutical compositions that are useful in inhibiting SHP2.
Detailed Description of the Disclosure
[0022] In a first aspect, compounds of Formula Γ are described:
Figure imgf000016_0001
Γ and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein B, X1, X2, R2, R3, R4, and Y2 are described as above.
[0023] In another aspect, compounds of the Formula I are described:
Figure imgf000016_0002
I and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein A, B, X1, X2, R1, R2, R3, Y1, Y2, and n are described as above.
[0024] In another aspect, compounds of the Formula II are described:
Figure imgf000017_0001
II and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein A, B, X1, X2, R1, R2, R3, Y2, and n are described as above.
[0025] In another aspect, compounds of the Formula III are described:
Figure imgf000017_0002
III and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein A, B, X1, X2, R1, R2, R3, Y2, and n are described as above.
[0026] In a first aspect, compounds of Formula IV are described:
Figure imgf000017_0003
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof wherein B, X1, X2, R2 R3, R4, and Y2 are described as above. [0027] The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.
General Information
[0028] The articles "a" and "an" are used in this disclosure and may refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" may mean one element or more than one element.
[0029] The term "and/or" is used in this disclosure to possibly mean either "and" or "or" unless indicated otherwise.
[0030] As used herein, "optional" or "optionally," may mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" may encompass both "aryl" and "substituted aryl" as defined herein. It will be understood by those ordinarily skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible, and/or inherently unstable.
[0031] The term "optionally substituted" is understood to possibly mean that a given chemical moiety (e.g. an alkyl group) can (but is not required to) be bonded other substituents (e.g. heteroatoms). For instance, an alkyl group that is optionally substituted may be a fully saturated alkyl chain (i.e. a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group may have substituents different from hydrogen. For instance, it can, at any point along the chain be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus the term "optionally substituted" may mean that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups. [0032] The term "aryl" may refer to cyclic, aromatic hydrocarbon groups that have 1 to 2 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H,
-halogen, -O-Ci-Cealkyl, -Ci-Cealkyl, -OCi-Cealkenyl, -OCi-Cealkynyl, -Ci-Cealkenyl, -Ci-Cealkynyl, -OH, -OP(0)(OH)2, -OC(0)Ci-C6alkyl, -C(0)Ci-C6alkyl,
-OC(0)OCi-C6alkyl, -NH2, - H(Ci-C6alkyl), -N(Ci-C6alkyl)2, -S(0)2-Ci-C6alkyl, -S(0) HCi-Cealkyl, and -S(0)N(Ci-Cealkyl)2. The substituents can themselves be optionally substituted.
[0033] Unless otherwise specifically defined, "heteroaryl" may mean a monovalent or multivalent monocyclic aromatic radical or a polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from N, S, P, and O, the remaining ring atoms being C. Heteroaryl as herein defined also may mean a bicyclic heteroaromatic group wherein the heteroatom is selected from N, S, P, and O. The term may also include multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. The term may also include multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, can be condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycles, (to form for example a 1, 2, 3, 4-tetrahydronaphthyridinyl such as 1, 2, 3, 4-tetrahydro- 1,8- naphthyridinyl), carbocycles (to form for example 5,6,7, 8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system and at any suitable atom of the multiple condensed ring system including a carbon atom and heteroatom (e.g., a nitrogen). The heteroaromatic radical may by optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazolyl, benzimidazolyl, thieno[3,2- b] thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[l,2- a] pyridinyl, imidazo[l,5-a]pyrazinyl, indazolyl, 1 -methyl- lH-indazolyl, pyrrolo[2,3- c] pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][l,6]naphthyridinyl, thieno[2,3- b] pyrazinyl, quinazolinyl, tetrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, isoindolin-l-one, indolin-2-one, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[l,2-a]pyrimidinyl, tetrahydro pyrrolo[l,2-a]pyrimidinyl, 3,4-dihydro-2H-l 2-pyrrolo[2,l-b]pyrimidine, dibenzo[b,d] thiophene, pyridin-2-one, benzo[<i]isoxazolyl, benzo[<i] oxazolyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, lH-pyrido[3,4-b][l,4] thiazinyl, 2-methylbenzo[<i]oxazolyl, 1,2,3,4- tetrahydropyrrolo[l,2-a]pyrimidyl, 2,3-dihydrobenzofuranyl, benzooxazolyl,
benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2- b]pyridinyl, [l,2,4]triazolo[l,5-a]pyridinyl, benzo [l,2,3]triazolyl, 1-methyl-lH- benzo[<i] [ 1 ,2,3 Jtriazolyl, imidazo[ 1 ,2-a]pyrimidinyl, [ 1 ,2,4]triazolo[4,3 -b]pyridazinyl, benzo[c][l,2,5]thiadiazolyl, quinoxalinyl, benzo[c][l,2,5]oxadiazolyl, l,3-dihydro-2H- benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo [l,5-b][l,2]oxazinyl, 3,4-dihydro-2H- benzo[b][l,4]oxazinyl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2, l-b][l,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, benzo[<i][l,3] dioxolyl, pyrazolo[l,5-a]pyridinyl, and derivatives of any of the foregoing.
[0034] "Alkyl" may refer to a straight or branched chain saturated hydrocarbon. Ci- C6alkyl groups contain 1 to 6 carbon atoms. Examples of a Ci-C6alkyl group may include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
[0035] The term "alkenyl" may mean an aliphatic hydrocarbon group containing a carbon— carbon double bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups may have about 2 to about 4 carbon atoms in the chain. Branched may mean that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkenyl chain. Exemplary alkenyl groups may include, but are not limited to, ethenyl, propenyl, n-butenyl, and i-butenyl. A C2-C6 alkenyl group is an alkenyl group containing between 2 and 6 carbon atoms.
[0036] The term "alkynyl" may mean an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups may have about 2 to about 4 carbon atoms in the chain. Branched may mean that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups may include, but are not limited to, ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, and n-pentynyl. A C2-C6 alkynyl group is an alkynyl group containing between 2 and 6 carbon atoms.
[0037] The term "cycloalkyl" may mean monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms. Examples of cycloalkyl groups may include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl. A C3-C8 cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. A cycloalkyl group may be fused (e.g., decalin) or bridged (e.g., norbornane).
[0038] The term "cycloalkenyl" may mean monocyclic, non-aromatic unsaturated carbon rings containing 4-18 carbon atoms. Examples of cycloalkenyl groups may include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl. A C4- C8 cycloalkenyl is a cycloalkenyl group containing between 4 and 8 carbon atoms.
[0039] In some embodiments, the terms "heterocyclyl" or "heterocycloalkyl" or
"heterocycle" may refer to monocyclic or polycyclic 3 to 24-membered rings containing carbon and heteroatoms selected from oxygen, phosphorus, nitrogen, and sulfur and wherein there are no delocalized π electrons (aromaticity) shared among the ring carbon or
heteroatoms. Heterocyclyl rings may include, but are not limited to, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl. A heteroycyclyl or heterocycloalkyl ring may also be fused or bridged, e.g., can be a bicyclic ring.
[0040] In some embodiments "heterocyclyl" or "heterocycloalkyl" or "heterocycle" may be a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-24 atoms of which at least one atom is chosen from nitrogen, sulfur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulfur atom may be optionally oxidised to form the S-oxides. "Heterocyclyl" may be a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulfur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulfur atom may be optionally oxidised to form S-oxide(s). Non-limiting examples and suitable values of the term "heterocyclyl" may include thiazolidinyl, pyrrolidinyl, pyrrolidin-2-one, pyrrolinyl, 2-pyrrolidonyl, 2,5- dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydro thienyl, 2,4-dioxoimidazolidinyl, 2-oxo-l,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydro uracilyl, 1,3-benzodioxolyl, 1,2,4- oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothienyl, tetrahydropyranyl, piperidyl, 1- oxo-l,3-dihydroisoindolyl, piperazinyl, thiomorpholino, 1,1-dioxothiomorpholino, tetrahydropyranyl, 1,3-dioxolanyl, homopiperazinyl, thienyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, pyranyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl and 1-isoquinolonyl.
[0041] As used herein, the term "halo" or "halogen" may mean a fluoro, chloro, bromo, or iodo group.
[0042] The term "carbonyl" may refer to a functional group comprising a carbon atom double-bonded to an oxygen atom. It can be abbreviated herein as "oxo," as C(O), or as C=0.
[0043] "Spirocycle" or "spirocyclic" may mean carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples may include, but are not limited to, spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another carbocyclic, heterocyclic, aromatic, or heteroaromatic ring. One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., O, N, S, or P). A C5-C12 spirocycle is a spirocycle containing between 5 and 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom. [0044] The term "spirocyclic heterocycle," "spiroheterocyclyl," or "spiroheterocycle" is understood to possibly mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl). A spirocyclic heterocycle can contain between 5 and 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
[0045] The disclosure also includes pharmaceutical compositions comprising an effective amount of one or more disclosed compounds and a pharmaceutically acceptable carrier. As used herein "pharmaceutically acceptable carrier, diluent or excipient" may include without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier that has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
[0046] The disclosure may include pharmaceutically acceptable salts of the compounds disclosed herein. Representative "pharmaceutically acceptable salts" may include, e.g., water- soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2- disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, sethionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2- naphthoate, oleate, oxalate, palmitate, pamoate, l,l-methene-bis-2-hydroxy-3-naphthoate, einbonate, pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p- toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.
[0047] "Pharmaceutically acceptable salt" also includes both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" may refer to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which may be formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-l,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5- disulfonic acid, naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
[0048] "Pharmaceutically acceptable base addition salt" may refer to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases may include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. For example, inorganic salts may include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases may include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine,
trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine,
tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
[0049] The term "tautomers" may refer to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another. A "tautomer" is a single member of this set of compounds. Typically a single tautomer is drawn but it may be understood that this single structure may represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it may be understood that both the enol and ketone forms are part of the disclosure.
[0050] For example, compounds of the Present disclosure can exist in tautomeric form. In some embodiments of Formula I, II, III, or IV, R2 can be -OH and tautomers of the compounds can exist in equilibrium:
Figure imgf000025_0001
[0051] The disclosure may include prodrugs of the compounds described herein. The term "prodrug," as used in this disclosure, may mean a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound. Furthermore, as used herein a prodrug may be a drug which is inactive in the body, but may be transformed in the body typically either during absorption or after absorption from the gastrointestinal tract into the active compound. The conversion of the prodrug into the active compound in the body may be done chemically or biologically (i.e., using an enzyme).
[0052] The disclosure may include solvates of the compounds described herein. The term "solvate" may refer to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents may include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates may include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
[0053] The disclosure may include isomers of the compounds described herein. The term "isomer" may refer to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of present disclosure may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. [0054] The disclosure may include stereoisomers of the compounds described herein. The term "stereoisomers" may refer to the set of compounds which have the same number and type of atoms and share the same bond connectivity between those atoms, but differ in three dimensional structure. The term "stereoisomer" may refer to any member of this set of compounds. For instance, a stereoisomer may be an enantiomer or a diastereomer.
[0055] In addition, the present disclosure may embrace all geometric and positional isomers. For example, if a compound of the present disclosure incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis or trans configuration.
[0056] The term "enantiomers" may refer to a pair of stereoisomers which are non- superimposable mirror images of one another. The term "enantiomer" may refer to a single member of this pair of stereoisomers. The term "racemic" may refer to a 1 : 1 mixture of a pair of enantiomers. The disclosure may include enantiomers of the compounds described herein. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. In some embodiments the compounds may be the (^-enantiomer. In other embodiments the compounds may be the (R)-enantiomer. In yet other embodiments, the compounds may be the (+) or (-) enantiomers.
[0057] In some embodiments, compounds and compositions of the disclosure may be enriched to provide predominantly one enantiomer of a compound described herein. An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.5 or even 100 mol percent. In some embodiments, the compound described herein enriched in one enantiomer may be substantially free of the other enantiomer, wherein substantially free may mean that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture. For example, if a composition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2 mol percent of the second enantiomer. [0058] The term "diastereomers" may refer to the set of stereoisomers which cannot be made superimposable by rotation around single bonds. For example, cis- and trans- double bonds, endo- and exo- substitution on bicyclic ring systems, and compounds containing multiple stereogenic centers with different relative configurations may be considered to be diastereomers. The term "diastereomer" may refer to any member of this set of compounds. In some examples presented, the synthetic route may produce a single diastereomer or a mixture of diastereomers. The disclosure may include diastereomers of the compounds described herein.
[0059] In some embodiments, the compounds and compositions of the disclosure may be enriched to provide predominantly one diastereomer of a compound disclosed herein. A diastereomerically enriched mixture may comprise, for example, at least 60 mol percent of one diastereomer, or more preferably at least 75, 99, 95, 96, 97, 98, 99, or even 100 mol percent.
[0060] The compounds described herein further include all pharmaceutically acceptable isotopically labeled compounds. An "isotopically" or "radio-labeled" compound may be a compound where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). For example, in some embodiments, in the compounds described herein hydrogen atoms are replaced or substituted by one or more deuterium or tritium. Certain isotopically labeled compounds of this disclosure, for example, those incorporating a radioactive isotope, may be useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e., 3H, and carbon 14, i.e., 14C, may be particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Suitable isotopes that may be incorporated in compounds described herein include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), UC, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36C1 , 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I, and 131I.
Substitution with positron emitting isotopes, such as UC, 18F, 150, and 13N, can be useful in Positron Emission Topography (PET) studies.
[0061] An "effective amount" when used in connection with a compound may be an amount effective for treating or preventing a disease in a subject as described herein. [0062] The term "carrier," as used in this disclosure, may encompass carriers, excipients, and diluents and may mean a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
[0063] The term "treating" with regard to a subject, may refer to improving at least one symptom of the subject's disorder. Treating may include curing, improving, or at least partially ameliorating the disorder.
[0064] The term "prevent" or "preventing" with regard to a subject may refer to keeping a disease or disorder from afflicting the subject. Preventing may include prophylactic treatment. For instance, preventing can include administering to the subject one or more compounds disclosed herein before a subject is afflicted with a disease and the administration will keep the subject from being afflicted with the disease.
[0065] The term "disorder" is used in this disclosure and may be used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
[0066] The term "administer," "administering," or "administration" as used in this disclosure refers to either directly administering one or more disclosed compounds or a pharmaceutically acceptable salt of the one or more disclosed compounds or a composition comprising one or more disclosed compounds to a subject, or administering a prodrug derivative or analog of the one or more disclosed compounds or pharmaceutically acceptable salts of the one or more disclosed compounds or compositions to the subject, which may form an equivalent amount of active compound within the subject's body.
[0067] A "patient" or "subject" may be a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
Compounds of the Disclosure
[0068] Compounds of the disclosure include compounds of Formula Γ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers of any of the foregoing.
[0069] In one or more embodiments of the compounds of Formula I, the compound is of the Formula I-A:
Figure imgf000029_0001
I-A and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
A is aryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -C3-C8cycloalkyl, -OH, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, -NR5S(0) R5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
R2 is -H, -ORb, -NR5R6, -CN, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -NH2, halogen, -C(0)ORb, -C3-C8cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom; Y2 _NRa_ _(CRa2)m_ _c(0)-, -C(Ra)2 H-, -(CRa 2)mO-, -C(0)N(Ra)-, -N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0- -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-,
-C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5,
- R5S(0)NR5R6, - R5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000030_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, - HRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -COORb, -CO HRb, -CO H(CH2)nCOORb,
- HCOORb, -CF3, -CHF2, or -CH2F;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. [0070] In one or more embodiments of the compounds of Formula I, the compound is of the Formula I-B:
Figure imgf000031_0001
I-B and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
A is heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -Cs-Cscycloalkyl, -OH, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0)NR5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
R2 is -H, -ORb, -NR5R6, -CN, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -NH2, halogen, -C(0)ORb, -C3-C8cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom;
Y2 is -NRa-, -(CR¾)m-, -C(O)-, -C(Ra)2 H-, -(CR¾)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-,
-C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or -Ci- C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5,
- R5S(0)NR5R6, - R5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000032_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, - HRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -COORb, -CO HRb, -CO H(CH2)nCOORb,
- HCOORb, -CF3, -CHF2, or -CH2F;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0071] In one or more embodiments of the compounds of Formula II, the compound is of the Formula II- A:
Figure imgf000033_0001
II-A and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0072] In one or more embodiments of the compounds of the Formula II- A, the compound is of the Formula II-A1 :
Figure imgf000033_0002
II- A 1 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12- membered spiroheterocycle along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, or - H2.
[0073] In one or more embodiments of the compounds of Formula II- A, the compound is of the Formula II- A2:
Figure imgf000034_0001
II-A2 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0074] In one or more embodiments of the compounds of Formula II- A, the compound is of the Formula II- A3 :
Figure imgf000034_0002
II-A3 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0075] In one or more embodiments of the compounds of Formula II, the compound is the Formula II-B:
Figure imgf000034_0003
II-B and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof. [0076] In one or more embodiments of the compounds of Formula II-B, the compound is of the Formula II-B 1 :
Figure imgf000035_0001
II-B 1 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12- membered spiroheterocycle along with the carbon atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH,
[0077] In one or more embodiments of the compounds of Formula II-B, the compound is of the Formula II-B2:
Figure imgf000035_0002
II-B2 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0078] In one or more embodiments of the compounds of Formula II-B, the compound is of the Formula II-B3 :
Figure imgf000036_0001
II-B3 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0079] In one or more embodiments of the compounds of Formula II-B, the compound is of the Formula II-B4:
Figure imgf000036_0002
II-B4 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0080] In one or more embodiments of the compounds of Formula II-B, the compound is of the Formula II-B 5:
Figure imgf000036_0003
II-B5 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof. [0081] In one or more embodiments of the compounds of Formula II-B, the compound is of the Formula II-B6:
Figure imgf000037_0001
Π-Β6 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0082] In one or more embodiments of the compounds of Formula II, the compound is the Formula II-C:
Figure imgf000037_0002
II-C and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, or - H2
[0083] In one or more embodiments of the compounds of Formula II-C, the compound is of the Formula II-C 1 :
Figure imgf000038_0001
II-C1 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0084] In one or more embodiments of the compounds of Formula II, the compound is the Formula II-D:
Figure imgf000038_0002
II-D and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, or - H2
[0085] In one or more embodiments of the compounds of Formula II-D, the compound is of the Formula II-D 1 :
Figure imgf000039_0001
II-D1 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0086] In one or more embodiments of the compounds of Formula II, the compound is the Formula II-E:
Figure imgf000039_0002
II-E and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0087] In one or more embodiments of the compounds of Formula II, the compound is the Formula II-F:
Figure imgf000039_0003
II-F and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0088] In one or more embodiments of the compounds of Formula II, the compound is the Formula II-G:
Figure imgf000040_0001
II-G and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein R2 is an aryl or heteroaryl.
[0089] In one or more embodiments of the compounds of Formula III, the compound is of the Formula III- A:
Figure imgf000040_0002
III-A and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0090] In one or more embodiments of the compounds of Formula III-A, the compound is of the Formula III-A 1 :
Figure imgf000041_0001
III-A1 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein
C forms a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12- membered spiroheterocycle along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH,
[0091] In one or more embodiments of the compounds of Formula III- A, the compound is of the Formula III- A2:
Figure imgf000041_0002
III-A2 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0092] In one or more embodiments of the compounds of Formula III- A, the compound is of the Formula III- A3 :
Figure imgf000042_0001
III-A3 and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[0093] In some embodiments, the compounds of the disclosure are compounds of Formula IV:
Figure imgf000042_0002
IV and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof wherein:
Figure imgf000042_0003
A is a 5- to 12-membered monocyclic or olycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
Figure imgf000042_0004
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl,
-C4-C8cycloalkenyl, -Ci-Cealkynyl, -Cs-Csc cloalkyl, -OH, -OR5, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, - H-, -S(0)2-, -S(0)2- H-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more -Ci- Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F;
R2 is -H, -OH, - R5R6, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl,
-C2-C6alkynyl, - H2, halogen, -C3-C8cycloalkyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m- -C(O)-, -C(Ra)2 H-, -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3, -CHF2, or -CH2F; R is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, - HRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, - H2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0094] In one or more embodiments of Formula IV, R4 is H.
[0095] In one or more embodiments of Formula IV, R4 is
Figure imgf000044_0001
. In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula IV, Y1 is -S-. In one or more embodiments of Formula IV, Y1 is a direct bond.
[0096] In one or more embodiments of the compounds of Formula IV, Y2 is -(CRa 2)m- In one or more embodiments of the compounds of Formula IV, Y2 is -NRa-
[0097] In one or more embodiments of Formula IV, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV, A is phenyl. In one or more embodiments of Formula IV, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV, A is pyridinyl. In one or more embodiments of Formula IV, A is indazolyl. In one or more embodiments of Formula IV, A is a 5- to 12-membered monocyclic or poly cyclic aryl or heteroaryl.
[0098] In one or more embodiments of Formula IV, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV, n is independently, at each occurrence, 1 or 2.
[0099] In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or -NFh. In one or more embodiments of Formula IV, R1 is independently, at each occurrence, -H, -CN or halogen.
[00100] In one or more embodiments of Formula IV, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00101] In one or more embodiments of Formula IV, R2 is -H. In one or more
embodiments of Formula IV, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In one or more embodiments of Formula IV, R2 is -OH. In one or more embodiments of Formula IV, R2 is -NR5R6. In one or more embodiments of Formula IV, R2
[00102] In one or more embodiments of Formula IV, Ra is -H.
[00103] In one or more embodiments of Formula IV, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV, R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
[00104] In one or more embodiments of Formula IV, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000046_0001
[00105] In one or more embodiments of Formula IV, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12- membered polycyclic heterocycle, which is optionally substituted with one or more
-Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000046_0002
[00106] In one or more embodiments of Formula IV, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV, R and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00107] In one or more embodiments of Formula IV, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00108] In one or more embodiments of Formula IV, X1 is N and X2 is N. In one or more embodiments of Formula IV, X1 is C and X2 is CH. In one or more embodiments of Formula IV, X1 is C and X2 is N. In one or more embodiments of Formula IV, X1 is N and X2 is CH.
[00109] In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heterocycle. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00110] In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV, the heterocyclyl ring is bridged.
[00111] In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl. [00112] In one or more embodiments of Formula IV, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00113] In one or more embodiments of Formula IV, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV, B is substituted with one or more -Ci-Cealkyl, -OH, - Fh, oxo, -(CH2)n H2,
-(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV, B is substituted with one or more oxo. In one or more embodiments of Formula IV, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV, B is substituted with one or more -OH. In one or more embodiments of Formula IV, B is substituted with one or more - H2. In one or more embodiments of Formula IV, B is substituted with one or more -CF3. In one or more embodiments of Formula IV, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00114] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00115] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00116] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00117] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00118] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00119] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00120] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00121] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00122] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00123] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00124] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00125] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00126] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00127] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00128] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00129] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is H; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00130] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
, A is a monocyclic or polycyclic aryl or pyridinyl,
Figure imgf000056_0001
b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00131] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000057_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00132] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000057_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra-, wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00133] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
, A is a monocyclic or polycyclic aryl or pyridinyl,
Figure imgf000058_0001
b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00134] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000058_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00135] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
, A is a monocyclic or polycyclic aryl or pyridinyl,
Figure imgf000059_0001
b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00136] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is
Figure imgf000060_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra-, wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00137] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000060_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00138] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000061_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00139] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000061_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00140] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000062_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00141] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000062_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra-, wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00142] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
, A is a monocyclic or polycyclic aryl or pyridinyl,
Figure imgf000063_0001
b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00143] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000063_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00144] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
, A is a monocyclic or polycyclic aryl or pyridinyl,
Figure imgf000064_0001
b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00145] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is
Figure imgf000065_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is -S-; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra-, wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00146] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000065_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00147] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000066_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00148] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000066_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00149] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000067_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00150] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000067_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra-, wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00151] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000068_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00152] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000068_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00153] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R is
Figure imgf000069_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00154] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features: a) R4 is
Figure imgf000070_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00155] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000070_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. [00156] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000071_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00157] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000071_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00158] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000072_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00159] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000072_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra-, wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00160] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000073_0001
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is C and X2 is N; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00161] In some embodiments, the compounds of the disclosure compounds of Formula IV, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, have one, two, or three or more of the following features:
a) R4 is
Figure imgf000073_0002
, A is a monocyclic or polycyclic aryl or pyridinyl, and Y1 is a direct bond; b) X1 is N and X2 is CH; c) B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein the heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; d) R2 is -H, -Ci-Cealkyl, or - H2; e) Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3; f) R3 is combined with Ra to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00162] In certain embodiments of Formula IV, the compound is of Formula IV-A:
Figure imgf000074_0001
IV-A and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB1 is N, R9, CR9, S, or O; XB2 is N, R9, CR9, S, or O; and XB3 is N, NR9, CR9, S, or O, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB1, XB2, and XB3 is not CR9, or provided that if each of XB1, XB2, and XB3 are CR9, X1 must be N.
[00163] In certain embodiments of Formula IV-A, XB1 is N or NR9. In certain
embodiments of Formula IV-A, XB1 is CR9. In certain embodiments of Formula IV-A, XB1 is S. In certain embodiments of Formula IV-A, XB1 is O. In certain embodiments of Formula IV-A, XB2 is N or NR9. In certain embodiments of Formula IV-A, XB2 is CR9. In certain embodiments of Formula IV-A, XB2 is S. In certain embodiments of Formula IV-A, XB2 is O. In certain embodiments of Formula IV-A, XB3 is N or NR9. In certain embodiments of Formula IV-A, XB3 is CR9. In certain embodiments of Formula IV-A, XB3 is S. In certain embodiments of Formula IV-A, XB3 is O. [00164] In certain embodiments of Formula IV- A, XB1 is N, NR9, or CR9; XB2 is N, R9, or CR9; and XB3 is N, NR9, or CR9. In certain embodiments of Formula IV- A, XB1 is N or NR9. In certain embodiments of Formula IV- A, XB1 is CR9. In certain embodiments of Formula IV- A, XB2 is N or NR9. In certain embodiments of Formula IV- A, XB2 is CR9. In certain embodiments of Formula IV- A, XB3 is N or NR9. In certain embodiments of Formula IV-A, XB3 is CR9.
[00165] In some embodiments of Formula IV-A, R9 is -(Ο¾)η0Η and n is 1. In some embodiments of Formula IV-A, R9 is H.
[00167] In one or more embodiments of Formula IV-A, R4 is H.
[00168] In one or more embodiments of Formula IV-A, R4 is
Figure imgf000075_0002
In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula IV-A, Y1 is -S-. In one or more embodiments of Formula IV-A, Y1 is a direct bond.
[00169] In one or more embodiments of the compounds of Formula IV-A, Y2 is
-(CR¾)m-. In one or more embodiments of the compounds of Formula IV-A, Y2 is -NRa- [00170] In one or more embodiments of Formula IV-A, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-A, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-A, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-A, A is phenyl. In one or more embodiments of Formula IV-A, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-A, A is pyridinyl. In one or more embodiments of Formula IV- A, A is indazolyl. In one or more embodiments of Formula IV-A, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00171] In one or more embodiments of Formula IV-A, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-A, n is independently, at each occurrence, 1 or 2.
[00172] In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-A, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-A, R1 is independently, at each occurrence, -H, -CN or halogen.
[00173] In one or more embodiments of Formula IV-A, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-A, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- A, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00174] In one or more embodiments of Formula IV-A, R2 is -H. In one or more embodiments of Formula IV-A, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-A, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV- A, R2 is -OH. In one or more embodiments of Formula IV- A, R2 is - R5R6. In one or more embodiments of Formula IV-A, R2 is - H2.
[00175] In one or more embodiments of Formula IV-A, Ra is -H.
[00176] In one or more embodiments of Formula IV-A, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-A, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-A, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-A, R3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00177] In one or more embodiments of Formula IV-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000077_0001
[00178] In one or more embodiments of Formula IV-A, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000077_0002
[00179] In one or more embodiments of Formula IV- A, R and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NFh, -OH, -(CFh^ Fh, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV- A, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NFh. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- A, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00180] In one or more embodiments of Formula IV- A, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV- A, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- A, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00181] In one or more embodiments of Formula IV- A, X1 is N and X2 is N. In one or more embodiments of Formula IV- A, X1 is C and X2 is CH. In one or more embodiments of Formula IV- A, X1 is C and X2 is N. In one or more embodiments of Formula IV- A, X1 is N and X2 is CH.
[00182] In certain embodiments of Formula IV, the compound is of Formula IV-B:
Figure imgf000078_0001
IV-B and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB4 is N or CR9; XB5 is N or CR9; XB6 is N or CR9; and XB7 is N or CR9, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB4, XB5, XB6, and XB7 is not CR9, or provided that if each of XB4, XB5, XB6, and XB7 are CR9, X1 must be N.
[00183] In certain embodiments of Formula IV-B, XB4 is N. In certain embodiments of Formula IV-B, XB4 is CR9. In certain embodiments of Formula IV-B, XB5 is N. In certain embodiments of Formula IV-B, XB5 is CR9. In certain embodiments of Formula IV-B, XB6 is N. In certain embodiments of Formula IV-B, XB6 is CR9. In certain embodiments of
Formula IV-B, XB7 is N. In certain embodiments of Formula IV-B, XB7 is CR9. In certain embodiments of Formula IV-B, XB4 is N, XB5 is CR9, XB6 is N, and XB7 is CR9. In certain such embodiments, R9 is independently, at each occurrence, -H.
[00184] In some embodiments of Formula IV-B, R9 is -(CH2)nOH and n is 1. In some embodiments of Formula IV-B, R9 is H.
[00185] In one or more embodiments of Formula IV-B, R4 is H.
[00186] In one or more embodiments of Formula IV-B, R4 is
Figure imgf000079_0001
In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula IV-B, Y1 is -S-. In one or more embodiments of Formula IV-B, Y1 is a direct bond.
[00187] In one or more embodiments of the compounds of Formula IV-B, Y2 is -(CR¾)m-. In one or more embodiments of the compounds of Formula IV-B, Y2 is - Ra-
[00188] In one or more embodiments of Formula IV-B, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-B, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-B, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-B, A is phenyl. In one or more embodiments of Formula IV-B, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-B, A is pyridinyl. In one or more embodiments of Formula IV- B, A is indazolyl. In one or more embodiments of Formula IV-B, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl. [00189] In one or more embodiments of Formula IV-B, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-B, n is independently, at each occurrence, 1 or 2.
[00190] In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-B, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-B, R1 is independently, at each occurrence, -H, -CN or halogen.
[00191] In one or more embodiments of Formula IV-B, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-B, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- B, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00192] In one or more embodiments of Formula IV-B, R2 is -H. In one or more embodiments of Formula IV-B, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-B, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In one or more embodiments of Formula IV-B, R2 is -OH. In one or more embodiments of Formula IV-B, R2 is -NR5R6. In one or more embodiments of Formula IV-B, R2 is -NH2.
[00193] In one or more embodiments of Formula IV-B, Ra is -H.
[00194] In one or more embodiments of Formula IV-B, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-B, R3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle. In one or more embodiments of Formula IV-B, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-B, R is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00195] In one or more embodiments of Formula IV-B, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-B, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-B, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000081_0001
[00196] In one or more embodiments of Formula IV-B, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-B, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-B, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000081_0002
[00197] In one or more embodiments of Formula IV-B, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-B, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- B, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00198] In one or more embodiments of Formula IV-B, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-B, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- B, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00199] In one or more embodiments of Formula IV-B, X1 is N and X2 is N. In one or more embodiments of Formula IV-B, X1 is C and X2 is CH. In one or more embodiments of Formula IV-B, X1 is C and X2 is N. In one or more embodiments of Formula IV-B, X1 is N and X2 is CH.
[00200] In certain embodiments of Formula IV, the compound is of Formula IV-C:
Figure imgf000082_0001
IV-C and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
[00201] In one or more embodiments of Formula IV-C, R4 is H.
[00202] In one or more embodiments of Formula IV-C, R4 is
Figure imgf000082_0002
. In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula IV-C, Y1 is -S-. In one or more embodiments of Formula IV-C, Y1 is a direct bond. [00203] In one or more embodiments of Formula IV-C, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-C, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-C, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-C, A is phenyl. In one or more embodiments of Formula IV-C, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-C, A is pyridinyl. In one or more embodiments of Formula IV- C, A is indazolyl. In one or more embodiments of Formula IV-C, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00204] In one or more embodiments of Formula IV-C, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-C, n is independently, at each occurrence, 1 or 2.
[00205] In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-C, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-C, R1 is independently, at each occurrence, -H, -CN or halogen.
[00206] In one or more embodiments of Formula IV-C, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-C, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- C, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00207] In one or more embodiments of Formula IV-C, R2 is -H. In one or more embodiments of Formula IV-C, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-C, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-C, R2 is -OH. In one or more embodiments of Formula IV-C, R2 is - R5R6. In one or more embodiments of Formula IV-C, R2 is -NHz.
[00208] In one or more embodiments of Formula IV-C, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-C, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-C, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NHz, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3,
Figure imgf000084_0001
[00209] In one or more embodiments of Formula IV-C, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-C, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NH2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-C, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3,
Figure imgf000084_0002
[00210] In one or more embodiments of Formula IV-C, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-C, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NH2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- C, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00211] In one or more embodiments of Formula IV-C, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-C, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- C, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00212] In one or more embodiments of Formula IV-C, X1 is N and X2 is N. In one or more embodiments of Formula IV-C, X1 is C and X2 is CH. In one or more embodiments of Formula IV-C, X1 is C and X2 is N. In one or more embodiments of Formula IV-C, X1 is N and X2 is CH.
[00213] In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00214] In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-C, the heterocyclyl ring is bridged.
[00215] In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl. [00216] In one or more embodiments of Formula IV-C, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-C, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00217] In one or more embodiments of Formula IV-C, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-C, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-C, B is substituted with one or more oxo. In one or more embodiments of Formula IV-C, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-C, B is substituted with one or more -OH. In one or more embodiments of Formula IV-C, B is substituted with one or more - H2. In one or more embodiments of Formula IV-C, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-C, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-C, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-C, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00218] In certain embodiments of Formula IV, the compound is of Formula IV-D:
Figure imgf000086_0001
IV-D and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CFIF2, or -CH2F. In some embodiments of Formula IV-D, the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In certain such embodiments, n is 1. In some embodiments of Formula IV-D, the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1.
[00219] In certain embodiments of Formula IV-D, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3- to 12-membered monocyclic
heterocycle. In certain embodiments of Formula IV-D, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3-to 12-membered polycyclic heterocycle. In certain embodiments of Formula IV-D, along with the nitrogen atom to which it is attached, is an optionally substituted 5- to 12-membered spiroheterocycle.
[00220] In certain embodiments of Formula IV-D, C ring, along with the nitrogen atom to
which it is attached, is an optionally substituted O . In certain embodiments of
Formula IV-D, C ring, along with the nitrogen atom to which it is attached, is an optionally substituted — . In certain embodiments of Formula th the
Figure imgf000087_0001
nitrogen atom to which it is attached, is an optionally substituted [00221] In one or more embodiments of Formula IV-D, R4 is H.
[00222] In one or more embodiments of Formula IV-D, R4 is
Figure imgf000087_0002
. In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula IV-D, Y1 is -S-. In one or more embodiments of Formula IV-D, Y1 is a direct bond.
[00223] In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic cycloalkyl. In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic heterocycloalkyl. In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-D, A is phenyl. In one or more embodiments of Formula IV-D, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-D, A is pyridinyl. In one or more embodiments of Formula IV- D, A is indazolyl. In one or more embodiments of Formula IV-D, A is a 5- to 12-membered monocyclic or poly cyclic aryl or heteroaryl.
[00224] In one or more embodiments of Formula IV-D, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-D, n is independently, at each occurrence, 1 or 2.
[00225] In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-D, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-D, R1 is independently, at each occurrence, -H, -CN or halogen.
[00226] In one or more embodiments of Formula IV-D, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-D, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- D, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00227] In one or more embodiments of Formula IV-D, R2 is -H. In one or more embodiments of Formula IV-D, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-D, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In one or more embodiments of Formula IV-D, R2 is -OH. In one or more embodiments of Formula IV-D, R2 is -NR5R6. In one or more embodiments of Formula IV-D, R2 is -NH2.
[00228] In one or more embodiments of Formula IV-D, X1 is N and X2 is N. In one or more embodiments of Formula IV-D, X1 is C and X2 is CH. In one or more embodiments of Formula IV-D, X1 is C and X2 is N. In one or more embodiments of Formula IV-D, X1 is N and X2 is CH.
[00229] In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00230] In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-D, the heterocyclyl ring is bridged.
[00231] In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00232] In one or more embodiments of Formula IV-D, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-D, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00233] In one or more embodiments of Formula IV-D, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-D, B is substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo,
Figure imgf000089_0001
-(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-D, B is substituted with one or more oxo. In one or more embodiments of Formula IV-D, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-D, B is substituted with one or more -OH. In one or more embodiments of Formula IV-D, B is substituted with one or more - H2. In one or more embodiments of Formula IV-D, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-D, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-D, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-D, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00234] In certain embodiments of Formula IV, the compound is of Formula IV-E:
Figure imgf000090_0001
IV-E and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB1 is N, NR9, CR9, S, or O; XB2 is N, R9, CR9, S, or O; and XB3 is N, NR9, CR9, S, or O, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB1, XB2, and XB3 is not CR9, or provided that if each of XB1, XB2, and XB3 are CR9, X1 must be N.
[00235] In certain embodiments of Formula IV-E, XB1 is N or NR9. In certain
embodiments of Formula IV-E, XB1 is CR9. In certain embodiments of Formula IV-E, XB1 is S. In certain embodiments of Formula IV-E, XB1 is O. In certain embodiments of Formula IV-E, XB2 is N or NR9. In certain embodiments of Formula IV-E, XB2 is CR9. In certain embodiments of Formula IV-E, XB2 is S. In certain embodiments of Formula IV-E, XB2 is O. In certain embodiments of Formula IV-E, XB3 is N or NR9. In certain embodiments of Formula IV-E, XB3 is CR9. In certain embodiments of Formula IV-E, XB3 is S. In certain embodiments of Formula IV-E, XB3 is O.
[00236] In certain embodiments of Formula IV-E, XB1 is N, NR9, or CR9; XB2 is N, NR9, or CR9; and XB3 is N, NR9, or CR9. In certain embodiments of Formula IV-E, XB1 is N or NR9. In certain embodiments of Formula IV-E, XB1 is CR9. In certain embodiments of Formula IV-E, XB2 is N or NR9. In certain embodiments of Formula IV-E, XB2 is CR9. In certain embodiments of Formula IV-E, XB3 is N or NR9. In certain embodiments of Formula
IV-E, XB3 is CR9. [00237] In some embodiments of Formula IV-E, R9 is -(Ο¾)η0Η and n is 1. In some embodiments of Formula IV-E, R9 is H.
Figure imgf000091_0001
[00239] In one or more embodiments of the compounds of Formula IV-E, Y2 is -(CR¾)m-. In one or more embodiments of the compounds of Formula IV-E, Y2 is - Ra-
[00240] In one or more embodiments of Formula IV-E, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-E, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-E, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-E, A is phenyl. In one or more embodiments of Formula IV-E, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-E, A is pyridinyl. In one or more embodiments of Formula IV- E, A is indazolyl. In one or more embodiments of Formula IV-E, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00241] In one or more embodiments of Formula IV-E, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-E, n is independently, at each occurrence, 1 or 2.
[00242] In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-E, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-E, R1 is independently, at each occurrence, -H, -CN or halogen.
[00243] In one or more embodiments of Formula IV-E, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-E, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-E, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00244] In one or more embodiments of Formula IV-E, R2 is -H. In one or more embodiments of Formula IV-E, R2 is -Ci-C6alkyl, wherein each alkyl is optionally
substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-E, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-E, R2 is -OH. In one or more embodiments of Formula IV-E, R2 is - R5R6. In one or more embodiments of Formula IV-E, R2 is - H2.
[00245] In one or more embodiments of Formula IV-E, Ra is -H.
[00246] In one or more embodiments of Formula IV-E, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-E, R3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle. In one or more embodiments of Formula IV-E, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-E, R3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00247] In one or more embodiments of Formula IV-E, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-E, R and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-E, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000093_0001
[00248] In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-E, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-E, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000093_0002
[00249] In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00250] In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-E, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00251] In one or more embodiments of Formula IV-E, X1 is N and X2 is N. In one or more embodiments of Formula IV-E, X1 is C and X2 is CH. In one or more embodiments of Formula IV-E, X1 is C and X2 is N. In one or more embodiments of Formula IV-E, X1 is N and X2 is CH.
[00252] In certain embodiments of Formula IV, the compound is of Formula IV-F:
Figure imgf000094_0001
IV-F and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB4 is N or CR9; XB5 is N or CR9; XB6 is N or CR9; and XB7 is N or CR9, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB4, XB5, XB6, and XB7 is not CR9, or provided that if each of XB4, XB5, XB6, and XB7 are CR9, X1 must be N.
[00253] In certain embodiments of Formula IV-F, XB4 is N. In certain embodiments of Formula IV-F, XB4 is CR9. In certain embodiments of Formula IV-F, XB5 is N. In certain embodiments of Formula IV-F, XB5 is CR9. In certain embodiments of Formula IV-F, XB6 is N. In certain embodiments of Formula IV-F, XB6 is CR9. In certain embodiments of Formula IV-F, XB7 is N. In certain embodiments of Formula IV-F, XB7 is CR9. In certain
embodiments of Formula IV-F, XB4 is N, XB5 is CR9, XB6 is N, and XB7 is CR9. In certain such embodiments, R9 is independently, at each occurrence, -H. [00254] In some embodiments of Formula IV-F, R9 is -(Ο¾)η0Η and n is 1. In some embodiments of Formula IV-F, R9 is H.
[00255] In one or more embodiments of the compounds of Formula IV-F, Y2 is -(CR¾)m-. In one or more embodiments of the compounds of Formula IV-F, Y2 is -NRa-
[00256] In one or more embodiments of Formula IV-F, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-F, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-F, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-F, A is phenyl. In one or more embodiments of Formula IV-F, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-F, A is pyridinyl. In one or more embodiments of Formula IV- F, A is indazolyl. In one or more embodiments of Formula IV-F, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00257] In one or more embodiments of Formula IV-F, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-F, n is independently, at each occurrence, 1 or 2.
[00258] In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-F, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H, halogen or -NR5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-F, R1 is independently, at each occurrence, -H, -CN or halogen.
[00259] In one or more embodiments of Formula IV-F, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-F, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-F, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl. [00260] In one or more embodiments of Formula IV-F, R2 is -H. In one or more embodiments of Formula IV-F, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-F, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-F, R2 is -OH. In one or more embodiments of Formula IV-F, R2 is -NR5R6. In one or more embodiments of Formula IV-
Figure imgf000096_0001
[00261] In one or more embodiments of Formula IV-F, Ra is -H.
[00262] In one or more embodiments of Formula IV-F, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-F, R3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle. In one or more embodiments of Formula IV-F, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-F, R3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00263] In one or more embodiments of Formula IV-F, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-F, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-F, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000096_0002
[00264] In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-F, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-F, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000097_0001
[00265] In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00266] In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-F, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00267] In one or more embodiments of Formula IV-F, X1 is N and X2 is N. In one or more embodiments of Formula IV-F, X1 is C and X2 is CH. In one or more embodiments of Formula IV-F, X1 is C and X2 is N. In one or more embodiments of Formula IV-F, X1 is N and X2 is CH.
[00268] In certain embodiments of Formula IV, the compound is of Formula IV-G:
Figure imgf000098_0001
IV-G and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
[00269] In one or more embodiments of Formula IV-G, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-G, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-G, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-G, A is phenyl. In one or more embodiments of Formula IV-G, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-G, A is pyridinyl. In one or more embodiments of Formula IV- G, A is indazolyl. In one or more embodiments of Formula IV-G, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00270] In one or more embodiments of Formula IV-G, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-G, n is independently, at each occurrence, 1 or 2.
[00271] In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-G, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-G, R1 is independently, at each occurrence, -H, -CN or halogen. [00272] In one or more embodiments of Formula IV-G, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-G, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- G, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00273] In one or more embodiments of Formula IV-G, R2 is -H. In one or more embodiments of Formula IV-G, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-G, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-G, R2 is -OH. In one or more embodiments of Formula IV-G, R2 is - R5R6. In one or more embodiments of Formula IV-G, R2 is - H2.
[00274] In one or more embodiments of Formula IV-G, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-G, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-G, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000099_0001
[00275] In one or more embodiments of Formula IV-G, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-G, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-G, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00276] In one or more embodiments of Formula IV-G, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-G, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- G, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00277] In one or more embodiments of Formula IV-G, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-G, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- G, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00278] In one or more embodiments of Formula IV-G, X1 is N and X2 is N. In one or more embodiments of Formula IV-G, X1 is C and X2 is CH. In one or more embodiments of Formula IV-G, X1 is C and X2 is N. In one or more embodiments of Formula IV-G, X1 is N and X2 is CH.
[00279] In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle. [00280] In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-G, the heterocyclyl ring is bridged.
[00281] In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00282] In one or more embodiments of Formula IV-G, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-G, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00283] In one or more embodiments of Formula IV-G, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-G, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-G, B is substituted with one or more oxo. In one or more embodiments of Formula IV-G, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-G, B is substituted with one or more -OH. In one or more embodiments of Formula IV-G, B is substituted with one or more - H2. In one or more embodiments of Formula IV-G, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-G, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-G, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-G, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00284] In certain embodiments of Formula IV, the compound is of Formula IV-H:
Figure imgf000102_0001
IV-H and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In some embodiments of Formula IV-H, the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In certain such embodiments, n is 1. In some embodiments of Formula IV-H, the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1.
[00285] In certain embodiments of Formula IV-H, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3- to 12-membered monocyclic heterocycle. In certain embodiments of Formula IV-H, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3-to 12-membered polycyclic heterocycle. In certain embodiments of Formula IV-H, along with the nitrogen atom to which it is attached, is an optionally substituted 5- to 12-membered spiroheterocycle.
[00286] In certain embodiments of Formula IV-H, C ring, along with the nitrogen atom to
which it is attached
Figure imgf000102_0002
In certain embodiments of
Formula IV-H, C ring, along with the nitrogen atom to which it is attached, is an optionally
Figure imgf000103_0001
substituted ^— . In certain embodiments of Formula th the
nitrogen atom to which it is attached, is an optionally sub
Figure imgf000103_0002
[00287] In one or more embodiments of Formula IV-H, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-H, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-H, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-H, A is phenyl. In one or more embodiments of Formula IV-H, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-H, A is pyridinyl. In one or more embodiments of Formula IV- H, A is indazolyl. In one or more embodiments of Formula IV-H, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00288] In one or more embodiments of Formula IV-H, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-H, n is independently, at each occurrence, 1 or 2.
[00289] In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-H, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-H, R1 is independently, at each occurrence, -H, -CN or halogen.
[00290] In one or more embodiments of Formula IV-H, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-H, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- H, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl. [00291] In one or more embodiments of Formula IV-H, R2 is -H. In one or more embodiments of Formula IV-H, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-H, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-H, R2 is -OH. In one or more embodiments of Formula IV-H, R2 is - R5R6. In one or more embodiments of Formula IV-H, R2 is - H2.
[00292] In one or more embodiments of Formula IV-H, X1 is N and X2 is N. In one or more embodiments of Formula IV-H, X1 is C and X2 is CH. In one or more embodiments of Formula IV-H, X1 is C and X2 is N. In one or more embodiments of Formula IV-H, X1 is N and X2 is CH.
[00293] In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00294] In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-H, the heterocyclyl ring is bridged.
[00295] In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00296] In one or more embodiments of Formula IV-H, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-H, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00297] In one or more embodiments of Formula IV-H, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-H, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2,
-(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-H, B is substituted with one or more oxo. In one or more embodiments of Formula IV-H, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-H, B is substituted with one or more -OH. In one or more embodiments of Formula IV-H, B is substituted with one or more - H2. In one or more embodiments of Formula IV-H, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-H, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-H, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-H, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00298] In certain embodiments of Formula IV, the compound is of Formula IV-I:
Figure imgf000105_0001
IV-I and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB1 is N, NR9, CR9, S, or O; XB2 is N, R9, CR9, S, or O; and XB3 is N, NR9, CR9, S, or O, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB1, XB2, and XB3 is not CR9, or provided that if each of XB1, XB2, and XB3 are CR9, X1 must be N.
[00299] In certain embodiments of Formula IV-I, XB1 is N or NR9. In certain embodiments of Formula IV-I, XB1 is CR9. In certain embodiments of Formula IV-I, XB1 is S. In certain embodiments of Formula IV-I, XB1 is O. In certain embodiments of Formula IV-I, XB2 is N or NR9. In certain embodiments of Formula IV-I, XB2 is CR9. In certain embodiments of Formula IV-I, X is S. In certain embodiments of Formula IV-I, X is O. In certain embodiments of Formula IV-I, XB3 is N or R9. In certain embodiments of Formula IV-I, XB3 is CR9. In certain embodiments of Formula IV-I, XB3 is S. In certain embodiments of Formula IV-I, XB3 is O.
[00300] In certain embodiments of Formula IV-I, XB1 is N, NR9, or CR9; XB2 is N, NR9, or CR9; and XB3 is N, NR9, or CR9. In certain embodiments of Formula IV-I, XB1 is N or NR9. In certain embodiments of Formula IV-I, XB1 is CR9. In certain embodiments of Formula IV- I, XB2 is N or NR9. In certain embodiments of Formula IV-I, XB2 is CR9. In certain embodiments of Formula IV-I, XB3 is N or NR9. In certain embodiments of Formula IV-I, XB3 is CR9.
[00301] In some embodiments of Formula IV-I, R9 is -(Ο¾)η0Η and n is 1. In some embodiments of Formula IV-I, R9 is H.
[00302] In certain embodiments of Formula IV-I,
Figure imgf000106_0001
wherein is
Figure imgf000106_0002
[00303] In one or more embodiments of the compounds of Formula IV-I, Y2 is -(CR¾)m In one or more embodiments of the compounds of Formula IV-I, Y2 is -NRa-
[00304] In one or more embodiments of Formula IV-I, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-I, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-I, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-I, A is phenyl. In one or more embodiments of Formula IV-I, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-I, A is pyridinyl. In one or more embodiments of Formula IV-I, A is indazolyl. In one or more embodiments of Formula IV-I, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00305] In one or more embodiments of Formula IV-I, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-I, n is independently, at each occurrence, 1 or 2.
[00306] In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-I, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-I, R1 is independently, at each occurrence, -H, -CN or halogen.
[00307] In one or more embodiments of Formula IV-I, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-I, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-I, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00308] In one or more embodiments of Formula IV-I, R2 is -H. In one or more embodiments of Formula IV-I, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-I, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In one or more embodiments of Formula IV-I, R2 is -OH. In one or more embodiments of Formula IV-I, R2 is -NR5R6. In one or more embodiments of Formula IV-I, [00309] In one or more embodiments of Formula IV-I, Ra is -H.
[00310] In one or more embodiments of Formula IV-I, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-I, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-I, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-I, R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
[00311] In one or more embodiments of Formula IV-I, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-I, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-I, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000108_0001
[00312] In one or more embodiments of Formula IV-I, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-I, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-I, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000108_0002
[00313] In one or more embodiments of Formula IV-I, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-I, R and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-I, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CFI2F.
[00314] In one or more embodiments of Formula IV-I, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-I, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-I, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00315] In one or more embodiments of Formula IV-I, X1 is N and X2 is N. In one or more embodiments of Formula IV-I, X1 is C and X2 is CH. In one or more embodiments of Formula IV-I, X1 is C and X2 is N. In one or more embodiments of Formula IV-I, X1 is N and X2 is CH.
[00316] In certain embodiments of Formula IV, the compound is of Formula IV-J:
Figure imgf000109_0001
IV-J and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB4 is N or CR9; XB5 is N or CR9; XB6 is N or CR9; and XB7 is N or CR9, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB4, XB5, XB6, and XB7 is not CR9, or provided that if each of XB4, XB5, XB6, and XB7 are CR9, X1 must be N.
[00317] In certain embodiments of Formula IV-J, XB4 is N. In certain embodiments of Formula IV-J, XB4 is CR9. In certain embodiments of Formula IV-J, XB5 is N. In certain embodiments of Formula IV-J, XB5 is CR9. In certain embodiments of Formula IV-J, XB6 is N. In certain embodiments of Formula IV-J, XB6 is CR9. In certain embodiments of Formula IV-J, XB7 is N. In certain embodiments of Formula IV-J, XB7 is CR9. In certain
embodiments of Formula IV-J, XB4 is N, XB5 is CR9, XB6 is N, and XB7 is CR9. In certain such embodiments, R9 is independently, at each occurrence, -H.
[00318] In some embodiments of Formula IV-J, R9 is -(CH2)nOH and n is 1. In some embodiments of Formula IV-J, R9 is H.
[00319] In one or more embodiments of the compounds of Formula IV-J, Y2 is -(CR¾)m-. In one or more embodiments of the compounds of Formula IV-J, Y2 is - Ra-
[00320] In one or more embodiments of Formula IV-J, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-J, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-J, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-J, A is phenyl. In one or more embodiments of Formula IV-J, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-J, A is pyridinyl. In one or more embodiments of Formula IV-J, A is indazolyl. In one or more embodiments of Formula IV-J, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00321] In one or more embodiments of Formula IV-J, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-J, n is independently, at each occurrence, 1 or 2.
[00322] In one or more embodiments of Formula IV-J, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-J, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-J, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-J, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-J, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-J, R1 is independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV- J, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV- J, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV- J, R1 is independently, at each occurrence, -H, -CN or halogen.
[00323] In one or more embodiments of Formula IV- J, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV- J, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- J, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00324] In one or more embodiments of Formula IV- J, R2 is -H. In one or more embodiments of Formula IV- J, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV- J, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV- J, R2 is -OH. In one or more embodiments of Formula IV- J, R2 is - R5R6. In one or more embodiments of Formula IV- J,
Figure imgf000111_0001
[00325] In one or more embodiments of Formula IV- J, Ra is -H.
[00326] In one or more embodiments of Formula IV- J, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV- J, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-J, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-J, R3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00327] In one or more embodiments of Formula IV-J, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-J, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-J, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00328] In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV- J, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- J, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00329] In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00330] In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- J, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00331] In one or more embodiments of Formula IV- J, X1 is N and X2 is N. In one or more embodiments of Formula IV- J, X1 is C and X2 is CH. In one or more embodiments of Formula IV- J, X1 is C and X2 is N. In one or more embodiments of Formula IV- J, X1 is N and X2 is CH.
[00332] In certain embodiments of Formula IV, the compound is of Formula IV-K:
Figure imgf000113_0001
IV-K and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
[00333] In one or more embodiments of Formula IV-K, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-K, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-K, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-K, A is phenyl. In one or more embodiments of Formula IV-K, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-K, A is pyridinyl. In one or more embodiments of Formula IV- K, A is indazolyl. In one or more embodiments of Formula IV-K, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00334] In one or more embodiments of Formula IV-K, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-K, n is independently, at each occurrence, 1 or 2.
[00335] In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-K, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-K, R1 is independently, at each occurrence, -H, -CN or halogen.
[00336] In one or more embodiments of Formula IV-K, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-K, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV- K, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00337] In one or more embodiments of Formula IV-K, R2 is -H. In one or more embodiments of Formula IV-K, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-K, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-K, R2 is -OH. In one or more embodiments of Formula IV-K, R2 is - R5R6. In one or more embodiments of Formula IV-K, R2 is - H2.
[00338] In one or more embodiments of Formula IV-K, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-K, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-K, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000114_0001
[00339] In one or more embodiments of Formula IV-K, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CFIF2, or -CH2F. In one or more embodiments of Formula IV-K, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-K, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000115_0001
[00340] In one or more embodiments of Formula IV-K, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-K, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- K, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00341] In one or more embodiments of Formula IV-K, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-K, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- K, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00342] In one or more embodiments of Formula IV-K, X1 is N and X2 is N. In one or more embodiments of Formula IV-K, X1 is C and X2 is CH. In one or more embodiments of Formula IV-K, X1 is C and X2 is N. In one or more embodiments of Formula IV-K, X1 is N and X2 is CH. [00343] In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00344] In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-K, the heterocyclyl ring is bridged.
[00345] In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00346] In one or more embodiments of Formula IV-K, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-K, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00347] In one or more embodiments of Formula IV-K, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-K, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2,
-(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-K, B is substituted with one or more oxo. In one or more embodiments of Formula IV-K, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-K, B is substituted with one or more -OH. In one or more embodiments of Formula IV-K, B is substituted with one or more - H2. In one or more embodiments of Formula IV-K, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-K, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-K, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-K, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00348] In certain embodiments of Formula IV, the compound is of Formula IV-L:
Figure imgf000117_0001
IV-L and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered poly cyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(C h Fh, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In some embodiments of Formula IV-L, the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In certain such embodiments, n is 1. In some embodiments of Formula IV-L, the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1.
[00349] In certain embodiments of Formula IV-L, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3- to 12-membered monocyclic heterocycle. In certain embodiments of Formula IV-L, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3-to 12-membered polycyclic heterocycle. In certain embodiments of Formula IV-L, along with the nitrogen atom to which it is attached, is an optionally substituted 5- to 12-membered spiroheterocycle.
[00350] In certain embodiments of Formula IV-L, C ring, along with the nitrogen atom to
which it is attached
Figure imgf000117_0002
In certain embodiments of
Formula IV-L, C ring, along with the nitrogen atom to which it is attached, is an optionally
Figure imgf000118_0001
substituted ^— . In certain embodiments of Formula th the
nitrogen atom to which it is attached, is an optionally sub
Figure imgf000118_0002
[00351] In one or more embodiments of Formula IV-L, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula IV-L, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula IV-L, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula IV-L, A is phenyl. In one or more embodiments of Formula IV-L, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-L, A is pyridinyl. In one or more embodiments of Formula IV- L, A is indazolyl. In one or more embodiments of Formula IV-L, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00352] In one or more embodiments of Formula IV-L, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-L, n is independently, at each occurrence, 1 or 2.
[00353] In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-L, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-L, R1 is independently, at each occurrence, -H, -CN or halogen.
[00354] In one or more embodiments of Formula IV-L, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula IV-L, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-L, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl. [00355] In one or more embodiments of Formula IV-L, R2 is -H. In one or more embodiments of Formula IV-L, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-K, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-L, R2 is -OH. In one or more embodiments of Formula IV-L, R2 is - R5R6. In one or more embodiments of Formula IV-L, R2 is - H2.
[00356] In one or more embodiments of Formula IV-L, X1 is N and X2 is N. In one or more embodiments of Formula IV-L, X1 is C and X2 is CH. In one or more embodiments of Formula IV-L, X1 is C and X2 is N. In one or more embodiments of Formula IV-L, X1 is N and X2 is CH.
[00357] In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00358] In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-L, the heterocyclyl ring is bridged.
[00359] In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00360] In one or more embodiments of Formula IV-L, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-L, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00361] In one or more embodiments of Formula IV-L, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-L, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)nNH2,
-(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-L, B is substituted with one or more oxo. In one or more embodiments of Formula IV-L, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-L, B is substituted with one or more -OH. In one or more embodiments of Formula IV-L, B is substituted with one or more - H2. In one or more embodiments of Formula IV-L, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-L, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-L, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-L, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00362] In certain embodiments of Formula IV, the compound is of Formula IV-M:
Figure imgf000120_0001
IV-M and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB1 is N, NR9, CR9, S, or O; XB2 is N, R9, CR9, S, or O; and XB3 is N, NR9, CR9, S, or O, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB1, XB2, and XB3 is not CR9, or provided that if each of XB1, XB2, and XB3 are CR9, X1 must be N.
[00363] In certain embodiments of Formula IV-M, XB1 is N or NR9. In certain
embodiments of Formula IV-M, XB1 is CR9. In certain embodiments of Formula IV-M, XB1 is S. In certain embodiments of Formula IV-M, XB1 is O. In certain embodiments of Formula IV-M, XB2 is N or NR9. In certain embodiments of Formula IV-M, XB2 is CR9. In certain embodiments of Formula IV-M, X is S. In certain embodiments of Formula IV-M, XB2 is O. In certain embodiments of Formula IV-M, XB3 is N or R9. In certain
embodiments of Formula IV-M, XB3 is CR9. In certain embodiments of Formula IV-M, XB3 is S. In certain embodiments of Formula IV-M, XB3 is O.
[00364] In certain embodiments of Formula IV-M, XB1 is N, NR9, or CR9; XB2 is N, NR9, or CR9; and XB3 is N, NR9, or CR9. In certain embodiments of Formula IV-M, XB1 is N or NR9. In certain embodiments of Formula IV-M, XB1 is CR9. In certain embodiments of Formula IV-M, XB2 is N or NR9. In certain embodiments of Formula IV-M, XB2 is CR9. In certain embodiments of Formula IV-M, XB3 is N or NR9. In certain embodiments of Formula IV-M, XB3 is CR9.
[00365] In some embodiments of Formula IV-M, R9 is -(Ο¾)η0Η and n is 1. In some embodiments of Formula IV-M, R9 is H.
Figure imgf000121_0001
[00367] In one or more embodiments of the compounds of Formula IV-M, Y2 is
-(CR¾)m-. In one or more embodiments of the compounds of Formula IV-M, Y2 is -NRa-
[00368] In one or more embodiments of Formula IV-M, R2 is -H. In one or more embodiments of Formula IV-M, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-M, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-M, R2 is -OH. In one or more embodiments of Formula IV-M, R2 is - R5R6. In one or more embodiments of Formula IV-M, R2 is - H2.
[00369] In one or more embodiments of Formula IV-M, Ra is -H.
[00370] In one or more embodiments of Formula IV-M, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-M, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-M, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-M, R3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00371] In one or more embodiments of Formula IV-M, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-M, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-M, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000122_0001
[00372] In one or more embodiments of Formula IV-M, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-M, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-M, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00373] In one or more embodiments of Formula IV-M, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-M, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- M, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00374] In one or more embodiments of Formula IV-M, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-M, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- M, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00375] In one or more embodiments of Formula IV-M, X1 is N and X2 is N. In one or more embodiments of Formula IV-M, X1 is C and X2 is CH. In one or more embodiments of Formula IV-M, X1 is C and X2 is N. In one or more embodiments of Formula IV-M, X1 is N and X2 is CH.
[00376] In certain embodiments of Formula IV, the compound is of Formula IV-N:
Figure imgf000124_0001
IV-N and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB4 is N or CR9; XB5 is N or CR9; XB6 is N or CR9; and XB7 is N or CR9, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, -NH2, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that if X1 is C, at least one of XB4, XB5, XB6, and XB7 is not CR9, or provided that if each of XB4, XB5, XB6, and XB7 are CR9, X1 must be N.
[00377] In certain embodiments of Formula IV-N, XB4 is N. In certain embodiments of Formula IV-N, XB4 is CR9. In certain embodiments of Formula IV-N, XB5 is N. In certain embodiments of Formula IV-N, XB5 is CR9. In certain embodiments of Formula IV-N, XB6 is N. In certain embodiments of Formula IV-N, XB6 is CR9. In certain embodiments of Formula IV-N, XB7 is N. In certain embodiments of Formula IV-N, XB7 is CR9. In certain embodiments of Formula IV-N, XB4 is N, XB5 is CR9, XB6 is N, and XB7 is CR9. In certain such embodiments, R9 is independently, at each occurrence, -H.
[00378] In some embodiments of Formula IV-N, R9 is -(CH2)nOH and n is 1. In some embodiments of Formula IV-N, R9 is H.
[00379] In one or more embodiments of the compounds of Formula IV-N, Y2 is
-(CRa 2)m- In one or more embodiments of the compounds of Formula IV-N, Y2 is -NRa-
[00380] In one or more embodiments of Formula IV-N, R2 is -H. In one or more embodiments of Formula IV-N, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-N, R2 is -H, -OH, -NR5R6,
-Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In one or more embodiments of Formula IV-N, R2 is -OH. In one or more embodiments of Formula IV-N, R2 is -NR5R6. In one or more embodiments of Formula IV-N, R2 is -NH2. [00381] In one or more embodiments of Formula IV-N, Ra is -H.
[00382] In one or more embodiments of Formula IV-N, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula IV-N, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula IV-N, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula IV-N, R3 is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00383] In one or more embodiments of Formula IV-N, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -NFh, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-N, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NFh. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-N, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3,
Figure imgf000125_0001
[00384] In one or more embodiments of Formula IV-N, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-N, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NH2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-N, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3,
Figure imgf000125_0002
[00385] In one or more embodiments of Formula IV-N, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-N, R and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NH2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- N, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00386] In one or more embodiments of Formula IV-N, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-N, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NH2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- N, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00387] In one or more embodiments of Formula IV-N, X1 is N and X2 is N. In one or more embodiments of Formula IV-N, X1 is C and X2 is CH. In one or more embodiments of Formula IV-N, X1 is C and X2 is N. In one or more embodiments of Formula IV-N, X1 is N and X2 is CH.
[00388] In certain embodiments of Formula IV, the compound is of Formula IV-O:
Figure imgf000126_0001
IV-O harmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof. [00389] In one or more embodiments of Formula IV-O, R2 is -H. In one or more embodiments of Formula IV-O, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-O, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-O, R2 is -OH. In one or more embodiments of Formula IV-O, R2 is - R5R6. In one or more embodiments of Formula IV-O, R2 is - H2.
[00390] In one or more embodiments of Formula IV-O, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-O, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-O, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000127_0001
[00391] In one or more embodiments of Formula IV-O, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-O, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-O, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000127_0002
[00392] In one or more embodiments of Formula IV-O, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-O, R and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- O, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00393] In one or more embodiments of Formula IV-O, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-O, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula IV- O, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00394] In one or more embodiments of Formula IV-O, X1 is N and X2 is N. In one or more embodiments of Formula IV-O, X1 is C and X2 is CH. In one or more embodiments of Formula IV-O, X1 is C and X2 is N. In one or more embodiments of Formula IV-O, X1 is N and X2 is CH.
[00395] In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00396] In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-O, the heterocyclyl ring is bridged. [00397] In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00398] In one or more embodiments of Formula IV-O, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-O, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00399] In one or more embodiments of Formula IV-O, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-O, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-O, B is substituted with one or more oxo. In one or more embodiments of Formula IV-O, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-O, B is substituted with one or more -OH. In one or more embodiments of Formula IV-O, B is substituted with one or more - H2. In one or more embodiments of Formula IV-O, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-O, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-O, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-O, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00400] In certain embodiments of Formula IV, the compound is of Formula IV-P:
Figure imgf000129_0001
IV-P and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
C forms a 3- to 12-membered monocyclic heterocycle, 3- to 12-membered polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, along with the nitrogen atom to which it is attached, wherein the heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(0¾)η Η2, -(Ο¾)η0Η, -CF3, -CHF2, or -CH2F. In some embodiments of Formula IV-P, the C ring is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In certain such embodiments, n is 1. In some embodiments of Formula IV-P, the C ring is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1.
[00401] In certain embodiments of Formula IV-P, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3- to 12-membered monocyclic
heterocycle. In certain embodiments of Formula IV-P, the C ring, along with the nitrogen atom to which it is attached, is an optionally substituted 3-to 12-membered polycyclic heterocycle. In certain embodiments of Formula IV-P, along with the nitrogen atom to which it is attached, is an optionally substituted 5- to 12-membered spiroheterocycle.
[00402] In certain embodiments of Formula IV-P, C ring, along with the nitrogen atom to
which it is attached
Figure imgf000130_0001
In certain embodiments of
Formula I -P, C ring, along with the nitrogen atom to which it is attached, is an optionally substituted
Figure imgf000130_0002
In certain embodiments of Formula IV-P, C ring, along with the
nitrogen atom to which it is attached, is an optionally substitute
Figure imgf000130_0003
[00403] In one or more embodiments of Formula IV-P, R2 is -H. In one or more embodiments of Formula IV-P, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-P, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula IV-P, R2 is -OH. In one or more embodiments of Formula IV-P, R2 is -NR5R6. In one or more embodiments of Formula IV- P, R2 is -NHz.
[00404] In one or more embodiments of Formula IV-P, X1 is N and X2 is N. In one or more embodiments of Formula IV-P, X1 is C and X2 is CH. In one or more embodiments of Formula IV-P, X1 is C and X2 is N. In one or more embodiments of Formula IV-P, X1 is N and X2 is CH.
[00405] In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00406] In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-P, the heterocyclyl ring is bridged.
[00407] In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00408] In one or more embodiments of Formula IV-P, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-P, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00409] In one or more embodiments of Formula IV-P, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-P, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CFIF2, or -CH2F. In one or more embodiments of Formula IV-P, B is substituted with one or more oxo. In one or more embodiments of Formula IV-P, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV-P, B is substituted with one or more -OH. In one or more embodiments of Formula IV-P, B is substituted with one or more - H2. In one or more embodiments of Formula IV-P, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-P, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-P, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-P, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00410] In certain embodiments of Formula IV, the compound is of Formula IV-Q:
Figure imgf000132_0001
IV-Q
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof wherein:
Figure imgf000132_0002
A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl, provided that
Figure imgf000132_0003
R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6;
Y1 is -S- or a direct bond;
X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; R2 is -H, -OH, - R5R6, -Ci-Cealkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6;
Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
R3 is combined with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl;
m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00411] In one or more embodiments of Formula IV-Q, Y1 is -S-. In one or more embodiments of Formula IV-Q, Y1 is a direct bond.
[00412] In one or more embodiments of Formula IV-Q, A is a monocyclic or poly cyclic aryl. In one or more embodiments of Formula IV-Q, A is phenyl. In one or more
embodiments of Formula IV-Q, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula IV-Q, A is pyridinyl. In one or more embodiments of Formula IV- Q, A is indazolyl.
[00413] In one or more embodiments of Formula IV-Q, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula IV-Q, n is independently, at each occurrence, 1 or 2.
[00414] In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula IV- Q, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H, halogen or -NR5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula IV-Q, R1 is independently, at each occurrence, -H, -CN or halogen.
[00415] In one or more embodiments of Formula IV-Q, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula IV-Q, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00416] In one or more embodiments of Formula IV-Q, R2 is -H. In one or more embodiments of Formula IV-Q, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula IV-Q, R2 is -OH. In one or more embodiments of Formula IV-Q, R2 is - R5R6. In one or more embodiments of Formula IV-
Figure imgf000134_0001
[00417] In one or more embodiments of Formula IV-Q, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-Q, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1.
[00418] In one or more embodiments of Formula IV-Q, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-Q, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1.
[00419] In one or more embodiments of Formula IV-Q, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-Q, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. [00420] In one or more embodiments of Formula IV-Q, R and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NFh, -OH, -(CFh^ Fh, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula IV-Q, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or -NFh. In certain such embodiments, n is 1.
[00421] In one or more embodiments of Formula IV-Q, X1 is N and X2 is N. In one or more embodiments of Formula IV-Q, X1 is C and X2 is CH. In one or more embodiments of Formula IV-Q, X1 is C and X2 is N. In one or more embodiments of Formula IV-Q, X1 is N and X2 is CH.
[00422] In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heterocycle. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00423] In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula IV-Q, the heterocyclyl ring is bridged.
[00424] In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12- membered heteroaryl. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00425] In one or more embodiments of Formula IV-Q, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula IV-Q, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00426] In one or more embodiments of Formula IV-Q, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula IV-Q, B is substituted with one or more oxo. In one or more embodiments of Formula IV-Q, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula IV- Q, B is substituted with one or more -OH. In one or more embodiments of Formula IV-Q, B is substituted with one or more - H2. In one or more embodiments of Formula IV-Q, B is substituted with one or more -CF3. In one or more embodiments of Formula IV-Q, B is substituted with one or more -CHF2. In one or more embodiments of Formula IV-Q, B is substituted with one or more -CH2F. In one or more embodiments of Formula IV-Q, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00427] In one or more embodiments, a compound of the present disclosure (e.g., a compound of Formula Γ, I, II, III, or IV) can be selected from:
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001

Figure imgf000139_0001

Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
50
Figure imgf000144_0001
51
Figure imgf000144_0002
and
52
Figure imgf000144_0003
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers of any of the foregoing.
[00428] In some embodiments, the compounds of the disclosure are compounds of Formula V:
Figure imgf000144_0004
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, wherein:
Figure imgf000144_0005
A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
Figure imgf000144_0006
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -C3-C8cycloalkyl, -OH, -OR5, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more -Ci- Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or
R2 is -H, -OH, -NR5R6, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl,
-C2-C6alkynyl, -NH2, halogen, -C3-C8cycloalkyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl is not attached via a nitrogen atom;
Y2 is -NRa- -(CR¾)m- -C(O)-, -C(Ra)2NH-, -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0- -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more -NH2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000146_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R10 is -H or -Ci-Cealkyl;
m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00429] In one or more embodiments of Formula V, R4 is H.
[00430] In one or more embodiments of Formula V, R4 is
Figure imgf000146_0002
. In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula V, Y1 is -S-. In one or more embodiments of Formula V, Y1 is a direct bond.
[00431] In one or more embodiments of the compounds of Formula V, Y2 is -(CR¾)m-. In one or more embodiments of the compounds of Formula V, Y2 is -NRa- [00432] In one or more embodiments of the compounds of Formula V, R is -H. In one or more embodiments of the compounds of Formula V, R10 is -Ci-C6alkyl.
[00433] In one or more embodiments of Formula V, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula V, A is a monocyclic or poly cyclic heterocycloalkyl. In one or more embodiments of Formula V, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula V, A is phenyl. In one or more embodiments of Formula V, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula V, A is pyridinyl. In one or more embodiments of Formula V, A is indazolyl. In one or more embodiments of Formula V, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl.
[00434] In one or more embodiments of Formula V, n is independently, at each
occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula V, n is independently, at each occurrence, 1 or 2.
[00435] In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -OR5 or halogen. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula V, R1 is independently, at each
occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or -NFh. In one or more embodiments of Formula V, R1 is independently, at each occurrence, -H, -CN or halogen.
[00436] In one or more embodiments of Formula V, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula V, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula V, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00437] In one or more embodiments of Formula V, R2 is -H. In one or more
embodiments of Formula V, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula V, R2 is -H, -OH, - R5R6, -Ci-C6alkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula V, R2 is -OH. In one or more
embodiments of Formula V, R2 is - R5R6. In one or more embodiments of Formula V, R2 is
[00438] In one or more embodiments of Formula V, Ra is -H.
[00439] In one or more embodiments of Formula V, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula V, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula V, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula V, R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
[00440] In one or more embodiments of Formula V, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000148_0001
[00441] In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12- membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00442] In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00443] In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00444] In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heterocycle. In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 7- to 12-membered heterocycle.
[00445] In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula V, the heterocyclyl ring is bridged. [00446] In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic or polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00447] In one or more embodiments of Formula V, B, including the atoms at the points of attachment, is an optionally substituted polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula V, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00448] In one or more embodiments of Formula V, B is substituted with one or more -(CH2)nOH. In certain such embodiments, n is 1. In one or more embodiments of Formula V, B is substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V, B is substituted with one or more oxo. In one or more embodiments of Formula V, B is substituted with one or more -Ci-C6alkyl. In one or more embodiments of Formula V, B is substituted with one or more -OH. In one or more embodiments of Formula V, B is substituted with one or more - H2. In one or more embodiments of Formula V, B is substituted with one or more -CF3. In one or more embodiments of Formula V, B is substituted with one or more -CHF2. In one or more embodiments of Formula V, B is substituted with one or more -CH2F. In one or more embodiments of Formula V, B is substituted with one or more -(CH2)nNH2. In certain such embodiments, n is 1.
[00449] In certain embodiments of Formula V, the compound is of Formula V-A:
Figure imgf000150_0001
V-A and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein XB4 is N or CR9; XB5 is N or CR9; XB6 is N or CR9; and XB7 is N or CR9, wherein R9 is independently, at each occurrence, -H, -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00450] In certain embodiments of Formula V-A, XB4 is N. In certain embodiments of Formula V-A, XB4 is CR9. In certain embodiments of Formula V-A, XB5 is N. In certain embodiments of Formula V-A, XB5 is CR9. In certain embodiments of Formula V-A, XB6 is N. In certain embodiments of Formula V-A, XB6 is CR9. In certain embodiments of Formula V-A, XB7 is N. In certain embodiments of Formula V-A, XB7 is CR9.
[00451] In some embodiments of Formula V-A, R9 is -(CH2)nOH and n is 1. In some embodiments of Formula V-A, R9 is H.
[00452] In one or more embodiments of the compounds of Formula V-A, R10 is -H. In one or more embodiments of the compounds of Formula V-A, R10 is -Ci-C6alkyl.
[00453] In one or more embodiments of Formula V-A, R4 is H.
[00454] In one or more embodiments of Formula V-A, R4 is
Figure imgf000151_0001
In certain such embodiments, Y1 is -S- or a direct bond. In one or more embodiments of Formula V-A, Y1 is -S-. In one or more embodiments of Formula V-A, Y1 is a direct bond.
[00455] In one or more embodiments of the compounds of Formula V-A, Y2 is -(CR¾)m-. In one or more embodiments of the compounds of Formula V-A, Y2 is - Ra-
[00456] In one or more embodiments of Formula V-A, A is a monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula V-A, A is a monocyclic or polycyclic heterocycloalkyl. In one or more embodiments of Formula V-A, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula V-A, A is phenyl. In one or more embodiments of Formula V-A, A is a monocyclic or polycyclic heteroaryl. In one or more embodiments of Formula V-A, A is pyridinyl. In one or more embodiments of Formula V-A, A is indazolyl. In one or more embodiments of Formula V-A, A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl. [00457] In one or more embodiments of Formula V-A, n is independently, at each occurrence, 0, 1, 2, or 3. In one or more embodiments of Formula V-A, n is independently, at each occurrence, 1 or 2.
[00458] In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H, -OR5 or halogen. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H or -OR5. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H or halogen. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H or - R5R6. In one or more embodiments of Formula V-A, R1 is
independently, at each occurrence, -H, -OR5 or - R5R6. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H, halogen or - R5R6. In certain such embodiments, R5 and R6 are both -H. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2. In one or more embodiments of Formula V-A, R1 is independently, at each occurrence, -H, -CN or halogen.
[00459] In one or more embodiments of Formula V-A, R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl. In one or more embodiments of Formula V-A, R5 and R6 are independently, at each occurrence, -H. In one or more embodiments of Formula V-A, R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
[00460] In one or more embodiments of Formula V-A, R2 is -H. In one or more embodiments of Formula V-A, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In certain such embodiments, R2 is methyl. In one or more embodiments of Formula V-A, R2 is -H, -OH, -NR5R6, -Ci-C6alkyl, or -NH2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or -NR5R6. In one or more embodiments of Formula V-A, R2 is -OH. In one or more embodiments of Formula V-A, R2 is -NR5R6. In one or more embodiments of Formula V-A,
Figure imgf000152_0001
[00461] In one or more embodiments of Formula V-A, Ra is -H.
[00462] In one or more embodiments of Formula V-A, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula V-A, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula V-A, R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle. In one or more embodiments of Formula V-A, R is an optionally substituted 5- to 12- membered polycyclic heterocycle.
[00463] In one or more embodiments of Formula V-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000153_0001
[00464] In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, - H2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)n H2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V-A, R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3,
Figure imgf000153_0002
[00465] In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00466] In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered spiroheterocycle, which is optionally substituted with one or more -Ci-Cealkyl, -NH2, -OH, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F. In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12-membered
spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -(CH2)nNH2, or - H2. In certain such embodiments, n is 1. In one or more embodiments of Formula V-A, R3 and Ra together with the atoms to which they are attached combine to form a 10- to 12- membered spiroheterocycle, which is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, oxo, heteroaryl, heterocyclyl, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00467] In one or more embodiments of Formula Γ IV, or V, R4 is H. In one or more
embodiments of Formula Γ, I, IV, or V, R4 is
Figure imgf000154_0001
[00468] In one or more embodiments of Formula Γ, I, II, III, IV, or V, A is a 5- to 12- membered monocyclic or poly cyclic cycloalkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, A is a monocyclic or polycyclic heterocycloalkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, A is a monocyclic or polycyclic aryl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, A is a monocyclic or polycyclic heteroaryl.
[00469] In one or more embodiments of Formula Γ, I, IV, or V, Y1 is -S-. In one or more embodiments of Formula Γ, I, IV, or V, Y1 is a direct bond.
[00470] In one or more embodiments of Formula Γ, I, II, III, IV, or V, Y2 is - Ra- In one or more embodiments of Formula Γ, I, II, III, IV, or V, Y2 is -(CRa 2)m- In one or more embodiments of Formula Γ, I, II, III, IV, or V, Y2 is -C(O)-. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Y2 is -C(Ra)2 H- or -(CR¾)mO-. In one or more
embodiments of Formula Γ, I, II, III, IV, or V, Y2 is -C(0)N(Ra)-, -N(Ra)C(0)-,
-S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(S)-, or -C(S)N(Ra)-. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Y2 is -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, or -C(0)N(Ra)0-. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Y2 is -C(0)0- -OC(O)-, or -OC(0)0-.
[00471] In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is -OH. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is an optionally substituted -C2-C6alkenyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is an optionally substituted -C4-C8cycloalkenyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is an optionally substituted -C2-C6alkynyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is an optionally substituted -C3-C8cycloalkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R2 is an optionally substituted monocyclic or poly cyclic heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
[00472] In one or more embodiments of Formula Γ, I, II, III, IV, or V, Ra is -H. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Ra is -OH. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Ra is an optionally substituted -C3-C8cycloalkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Ra is an optionally substituted
-Ci-C6alkyl.
[00473] In one or more embodiments of Formula Γ, I, II, III, IV, or V, Rb is H. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Rb is an optionally substituted
-Ci-C6alkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Rb is an optionally substituted -C3-C8cycloalkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R is an optionally substituted -C2-C6alkenyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, Rb is an optionally substituted monocyclic or polycyclic heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
[00474] In one or more embodiments of Formula Γ, I, II, III, IV, or V, R3 is an optionally substituted -Ci-C6alkyl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R3 is an optionally substituted 3- to 12- membered monocyclic heterocycle. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
[00475] In one or more embodiments of Formula Γ, I, II, III, IV, or V, R3 and Ra together with the atom to which they are attached combine to form an optionally substituted 3- to 12- membered monocyclic heterocycle. In one or more embodiments of Formula Γ, I, II, III, IV, or V, R3 and Ra together with the atoms to which they are attached combine to form an optionally substituted 3- to 12-membered polycyclic heterocycle. In one or more
embodiments of Formula Γ, I, II, III, IV, or V, R3 and Ra together with the atoms to which they are attached combine to form an optionally substituted 5- to 12-membered
spiroheterocycle.
[00476] In one or more embodiments of Formula Γ, I, II, III, or IV, X1 is N. In one or more embodiments of Formula Γ, I, II, III, or IV, X1 is C.
[00477] In one or more embodiments of Formula Γ, I, II, III, or IV, X2 is N. In one or more embodiments of Formula Γ, I, II, III, or IV, X2 is CH.
[00478] In one or more embodiments of Formula Γ, I, II, III, or IV, X1 is N and X2 is N. In one or more embodiments of Formula Γ, I, II, III, or IV, X1 is N and X2 is CH. In one or more embodiments of Formula Γ, I, II, III, or IV, X1 is C and X2 is N. In one or more embodiments of Formula Γ, I, II, III, or IV, X1 is C and X2 is CH.
[00479] In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle. In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 5 to 6-membered heterocycle. In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heterocycle.
[00480] In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a polycyclic 5- to 12-membered heterocyclyl. In certain embodiments, the heteroycyclyl ring is fused. In one or more embodiments of Formula Γ, I, II, III, IV, or V, the heterocyclyl ring is bridged.
[00481] In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 5 to 6-membered heteroaryl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a monocyclic 7- to 12-membered heteroaryl.
[00482] In one or more embodiments of Formula Γ, I, II, III, IV, or V, B, including the atoms at the points of attachment, is a polycyclic 5- to 12-membered heteroaryl. In one or more embodiments of Formula Γ, I, II, III, IV, or V, the polycyclic heteroaryl is a multiple condensed ring as described above. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
[00483] In one or more embodiments of Formula Γ, I, II, III, or IV, B, including the atoms
at the points of attachment, is
Figure imgf000157_0001
[00484] of Formula Γ, I, II, III, or IV, B, including the atoms
at the poi
Figure imgf000157_0002
and X1 is C, thereby forming
[00485] In one or more e of Formula Γ, I, II, III, or IV, B, including the atoms
at the points of attachment,
Figure imgf000157_0003
and X1 is C, thereby forming
[00486] In one variation of Formula I, II, III, IV, or V, R2 is an optionally substituted -Ci-C6alkyl and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In certain instances of Formula I, II, III, IV, or V, R2 is an optionally substituted -Ci-C6alkyl and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5-membered heteroaryl. In certain instances of Formula I, II, III, IV, or V, R2 is an optionally substituted -Ci-C6alkyl and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 6- membered heteroaryl.
[00487] In one variation of Formula I, II, III, IV, or V, R2 is -OH and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5 to 6-membered heteroaryl. In certain instances of Formula I, II, III, IV, or V, R2 is -OH and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 5-membered heteroaryl. In certain instances of Formula I, II, III, IV, or V, R2 is -OH and B, including the atoms at the points of attachment, is an optionally substituted monocyclic 6-membered heteroaryl.
[00488] In one variation of Formula I, II, III, IV, or V, Y1 is -S- and A is an optionally substituted 5- to 12-membered monocyclic or polycyclic cycloalkyl. In certain instances of Formula I, II, III, IV, or V, Y1 is -S- and A is an optionally substituted monocyclic or polycyclic heterocycloalkyl. In certain instances of Formula I, II, III, IV, or V, Y1 is -S- and A is an optionally substituted monocyclic or polycyclic aryl. In certain instances of Formula I, II, III, IV, or V, Y1 is S and A is an optionally substituted monocyclic or polycyclic heteroaryl.
[00489] In one variation of Formula I, II, III, IV, or V, Y1 is a direct bond and A is an optionally substituted 5- to 12-membered monocyclic or polycyclic cycloalkyl. In certain instances of Formula I, II, III, IV, or V, Y1 is a direct bond and A is an optionally substituted monocyclic or polycyclic heterocycloalkyl. In certain instances of Formula I, II, III, IV, or V, Y1 is a direct bond and A is an optionally substituted monocyclic or polycyclic aryl. In certain instances of Formula I, II, III, IV, or V, Y1 is a direct bond and A is an optionally substituted monocyclic or polycyclic heteroaryl.
Methods of Synthesizing the Disclosed Compounds
[00490] The compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the schemes given below.
[00491] The compounds of any of the formulae described herein may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes and examples. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of the present disclosure.
[00492] Those skilled in the art will recognize if a stereocenter exists in any of the compounds of the present disclosure. Accordingly, the present disclosure may include both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994).
Preparation of Compounds
[00493] The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
[00494] The compounds of the present disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. These methods include but are not limited to those methods described below.
Scheme 1. General synthesis of l-(5-Aryl (or heteroaiyl)-6-methylimidazo[l,5-a]pyrazin-8- -4-amines.
Figure imgf000159_0001
Figure imgf000159_0002
[00495] A general synthesis of l-(5-Aryl (or heteroaiyl)-6-methylimidazo[l,5-a]pyrazin-8- yl)-4-amines is in Scheme 1. 2-Chloro-3-cyano-5-methylpyrazine can be coupled to an appropriately substituted amine, brominated and subsequently coupled to an appropriately substituted aryl- or heteroaryl boronic acid in the presence of palladium based catalyst. The resulting bi-aryl compound can then be formylated and cyclized to form an appropriately substituted imidazole-pyrazine. Additional deprotection and/or functionalization steps can be required to produce the final compound. Scheme 2. General synthesis of amino imidazo[l,5-a]pyrazines (or an alternative bi-cyclic structure).
Figure imgf000160_0001
X = C, N, S, CO, O
[00496] A general synthesis of amino imidazo[l,5-a]pyrazines (or an alternative bi-cyclic structure) is outlined in Scheme 2. 5-Bromo-8-chloroimidazo[l,5-a]pyrazine (or an alternative bi-cyclic structure) can be coupled to a substituted primary or secondary amine to give 5-bromo-imidazo[l,5-a]pyrazin-8-amine. The resulting intermediate can be coupled to a substituted aryl- or heteroaryl-thiol in the presence of a copper catalyst (e.g., Cul) or under SNAr conditions, alternatively, the resulting intermediate can be coupled to an appropriately substituted aryl or heteroaryl boronic acid in the presence of Pd catalyst. Additional deprotection and/or functionalization steps can be required to produce the final compound.
Methods of Using the Disclosed Compounds and Compositions
Methods and Uses of the Disclosure
[00497] Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof. The methods may involve administering to a patient in need of treatment for diseases or disorders associated with SHP2 modulation an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula Γ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical compositions of the present disclosure. In some embodiments, the disease can be, but is not limited to Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R). SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers. SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
[00498] In addition, SHP2 plays a role in transducing signals originating from immune checkpoint molecules, including but not limited to programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In this context, modulation of SHP2 function can lead to immune activation, specifically anti-cancer immune responses.
[00499] Another aspect of the disclosure is directed to a method of inhibiting SHP2. The method involves administering to a patient in need thereof an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula Γ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical compositions of the present disclosure.
[00500] The present disclosure relates to compounds or compositions disclosed herein that are capable of modulating the activity of (e.g., inhibiting) SHP2. The present disclosure also relates to the therapeutic use of such compounds and compositions.
[00501] One or more disclosed compounds or compositions can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects. In some embodiments, SHP2 is inhibited after treatment with less than 1000 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 1 nM to about 10 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with less than about 1 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 10 nM to about 100 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 100 nM to about 10 μΜ of a compound of the disclosure.
[00502] Another aspect of the present disclosure relates to a one or more compounds of the present disclosure (e.g., compounds of Formula Γ I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or one or more compositions of the present disclosure, for use in treating or preventing a disease associated with SHP2 modulation. In some embodiments, the disease is Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R). SFIP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SFIP2 significantly inhibited cell growth of lung cancer cell lines with SFIP2 mutation or
EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers. SFIP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
[00503] In another aspect, the present disclosure relates to the use of one or more compounds of the present disclosure (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease. In some embodiments, the disease is associated with SHP2 modulation.
[00504] In another aspect, the present disclosure relates to one or more compounds of the present disclosure (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. In some embodiments, the medicament is used for treating or preventing a disease associated with SHP2 modulation.
[00505] In one aspect, the present disclosure relates to one or more compositions comprising one or more compounds of the present disclosure (e.g., compounds of Formula Γ, I, II, III, IV, or V, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. In some embodiments, the medicament is used for treating or preventing a disease associated with SHP2 modulation.
Pharmaceutical Compositions and Modes of Administration of the Disclosure
[00506] Another aspect of the present disclosure relates to pharmaceutical compositions comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can further include an excipient, diluent, or surfactant.
[00507] Compositions of the disclosure can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20%) of one or more of the disclosed compounds by weight or volume.
[00508] Administration of the disclosed compounds and compositions may be
accomplished via any mode of administration for therapeutic agents. These modes may include systemic or local administration such as oral, nasal, parenteral, intravenous, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
[00509] Depending on the intended mode of administration, the disclosed compounds or pharmaceutical compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be
administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
[00510] Illustrative pharmaceutical compositions may include tablets and gelatin capsules comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier, such as, but not limited to, a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or
polyvinylpyrrolidone, if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, algiic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl- cyclodextrin, PEG400, PEG200.
[00511] Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc. For example, one or more of the disclosed compounds are dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
[00512] One or more of the disclosed compounds or compositions can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
[00513] One or more disclosed compounds or compositions can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of
phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described for instance in U.S. Pat. No. 5,262,564, the contents of which are hereby incorporated by reference.
[00514] One or more disclosed compounds or compositions can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled. The disclosed compounds can also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer,
polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the one or more disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans,
polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels. In some embodiments, one or more disclosed compounds are not covalently bound to a polymer, e.g., a polycarboxylic acid polymer, or a polyacrylate.
[00515] One or more disclosed compounds or compositions can be delivered by parental administration. Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
Dosage Regimens of the Disclosure
[00516] The dosage regimen utilizing one or more of the disclosed compounds or compositions may be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[00517] Effective dosage amounts of the disclosed compounds, when used for the indicated effects, may range from about 0.5 mg to about 5000 mg of the disclosed
compounds as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compounds, or, in a range of from one amount to another amount in the list of doses. In some embodiments, the compositions are in the form of a tablet that can be scored.
[00518] If desired, the effective daily dose of one or more compounds or compositions of this disclosure may be administered as one, two, three, four, five, six, or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments of this disclosure, the one or more compounds or compositions of this disclosure, or mixtures thereof, may be administered two or three times daily. In some embodiments, the one or more compounds or compositions of this disclosure will be administered once daily.
[00519] In some embodiments, one or more compounds or compositions described herein may be used alone or together or conjointly administered, or used in combination, with another type of therapeutic agent. Conjoint administration or used in combination may refer to any form of administration of two or more different therapeutic compounds or
compositions such that the second compound or composition is administered while the previously administered therapeutic compound or composition is still effective in the body. For example, the different therapeutic compounds or compositions can be administered either in the same formulation or in a separate formulation, either simultaneously, sequentially, or by separate dosing of the individual components of the treatment. In some embodiments, the different therapeutic compounds or compositions can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic compounds or compositions.
Kits
[00520] In some embodiments, this disclosure also provides a pharmaceutical package or kit comprising one or more containers filled with at least one compound or composition of this disclosure. Optionally associated with such a container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of
pharmaceuticals or biological products, which notice reflects (a) approval by the agency of manufacture, use or sale for human administration, (b) directions for use, or both. In some embodiments, the kit comprises at least two containers, at least one of which contains at least one compound or composition of this disclosure. In some embodiments, the kit contains at least two containers, and each of the at least two containers contains at least one compound or composition of this disclosure.
[00521] In some embodiments, the kit includes additional materials to facilitate delivery of the subject compounds and compositions. For example, the kit may include one or more of a catheter, tubing, infusion bag, syringe, and the like. In some embodiments, the compounds and compositions may be packaged in a lyophilized form, and the kit includes at least two containers: a container comprising the lyophilized compounds or compositions and a container comprising a suitable amount of water, buffer, or other liquid suitable for reconstituting the lyophilized material.
[00522] The foregoing applies to any of the compounds, compositions, methods, and uses described herein. This disclosure specifically contemplates any combination of the features of such compounds, compositions, methods, and uses (alone or in combination) with the features described for the various kits described in this section.
Exemplary Embodiments
[00523] Some embodiments of this disclosure are Embodiment I, as follows: [00524] Embodiment 1-1. A compound of the Formula Γ :
Figure imgf000167_0001
Γ or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof wherein:
Figure imgf000167_0002
A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -Cs-Csc cloalkyl, -OH, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0)NR5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
R2 is -H, -ORb, -NR5R6,-CN, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -NH2, halogen, -C(0)ORb, -C3-C8cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1- 5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl or heteroaryl is not attached via a nitrogen atom;
Y2 is -NRa-, -(CR¾)m-, -C(O)-, -C(Ra)2 H-, -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-,
-C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5,
- R5S(0)NR5R6, - R5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000168_0001
R3 is, at each occurrence, selected from the group consisting of -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -ORb, - HRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, heteroaryl, heterocyclyl, -(CH2)n H2, -COORb, -CO HRb, -CO H(CH2)nCOORb,
- HCOORb, -CF3, -CHF2, or -CH2F;
R5 and R6 are independently, at each occurrence,-H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00525] Embodiment 1-2. The compound of Embodiment I-l, wherein R4 is -H. 00526] Embodiment 1-3. The compound of Embodiment I-l, wherein R4 is
Figure imgf000169_0001
[00527] Embodiment 1-4. The compound of Embodiment I-l or 1-3, wherein A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl.
[00528] Embodiment 1-5. The compound of Embodiment I-l or 1-3, wherein A is monocyclic or polycyclic heterocycloalkyl.
[00529] Embodiment 1-6. The compound of Embodiment I-l or 1-3, wherein A is monocyclic or polycyclic aryl.
[00530] Embodiment 1-7. The compound of Embodiment I-l or 1-3, wherein A is monocyclic or polycyclic heteroaryl.
[00531] Embodiment 1-8. The compound of any one of Embodiments I-l or 1-3 to 1-7, wherein Y1 is -S-.
[00532] Embodiment 1-9. The compound of any one of Embodiments I-l or 1-3 to 1-7, wherein Y1 is a direct bond.
[00533] Embodiment I- 10. The compound of any one of Embodiments I-l to 1-9, wherein Y2 is - Ra-
[00534] Embodiment I-l 1. The compound of any one of Embodiments I-l to 1-9, wherein
Figure imgf000169_0002
[00535] Embodiment 1-12. The compound of any one of Embodiments I-l to 1-9, wherein Y2 is -C(O)-.
[00536] Embodiment 1-13. The compound of any one of Embodiments I-l to 1-9, wherein Y2 is -C(Ra)2 H- or -(CRa 2)mO-.
[00537] Embodiment 1-14. The compound of any one of Embodiments I-l to 1-9, wherein Y2 is -C(0)N(Ra)-, -N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(S)-, or
-C(S)N(Ra)-. [00538] Embodiment 1-15. The compound of any one of Embodiments I-l to 1-9, wherein Y2 is -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -OC(0)N(Ra)-, -N(Ra)C(0)0- or
-C(0)N(Ra)0-.
[00539] Embodiment 1-16. The compound of any one of Embodiments I-l to 1-9, wherein Y2 is -C(0)0- -OC(O)-, or -OC(0)0-.
[00540] Embodiment 1-17. The compound of any one of Embodiments I-l to 1-16, wherein R2 is -ORb.
[00541] Embodiment 1-18. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted -Ci-C6alkyl.
[00542] Embodiment 1-19. The compound of any one of Embodiments I-l to 1-16, wherein R2 is -CN.
[00543] Embodiment 1-20. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted -C2-C6alkenyl.
[00544] Embodiment 1-21. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted -C4-C8cycloalkenyl.
[00545] Embodiment 1-22. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted -C2-C6alkynyl.
[00546] Embodiment 1-23. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted -C3-C8cycloalkyl.
[00547] Embodiment 1-24. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
[00548] Embodiment 1-25. The compound of any one of Embodiments I-l to 1-16, wherein R2 is an optionally substituted heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
[00549] Embodiment 1-26. The compound of any one of Embodiments I-l to 1-25, wherein Ra is -H.
[00550] Embodiment 1-27. The compound of any one of Embodiments I-l to 1-25, wherein Ra is -OH. [00551] Embodiment 1-28. The compound of any one of Embodiments 1-1 to 1-25, wherein Ra is an optionally substituted -C3-C8cycloalkyl.
[00552] Embodiment 1-29. The compound of any one of Embodiments 1-1 to 1-25, wherein Ra is an optionally substituted -Ci-C6alkyl.
[00553] Embodiment 1-30. The compound of any one of Embodiments 1-1 to 1-29, wherein Rb is -H.
[00554] Embodiment 1-31. The compound of any one of Embodiments 1-1 to 1-29, wherein R is an optionally substituted -Ci-C6alkyl.
[00555] Embodiment 1-32. The compound of any one of Embodiments 1-1 to 1-29, wherein R is an optionally substituted -C3-C8cycloalkyl.
[00556] Embodiment 1-33. The compound of any one of Embodiments 1-1 to 1-29, wherein R is an optionally substituted -C2-C6alkenyl.
[00557] Embodiment 1-34. The compound of any one of Embodiments 1-1 to 1-29, wherein R is an optionally substituted heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
[00558] Embodiment 1-35. The compound of any one of Embodiments 1-1 to 1-34, wherein R3 is an optionally substituted -Ci-C6alkyl.
[00559] Embodiment 1-36. The compound of any one of Embodiments 1-1 to 1-34, wherein R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle.
[00560] Embodiment 1-37. The compound of any one of Embodiments 1-1 to 1-34, wherein R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle.
[00561] Embodiment 1-38. The compound of any one of Embodiments 1-1 to 1-34, wherein R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
[00562] Embodiment 1-39. The compound of any one of Embodiments 1-1 to 1-25 or 1-30 to 1-34, wherein R3 and Ra together with the atom to which they are attached combine to form an optionally substituted 3- to 12-membered monocyclic heterocycle.
[00563] Embodiment 1-40. The compound of any one of Embodiments 1-1 to 1-25 or 1-30 to 1-34, wherein R3 and Ra together with the atoms to which they are attached combine to form an optionally substituted 3- to 12-membered polycyclic heterocycle. [00564] Embodiment 1-41. The compound of any one of Embodiments I-l to 1-25 or 1-30 to 1-34, wherein R3 and Ra together with the atoms to which they are attached combine to form an optionally substituted 5- to 12-membered spiroheterocycle.
[00565] Embodiment 1-42. The compound of any one of Embodiments I-l to 1-41, wherein X1 is N and X2 is N.
[00566] Embodiment 1-43. The compound of any one of Embodiments I-l to 1-41, wherein X1 is N and X2 is CH.
[00567] Embodiment 1-44. The compound of any one of Embodiments I-l to 1-41, wherein X1 is C and X2 is N.
[00568] Embodiment 1-45. The compound of any one of Embodiments I-l to 1-41, wherein X1 is C and X2 is CH.
[00569] Embodiment 1-46. The compound of any one of the preceding Embodiments, wherein B, including the atoms at the points of attachment, is a monocyclic 3- to 12- membered heteroaryl.
[00570] Embodiment 1-47. The c ents I-l to 1-41, wherein
Figure imgf000172_0001
B, including the atoms at the points of attachment, is —' and X1 is N, thereby forming
Figure imgf000172_0002
[00571] Embodiment 1-48. The compound of any one of Embodiments I-l to 1-41, wherein
B, including the atoms at the points of attachment, is
Figure imgf000172_0003
C, thereby forming
Figure imgf000172_0004
[00572] Embodiment 1-49. The compound of any one of Embodiments 1-1 to 1-41, wherein
Figure imgf000173_0001
B, including the atoms at the points of attachment, is and X1 is C, thereby forming
Figure imgf000173_0002
[00573] Embodiment 1-50. A compound that is
Figure imgf000173_0003
[00574] Embodiment 1-51. A compound that is
Figure imgf000173_0004
[00575] Embodiment 1-52. A pharmaceutical composition comprising a compound of any one of Embodiments 1-1 to 1-51 and a pharmaceutically acceptable carrier.
[00576] Embodiment 1-53. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiments 1-1 to 1-51.
[00577] Embodiment 1-54. The method of Embodiment 1-53, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00578] Embodiment 1-55. A compound of any one of Embodiments 1-1 to 1-51 for use in treating or preventing a disease associated with SHP2 modulation.
[00579] Embodiment 1-56. Use of a compound of any one of Embodiments 1-1 to 1-51 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[00580] Some embodiments of this disclosure are Embodiment II, as follows: [00581] Embodiment II- 1. A compound of the Formula IV:
Figure imgf000174_0001
IV or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof wherein:
Figure imgf000174_0002
A is a 5- to 12-membered monocyclic or olycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
Figure imgf000174_0003
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -C3-C8cycloalkyl, -OH, -OR5, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3,
Figure imgf000174_0004
R2 is -H, -OH, -NR5R6, -Ci-Cealkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl,
-C2-C6alkynyl, -NH2, halogen, -C3-C8cycloalkyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl,
cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m- -C(O)-, -C(Ra)2NH- -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0-, -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000175_0001
R3 is -H, -C i-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN; R and R are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, - H2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00582] Embodiment II-2. The compound of Embodiment II- 1, wherein Y2 is -NRa-
[00583] Embodiment II-3. The compound of Embodiment II- 1, wherein Y2 is -(CR¾)m-.
[00584] Embodiment II-4. The compound of Embodiment II- 1, wherein Y2 is -C(O)-.
[00585] Embodiment II-5. The compound of Embodiment II- 1, wherein Y2 is -C(Ra)2NH-
Figure imgf000176_0001
[00586] Embodiment II-6. The compound of Embodiment II- 1, wherein Y2 is
-C(0)N(Ra)-, -N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(S)-, or -C(S)N(Ra)-.
[00587] Embodiment II-7. The compound of Embodiment II- 1, wherein Y2 is
-N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -OC(0)N(Ra)-, -N(Ra)C(0)0- or -C(0)N(Ra)0-.
[00588] Embodiment II-8. The compound of Embodiment II- 1, wherein Y2 is -C(0)0- -OC(O)-, or -OC(0)0-.
[00589] Embodiment II-9. The compound of any one of Embodiments II- 1 to II-8, wherein Ra is -H.
[00590] Embodiment 11-10. The compound of any one of Embodiments II- 1 to II-8, wherein Ra is -OH.
[00591] Embodiment II- 1 1. The compound of any one of Embodiments II- 1 to II-8, wherein Ra is an optionally substituted -C3-C8cycloalkyl.
[00592] Embodiment 11-12. The compound of any one of Embodiments II- 1 to II-8, wherein Ra is an optionally substituted -Ci-C6alkyl.
[00593] Embodiment 11-13. The compound of any one of Embodiments II- 1 to II-
12, wherein Rb is -H.
[00594] Embodiment 11-14. The compound of any one of Embodiments II- 1 to II-
12, wherein Rb is an optionally substituted -Ci-C6alkyl. [00595] Embodiment 11-15. The compound of any one of Embodiments II- 1 to II-
12, wherein Rb is an optionally substituted -C3-C8cycloalkyl.
[00596] Embodiment 11-16. The compound of any one of Embodiments II- 1 to II-
12, wherein Rb is an optionally substituted -C2-C6alkenyl.
[00597] Embodiment 11-17. The compound of any one of Embodiments II- 1 to II-
12, wherein Rb is an optionally substituted heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
[00598] Embodiment 11-18. The compound of any one of Embodiments II- 1 to II-
17, wherein R3 is an optionally substituted -Ci-C6alkyl.
[00599] Embodiment 11-19. The compound of any one of Embodiments II- 1 to II-
17, wherein R3 is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocycle.
[00600] Embodiment 11-20. The compound of any one of Embodiments II- 1 to II-
17, wherein R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle.
[00601] Embodiment 11-21. The compound of any one of Embodiments II- 1 to II-
17, wherein R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
[00602] Embodiment 11-22. The compound of any one of Embodiments II- 1 to II-8, wherein R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00603] Embodiment 11-23. The compound of any one of Embodiments II- 1 to II-8, wherein R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00604] Embodiment 11-24. The compound of any one of Embodiments II- 1 to II-8, wherein R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00605] Embodiment 11-25. The compound of Embodiment 11-22 or 11-23, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl. [00606] Embodiment 11-26. The compound of any one of Embodiments 11-22, 11-23, or 11-25, wherein the heterocycle is optionally substituted with one or more -(CH2)n H2, wherein n is 1.
[00607] Embodiment 11-27. The compound of any one of Embodiments 11-22, 11-23,
11-25, or 11-26, wherein the heterocycle is optionally substituted with one or more - H2.
[00608] Embodiment 11-28. The compound of Embodiment 11-24, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl.
[00609] Embodiment 11-29. The compound of Embodiment 11-24 or 11-28, wherein the spiroheterocycle is optionally substituted with one or more -(CH2)n H2, wherein n is 1.
[00610] Embodiment 11-30. The compound of any one of Embodiments 11-24, 11-28, or 11-29, wherein the spiroheterocycle is optionally substituted with one or more - H2.
[00611] Embodiment II-31. The compound of Embodiment II- 1, wherein the compound of Formula IV is a compound of Formula IV-Q:
Figure imgf000178_0001
IV-Q
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer,
thereof wherein:
Figure imgf000178_0002
A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl, provided that the heteroaryl is not
Figure imgf000178_0003
R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6;
Y1 is -S- or a direct bond;
X1 is N or C;
X2 is N or CH; B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F;
R2 is -H, -OH, - R5R6, -Ci-Cealkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6;
Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
R3 is combined with Ra to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl;
m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00612] Embodiment 11-32. The compound of Embodiment II-31, wherein R3 and
Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2.
[00613] Embodiment 11-33. The compound of Embodiment II-31, wherein R3 and
Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00614] Embodiment 11-34. The compound of Embodiment II-31, wherein R3 and
Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00615] Embodiment 11-35. The compound of Embodiment 11-32 or 11-33, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl. [00616] Embodiment 11-36. The compound of any one of Embodiments 11-32, 11-33, or 11-35, wherein the heterocycle is optionally substituted with one or more -(CH2)n H2, wherein n is 1.
[00617] Embodiment 11-37. The compound of any one of Embodiments 11-32, 11-33,
11-35, or 11-36, wherein the heterocycle is optionally substituted with one or more - H2.
[00618] Embodiment 11-38. The compound of Embodiment 11-34, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl.
[00619] Embodiment 11-39. The compound of Embodiment 11-34 or 11-38, wherein the spiroheterocycle is optionally substituted with one or more -(0¾)η Η2, wherein n is 1.
[00620] Embodiment 11-40. The compound of any one of Embodiments 11-34, 11-38, or 11-39, wherein the spiroheterocycle is optionally substituted with one or more - H2.
[00621] Embodiment 11-41. The compound any one of Embodiments II- 1 to 11-40,
wherein R4 is
Figure imgf000180_0001
[00622] Embodiment 11-42. The compound of any one of Embodiments II- 1 to II-
41, wherein A is monocyclic or poly cyclic aryl.
[00623] Embodiment 11-43. The compound of Embodiment 11-42, wherein A is phenyl.
[00624] Embodiment 11-44. The compound of any one of Embodiments II- 1 to II-
41, wherein A is monocyclic or polycyclic heteroaryl.
[00625] Embodiment 11-45. The compound of Embodiment 11-44, wherein A is pyridinyl.
[00626] Embodiment 11-46. The compound of any one of Embodiments II- 1 to II-
45, wherein Y1 is -S-.
[00627] Embodiment 11-47. The compound of any one of Embodiments II- 1 to II-
45, wherein Y1 is a direct bond.
[00628] Embodiment 11-48. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H, -OR5 or halogen. [00629] Embodiment 11-49. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H, -OR5 or - R5R6.
[00630] Embodiment 11-50. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H, halogen or - R5R6.
[00631] Embodiment 11-51. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H or -OR5.
[00632] Embodiment 11-52. The compound of Embodiment 11-48 or 11-51, wherein
R5 is -H or -Ci-Cealkyl.
[00633] Embodiment 11-53. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H or halogen.
[00634] Embodiment 11-54. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H or - R5R6.
[00635] Embodiment 11-55. The compound of any one of Embodiments II- 1 to II-
47, wherein R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or - H2.
[00636] Embodiment 11-56. The compound of any one of Embodiments 11-49, 11-50, or 11-54, wherein R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl.
[00637] Embodiment 11-57. The compound of Embodiment 11-56, wherein R5 and
R6 are independently, at each occurrence, -H.
[00638] Embodiment 11-58. The compound of Embodiment 11-56, wherein R5 and
R6 are independently, at each occurrence, -Ci-C6alkyl.
[00639] Embodiment 11-59. The compound any one of Embodiments II- 1 to 11-40, wherein R4 is -H.
[00640] Embodiment 11-60. The compound of any one of Embodiments II- 1 to II-
59, wherein R2 is -OH.
[00641] Embodiment 11-61. The compound of any one of Embodiments II- 1 to II-
59, wherein R2 is -Ci-C6alkyl, wherein the alkyl is optionally substituted with one or more - OH, halogen, -OR5, or - R5R6.
[00642] Embodiment 11-62. The compound of any one of Embodiments II- 1 to II-
59, wherein R2 is methyl. [00643] Embodiment 11-63. The compound of any one of Embodiments II- 1 to II-
59, wherein R2 is - R5R6.
[00644] Embodiment 11-64. The compound of Embodiment 11-63, wherein R5 and
R6 are independently, at each occurrence, -H.
[00645] Embodiment 11-65. The compound of Embodiment 11-63, wherein R5 and
R6 are independently, at each occurrence, -Ci-C6alkyl.
[00646] Embodiment 11-66. The compound of any one of Embodiments II- 1 to II-
59, wherein R2 is -H.
[00647] Embodiment 11-67. The compound of any one of Embodiments II- 1 to II-
59, wherein R2 is - H2.
[00648] Embodiment 11-68. The compound of any one of Embodiments II- 1 to II-
67, wherein X1 is N and X2 is N.
[00649] Embodiment 11-69. The compound of any one of Embodiments II- 1 to II-
67, wherein X1 is N and X2 is CH.
[00650] Embodiment 11-70. The compound of any one of Embodiments II- 1 to II-
67, wherein X1 is C and X2 is N.
[00651] Embodiment 11-71. The compound of any one of Embodiments II- 1 to II-
67, wherein X1 is C and X2 is CH.
[00652] Embodiment 11-72. The compound of any one of Embodiments II- 1 to II-
71, wherein B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heterocycle, wherein each heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00653] Embodiment 11-73. The compound of any one of Embodiments II- 1 to II-
71, wherein B, including the atoms at the points of attachment, is a polycyclic 5- to 12- membered heterocycle, wherein each heterocycle is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00654] Embodiment 11-74. The compound of Embodiment 11-72 or 11-73, wherein the B heterocycle is substituted with one or more oxo.
[00655] Embodiment 11-75. The compound of any one of Embodiments II- 1 to II-
71, wherein B, including the atoms at the points of attachment, is a monocyclic 5- to 12- membered heteroaryl, wherein each heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00656] Embodiment 11-76. The compound of any one of Embodiments II- 1 to II-
71, wherein B, including the atoms at the points of attachment, is a polycyclic 5- to 12- membered heteroaryl, wherein each heteroaryl is optionally substituted with one or more -Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
[00657] Embodiment 11-77. The compound of Embodiment 11-75 or 11-76, wherein the B heteroaryl is substituted with one or more -Ci-C6alkyl.
[00658] Embodiment 11-78. The compound of any one of Embodiments 11-75 to II-
77, wherein the B heteroaryl is substituted with one or more -OH.
[00659] Embodiment 11-79. The compound of any one of Embodiments 11-75 to II-
78, wherein the B heteroaryl is substituted with one or more - H2.
[00660] Embodiment 11-80. The compound of any one of Embodiments 11-75 to II-
79, wherein the B heteroaryl is substituted with one or more -(CH2)n H2.
[00661] Embodiment 11-81. The compound of any one of Embodiments 11-75 to II-
80, wherein the B heteroaryl is substituted with one or more -(CH2)nOH.
[00662] Embodiment 11-82. The compound of Embodiment 11-80 or 11-81, wherein n is 1.
[00663] Embodiment 11-83. The compound of any one of Embodiments 11-75 to II-
82, wherein the B heteroaryl is substituted with one or more -CF3.
[00664] Embodiment 11-84. The compound of any one of Embodiments 11-75 to II-
83, wherein the B heteroaryl is substituted with one or more -CHF2.
[00665] Embodiment 11-85. The compound of any one of Embodiments 11-75 to II-
84, wherein the B heteroaryl is substituted with one or more -CH2F.
[00666] Embodiment 11-86. A compound selected from the group consisting of:
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001

Figure imgf000191_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer of any of the foregoing.
[00667] Embodiment 11-87. A pharmaceutical composition comprising a compound of any one of Embodiments II- 1 to 11-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier. [00668] Embodiment 11-88. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiments II- 1 to 11-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
[00669] Embodiment 11-89. The method of Embodiment 11-88, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00670] Embodiment 11-90. A compound of any one of Embodiments II- 1 to 11-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
[00671] Embodiment 11-91. A compound of any one of Embodiments II- 1 to 11-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
[00672] Embodiment 11-92. Use of a compound of any one of Embodiments II- 1 to
11-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[00673] Embodiment 11-93. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment 11-87.
[00674] Embodiment 11-94. The method of Embodiment 11-93, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00675] Embodiment 11-95. A pharmaceutical composition of Embodiment 11-87 for use as a medicament.
[00676] Embodiment 11-96. A pharmaceutical composition of Embodiment 11-87 for use in treating or preventing a disease associated with SHP2 modulation.
[00677] Embodiment 11-97. Use of a pharmaceutical composition of Embodiment
11-87 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation. Examples
[00678] The disclosure is further illustrated by the following examples and synthesis examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
[00679] Definitions used in the following examples and elsewhere herein are:
CH2CI2, DCM Methylene chloride, Dichloromethane
CH3CN, MeCN Acetonitrile
Cul Copper (I) iodide
DIPEA Diisopropylethyl amine
DMF N,N-Dimethylformamide
EtOAc Ethyl acetate
hr or h hour
H2O Water
HC1 Hydrochloric acid
K3PO4 Potassium phosphate (tribasic)
MeOH Methanol
min minute
Na2S04 Sodium sulfate
BS N-bromosuccinimide
MP N-methyl pyrrolidone
Pd(dppf)Cl2 [1,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
POCh Phosphorous oxychloride
Example 1.
Synthesis of 4-methyl-l-(6-methylimidazo[l,5-a]pyrazin-8-yl)piperidin-4-amine.
Figure imgf000194_0001
Step 1.
[00680] To a solution of diethylaminomalonate hydrochloride (25 g, 0.12 mol) in water (20 mL) was added solid sodium hydrogen carbonate until pH > 7. After extraction with ethyl acetate, the organic phase was separated and evaporated under reduced pressure. The residue was taken into a methanolic ammonia solution (6M, 300 mL) and the reaction mixture was heated in a high pressure reactor at 80 °C overnight. The resulting mixture was concentrated under reduced pressure, the residue was washed successively with methanol and diethyl ether to afford aminomalonamide (10 g, 73%). 1H MR (400 MHz, DMSO- d6) δ 7.41 (s, 3H), 7.25 (s, 3H), 3.76 (s, 1H).
Step 2.
[00681] Sodium bisulfite (24 g, 0.23 mol) was added to 25 mL of 40% methylglyoxal solution followed by gradual addition of 86 mL of water containing sodium hydroxide (0.86 g, 0.021 mol). The solution was heated to 80 °C for 1 hr, aminomalonamide (18 g, 0.15 mol) was added and the temperature of the solution maintained at 80 °C for 2 more hrs with stirring. Sodium acetate (32.78 g, 0.4 mol) was added, the solution cooled to 20 °C and 25 mL of 30%) hydrogen peroxide added gradually with stirring at 60-65 °C. After cooling to room termperature, the product was removed, washed with cold water to give 5-methyl-3- oxo-3,4-dihydropyrazine-2-carboxamide (8.5 g, 36%>) which was used in the next step without further purification. ¾ MR (400 MHz, DMSO- d6) δ 13.21 (s, 1H), 8.75 (s, 1H), 8.03 (s, 1H), 7.83 (s, 1H), 2.37 (s, 3H). Step 3.
[00682] 5-Methyl-3-oxo-3,4-dihydropyrazine-2-carboxamide (2.0 g, 0.013 mol), was suspended in Et3N (3.63 mL, 0.026 mol), cooled to 0 °C and reacted with 36.5 mL POCb. The mixture was heated to reflux for 2 hr and concentrated under reduced pressure. The resulting black oil was extracted with ether (5x50 mL), and the combined extracts were treated with 10% Na2C03 (150 mL). The organic layers were separated, washed with water and brine, dried (Na2S04), and concentrated under reduced pressure. The crude product was purified by flash column chromatography to afford 3-chloro-5-methylpyrazine-2-carbonitrile (1.5 g, 75%) as a fluffy solid. ¾ NMR (400 MHz, DMSO- d6) δ 8.77 (s, 1H), 2.63 (s, 3H).
Step 4.
[00683] 3-Chloro-5-methylpyrazine-2-carbonitrile (1.1 g, 0.007 mol) was dissolved in anhydrous DMF (11 mL) and DIPEA (3.74 mL, 0.021 mol) was added. After stirring for 30 min at room temperature tert-butyl (4-methylpiperidin-4-yl)carbamate (1.84 g, 0.008 mol) was added in one portion. The reaction mixture was stirred overnight at room temperature, then diluted with EtOAc and extracted with 2% NaCl (aq.). The organic layer was dried over Na2SC"4 and concentrated under reduced pressure. The desired product was purified via column chromatography (DCM/acetone 97:3) to yield tert-butyl N-[l-(3-cyano-6- methylpyrazin-2-yl)-4-methylpiperidin-4-yl]carbamate as a pale yellow solid (2.14 g, 90%). 1H MR (400 MHz, DMSO-i¾) δ 7.97 (s, 1H), 6.67 (bs, 1H), 3.96 (dt, J = 13.7, 4.3 Hz, 2H), 3.39 (dd, J = 13.4, 10.3 Hz, 2H), 2.42 (s, 3H), 2.15 (d, J = 13.4 Hz, 2H), 1.51 (ddd, J = 14.1, 10.6, 3.9 Hz, 2H), 1.40 (s, 9H), 1.27 (s, 3H).
Step 5.
[00684] tert-Butyl N-[l-(3-cyano-6-methylpyrazin-2-yl)-4-methylpiperidin-4-yl]carbamate (1 g, 0.003 mol) was dissolved in anhydrous DCM (20 mL) and cooled to -78 °C and DIBAL-H 1 M in hexanes (9 mL, 0.009 mol) was added in small portions. After 1 hr, the reaction mixture was allowed to warm to room temperature and saturated solution of NH 1 (4 mL) and saturated solution of sodium potassium tartrate (30 mL) were added. This solution was stirred until organic and water layers separated. The water layer was removed and the organic layer was dried over Na2S04 and concentrated under reduced pressure to give crude tert-butyl N-{ l-[3-(aminomethyl)-6-methylpyrazin-2-yl]-4-methylpiperidin-4- yl}carbamate (1 g, 100%) which was used in next step without further purification. ¾ NMR (400 MHz, DMSO-i¾) δ 8.01 (s, 1H), 6.53 (s, 2H), 3.72 (s, 2H), 3.19 - 3.08 (m, 3H), 3.04 - 2.95 (m, 2H), 2.35 (s, 3H), 2.18 - 2.10 (m, 2H), 1.60 - 1.50 (m, 2H), 1.39 (s, 9H), 1.27 (s, 3H).
Step 6.
[00685] tert-Butyl N-{ l-[3-(aminomethyl)-6-methylpyrazin-2-yl]-4-methylpiperidin-4- yl}carbamate (0.88 g, 0.002 mol) was dissolved in formic acid (17.6 mL) and stirred at 105 °C for 2 hrs. Formic acid was removed under reduced pressure and obtained red oil was portioned between water and DCM. The organic layer was removed and the aqueous phase was basified with NaHCCb (aq.) to pH 11 then extracted with mixture of isopropyl alcohol and chloroform 1 :3 (4x50 mL). The organic layers were combined, dried over MgSCb and concentrated under reduced pressure. The desired product was purified via column chromatography (MeOH with NH3 3M/DCM from 0: 100 to 3 :97) to give 4-methyl-l-{6- methylimidazo[l,5-a]pyrazin-8-yl}piperidin-4-amine as a yellow oil (0.224 g, 25%). ¾ NMR (400 MHz, OMSO-d6) δ 8.38 (s, 1H), 8.10 (s, 1H), 8.01 (s, 1H), 4.37 (d, J = 5.5 Hz, 2H), 3.19 (ddd, J = 12.7, 9.0, 3.5 Hz, 2H), 3.13 - 3.04 (m, 3H), 2.36 (s, 3H), 1.57 (ddd, J = 12.9, 9.1, 3.8 Hz, 2H), 1.52 - 1.42 (m, 2H), 1.24 (s, 1H), 1.10 (s, 3H).
Step 7.
[00686] 4-Methyl-l-{6-methylimidazo[l,5-a]pyrazin-8-yl}piperidin-4-amine (0.2 g, 0.55 mmol) was suspended in POCb (10 mL) and stirred at 90 °C for 2 hr. POCb was removed under reduced pressure and the obtained solid was portioned between water and DCM. The layers were separated, the aqueous layer was washed with NaHCCb (aq.), and extracted with mixture of isopropyl alcohol and chloroform 1 :3. The organic layers were combined, dried over Na2S04 and concentrated under reduced pressure. Purification by reparative TLC chromatography (1000 microns) (MeOH with NH3 3M/DCM 8:92; developed x2) resulted in 4-methyl-l-(6-methylimidazo[l,5-a]pyrazin-8-yl)piperidin-4-amine as yellow oil (16.6 mg, 9%). ¾ NMR (400 MHz, OMSO-d6) δ 8.26 (s, 1H), 7.70 (s, 1H), 7.50 (t, J = 1.1 Hz, 1H), 3.98 - 3.87 (m, 2H), 3.75 - 3.63 (m, 2H), 2.12 (d, J = 1.1 Hz, 3H), 1.54 - 1.41 (m, 4H), 1.09 (s, 3H); LC-MS (ESI) m/z: [M + H] calculated for Ci3H20N5: 246.2; found 246.3. Example 2. Synthesis of l-(5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl)-4- methylpiperidin-4-amine.
Figure imgf000197_0001
Step 1.
[00687] tert-Butyl N-[l-(3-cyano-6-methylpyrazin-2-yl)-4-methylpiperidin-4-yl]carbamate (1 g, 0.003 mol) was dissolved in anhydrous DMF (15 mL) and the reaction flask was protected from light with aluminum foil. The reaction mixture was cooled to 0 °C and NBS was added (0.8 g, 0.004 mol). The reaction mixture was stirred at room temperature for 72 hrs and then washed with water and EtOAc. The organic phase was extracted with 10% NaCl (aq.) (3 x 100 mL). The combined organic layers were dried over MgS04 and concentrated under reduced pressure to give tert-butyl N-[l-(5-bromo-3-cyano-6-methylpyrazin-2-yl)-4- methylpiperidin-4-yl]carbamate as a pale yellow solid (1 g, 81%). ¾ NMR (400 MHz, DMSO- d6) δ 6.69 (s, 1H), 4.00 (dt, J = 14.1, 4.2 Hz, 2H), 3.46 - 3.35 (m, 2H), 2.15 (d, J = 13.5 Hz, 2H), 1.50 (ddd, J = 14.0, 10.7, 3.9 Hz, 2H), 1.40 (s, 9H), 1.26 (s, 3H). UPLC [M+l] = 409.9.
Step 2.
[00688] tert-Butyl N-[l-(5-bromo-3-cyano-6-methylpyrazin-2-yl)-4-methylpiperidin-4- yl]carbamate (0.2 g, 49 mmol) was suspended in EtOH (6.6 mL) and toluene (5 mL) and the received solution was degassed with argon for 15 min. Then K2CO3 (0.34 g, 0.002 mol) followed by 2,3-dichlorophenylboronic acid (0.1 g, 53 mmol) was added. The reaction mixture was degassed for another 15 min and tetrakis(triphenylphosphine)palladium(0) was added (0.03 g, 2 mmol). The reaction mixture was stirred at 80 °C overnight. The solvent was concentrated under reduced pressure and the resulting solid was portioned between water and DCM. The aqueous layer was extracted with DCM (2x 100 mL). Purification with column chromatography (hexane/ethyl acetate 4: 1) resulted in tert-butyl N-{ l-[3-cyano-5-(2,3- dichlorophenyl)-6-methylpyrazin-2-yl]-4-methylpiperidin-4-yl} carbamate as a pale yellow solid (0.35 g, 10%). ¾ NMR (400 MHz, OMSO-d6) δ 7.78 (dd, J = 7.9, 1.8 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.46 (dd, J = 7.6, 1.8 Hz, 1H), 6.71 (s, 1H), 4.14 - 4.05 (m, 2H), 3.48 (t, J = 11.9 Hz, 2H), 2.24 (s, 3H), 2.20 (d, J = 14.0 Hz, 2H), 1.61 - 1.50 (m, 2H), 1.41 (s, 3H), 1.29 (s, 3H); UPLC [M+l] = 475.55.
Step 3.
[00689] fert-Butyl N-{ l-[3-cyano-5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl]-4- methylpiperidin-4-yl} carbamate (0.04 g, 8.4 mmol) was dissolved in anhydrous DCM (2 mL) under Ar, cooled to -78 °C and DIBAL-H 1 M in hexanes (0.3 mL, 25.1 mmol) was added in small portions. After 1 hr, the reaction mixture was allowed to warm to room temperature and saturated solution of H4CI (1 mL) and saturated solution of sodium potassium tartare (7 mL) was added. The resulting solution was stirred until organic and water layers separated. The layers were separated and the organic layer was dried over
Na2S04 and concentrated under reduced pressure to give crude tert-butyl N-{ l-[3- (aminomethyl)-5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl]-4-methylpiperidin-4- yl}carbamate (0.03 g, 75%) which was used in next step without further purification. ¾ NMR (400 MHz, OMSO-d6) δ 7.73 (dd, J = 7.9, 1.7 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.43 (dd, J = 7.7, 1.8 Hz, 1H), 6.57 (s, 1H), 3.77 (s, 2H), 3.27 (m, 3H), 3.19 - 3.05 (m, 2H), 2.19 (d, J = 1.9 Hz, 2H), 2.17 - 2.12 (m, 2H), 1.65 - 1.53 (m, 3H), 1.40 (s, 9H), 1.29 (d, J = 3.9 Hz, 3H); UPLC [M+l] = 480.15.
Step 4.
[00690] fert-Butyl N-{ l-[3-(aminomethyl)-5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl]- 4-methylpiperidin-4-yl} carbamate (0.08 g, 16.6 mmol) was dissolved in formic acid (1.6 mL) and stirred at 105 °C for 2 hrs. Formic acid was removed under reduced pressure, and the resulting red oil was portioned between water and DCM. An aqueous phase was basified with NaHCCb (aq.) to pH 11 then extracted with mixture of isopropyl alcohol and chloroform 1 :3 (4x50 mL). The organic layers were combined, dried over MgS04, and concentrated under reduced pressure. Purification by preparative TLC (MeOH with L 3M/DCM 4:96) resulted in N-{[3-(4-amino-4-methylpiperidin-l-yl)-6-(2,3-dichlorophenyl)-5-methylpyrazin-2- yl]methyl}formamide (0.017 g, 25%) as an yellow oil. ¾ NMR (400 MHz, OMSO-d6) δ 8.07 (d, J = 1.6 Hz, 1H), 7.74 (dd, J = 7.9, 1.7 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.43 (dd, J = 7.7, 1.7 Hz, 1H), 4.42 (d, J = 5.6 Hz, 2H), 3.31 - 3.14 (m, 3H), 2.20 (s, 3H), 1.66 - 1.47 (m, 4H), 1.13 (s, 3H). UPLC [M+l] = 409.5.
Step 5.
[00691] N-{[3-(4-amino-4-methylpiperidin-l-yl)-6-(2,3-dichlorophenyl)-5-methylpyrazin- 2-yl]methyl}formamide (0.017 g, 4.2 mmol) was suspended in POCb (1 mL) and stirred at 90 °C for 2 hrs then at room temperature overnight. POCh was removed under reduced pressure. Purification by preparative HPLC resulted in 3.4 mg (21%) of l-(5-(2,3- dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl)-4-methylpiperidin-4-amine. ¾ NMR (400 MHz, OMSO-d6) δ 8.28 (s, 1H), 7.93 - 7.83 (m, 2H), 7.64 - 7.50 (m, 3H), 4.07 - 3.97 (m, 2H), 3.82 - 3.72 (m, 2H), 1.95 (s, 3H), 1.76 - 1.61 (m, 4H), 1.34 - 1.19 (m, 3H); LC-MS (ESI) m/z: [M + H] calculated for C19H22CI2N5 : 390.1; found 390.3.
Example 3. Synthesis of (lR)-8-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8- yl]-8-azaspiro[4.5]decan-l -amine.
[00692] (lR)-8-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl]-8- azaspiro[4.5]decan-l -amine was synthesized in the was synthesized in the manner similar to Example 2, except tert-Butyl N-[l-(3-cyano-6-methylpyrazin-2-yl)-4-methylpiperidin-4- yl]carbamate was substituted with tert-butyl (R)-(8-azaspiro[4.5]decan-l-yl)carbamate. ¾ MR 1H MR (400 MHz, DMSO- d6) δ 7.89 - 7.80 (m, 2H), 7.61 - 7.52 (m, 3H), 4.48 - 4.33 (m, 2H), 2.73 (t, J = 7.4 Hz, 1H), 1.94 (s, 3H), 1.92 - 1.79 (m, 2H), 1.78 - 1.16 (m, 8H). LC-MS (ESI) m/z: [M + H] calculated for C22H26CI2N5 : 431.3; found 431.5
Example 4. Synthesis of (lR)-8-[6-amino-5-(2,3-dichlorophenyl)imidazo[l,5-a]pyrazin-8- yl]-8-azaspiro[4.5]decan-l -amine.
Figure imgf000199_0001
Step 1.
[00693] 3-Bromo-6-chloropyrazine-2-amine (5.00 g, 24.0 mmol) and Na2C03 10H2O (20.6 g, 72.0 mmol) were suspended in mixture dioxane: water, 4: 1. The solvent was degassed by passing argon through it and Pd(dppf)Ch (0.88 g, 1.20 mmol) was added. The reaction was carried out 6 hrs at 110 °C. The reaction mixture was filtered through celite pad (AcOEt). The residue was purified by column chromatography (hexane: AcOEt, 9: 1 -> 4: 1) to give 4.63 g (70%) of 6-chloro-3-(2,3-dichlorophenyl)pyrazin-2-amine. ¾ NMR (400 MHz, DMSO- d6) δ 7.85 (s, 1H), 7.74 (dd, J = 8.0, 1.6 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.39 (dd, J = 7.6, 1.6 Hz, 1H), 6.70 (s, 2H). LC-MS (ESI) m/z: [M + H] found 275.7.
Step 2.
[00694] 6-Chloro-3-(2,3-dichlorophenyl)pyrazin-2-amine (1.8 g, 6.56 mmol) was dissolved in DMF, then cooled down to 0 °C. At this temperature, BS (1.75 g, 9.83 mmol) in one portion was added. The reaction was carried out at room temperature overnight. The reaction mixture was partitioned between DCM and water and the organic phase was washed with water and brine. Next, the combined water phases were extracted with DCM. The combined organic phases were dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give 2.14 g (92%) of 5- bromo-6-chloro-3-(2,3-dichlorophenyl)pyrazin-2-amine. ¾ NMR (400 MHz, DMSO- d6) δ 7.76 (dd, J = 7.8, 1.8 Hz, 1H), 7.52 - 7.43 (m, 2H), 6.92 (s, 2H).
Step 3.
[00695] 5-Bromo-6-chloro-3-(2,3-dichlorophenyl)pyrazin-2-amine (2.14 g, 6.05 mmol) was dissolved in anhydrous DMF, then CuCN (1.09 g, 12.1 mmol) was added. The reaction was carried out overnight at 100 °C. The reaction mixture was filtered through celite pad and the filtrate was concentrated under reduced pressure. The crude product (3.2 g, 176%) was used in next step without purification. ¾ NMR (300 MHz, DMSO- d6) δ 7.97 (s, 2H), 7.78 (d, J = 7.6 Hz, 1H), 7.56 - 7.39 (m, 2H). LC-MS (ESI) m/z: [M - H] found 498.6 (negative ionization).
Step 4.
[00696] 5-Amino-3-chloro-6-(2,3-dichlorophenyl)pyrazine-2-carbonitrile (1.81 g, 6.04 mmol) was suspended in ACN, then B0C2O (4.62 g, 21.2 mmol) was added followed by DMAP (0.04 g, 0.30 mmol). The reaction was carried out at room temperature overnight, then the next portion of DMAP (0.22 g, 1.81 mmol) was added. The reaction was continued at room temperature for 4 hrs. The solvent was removed under reduced pressure and the residue was adsorbed on silica gel for purification. The crude product was purified by column chromatography to give 1.09 g (45%) tert-butyl N-[6-chloro-5-cyano-3-(2,3- dichlorophenyl)pyrazin-2-yl]carbamate. ¾ MR (300 MHz, DMSO- d6) δ 10.65 (s, 1H), 7.76 (dd, J = 7.6, 2.0 Hz, 1H), 7.54 - 7.42 (m, 2H), 1.30 (s, 9H). LC-MS (ESI) m/z: [M - H] found 398.5 (negative ionization).
Step 5.
[00697] tert-Butyl N-[6-chloro-5-cyano-3-(2,3-dichlorophenyl)pyrazin-2-yl]carbamate (1.09 g, 2.73 mmol) and DIPEA (1.43 mL, 8.18 mmol) were dissolved in anhydrous DMF. After 15 minutes, N-{8-azaspiro[4.5]decan-l-yl}-2-methylpropane-2-sulfinamide (0.78 g, 3.00 mmol) was added and the reaction was carried out at room temperature overnight. The reaction mixture was partitioned between AcOEt and water. The separated water layer was extracted with AcOEt. The combined organic phases were dried over MgS04, filtered and concentrated under reduced pressure. The resulting residue was purified by a column chromatography to give tert-butyl N-[5-cyano-3-(2,3-dichlorophenyl)-6-[(lR)-l-[(2- methylpropane-2-sulfinyl)amino]-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]carbamate (1.18 g, 70%). ¾ MR (400 MHz, DMSO- d6) δ 9.80 (s, 1H), 7.66 (dd, J = 6.9, 2.7 Hz, 1H), 7.46 - 7.39 (m, 2H), 5.05 (d, J = 8.1 Hz, 1H), 4.55 - 4.40 (m, 2H), 3.28 - 3.12 (m, 3H), 2.01 - 1.82 (m, 4H), 1.76 - 1.61 (m, 3H), 1.53 - 1.45 (m, 1H), 1.42 - 1.32 (m, 2H), 1.28 (s, 9H), 1.12 (s, 9H). LC-MS (ESI) m/z: [M + H] found 622.9.
Step 6.
[00698] tert-Butyl N-[5-cyano-3-(2,3-dichlorophenyl)-6-[(lR)-l-[(2-methylpropane-2- sulfinyl)amino]-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]carbamate (0.50 g, 0.80 mmol) was dissolved in anhydrous DCM and cooled to -78 °C. A 1 M solution of DIBAL-H in hexane (2.41 mL, 2.41 mmol) was added dropwise and the reaction was carried out at -78 °C for 2 hrs and mixture was allowed to warm to 0 °C. The reaction was then quenched by addition of NaHC03 sat. aq., followed by Rochelle's salt sat. aq. This resulting mixture was stirred until the organic and water layers separated. The aqueous layer was extracted with DCM. The combined organic phases were dried over Na2S04 and concentrated under reduced pressure to give crude tert-butyl N-[5-(aminomethyl)-3-(2,3-dichlorophenyl)-6-[(lR)-l-[(2- methylpropane-2-sulfinyl)amino]-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]carbamate (0.48 g, 95% yield) which was used in next step without further purification. ¾ NMR (400 MHz, OMSO-d6) δ 9.27 (s, 1H), 7.65 - 7.57 (m, 1H), 7.46 - 7.34 (m, 2H), 5.06 - 4.88 (m, 1H), 3.95 - 3.83 (m, 1H), 3.80 (s, 2H), 3.62 - 3.51 (m, 1H), 3.20 (q, J = 7.7 Hz, 1H), 3.08-3.00 (m, 1H), 2.91 (q, J = 12.7 Hz, 2H), 2.14 - 1.98 (m, 1H), 1.97 - 1.88 (m, 1H), 1.87 - 1.72 (m, 2H), 1.69 - 1.50 (m, 4H), 1.48-1.41 (m, 1H), 1.40 - 1.30 (m, 2H), 1.21 (s, 9H), 1.14 (s, 9H). LC- MS (ESI) m/z: [M + H] found 626.6.
Step 7.
[00699] tert-Butyl N-[5-(aminomethyl)-3-(2,3-dichlorophenyl)-6-[(lR)-l-[(2- methylpropane-2-sulfinyl)amino]-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]carbamate (0.48 g, 0.77 mmol) was dissolved in anhydrous DCM and cooled to 0 °C. Acetic formic anhydride (0.39 mL, 5.37 mmol) was added dropwise and the reaction was allowed to stir overnight at 4 °C. Water (5 mL) was added, the layers were separated, and aqueous phase was extracted with DCM. The combined organic phases were dried over Na2S04, and concentrated under reduced pressure. The residue was purified by column column chromatography to give 0.27 g (54%) of tert-butyl N-[3-(2,3-dichlorophenyl)-5-(formamidomethyl)-6-[(lR)-l-[(2- methylpropane-2-sulfinyl)amino]-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]carbamate as a pale yellow solid. ¾ NMR (400 MHz, OMSO-d6) δ 9.33 (s, 1H), 8.38 - 8.28 (m, 1H), 8.10 (d, J = 1.6 Hz, 1H), 7.64 - 7.59 (m, 1H), 7.43 - 7.38 (m, 2H), 4.98 (d, J = 7.8 Hz, 1H), 4.43 (d, J = 5.6 Hz, 2H), 3.51 (s, 2H), 3.20 (q, J = 7.8 Hz, 1H), 2.94 (q, J = 12.1 Hz, 2H), 2.04 - 1.90 (m, 2H), 1.83 - 1.73 (m, 2H), 1.68 - 1.61 (m, 2H), 1.58 - 1.52 (m, 1H), 1.49 - 1.42 (m, 1H), 1.40-1.34 (m, 1H), 1.35 - 1.27 (m, 2H), 1.21 (s, 9H), 1.14 (s, 9H). LC-MS (ESI) m/z: [M + H] found 654.8.
Step 8.
[00700] tert-Butyl N-[3-(2,3-dichlorophenyl)-5-(formamidomethyl)-6-[(lR)-l-[(2- methylpropane-2-sulfinyl)amino]-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]carbamate (0.10 g, 0.15 mmol) was mixed with polyphosphoric acid (1.00 g, 10.2 mmol). The reaction mixture was heated to 100 °C and reaction was carried out at this temperature for 1 hr. The resulting mixture was concentrated under reduced pressure. Purification by preparative HPLC resulted in (lR)-8-[6-amino-5-(2,3-dichlorophenyl)imidazo[l,5-a]pyrazin-8-yl]-8-azaspiro[4.5]decan- 1-amine as a formate salt. ¾ NMR (300 MHz, Methanol-^) δ 8.49 (s, 3H), 7.81 - 7.67 (m, 2H), 7.55 - 7.46 (m, 2H), 7.41 (s, 1H), 4.45 - 4.25 (m, 2H), 3.66 - 3.54 (m, 2H), 2.35 (t, J = 7.4 Hz, 2H), 2.14 - 1.96 (m, 5H), 1.89 - 1.78 (m, 2H), 1.65 - 1.55 (m, 2H), 1.39 - 1.27 (m, 2H). LC-MS (ESI) m/z: [M+l]+ calculated for C21H25N6CI2: 431.1; found 431.2.
Example 5. Synthesis of l-[6-amino-5-(2,3-dichlorophenyl)imidazo[l,5-a]pyrazin-8-yl]-4- methylpiperidin-4-amine.
Figure imgf000203_0001
Step 1.
[00701] tert-Butyl N-[6-chloro-5-cyano-3-(2,3-dichlorophenyl)pyrazin-2-yl]carbamate (0.7 g, 1.75 mmol) and DIPEA (0.92 mL, 5.25 mmol) were dissolved in anhydrous DMF. After 15 minutes, tert-butyl (4-methylpiperidin-4-yl)carbamate (0.45 g, 0.21 mmol) was added and the reaction was allowed to stirr at room temperature over 72 hrs. The reaction mixture was diluted with EtOAc and washed with 5% NaCl solution. The organic phase was dried over Na2S04, filtered and concentrated under reduced pressure to give tert-butyl N-[6- (4-amino-4-methylpiperidin-l-yl)-5-cyano-3-(2,3-dichlorophenyl)pyrazin-2-yl]carbamate (0.99 g, 99%). ¾ MR (300 MHz, OMSO-d6) δ 7.66 (dd, J = 7.4, 2.2 Hz, 1H), 7.47 - 7.36 (m, 2H), 6.70 (s, 1H), 4.13 (d, J = 13.8 Hz, 2H), 3.45 (t, J = 11.9 Hz, 2H), 2.18 (d, J = 13.6 Hz, 2H), 1.63 - 1.47 (m, 2H), 1.41 (s, 9H), 1.28 (s, 12H).
Step 2.
[00702] tert-Butyl N-[6-(4-amino-4-methylpiperidin-l-yl)-5-cyano-3-(2,3- dichlorophenyl)pyrazin-2-yl]carbamate (0.83 g, 1.44 mmol) was dried overnight on vacuum pump and dissolved in anhydrous DCM. The solution was cooled to -60 °C and 1 M DIBAL- H in hexane (10 mL, 10.1 mmol) was added dropwise. The reaction was carried out at -30 °C for 4 hrs. After this time, the reaction mixture was allowed to warm to 0 °C. The reaction was then quenched by addition of H4CI sat. aq., followed by sodium potassium tartrate sat. aq. This resulting mixture was stirred until organic and water layers separated. The water layer was extracted with DCM. The combined organic phases were dried over Na2S04 and concentrated under reduced pressure to give crude tert-butyl N-[6-(4-amino-4- methylpiperidin-l-yl)-5-(aminomethyl)-3-(2,3-dichlorophenyl)pyrazin-2-yl]carbamate (0.6 g, 71% yield) which was used in next step without further purification. ¾ MR (400 MHz, OMSO-d6) δ 7.68 - 7.55 (m, 1H), 7.46 - 7.35 (m, 2H), 6.56 (s, 1H), 3.77 (s, 2H), 3.62 - 3.47 (m, 2H), 3.09 (m, 2H), 2.16 (m, 2H), 1.58 (m, 2H), 1.39 (s, 9H), 1.28 (s, 3H). LC-MS (ESI) m/z: [M + H] found 582.4.
Step 3.
[00703] rert-Butyl N-[6-(4-amino-4-methylpiperidin-l-yl)-5-(aminomethyl)-3-(2,3- dichlorophenyl)pyrazin-2-yl]carbamate (0.6 g, 1.38 mmol) was dissolved in anhydrous DCM and cooled to 0 °C in ice bath. Acetic formic anhydride (0.70 mL, 9.63 mmol) was added dropwise and the reaction was continued overnight at 4 °C. The reaction was quenched by addition of water. The layers were separated and the next water phase was extracted with DCM. The combined organic phases were dried over Na2S04 and concentrated under reduced pressure. The residue was purified by column chromatography to give 0.30 g (36%) of tert- butyl N-[6-(4-amino-4-methylpiperidin-l-yl)-3-(2,3-dichlorophenyl)-5-(formamidomethyl) pyrazin-2-yl]carbamate as a pale yellow solid. ¾ MR (400 MHz, DMSO-<f<5) δ 9.35 (s, 1H), 8.34 (d, J = 6.1 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.62 (dt, J = 7.6, 3.7 Hz, 1H), 7.47 - 7.34 (m, 2H), 6.59 (s, 1H), 4.43 (d, J = 5.6 Hz, 2H), 3.30 - 3.21 (m, 3H), 3.10 (t, J = 11.7 Hz, 2H), 2.17 (d, J = 13.2 Hz, 2H), 1.70 - 1.54 (m, 3H), 1.41 (s, 9H), 1.30 (s, 3H). LC-MS (ESI) m/z: [M + H] found 610.2.
Step 4.
[00704] rer/-Butyl N-[6-(4-amino-4-methylpiperidin-l-yl)-3-(2,3-dichlorophenyl)-5- (formamidomethyl) pyrazin-2-yl]carbamate (0.15 g, 0.25 mmol) was mixed with POCb (1.5 mL, 16.1 mmol). The reaction mixture was heated up to 90 °C and allowed to stir for 3 hrs. POCh was removed under reduced pressure. Purification by preparative HPLC resulted in 4.5 mg of l-[6-amino-5-(2,3-dichlorophenyl)imidazo[l,5-a]pyrazin-8-yl]-4-methylpiperidin-4- amine. ¾ NMR (400 MHz, DMSO-i¾) δ 8.36 (s, 1H), 7.82 - 7.72 (m, 2H), 7.56 - 7.46 (m, 2H), 7.36 (s, 1H), 4.64 (s, 2H), 4.06 (s, 2H), 3.71 (s, 2H), 1.72 (s, 4H), 1.32 (s, 3H). LC-MS (ESI) m/z: [M+l]+ calculated for C18H21N6CI2: 391.1; found 391.2. Example 6. Synthesis of (3,S',4)S)-8-{5-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-6- methylimidazo[l,2-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000205_0001
Step 1.
[00705] To a solution of propane- 1,2-diamine (46.28 g, 624.34 mmol, 53.32 mL) in EtOH (2000 mL) was added diethyl propanedioate (100 g, 624.34 mmol, 94.34 mL) at 0 °C. The mixture was stirred at 25 °C for 1.5 hrs, then heated to 120 °C and stirred for 20 hrs under O2. The resulting mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford ethyl 3-hydroxy-5-methyl-pyrazine-2- carboxylate (24 g, 658.70 mmol, 21.10% yield) as a white solid. LCMS (ESI): m/z: [M +H] calculated for C8H11N2O3: 183.07; found 183.1.
Step 2.
[00706] To a solution of ethyl 3-hydroxy-5-methyl-pyrazine-2-carboxylate (166 g, 911.21 mmol) in DCM (1500 mL) was added NBS (178.40 g, 1.00 mol) in one portion at 0 °C under N2. The mixture was stirred at 25 °C for 10 min. The resulting mixture was diluted with saturated aq.Na2S03 (1000 mL) and the aqueous phase was extracted with DCM. The combined organic phase was washed with brine (50 mL), dried with anhydrous Na2S04, and concentrated under reduced pressure to afford ethyl 6-bromo-3-hydroxy-5-methyl-pyrazine- 2-carboxylate (230 g, crude) as a dark brown solid. ¾ MR (400 MHz, CDC13-d) δ ppm 4.54 (q, J=7.13 Hz, 2 H) 2.77 (s, 1 H) 2.68 (s, 3 H) 1.46 (t, J=7.09 Hz, 3 H) Step 3.
[00707] To a solution of ethyl 6-bromo-3-hydroxy-5-methyl-pyrazine-2-carboxylate (115 g, 440.49 mmol) and K2CO3 (182.64 g, 1.32 mol) in DMF (2.1 L) was added PMB-C1 (103.48 g, 660.74 mmol, 89.98 mL) in one portion at 20 °C under N2. The mixture was stirred at 50 °C for 2 hr. The resulting mixture was diluted with water and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with brine (200 mL), dried with anhydrous Na2S04, and concentrated under reduced pressure. The remaining residue was purified by column chromatography to afford ethyl 6-bromo-3-[(4- methoxyphenyl)methoxy]-5-methyl-pyrazine-2-carboxylate (60 g, 35.73% yield) as a white solid. LCMS (ESI): m/z [M +Na] calculated for
Figure imgf000206_0001
403.04; found 403.1.
Step 4.
[00708] To a solution of ethyl 6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl- pyrazine-2-carboxylate (150 g, 393.47 mmol) in MeOH (1300 mL) was added a solution of LiOH (47.12 g, 1.97 mol) in H2O (400 mL) at 25 °C. The mixture was stirred at 25 °C for 15 hrs. To the resulting mixture was added aqueous HC1 (1M) drop wise into the reaction mixture until pH = 6 was reached. The resulting mixture was diluted with H2O (2000 mL) and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with brine (100 mL), dried with anhydrous Na2S04, and concentrated under reduced pressure to afford 6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazine-2-carboxylic acid (138 g, crude) as a light yellow solid. LCMS (ESI): m/z [M +Na] calculated for Ci4Hi3BrN204Na: 375.01; found 375.1.
Step 5.
[00709] To a solution of 6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazine-2- carboxylic acid (100 g, 283.15 mmol) and DPPA (116.89 g, 424.73 mmol, 92.04 mL) in toluene (1800 mL) was added TEA (57.30 g, 566.30 mmol, 78.82 mL) and t-BuOH (209.87 g, 2.83 mol, 270.80 mL) in one portion under N2. The resulting mixture was stirred at 110 °C for 1 hr. The mixture was diluted with H2O (1000 mL) and the aqueous phase was extracted with EtOAc. The combined organic fractions were washed with brine (10 mL), dried with anhydrous Na2S04, and concentrated under reduced pressure. The remaining residue was purified by column chromatography (S1O2, petroleum ether/ethyl acetate=10: l to 0: 1) to give 6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazin-2-amine (5 g, 15.42 mmol, 5.45% yield) and tert-butyl N-[6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazin-2- yljcarbamate (90 g, 212.12 mmol, 74.91% yield) as white solids. LCMS (ESI): m/z [M +H] calculated for CiuHzsBrNsCU: 424.08; found 424.2.
Step 6.
[00710] To a solution of K2CO3 (87.95 g, 636.36 mmol) in MeOH (1000 mL) was added tert-butyl N-[6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazin-2- yl]carbamate (90 g, 212.12 mmol) in one portion at 70 °C. The reaction was stirred at 70 °C for 15 hrs. The resulting reaction mixture was filtered and concentrated under reduced pressure to afford 6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazin-2-amine (90 g, crude) as a white solid. ¾ NMR (400 MHz, CDC13-d) δ ppm 7.38 (d, J=8.68 Hz, 2 H) 6.99 - 6.86 (m, 2 H) 5.30 (s, 2 H) 4.87 (br s, 2 H) 3.87 - 3.77 (m, 3 H) 2.49 - 2.38 (m, 3 H).
Step 7.
[00711] To a 40% solution of 2-chloroacetaldehyde (272.42 g, 1.39 mol, 223.29 mL) in H2O was added 6-bromo-3-[(4-methoxyphenyl)methoxy]-5-methyl-pyrazin-2-amine (50 g, 154.24 mmol) at 25 °C. The reaction was stirred at 120 °C for 1 hr. The resulting residue was purified by reverse phase column chromatography to afford 5-bromo-6-methyl- imidazo[l,2-a]pyrazin-8-ol (7 g, 30.70 mmol, 19.90% yield) as a white solid. LCMS (ESI): m/z [M +H] calculated for CvHvBrNsO: 227.97; found 228.1.
Step 8.
[00712] A solution of 5-bromo-6-methyl-imidazo[l,2-a]pyrazin-8-ol (5 g, 21.93 mmol) and TEA (2.22 g, 21.93 mmol, 3.05 mL) in POCh (100.86 g, 657.76 mmol, 61.12 mL) was heated to 120 °C for 0.5 h. The resulting reaction mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate (200 mL) and sat.aq. NaHCCb (400 mL). The organic layer was removed, washed with water, dried over Na2S04 and concentrated under reduced pressure. The remaining residue was purified by column chromatography (S1O2, Petroleum ether/Ethyl acetate=15: l) to afford 5-bromo-8-chloro-6- methyl-imidazo [1,2-a] pyrazine (3.83 g, 10.78 mmol, 49.19%) yield, 69.41%) purity) as a white solid. ¾ NMR (400 MHz, CDC13-d) δ ppm 7.93 (d, J=0.88 Hz, 1 H) 7.87 (d, J=1.10 Hz, 1 H) 2.66 (s, 3 H) LCMS: m/z: [M +H] calculated for CvHsBrClNs: 245.94; found 245.9. Step 9.
[00713] To a solution of 5-bromo-8-chloro-6-methylimidazo[l,2-a]pyrazine (135 mg, 547 μηιοΐ) in DMA (5.46 mL) was added (3,S', )S)-4-ammonio-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-ium chloride (159 mg, 656 μιηοΐ) and DIPEA (474 μΐ^, 2.73 mmol). The reaction mixture was stirred at 100 °C for 1 h. The resulting reaction mixture was concentrated under reduced pressure and the remaining residue was purified by column chromatography (0-10% MeOH/CH2Cl2) to afford (3^,45)-8-(5-bromo-6-methylimidazo[l,2- a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine. LCMS (ESI): m/z: [M + H] calculated for Ci6H23BrN50: 380.1; found 380.4.
Step 10.
[00714] A vial was charged with (3,S',4)S)-8-(5-bromo-6-methylimidazo[l,2-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (162 mg, 425 μπιοΐ), potassium 2-amino- 3-chloropyridine-4-thiolate (126 mg, 637 μπιοΐ), Pd2(dba)3 (23.2 mg, 25.4 μπιοΐ), Xantphos (24.5 mg, 42.5 μπιοΐ). The reaction vial was evacuated and purged with N2 three times. Dioxane and DIPEA (221 μΐ., 1.27 mmol) were added and the reaction mixture was stirred at 140 °C for 2 hrs. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The remaining residue was purified by prep phase HPLC to afford (3^,4,5)- 8-(5-((2-amino-3-chloropyridin-4-yl)thio)-6-methylimidazo[l,2-a]pyrazin-8-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-amine (60.0 mg, 130 μπιοΐ, 30.7 %) as the formic acid salt. ¾ MR (500 MHz, Methanol-^) δ 8.53 (s, 1H), 7.73 (d, J = 1.2 Hz, 1H), 7.55 (d, J = 5.5 Hz, 1H), 7.51 (d, J = 1.2 Hz, 1H), 5.74 (d, J = 5.6 Hz, 1H), 5.23 (dd, J = 31.5, 13.9 Hz, 3H), 4.38 - 4.24 (m, 1H), 4.02 (d, J = 9.0 Hz, 1H), 3.90 (d, J = 9.1 Hz, 1H), 3.69 - 3.51 (m, 2H), 2.50 (s, 3H), 1.97 - 1.86 (m, 3H), 1.75 (d, J = 13.3 Hz, 1H), 1.31 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z: [M + H] calculated for C2iH27ClN7OS: 460.2; found 460.5.
Example 7. Synthesis of (3,S', )S)-8-(5-(3-chlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000208_0001
[00715] A vial was charged with (3,S', )S)-8-(5-bromo-6-methylimidazo[l,2-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (125 mg, 328 μπιοΐ), (3- chlorophenyl)boronic acid (61.4 mg, 393 μηιοΐ), Pd(dppf)Cl2 · DCM (53.5 mg, 65.6 μηιοΐ), and K2CO3 (181 mg, 1.31 mmol). The vial was then evacuated and purged with N2 three times. Degassed ACN (3.28 mL) was added and the reaction mixture was stirred at 105 °C for 2 hrs. The resulting reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The remaining residue was purified by prep HPLC to afford (3S,4S)-8-(5- (3-chlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan- 4-amine (48.0 mg, 116 μιηοΐ, 35.5 %) as the formic acid salt. ¾ NMR (500 MHz, Methanol- d4) δ 8.53 (s, 1H), 7.61 - 7.53 (m, 2H), 7.48 (dd, J = 4.8, 1.6 Hz, 2H), 7.39 (dt, J = 7.0, 1.8 Hz, 1H), 7.20 (d, J = 1.2 Hz, 1H), 5.06 - 4.89 (m, 3H), 4.31 (qd, J = 6.6, 4.4 Hz, 1H), 4.00 (d, J = 9.0 Hz, 1H), 3.89 (d, J = 9.0 Hz, 1H), 3.45 (dddd, J = 35.4, 13.9, 10.8, 3.1 Hz, 2H), 2.17 (s, 3H), 2.00 - 1.81 (m, 3H), 1.77 - 1.69 (m, 1H), 1.31 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z: [M + H] calculated for C22H27CIN5O: 412.2; found 412.4.
Example 8. Synthesis of (3,S', )S)-8-(5-(lH-indazol-6-yl)-6-methylimidazo[l,2-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000209_0001
[00716] (3^ 5)-8-(5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl)-3-methyl- 2-oxa-8-azaspiro[4.5]decan-4-amine was synthesized in the manner similar to Example 7, except (3-chlorophenyl)boronic acid was replaced with (lH-indazol-6-yl)boronic acid. The product was isolated as the formic acid salt. ¾ NMR (500 MHz, methanol-^) δ 8.54 (s, 1H), 8.19 (d, J = 1.0 Hz, 1H), 8.01 (dd, J = 8.3, 0.9 Hz, 1H), 7.64 (q, J = 1.1 Hz, 1H), 7.47 (d, J = 1.2 Hz, 1H), 7.23 - 7.13 (m, 2H), 4.37 - 4.26 (m, 1H), 4.00 (d, J = 8.9 Hz, 1H), 3.89 (d, J = 8.9 Hz, 1H), 3.58 - 3.39 (m, 3H), 2.67 (s, 2H), 2.21 (s, 3H), 2.02 - 1.82 (m, 3H), 1.75 (d, J = 13.2 Hz, 1H), 1.31 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M + H] calculated for C23H28N7O: 418.2; found 418.5.
Example 9. Synthesis of (3,S',4)S)-8-(5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin- 8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000209_0002
[00717] To a vial was added (3,S', )S)-8-(5-bromo-6-methylimidazo[l,2-a]pyrazin-8-yl)-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (100 mg, 262 μηιοΐ), (2,3- dichlorophenyl)boronic acid (59.9 mg, 314 μmol), Antphos (19.4 mg, 52.4 μιηοΐ), Pd(OAc)2 (5.88 mg, 26.2 μιηοΐ), and Κ3(ΡΟ)4 (166 mg, 786 μιηοΐ). The mixture was evacuated under reduced pressure for 10 min before adding in degassed dioxane (2.61 mL). The resulting mixture was degassed and allowed to stir at 125 °C overnight in the capped vial. The resulting reaction mixture was filtered through a pad of celite washing with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by prep HPLC to yield (3,S',4)S)-8-(5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl)- 3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (17.0 mg, 38.0 μπιοΐ, 14.6 %) as the formic acid salt. ¾ MR (500 MHz, methanol-^) δ 8.56 (s, 1H), 7.78 (dd, J = 8.1, 1.6 Hz, 1H), 7.60 - 7.51 (m, 1H), 7.51 - 7.39 (m, 2H), 7.01 (d, J = 1.2 Hz, 1H), 4.91 (d, J = 2.1 Hz, 1H), 4.84 - 4.79 (m, 1H), 4.35 - 4.24 (m, 1H), 3.96 (d, J = 8.8 Hz, 1H), 3.83 (d, J = 8.7 Hz, 1H), 3.73 - 3.51 (m, 2H), 3.17 (d, J = 4.7 Hz, 1H), 2.10 (s, 3H), 2.04 - 1.85 (m, 3H), 1.77 (dd, J = 33.3, 13.4 Hz, 1H), 1.27 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M + H] calculated for C22H26CI2N5O: 446.1; found 446.3.
Example 10. Synthesis of (3,S',4)S)-8-(5-(3-chloro-2-fluorophenyl)-6-methylimidazo[l,2- a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
[00718] (35',45)-8-(5-(3-chloro-2-fluorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl)-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine was synthesized in the manner similar to Example 9, except (2,3-dichlorophenyl)boronic acid was substituted with (3-chloro-2- fluorophenyl)boronic acid. ¾ NMR (500 MHz, methanol-^) δ 7.72 (ddd, J = 7.8, 7.1, 1.9 Hz, 1H), 7.53 - 7.35 (m, 3H), 7.17 (q, J = 1.5 Hz, 1H), 4.99 - 4.88 (m, 2H), 4.37 - 4.23 (m, 1H), 3.97 (d, J = 8.8 Hz, 1H), 3.84 (d, J = 8.7 Hz, 1H), 3.73 - 3.44 (m, 2H), 3.18 (d, J = 5.0 Hz, 1H), 2.16 (d, J = 1.6 Hz, 3H), 2.00 - 1.85 (m, 3H), 1.84 - 1.69 (m, 1H), 1.28 (dd, J = 6.5, 1.6 Hz, 3H). LCMS (ESI): m/z [M +H] calculated for C22H26CIFN5O: 430.2; found 430.4. Example 11. Synthesis of ( ,S', )S^-8-[5-(3-chlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8- yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000211_0001
Step 1.
[00719] To a solution of methyl lH-imidazole-5-carboxylate (96 g, 761.22 mmol) and 1- chloropropan-2-one (105.65 g, 1.14 mol) in ACN (2 L) was added K2CO3 (210.41 g, 1.52 mol) in one portion at 75 °C. The mixture was stirred at 75 °C for 1 hr. Upon completion, the reaction mixture was filtered and the filtrate was evaporated under reduced pressure. The remaining residue was triturated with EtOAc (500 mL) and filtered. The resulting filtrate was concentrated under reduced pressure to afford methyl 3-acetonylimidazole-4-carboxylate (144 g, 41.54% yield) as a yellow solid. LCMS: m/z [M+H] calculated for CsHnNiCb:
183.07; found 183.3.
Step 2.
[00720] To a solution of methyl 3-acetonylimidazole-4-carboxylate (130 g, 713.59 mmol) in CH3COOH (700 mL) was added CH3COO H4 (275.03 g, 3.57 mol) in one portion at 130 °C. The reaction mixture was stirred at 130 °C for 48 hrs. Upon completion, the mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse-phase column chromatography to afford 6-methylimidazo[l,5-a]pyrazin-8-ol (40 g, 230.64 mmol, 32.32% yield) as a yellow solid. LCMS: m/z [M+H] calculated for C8H11N2O3: 150.06; found 150.02.
Step 3.
[00721] To a solution of 6-methylimidazo[l,5-a]pyrazin-8-ol (10 g, 67.05 mmol) in DMF (300 mL) was added NBS (12.17 g, 68.39 mmol) in one portion at 0 °C. The mixture was stirred at 0 °C for 5 min. Upon completion, the reaction mixture was quenched by the addition of aq.Na2S03 (60 mL), which caused the product to crash out as a white solid. The solid was filtered and the filter cake was dried under reduced pressure to afford 5-bromo-6- methyl-imidazo[l,5-a]pyrazin-8-ol (11.1 g, 72.6% yield) as a white solid. 1H MR (400 MHz, OMSO-d6) δ ppm 11.13 (br s, 1 H) 8.28 (s, 1 H) 7.88 (s, 1 H) 2.18 (s, 3 H).
Step 4.
[00722] To a solution of 5-bromo-6-methyl-imidazo[l,5-a]pyrazin-8-ol (8.9 g, 39.03 mmol) was added POCh (146.85 g, 957.73mmol, 89 mL) in one portion at 25 °C under a positive pressure of nitrogen. The mixture was heated to 120 °C and stirred for 45 minutes at 120 °C. Upon completion, the excess POCh was removed under reduced pressure. The mixture was then quenched with sat.aq.NaHCCb (100 mL) to remove any remaining POCh. The resulting mixture was poured into water (300 mL) and stirred for 2 min. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with water and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford 5-bromo-8-chloro-6-methyl-imidazo[l,5-a]pyrazine (7.8 g, 78.24% yield) as a yellow solid. 1H MR (400 MHz, methanol-^) δ ppm 8.63 (s, 1 H) 7.97 (s, 1 H) 2.53 (s, 3 H) LCMS: m/z: [M+H] calculated for CvHeBrClNs: 245.94; found 245.90.
Step 5.
[00723] 5-bromo-8-chloro-6-methylimidazo[l,5-a]pyrazine (450 mg, 1.82 mmol) was added to a flask containing 2-methyl-N-((3,S', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl)propane-2-sulfinamide (842 mg, 2.18 mmol) and DMA (9.09 mL), followed by DIEA (1.58 mL, 9.10 mmol). The mixture was stirred at 130 °C for 20 min, at which point LCMS indicated almost complete conversion to product. The solvent was removed under reduced pressure and the residue was partitioned between water/NH4OH and EtOAc. The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were dried over MgS04 and the solvent was removed under reduced pressure. The crude residue was purified by silica gel chromatography to give N-f^.^-S-IS-bromo-e- methylimidazo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]-2- methylpropane-2-sulfinamide (364 mg, 41.3 %) as a yellow oil. LC-MS (ESI): m/z: [M + H] calculated for CieHiiBrNsO: 380.1; found 380.1.
Step 6.
[00724] N-[(35',45)-8-{5-bromo-6-methylimidazo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide (90 mg, 185 μπιοΐ), [Ι, - Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (30.2 mg, 37.0 μηιοΐ), K2CO3 (102 mg, 740 μηιοΐ) and (3-chlorophenyl)boronic acid (37 mg, 240 μηιοΐ) were weighed into a 2 dram vial equipped with a screw cap septum and a stirbar. The reaction vessel was flushed 3 times with N2. ACN (1.84 mL, degassed by purging with N2 for 1 h) was added against N2 and the headspace of the reaction vessel was flushed 3 times with N2. The mixture was placed into a heating block preheated at 105 °C and stirred vigorously for 1.5 hrs. The mixture was filtered over celite, evaporated to dryness and redissolved in MeOH (4 mL). HC1 (4 N in dioxane, 2 mL) was added and the mixture was stirred at room
temperature for 10 min. The solvent was removed under reduced pressure and the crude product was purified by preparative HPLC to give ( ,S', )S^-8-[5-(3-chlorophenyl)-6- methylimidazo[l,5-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (22.1 mg, 53.6 μιηοΐ, 29 %) as a white solid. ¾ NMR (500 MHz, methanol-***) δ 8.56 (s, 1H), 7.81 (s, 1H), 7.69 (s, 1H), 7.65 - 7.56 (m, 2H), 7.52 (td, J = 1.7, 0.6 Hz, 1H), 7.42 (dt, J = 7.0, 1.7 Hz, 1H), 4.45 - 4.35 (m, 2H), 4.35 - 4.30 (m, 1H), 4.00 (d, J = 9.0 Hz, 1H), 3.89 (d, J = 9.0 Hz, 1H), 3.48 (ddd, J = 13.8, 10.4, 3.5 Hz, 1H), 3.40 (ddd, J = 13.8, 10.9, 2.9 Hz, 1H), 3.35 - 3.33 (m, 1H), 2.12 (s, 3H), 2.00 - 1.86 (m, 3H), 1.77 (d, J = 13.2 Hz, 1H), 1.32 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z [M + H] calculated for C22H26CIN5O: 412.2; found 412.3.
Example 12. Synthesis of (3,S', )S)-8-(5-(3-chloro-2-fluorophenyl)-6-methylimidazo[l,5- a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000213_0001
Step 1.
[00725] 5-bromo-8-chloro-6-methylimidazo[l,5-a]pyrazine (850 mg, 3.44 mmol) and N- [(3S,4S)-8-chloro-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]chloranamine (903 mg, 3.78 mmol) were suspended in ACN (17.2 mL) and DIPEA (2.97 mL, 17.2 mmol) was added. The mixture was heated to 100 °C in a sealed 40 mL vial. The solvent was removed under reduced pressure and the crude residue was purified by column chromatography to give (3S, S)-8-(5-bromo-6-methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine (1.20 g, 92.3 %). LCMS (ESI): m/z [M + H] calculated for CieHiiBrNsO: 380.1; found 380.1.
Step 2.
[00726] (3S, S)-8-(5-bromo-6-methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine (465 mg, 1.21 mmol) was dissolved in DCM (3.10 mL) and B0C2O (414 μΐ., 1.81 mmol) was added, followed by TEA (250 μΐ., 1.81 mmol). The reaction was stirred at room temperature for 5 hrs and then concentrated under reduced pressure. The crude residue was purified by column chromatography to give 244 mg (42%) of tert-butyl ((3S,4S)-8-(5-bromo-6-methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl)carbamate. LCMS (ESI): m/z [M + H] calculated for C2iH3oBrN503: 480.1; found 480.2.
Step 3.
[00727] To a vial was added tert-butyl ((3,S',4)S)-8-(5-bromo-6-methylimidazo[l,5- a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (60 mg, 124 μπιοΐ), (3- chloro-2-fluorophenyl)boronic acid (25.8 mg, 148 μπιοΐ), Antphos (9.18 mg, 24.8 μπιοΐ), Pd(OAc)2 (2.78 mg, 12.4 μιηοΐ) and K3(PO)4 (78.9 mg, 372 μιηοΐ). The mixture was evacuated under house vacuum for 10 min before adding in degassed dioxane (1.24 mL). The resulting mixture was filled with N2 and evacuated three times before stirring at 125 °C overnight in the capped vial. The resulting reaction mixture was filtered through a pad of celite with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography using 10% MeOH/DCM to yield tert-butyl ((3,S',4)S)-8-(5-(3-chloro-2-fluorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-yl)carbamate. LCMS (ESI): m/z [M + H] calculated for
C27H34C1FN503: 530.2; found 530.2.
Step 4.
[00728] To a solution fert-butyl ((3S,4S)-8-(5-(3-chloro-2-fluorophenyl)-6- methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (28 mg, 52.8 μιηοΐ) in MeOH (264 \dS) was added 4 M HC1 in dioxane (132 μΐ,, 528 μιηοΐ). The reaction mixture was stirred at 40 °C for 2 hrs. The resulting reaction mixture was concentrated under reduced pressure and the residue was purified by prep HPLC to yield (3,S', )S)-8-(5-(3-chloro-2-fluorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-amine (3.0 mg, 13.2 %) as the formic acid salt. ¾ MR (500 MHz, Methanol-^) δ 8.56 (s, 3H), 7.83 (s, 1H), 7.76 - 7.66 (m, 2H), 7.50 - 7.38 (m, 2H), 4.91 (s, 1H), 4.83 (d, J = 1.8 Hz, 1H), 4.44 - 4.24 (m, 1H), 3.96 (d, J = 8.9 Hz, 1H), 3.82 (d, J = 8.8 Hz, 1H), 3.63 - 3.43 (m, 2H), 3.17 (d, J = 4.7 Hz, 1H), 2.10 (s, 3H), 2.01 - 1.87 (m, 1H), 1.79 (dd, J = 36.5, 14.2 Hz, 3H), 1.28 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M + H] calculated for C22H26CIFN5O: 430.2; found 430.1.
Example 13. Synthesis of (3,S', )S)-8-{5-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-6- methylimidazo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000215_0001
DIPEA, DMA, 130 °C N "'Me DIPEA, dioxane, 140°C, 3h N MeOH
Figure imgf000215_0002
Step 1.
[00729] To a solution of methyl lH-imidazole-5-carboxylate (96 g, 761.22 mmol) and 1- chloropropan-2-one (105.65 g, 1.14 mol) in ACN (2 L) was added K2CO3 (210.41 g, 1.52 mol) in one portion at 75 °C. The mixture was stirred at 75 °C for 1 hr. Upon completion, the reaction mixture was filtered and the filtrate was evaporated under reduced pressure. The remaining residue was triturated with EtOAc (500 mL) and filtered. The resulting filtrate was concentrated under reduced pressure to afford methyl 3-acetonylimidazole-4-carboxylate (144 g, 41.54% yield) as a yellow solid. LCMS: m/z [M+H] calculated for C8H11N2O3:
183.07; found 183.3.
Step 2.
[00730] To a solution of methyl 3-acetonylimidazole-4-carboxylate (130 g, 713.59 mmol) in CH3COOH (700 mL) was added CH3COOHNH3 (275.03 g, 3.57 mol) in one portion at 130 °C. The reaction mixture was stirred at 130 °C for 48 hrs. Upon completion, the mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse- phase column chromatography to afford 6-methylimidazo[l,5-a]pyrazin-8-ol (40 g, 32.3% yield) as a yellow solid. LCMS: m/z: [M+H] calculated for CsHnNiCb: 150.06; found 150.02.
Step 3.
[00731] To a solution of 6-methylimidazo[l,5-a]pyrazin-8-ol (10 g, 67.05 mmol) in DMF (300 mL) was added BS (12.17 g, 68.39 mmol) in one portion at 0 °C. The mixture was stirred at 0 °C for 5 min. Upon completion, the reaction mixture was quenched by the addition of aq.Na2S03 (60 mL), which caused the product to crash out as a white solid. The solid was filtered and the filter cake was dried under reduced pressure to afford 5-bromo-6- methyl-imidazo[l,5-a]pyrazin-8-ol (11.1 g, 72.6% yield) as a white solid. 1H MR (400 MHz, OMSO-d6)6 ppm 11.13 (br s, 1 H) 8.28 (s, 1 H) 7.88 (s, 1 H) 2.18 (s, 3 H).
Step 4.
[00732] To a solution of 5-bromo-6-methyl-imidazo[l,5-a]pyrazin-8-ol (8.9 g, 39.03 mmol) was added POCh (146.85 g, 957.73mmol, 89 mL) in one portion at 25 °C under a positive pressure of nitrogen. The mixture was heated to 120 °C and stirred for 45 minutes at 120 °C. Upon completion, the excess POCh was removed under reduced pressure. The mixture was then quenched with sat.aq.NaHCCb (100 mL) to remove any remaining POCh. The resulting mixture was poured into water (300 mL) and stirred for 2 min. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with water and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford 5-bromo-8-chloro-6-methyl-imidazo[l,5-a]pyrazine (7.8 g, 78.24%) yield) as a yellow solid. 1H MR (400 MHz, Methanol-^) δ ppm 8.63 (s, 1 H) 7.97 (s, 1 H) 2.53 (s, 3 H) LCMS: m/z: [M+H] calculated for C7H6BrClN3: 245.94; found 245.90.
Step 5.
[00733] To a solution of 5-bromo-8-chloro-6-methylimidazo[l,5-a]pyrazine (450 mg, 1.82 mmol) and 2-methyl-N-((3,S', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)propane-2- sulfinamide (842 mg, 2.18 mmol) in DMA (9.09 mL) was added DIEA (1.58 mL, 9.10 mmol). The resultant reaction mixture was stirred at 130 °C for 20 min. The reaction mixture was concentrated under reduced pressure and the remaining residue was partitioned between water/NH4OH and EtOAc. The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were dried over MgS04 and the solvent was removed under reduced pressure. The crude residue was purified by silica gel
chromatography to afford N-[(3,S',4)S)-8-{5-bromo-6-methylimidazo[l,5-a]pyrazin-8-yl}-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide (364 mg, 41.3 %) as a yellow oil. LC-MS (ESI): m/z: [M + H] calculated for CieHiiBrNsO: 380.1; found 380.1.
Step 6.
[00734] A vial was charged with N-((3,S',4)S)-8-(5-bromoimidazo[l,5-a]pyrazin-8-yl)-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2-methylpropane-2-sulfinamide (60 mg, 123 μπιοΐ), potassium 2-amino-3-chloropyridine-4-thiolate (36.5 mg, 184 μπιοΐ) Pd2(dba)3 (6.74 mg, 7.37 μιηοΐ), Xantphos (7.05 mg, 12.2 μιηοΐ), and DIPEA (64.1 μί, 369 μιηοΐ). The reaction vial was evacuated and purged with N2 three times. Dioxane was added and the solution was stirred at 140 °C for 3 hrs. The resultant mixture was filtered and the filtrate was
concentrated under reduced pressure. The resulting residue was purified by column chromatography (0-10% MeOH/DCM) to afford N-((3^,45)-8-(5-((2-amino-3-chloropyridin- 4-yl)thio)-6-methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)- 2-methylpropane-2-sulfinamide. LCMS (ESI): m/z [M + H] calculated for C25H35CIN7O2S2: 564.2; found 564.5.
Step 7.
[00735] To a solution of N-((3^,45)-8-(5-((2-amino-3-chloropyridin-4-yl)thio)-6- methylimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2- methylpropane-2-sulfinamide (100 mg, 177 μπιοΐ) in MeOH (1.76 mL) was added 4 M HC1 (440 μΐ^, 1.76 mmol) in dioxane. The reaction mixture was stirred at 35 °C for 1 hr. The resulting reaction mixture was concentrated under reduced pressure and the resulting residue was purified by prep HPLC to afford (3,S', )S)-8-{5-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- 6-methylimidazo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (20.0 mg, 24.5 %) as the formic acid salt. 1H MR (500 MHz, methanol-^) δ 8.53 (s, 1H), 8.21 (s, 1H), 7.91 (s, 1H), 7.57 (d, J = 5.6 Hz, 1H), 5.82 (d, J = 5.5 Hz, 1H), 4.61 - 4.44 (m, 3H), 4.36 - 4.25 (m, 1H), 3.99 (d, J = 9.0 Hz, 1H), 3.87 (d, J = 9.0 Hz, 1H), 3.55 (dddd, J = 38.4, 13.8, 10.1, 3.8 Hz, 2H), 2.44 (d, J = 1.9 Hz, 3H), 2.01 - 1.84 (m, 3H), 1.77 (d, J = 13.8 Hz, 1H), 1.30 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z: [M + H] calculated for C21H27CIN7OS: 460.2; found 460.5. Example 14. Synthesis of l-[7-(2,3-dichlorophenyl)-[l,2,5]thiadiazolo[3,4-c]pyridin-4-yl]-4- methylpiperidin-4-amine.
Figure imgf000218_0001
Step 1.
[00736] To a solution of 7-bromo-4-chloro-[l,2,5]thiadiazolo[3,4-c]pyridine (160 mg, 638 μηιοΐ) in DMA (3.18 mL) was added tert-butyl (4-methylpiperidin-4-yl)carbamate (409 mg, 1.91 mmol) and DIPEA (555 μΐ^, 3.19 mmol). The reaction mixture was stirred in a capped vial at 100 °C for 1 hr. The resulting reaction mixture was concentrated under reduced pressure, removing as much of the DMA as possible. The residue was purified by column chromatographyusing 0-10% MeOH/DCM to yield the desired product tert-butyl (1- (7-bromo-[l,2,5]thiadiazolo[3,4-c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate. LCMS (ESI): m/z [M + H] calculated for Ci6H22BrN502S: 427.07; found 427.9.
Step 2.
[00737] To a vial was added tert-butyl (l-(7-bromo-[l,2,5]thiadiazolo[3,4-c]pyridin-4-yl)- 4-methylpiperidin-4-yl)carbamate (60 mg, 140 μπιοΐ), (2,3-dichlorophenyl)boronic acid (40.0 mg, 210 μιηοΐ), Pd(dppf)ClrDCM (22.8 mg, 28.0 μιηοΐ), and K2C03 (77.3 mg, 560 μπιοΐ). The vial was evacuated under house vacuum for 15 min before adding in
degassed ACN (1.39 mL). The resulting mixture was filled with N2 and evacuated three times before stirring at 100 °C for overnight in the capped vial. The resulting reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatographyusing 0-10%
MeOH/DCM to yield the desired product fert-butyl (l-(7-(2,3-dichlorophenyl)- [l,2,5]thiadiazolo[3,4-c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate. LCMS (ESI): m/z [M + H] calculated for C22H25C12N502S: 493.11; found 493.9. Step 3.
[00738] To a solution of fert-butyl (l-(7-(2,3-dichlorophenyl)-[l,2,5]thiadiazolo[3,4- c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate (69 mg, 139 μηιοΐ) in methanol (1.38 mL) was added 4 M HC1 in dioxane (347 μΐ., 1.39 mmol). The reaction was stirred in a capped vial at 35 °C for 1 hr. The resulting reaction mixture was concentrated under reduced pressure and the residue was purified by prep HPLC using 5-35% ACN+0.1% formic acid/H2O+0.1% formic acid to yield the desired product l-(7-(2,3-dichlorophenyl)- [l,2,5]thiadiazolo[3,4-c]pyridin-4-yl)-4-methylpiperidin-4-amine (30.0 mg, 54.7%) as the formic acid salt. ¾ MR (500 MHz, methanol-^) δ 8.54 (s, 2H), 8.00 (s, 1H), 7.63 (dd, J = 7.3, 2.2 Hz, 1H), 7.48 - 7.31 (m, 2H), 4.01 - 3.83 (m, 4H), 1.97 (t, J = 4.9 Hz, 4H), 1.57 (s, 3H). LCMS (ESI): m/z [M + H] calculated for CnHisCkNsS: 394.1; found 394.1.
Example 15. Synthesis of 4-((4-(4-amino-4-methylpiperidin-l-yl)-[l,2,5]thiadiazolo[3,4- c]pyridin-7-yl)thio)-3-chloropyridin-2-amine.
Figure imgf000219_0001
Step 1.
[00739] To a microwave vial was added tert-butyl (l-(7-bromo-[l,2,5]thiadiazolo[3,4- c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate (60mg, 140μπιο1), 3-chloro-4- (potassiosulfanyl)pyridin-2-amine (36.5 mg, 184 μπιοΐ), potassium 2-amino-3- chloropyridine-4-thiolate (41.7 mg, 210 μιηοΐ), Pd2(dba)3 (12.8 mg, 14.0
μπιοΐ), Xantphos (16.2 mg, 28.0 μιηοΐ), and DIPEA (73.0 μί, 420 μιηοΐ). The mixture was degassed and degassed dioxane (1.39 mL) was added. The reaction vial was evacuated and purged with N2 three times before stirring under microwave conditions at 140 °C for 3 hrs. The mixture was filtered through a pad of celite washing with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography o yield the desired product tert-butyl (l-(7-((2-amino-3-chloropyridin-4- yl)thio)-[l,2,5]thiadiazolo[3,4-c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate. LCMS (ESI): m/z: [M + H] calculated for C21H26CIN7O2S2: 507.13; found 508.1. Step 2.
[00740] To a solution of tert-butyl (l-(7-((2-amino-3-chloropyridin-4-yl)thio)- [l,2,5]thiadiazolo[3,4-c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate (61 mg, 120 μηιοΐ) in methanol (1.20 mL) was added 4 M HC1 in dioxane (300 μΐ^, 1.20 mmol). The reaction was stirred in a capped vial at 35 °C for 1 hr. The resulting reaction mixture was
concentrated under reduced pressure and the residue was purified by prep HPLC to yield 4- ((4-(4-amino-4-methylpiperidin-l-yl)-[l,2,5]thiadiazolo[3,4-c]pyridin-7-yl)thio)-3- chloropyridin-2-amine (40.0 mg, 98.0 μηιοΐ, 81.7 %) as the formic acid salt. ¾ MR (500 MHz, methanol-^) δ 8.50 (d, J = 37.7 Hz, 1H), 8.28 (s, 1H), 7.45 (d, J = 5.6 Hz, 1H), 5.80 (d, J = 5.5 Hz, 1H), 4.03 - 3.90 (m, 4H), 2.07 - 1.87 (m, 4H), 1.57 (d, J = 0.9 Hz, 3H).
LCMS (ESI): m/z [M + H] calculated for C16H19CIN7S2: 408.1; found 408.2.
Example 16. Synthesis of ( ,S', )S^-8-{8-[(2-amino-3-chloropyridin-4-yl)sulfanyl]pyrido[4,3- d]pyrimidin-5-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000220_0001
Step 1.
[00741] 8-bromo-5-chloropyrido[4,3-d]pyrimidine (179 mg, 732 μιηοΐ) and (3S,4S)-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (175 mg, 732 μπιοΐ) were dissolved in DMA (3.66 mL) and DIPEA (1.27 mL, 7.32 mmol) was added at room temperature. The mixture was heated to 120 °C for 3 hrs. The solvent was removed under reduced pressure and the crude residue was purified by silica gel chromatography to give (3S,4S)-$-{$- bromopyrido[4,3-d]pyrimidin-5-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (182 mg, 65.9 %) as a yellow solid. LC-MS (ESI): m/z [M + H] calculated for CieHioBrNsO: 379.3; found 379.9.
Step 2.
[00742] 3-chloro-4-(potassiosulfanyl)pyridin-2-amine (78.6 mg, 396 μιηοΐ), (3S,4S)-8-{8- bromopyrido[4,3-d]pyrimidin-5-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (100 mg, 264 μιηοΐ), Xantphos (30.5 mg, 52.8 μιηοΐ), Pd2dba3 (24.1 mg, 26.4 μιηοΐ) and DIEA (91.7 μί, 528 μηιοΐ) were weighed into a microwave vial equipped with a stir bar. The reaction vessel was purged with N2 and dioxane (2.63 mL) was added, followed by DIEA (91.7 μΐ., 528 μπιοΐ). The headspace of the reaction vessel was backfilled 3 times with N2 and the mixture was heated for 2 hrs at 120 °C under microwave irradiation. The resulting mixture was filtered over celite and the solvent was removed under reduced pressure. The crude residue was directly purified by preparative HPLC to give ( ,S', )S^-8-{8-[(2-amino-3- chloropyridin-4-yl)sulfanyl]pyrido[4,3-d]pyrimidin-5-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine (5.70 mg, 4.75 %) as a yellow solid. ¾ MR (500 MHz, Methanol-^) δ 9.57 (s, 1H), 9.25 (s, 1H), 8.65 (s, 1H), 8.42 (s, 1H), 7.46 (d, J = 5.6 Hz, 1H), 5.72 (d, J = 5.6 Hz, 1H), 4.38 - 4.30 (m, 2H), 4.27 (d, J = 13.7 Hz, 1H), 4.05 (d, J = 9.1 Hz, 1H), 3.94 (d, J = 9.1 Hz, 1H), 3.62 (ddd, J = 14.0, 1 1.1, 3.0 Hz, 1H), 3.52 (ddd, J = 14.0, 1 1.3, 2.9 Hz, 1H), 3.49 - 3.47 (m, 1H), 2.13 - 2.04 (m, 2H), 1.98 (d, J = 13.4 Hz, 1H), 1.83 (d, J = 13.3 Hz, 1H), 1.35 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z: [M + H] calculated for
C21H25CIN7OS: 458.1 ; found 458.5.
Example 17. Synthesis of (7R)-8-[8-(2,3-dichlorophenyl)pyrido[4,3-d]pyrimidin-5-yl]-8- azaspiro[4.5 ] decan- 1 -amine.
Figure imgf000221_0001
Step 1.
[00743] To a solution of 8-bromo-5-chloropyrido[4,3-d]pyrimidine (25 mg, 102 μπιοΐ) in DMA (1 mL) was added 2-methyl-N-((R)-8-azaspiro[4.5]decan-l-yl)propane-2- sulfinamide (28.9 mg, 1 12 μπιοΐ) and DIPEA (88.8 μΐ., 510 μπιοΐ). The mixture was capped and stirred at 80 °C for 2 hrs. The reaction was complete according to LCMS. The resulting reaction mixture was diluted with EtOAc and H2O. The organic layer was separated and then washed three more times with H2O. The resulting organic layer was separated, dried over MgSC"4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography using 0-100% EtO Ac/heptane to yield the desired product N-((R)-8- (8-bromopyrido[4,3-d]pyrimidin-5-yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2- sulfinamide (40.0 mg, 84.2 %). LCMS (ESI): m/z [M + H] calculated for CioifeBrNsOS: 466.12; found 466.3.
Step 2.
[00744] To a reaction vial was added N-((R)-8-(8-bromopyrido[4,3-d]pyrimidin-5-yl)-8- azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (20 mg, 42.8 μιηοΐ), (2,3- dichlorophenyl) boronic acid (12.2 mg, 64.1 μιηοΐ), potassium carbonate (17.6 mg, 128 μπιοΐ), and tetrakis (2.95 mg, 2.56 μιηοΐ). The vial was evacuated under high vacuum for 10 min before adding in degassed ethyl alcohol (548 μΐ.). The resulting mixture was purged and evacuated with N2 three times and then stirred at 80 °C for 1 hr. The resulting reaction mixture was filtered through a pad of celite washing with DCM and MeOH. The resulting filtrate was purified by column chromatography to yield N-((R)-8-(8-(2,3- dichlorophenyl)pyrido[4,3-d]pyrimidin-5-yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2- sulfinamide (1 1 mg, 48.4 %). LCMS (ESI): m/z [M + H] calculated for C27H32CI2N5OS: 533.5; found 533.3.
Step 3.
[00745] N-((R)-8-(8-(2,3-dichlorophenyl)pyrido[4,3-d]pyrimidin-5-yl)-8- azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (25 mg, 46.9 μπιοΐ) was dissolved in MeOH (2 mL) and then added 4 M HC1 in dioxane (1 mL, 4.00 mmol). The mixture was stirred in a capped vial for 1 hr. The resulting reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase chromatography to yield (7R)-8- [8-(2,3-dichlorophenyl)pyrido[4,3-d]pyrimidin-5-yl]-8-azaspiro[4.5]decan-l-amine (8.79 mg, 43.9 %) as the formic acid salt. ¾ MR (500 MHz, methanol-^) δ 9.59 (s, 1H), 9.19 (s, 1H), 8.57 (s, 1H), 8.34 (s, 1H), 7.65 (dd, J = 8.0, 1.6 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.36 (dd, J = 7.6, 1.6 Hz, 1H), 4.17 (dd, J = 25.8, 13.6 Hz, 3H), 3.51 (d, J = 12.9 Hz, 2H), 3.19 (d, J = 14.3 Hz, 1H), 2.30 - 2.12 (m, 1H), 2.10 - 1.76 (m, 5H), 1.76 - 1.53 (m, 3H). LCMS (ESI): m/z [M + H] calculated for C22H24CI2N5: 428.1 ; found 428.4. Example 18. Synthesis of (lR)-8-[8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-5-yl]-8- azaspiro[4.5 ] decan- 1 -amine.
Figure imgf000223_0001
[00746] (lR)-8-[8-(3-chlorophenyl)pyrido[4,3-d]pyrimidin-5-yl]-8-azaspiro[4.5]decan-l- amine was synthesized in the manner similar to Example 17, except (2,3- dichlorophenyl)boronic acid was substituted with (3-chlorophenyl)boronic acid. ¾ MR (500 MHz, methanol-^) δ 9.58 (s, 1H), 9.29 (s, 1H), 8.56 (s, 1H), 8.49 (s, 1H), 7.73 (t, J = 1.9 Hz, 1H), 7.59 (dt, J = 7.6, 1.4 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.43 (ddd, J = 8.0, 2.1, 1.2 Hz, 1H), 4.18 - 4.01 (m, 3H), 3.52 - 3.41 (m, 2H), 3.23 (t, J = 7.0 Hz, 1H), 2.29 - 2.17 (m, 1H), 2.07 - 1.78 (m, 5H), 1.78 - 1.53 (m, 3H). LCMS (ESI): m/z [M +H] calculated for C22H25CIN5: 394.2; found 394.3.
Example 19. Synthesis of 4-(4-amino-4-methylpiperidin-l-yl)-7-(2,3-dichlorophenyl)- -pyrrolo[3 ,4-c]pyridin- 1 -one.
Figure imgf000223_0002
Step 1.
[00747] 4-chloro-lH,2H,3H-pyrrolo[3,4-c]pyridin-l-one (50 mg, 296 μηιοΐ) and tert-butyl N-(4-methylpiperidin-4-yl)carbamate (317 mg, 1.48 mmol) were dissolved in DMA (1.47 mL) and DIPEA (514 μΐ., 2.96 mmol) was added. The mixture was heated to 110 °C for 4 hrs, the solvent was removed under reduced pressure and the crude residue was purified by silica gel chromatography to give tert-butyl N-(4-methyl-l-{ l-oxo-lH,2H,3H-pyrrolo[3,4-c]pyridin-4- yl}piperidin-4-yl)carbamate (72.0 mg, 70.5 %) as a brown solid. LC-MS (ESI): m/z [M + H] calculated for C18H26N4O3: 347.2; found 347.5.
Step 2.
[00748] tert-Butyl-N-(4-methyl-l-{ l-oxo-lH,2H,3H-pyrrolo[3,4-c]pyridin-4-yl}piperidin- 4-yl)carbamate (100 mg, 288 μηιοΐ) was dissolved in MeCN (1.44 mL) and BS (56.2 mg, 316 μπιοΐ) was added. After stirring for 30 min at room temperature the solvent was removed under reduced pressure and the crude residue was purified by silica gel chromatography to give tert-butyl-N-(l-{7-bromo-l-oxo-lH,2H,3H-pyrrolo[3,4-c]pyridin-4-yl}-4- methylpiperidin-4-yl)carbamate (98.0 mg, 80.3 %) as a beige solid. LC-MS (ESI): m/z [M + H] calculated for
Figure imgf000224_0001
424.1; found 423.7.
Step 3.
[00749] To a solution of ter/-butyl-N-(l-{7-bromo-l-oxo-lH,2H,3H-pyrrolo[3,4- c]pyridin-4-yl}-4-methylpiperidin-4-yl)carbamate (80 mg, 0.19 mmol) in dioxane (3 ml) was added (2,3-dichlorophenyl)boronic acid (72 mg, 0.38 mmol) and PdCl2(dppf) (15 mg, 0.019 mmol). An aqueous solution of CS2CO3 (72 mg, 0.38 mmol) in 1 mL of water was added. The reaction was sealed and microwaved at 100 °C for 2 hrs. It was then cooled to room temperature, extracted with EtOAc (3 x 15 mL). The combined organic layers were combined, washed with brine (5 mL), dried (MgS04), filtered and concentrated under reduced pressure to provide the desired product as a white solid. The solid was taken up in dioxane (2 mL) and a solution of HCl in dioxane (1 M, 1 mL, excess) was added. The reaction was stirred at room temperature for 2 hrs to give a yellow precipitate, which was filtered and air-dried to furnish the HCl salt of 4-(4-amino-4-methylpiperidin-l-yl)-7-(2,3-dichlorophenyl)-lH,2H,3H- pyrrolo[3,4-c]pyridin-l-one (20 mg, 27%). 1H MR (500 MHz, methanol-^) δ 8.00 (s, 1H), 7.65 (t, J = 6.3 Hz, 1H), 7.44 - 7.34 (m, 2H), 4.16 (s, 1H), 3.79 (s, 1H), 3.37 (s, 2H), 3.32 (s, 3H), 2.18 (s, 1H), 2.12 (d, J = 13.2 Hz, 2H), 1.60 (s, 3H); LC-MS (ESI): m/z [M + H] calculated for C19H21CI2N4O: 391.1; found 391.3. Example 20. Synthesis of 7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-4-(4- methylpiperidin- 1 -yl)- lH,2H,3H-pyrrolo[3 ,4-c]pyridin- 1 -one.
Figure imgf000225_0001
2. HCI, dioxane/MeOH
[00750] 3-Chloro-4-(potassiosulfanyl)pyridin-2-amine (52.4 mg, 264 μηιοΐ), fert-butyl N- (l-{7-bromo-l-oxo-lH,2H,3H-pyrrolo[3,4-c]pyridin-4-yl}-4-methylpiperidin-4-yl)carbamate (75 mg, 176 μιηοΐ), Xantphos (20.3 mg, 35.2 μιηοΐ) and Pd2dba3 (16.1 mg, 17.6 μιηοΐ) were added into a microwave vial. The reaction vessel was purged with N2 and dioxane (1.75 mL) was added, followed by DIEA (61.1 μΐ., 352 μιηοΐ). The headspace of the reaction vessel was backfilled 3 times with N2 and the mixture was heated for 2 hrs at 120 °C under microwave irradiation. The crude mixture was cooled to room temperature and filtered over celite. The solvent was removed under reduced pressure and the residue was taken up in MeOH (1 mL). HC1 in dioxane (4 M, 0.5 mL) was added and the mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the product was purified by preparative HPLC to give 4.6 mg (6 %) of 7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-4-(4- amino-4-methylpiperidin-l-yl)-lH,2H,3H-pyrrolo[3,4-c]pyridin-l-one. ¾ NMR (500 MHz, Methanol-^) δ 8.30 (d, J = 0.7 Hz, 1H), 7.54 (d, J = 6.4 Hz, 1H), 5.83 (d, J = 5.6 Hz, 1H), 4.64 (s, 2H), 4.18 (dt, J = 14.2, 4.6 Hz, 2H), 3.58 - 3.45 (m, 2H), 1.97 - 1.90 (m, 4H), 1.54 (s, 3H); LC-MS (ESI): m/z [M + H] calculated for C18H22CIN6OS: 405.1; found 405.3.
Example 21. Synthesis of l-{ l-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8- yl]-4-methylpiperidin-4-yl}methanamine.
Figure imgf000226_0001
2. HCl dioxane/MeOH
Step 1.
[00751] To a solution of 5-bromo-8-chloro-6-methylimidazo[l,2-a]pyrazine (500 mg, 2.02 mmol) in DMA (10.1 mL) was added tert-butyl N-[(l-chloro-4-methylpiperidin-4- yl)methyl]carbamate (583 mg, 2.21 mmol) and DIPEA (1.75 mL, 10.1 mmol). The reaction mixture was stirred in a capped vial at 100 °C for 1 hr. The resulting reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to yield tert-butyl N-[(l-{5-bromo-6-methylimidazo[l,2-a]pyrazin-8-yl}-4-methylpiperidin-4- yl)methyl]carbamate (580 mg, 65%) LCMS (ESI): m/z [M + H] calculated for
Ci9H29BrN502: 438.1; found 438.4.
Step 2.
[00752] To a vial was added (2,3-dichlorophenyl)boronic acid (121 mg, 638 μπιοΐ), (2,3- dichlorophenyl)boronic acid (121 mg, 638 μιηοΐ), AntPhos (34 mg, 91.2 μιηοΐ), Κ3Ρ04 (288 mg, 1.36 mmol) and Pd(OAc)2 (10 mg, 45.6 μπιοΐ). The mixture was evacuated under house vacuum for 10 min before adding in degassed dioxane (4.56 mL). The resulting mixture was filled with N2 and degassed three times before stirring at 110 °C for 2 hrs. The resulting reaction mixture was filtered through a pad of celite washing with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was taken up in MeOH (2 mL). HCl (4 M in dioxane, 1 mL) was added and the mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the crude residue was purified by preparative HPLC to give l-{ l-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8- yl]-4-methylpiperidin-4-yl}methanamine (4.40 mg, 2.39 %) as a colorless solid. ¾ MR (500 MHz, Methanol-^) δ 8.57 (s, 1H), 7.79 (dd, J = 8.1, 1.6 Hz, 1H), 7.58 - 7.52 (m, 1H), 7.49 (d, J = 1.3 Hz, 1H), 7.45 (dd, J = 7.7, 1.6 Hz, 1H), 7.03 (d, J = 1.2 Hz, 1H), 4.85 - 4.76 (m, 2H), 3.80 (dtd, J = 13.6, 10.3, 3.2 Hz, 2H), 2.92 (s, 2H), 2.11 (s, 3H), 1.72 (ddt, J = 13.4, 10.1, 3.7 Hz, 2H), 1.67 - 1.55 (m, 2H), 1.24 (s, 3H); LC-MS (ESI): m/z [M + H] calculated for C20H24CI2N5 : 404.1; found 404.1.
Example 22. Synthesis of (3,S',4)S)-8-[7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5- a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000227_0001
Step 1.
[00753] A 20 mL vial was charged with 7-bromo-4-chloro-6-methylpyrazolo[l,5- a]pyrazine (300 mg, 1.21 mmol), N-[(3S,4S)-8-chloro-3-methyl-2-oxa-8-azaspiro[4.5]decan- 4-yl]chloranamine (352 mg, 1.45 mmol), DMA (6 mL), and N,N-diisopropylethylamine (1.05 mL, 6.04 mmol), sequentially. The flask was then sealed and warmed to 85 °C. After stirring for 16 hrs, the reaction was cooled to room temperature and di-tert-butyl dicarbonate (1.05 g, 4.84 mmol) was added in one portion. After stirring for 1 hr, the reaction mixture was diluted with ethyl acetate (30 mL) and water (10 mL), and the layers were separated. The organic solution was then washed with water (10 mL), half-saturated aqueous sodium chloride (10 mL), and saturated aqueous sodium chloride (10 mL) sequentially. The organic solution was then dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to give an orange oil. This crude oil was purified by column chromatography to give tert-butyl N-[(3,S', )S)-8-{7-bromo-6-methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-yl]carbamate (475.7 mg, 82% yield) as a pale pink foam. LC-MS (ESI): m/z: [M + H] calculated for CiiHsiBrNsOs: 480.1; found 480.0.
Step 2.
[00754] A 20 mL vial was charged with fert-butyl N-[(3S, 4S)-8-{7-bromo-6- methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (200 mg, 0.4 mmol), (2,3-dichlorophenyl)boronic acid (95.3 mg, 0.5 mmol), tripotassium phosphate (263 mg, 1.24 mmol), 4-(anthracen-9-yl)-3-ter/-butyl-2,3-dihydro-l,3- benzoxaphosphole (30.8 mg, 0.08 mmol), and degassed dioxane (4 mL). The resulting slurry was then degassed for 10 min before palladium (II) acetate (9.34 mg, 0.04 mmol) was added, and the orange mixture was degassed for an additional 5 min. After this time, the vial was sealed and warmed to 105 °C. After stirring for 2 hrs, the reaction was filtered through a short pad of celite, and the filtrate was then concentrated under reduced pressure. The crude residue obtained was purified by column chromatography to give tert-butyl N-[(3,S', )S)-8-[7-(2,3- dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan- 4-yl]carbamate as an impure orange oil. This oil was carried into the next step without further manipulation. LC-MS (ESI): m/z [M + H] calculated for C27H34CI2N5O3: 546.2; found 546.1.
Step 3.
[00755] A 20 mL vial was charged with fert-butyl N-[(3S, S)-8-[7-(2,3-dichlorophenyl)-6- methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (227 mg, 0.4 mmol), DCM (2 mL), and TFA (0.5 mL), sequentially, at room temperature. The resulting yellow solution was left to stir for 1 hr before the reaction mixture was concentrated under reduced pressure to give an orange residue. This crude material was purified by preparative HPLC to give (3,S', )S)-8-[7-(2,3-dichlorophenyl)-6- methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (6.9 mg, 3.7% yield) as a fluffy white solid. (3,S', )S)-8-[7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5- a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine as a formate salt. ¾ NMR (500 MHz, methanol-^) δ 8.53 (s, 1H), 7.80 (d, J = 2.5 Hz, 1H), 7.70 (dd, J = 8.1, 1.5 Hz, 1H), 7.46 (t, J = 8.1, 7.6 Hz, 1H), 7.36 (dd, J = 7.7, 1.5 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H), 4.41 - 4.26 (m, 3H), 3.99 (d, J = 8.9 Hz, 1H), 3.87 (d, J = 9.0 Hz, 1H), 3.48 - 3.34 (m, 2H), 2.13 (s, 3H), 2.02 - 1.91 (m, 2H), 1.91 - 1.84 (m, 1H), 1.79 - 1.73 (m, 1H), 1.30 (d, J = 6.5 Hz, 3H). LC-MS (ESI): m/z [M + H] calculated for C22H26CI2N5O: 446.1; found 446.4.
Example 23. Synthesis of (3,S', )S)-8-[7-(2-chloro-3-methoxyphenyl)-6-methylpyrazolo[l,5- a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000228_0001
Step 1.
[00756] A 20 mL vial was charged with 7-bromo-4-chloro-6-methylpyrazolo[l,5- a]pyrazine (300 mg, 1.2 mmol), N-[(3S,4S)-8-chloro-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl]chloranamine (352 mg, 1.5 mmol), DMA (6 mL), and N,N-diisopropylethylamine (1.05 mL, 6.04 mmol), sequentially. The flask was then sealed and warmed to 85 °C. After stirring for 16 hrs, the reaction was cooled to room temperature, concentrated under reduced pressure and the resulting residue was purified by column chromatograpgy to give (3S,4S)-$-{$- bromo-7-methylimidazo[l,2-c]pyrimidin-5-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- amine (360 mg, 78%). LC-MS (ESI): m/z [M + H] calculated for CieHisBrNsO: 380.1; found 380.1.
Step 2.
[00757] To a solution of (3,S',4)S)-8-{8-bromo-7-methylimidazo[l,2-c]pyrimidin-5-yl}-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (75 mg, 0.2 mmol) and (2,3- dichlorophenyl)boronic acid (56 mg, 0.29 mmol) in DME (990 μΐ.) and H2O (197 μΐ.) was added sodium carbonate (42 mg, 0.3944 mmol) then tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02 mmol) was added to the reaction mixture. The mixture was stirred at 100 °C for 1 hr. After cooling to room temperature the mixture was filtered through a pad of celite and the solvent was removed under reduced pressure. The crude residue was purified by preparative HPLC to give 10 mg (17%) of (3^, 5)-8-[7-(2-chloro-3-methoxyphenyl)-6- methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine. ¾ NMR (500 MHz, methanol-^) δ 7.76 (d, J= 2.5 Hz, 1H), 7.43 (dd, J= 8.3, 7.6 Hz, 1H), 7.23 (dd, J= 8.4, 1.4 Hz, 1H), 6.97 (dd, J= 7.7, 1.4 Hz, 1H), 6.90 (d, J= 2.5 Hz, 1H), 4.30 - 4.17 (m, 2H), 3.96 (s, 3H), 3.92 (d, J= 8.7 Hz, 1H), 3.79 (d, J= 8.7 Hz, 1H), 3.49 (ddt, J= 13.8, 10.3, 3.5 Hz, 1H), 3.46 - 3.37 (m, 1H), 3.11 (d, J= 4.9 Hz, 1H), 2.11 (s, 3H), 1.94 (dddt, J= 27.6, 14.1, 10.3, 3.9 Hz, 2H), 1.84 - 1.69 (m, 2H), 1.25 (d, J= 6.5 Hz, 3H); LC-MS (ESI): m/z: [M + H] calculated for C23H29CIN5O2: 442.2; found 442.4.
Example 24. Synthesis of 4-{[4-(4-amino-4-methylpiperidin-l-yl)pyrazolo[l,5-a]pyrazin-7- yl]sulfanyl}-3-chloropyridin-2-amine.
Figure imgf000230_0001
Figure imgf000230_0002
Step 1.
[00758] A 4 mL vial was charged with 4-chloropyrazolo[l,5-a]pyrazine (50 mg, 0.3 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (83 mg, 0.39 mmol), DMA (2 mL), and N,N-diisopropylethylamine (281 μΐ., 1.6 mmol), sequentially. The flask was then sealed and warmed to 120 °C. After 16 hrs, the reaction was diluted with ethyl acetate (10 mL) and water (5 mL). The layers were separated, and the organic phase was washed with water (5 mL) and saturated aqueous sodium chloride (5 mL), sequentially. The washed organic solution was then dried over sodium sulfate. The dried solution was then filtered, and the filtrate was concentrated to give an orange oil. The crude material was purified by column chromatography to give to give tert-butyl N-(4-methyl-l-{pyrazolo[l,5-a]pyrazin-4- yl}piperidin-4-yl)carbamate (101 mg, 94.3% yield) as a pale yellow oil. LC-MS (ESI): m/z [M + H] calculated for C17H26N5O2: 332.2; found 332.0.
Step 2.
[00759] A 20 mL vial was charged with tert-butyl N-(4-methyl-l-{pyrazolo[l,5-a]pyrazin- 4-yl}piperidin-4-yl)carbamate (101 mg, 0.3 mmol) and DMA (2.54 mL) before it was cooled to 0 °C. Once cool, a solution of N-bromosuccinimide (57 mg, 0.3 mmol) in DMA (0.5 mL) was added to the mixture dropwise over 10 min to give a burgandy solution. After 0.5 hr, the reaction was diluted with water (5 mL) and ethyl acetate (10 mL). The biphasic mixture was separated, and the organic solution was washed with water (5 mL) and saturated aqueous sodium chloride (5 mL), sequentially. The combined aqueous washes were then extracted with ethyl acetate (10 mL), and the combined organic solutions were dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to an orange oil that was purified by column chromatography to give tert-butyl N-(l-{7-bromopyrazolo[l,5- a]pyrazin-4-yl}-4-methylpiperidin-4-yl)carbamate (37.3 mg, 30% yield) as a white solid. LC- MS (ESI): m/z [M + H] calculated for CnHisBrNsOi: 410.1; found 409.9.
Step 3.
[00760] A 2 mL microwave vial was charged with tert-butyl N-(l-{7-bromopyrazolo[l,5- a]pyrazin-4-yl}-4-methylpiperidin-4-yl)carbamate (37 mg, 0.09 mmol), 3-chloro-4- (potassiosulfanyl)pyridin-2-amine (22 mg, 0.11 mmol), xantphos (10 mg, 0.02 mmol), degassed dioxane (910 μΐ.), and N,N-diisopropylethylamine (47.4 μΐ., 0.27 mmol), sequentially. The resulting mixture was degassed by bubbling nitrogen gas through the solution for 10 min, and then tris(dibenzylideneacetone) dipalladium (8 mg, 0.01 mmol) was added to the vial in one portion. The mixture was then degassed for an additional 5 min before it was sealed. The mixture was then warmed to 120 °C via microwave radiation and stirred for 1.5 hrs. After this time, the mixture was then filtered through a pad of celite and concentrated to an orange oil. This oil was purified by column chromatography to give tert- butyl (l-(7-((2-amino-3-chloropyridin-4-yl)thio)pyrazolo[l,5-a]pyrazin-4-yl)-4- methylpiperidin-4-yl)carbamate as an impure orange oil that was carried forward to the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for C22H29CIN7O2S: 490.2; found 490.5.
Step 4.
[00761] A 20 mL vial was charged with tert-butyl N-(l-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]pyrazolo[l,5-a]pyrazin-4-yl}-4-methylpiperidin-4-yl)carbamate (45 mg, 0.09 mmol), DCM (2 mL), and TFA (0.5 mL), sequentially, to give a bright red-orange solution. This solution was left to stir at 23 °C for 1 hr. After this time, the reaction mixture was concentrated to a red-orange oil that was purified by preparative HPLC to give 4-{[4-(4- amino-4-methylpiperidin-l-yl)pyrazolo[l,5-a]pyrazin-7-yl]sulfanyl}-3-chloropyridin-2- amine (17 mg, 0.04 mmol, 46%) as a white solid. 4-{[4-(4-amino-4-methylpiperidin-l- yl)pyrazolo[l,5-a]pyrazin-7-yl]sulfanyl}-3-chloropyridin-2-amine as a formate salt. 1H MR (500 MHz, Methanol-^) δ 8.13 (s, 1H), 7.96 (d, J = 2.5 Hz, 1H), 7.82 (s, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.14 (d, J = 2.5 Hz, 1H), 5.67 (d, J = 5.6 Hz, 1H), 4.43 (dt, J = 13.9, 4.6 Hz, 2H), 3.67 (dt, J = 14.0, 6.9 Hz, 2H), 1.96 (dd, J = 6.8, 4.6 Hz, 4H), 1.55 (s, 3H); LC-MS (ESI): m/z: [M + H] calculated for C17H21CIN7S: 390.1; found 390.4. Example 25. Synthesis of (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]pyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000232_0001
Step 1.
[00762] A 20 mL vial was charged with 4-chloropyrazolo[l,5-a]pyrazine (200 mg, 1.30 mmol), (3,S', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (379 mg, 1.5 mmol), DMA (7 mL), and N,N-diisopropylethylamine (1 mL, 6.5 mmol), sequentially. The flask was then sealed and warmed to 120 °C. After stirring for 60 hrs, the reaction was cooled to room temperature, and di-tert-butyl dicarbonate (1.41 g, 6.5 mmol) was added in one portion. After stirring for 1 hr, the reaction mixture was diluted with ethyl acetate (20 mL) and water (5 mL), and the layers were separated. The organic solution was then washed with water (5 mL) and saturated aqueous sodium chloride (5 mL) sequentially. The combined aqueous washes were then extracted with ethyl acetate (20 mL), and the combined organic solutions were dried over sodium sulfate. The dried solution was then filtered, and the filtrate was concentrated to give an orange oil. This crude oil was purified by column chromatography to give tert-butyl N-[(3S, S)-3-methyl-8-{pyrazolo[l,5-a]pyrazin-4-yl}-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (503 mg, 100% yield) as a green oil. LC-MS (ESI): m/z [M + H] calculated for C20H30N5O3: 388.2; found 388.1.
Step 2.
[00763] A 20 mL vial was charged with fert-butyl N-[(3 4S)-3-methyl-8-{pyrazolo[l,5- a]pyrazin-4-yl}-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (555 mg, 1.4 mmol) and DMA (11 mL). The resulting pale tan solution was then cooled to 0 °C. Once cool, a solution of N- bromosuccinimide (227 mg, 1.28 mmol) in DMA (3 mL) was added to the reaction in a slow, dropwise fashion. The resulting solution was left to stir for 1 hr at 0 °C. After this time, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL), and the layers were separated. The aqueous phase was extracted with ethyl acetate (10 mL), and the combined organic solution was washed with water (2 x 10 mL) and saturated aqueous sodium chloride (10 mL), sequentially. The washed organic solution was then dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to give an orange oil that was purified by column chromatography to give tert-butyl N-[(3S,4S)-$-{7- bromopyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (92 mg, 14% yield) as a white foam. LC-MS (ESI): m/z [M + H] calculated for CioIMrNsCb: 466.1; found 466.2.
Step 3.
[00764] A 2 mL microwave vial was charged with tert-butyl N-[(3S, 4S)-8-{7- bromopyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (53 mg, 0.1 mmol), 3-chloro-4-(potassiosulfanyl)pyridin-2-amine (27 mg, 0.1 mmol), xantphos (13.1 mg, 0.02 mmol), degassed dioxane (1 mL), and N,N-diisopropylethylamine (59.2 μΐ^, 0.3 mmol), sequentially. The resulting mixture was degassed by bubbling nitrogen gas through the solution for 10 min, and then tris(dibenzylideneacetone) dipalladium (10 mg, 0.01 mmol) was added to the vial in one portion. The mixture was then degassed for an additional 5 min before it was sealed. The mixture was then warmed to 120 °C via microwave radiation and stirred for 1.5 hrs. After this time, the reaction mixture was filtered through a pad of celite and concentrated to an orange oil. This oil was purified by column chromatography to give tert-butyl-N-[(3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]pyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl]carbamate as an impure orange oil that was carried forward to the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for C25H33CIN7O3S : 546.2; found 546.5.
Step 4.
[00765] A 20 mL vial was charged with fert-butyl N-[(3S, 5)-8-{7-[(2-amino-3- chloropyridin-4-yl)sulfanyl]pyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (62 mg, 0.1 mmol) and DCM (2 mL), giving an orange solution. TFA (0.5 mL) was added to the solution, and the resulting mixture was left to stir for 1 hr. After this time, the reaction mixture was concentrated to an orange-red residue which was purified by preparative HPLC to give (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]pyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (23.4 mg, 46.2% yield) as a formate salt. 1H MR (500 MHz, Methanol-^) δ 8.16 (s, 1H), 7.95 (d, J = 2.5 Hz, 1H), 7.80 (s, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.11 (d, J = 2.5 Hz, 1H), 5.67 (d, J = 5.5 Hz, 1H), 4.58 - 4.47 (m, 2H), 4.37 - 4.28 (m, 1H), 4.04 (d, J = 9.2 Hz, 1H), 3.93 (d, J = 9.3 Hz, 1H), 3.52 - 3.44 (m, 2H), 3.40 (ddd, J = 14.0, 11.3, 2.9 Hz, 1H), 2.00 - 1.90 (m, 3H), 1.78 (d, J = 13.3 Hz, 1H), 1.33 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z [M + H] calculated for C20H25CIN7OS: 446.1; found 446.2.
Example 26. Synthesis of (3,S',4)S)-8-[7-(2,3-dichlorophenyl)pyrazolo[l,5-a]pyrazin-4-yl]-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000234_0001
Step 1.
[00766] A 2 mL vial was charged with fert-butyl N-[(3^,45)-8-{7-bromopyrazolo[l,5- a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (32 mg, 0.07 mmol), (2,3-dichlorophenyl)boronic acid (16 mg, 0.08 mmol), potassium carbonate (37 mg, 0.27 mmol), and degassed acetonitrile (677 μΐ.). The resulting mixture was degassed by bubbling nitrogen gas through the solution for 10 min, and then Pd(dppf)Cl2 (11 mg, 0.014 mmol) was added to the vial. The mixture was then degassed for an additional 5 min and warmed to 105 °C for 2 hrs. The resulting mixture was cooled and filtered through a pad of celite. The filtrate was then concentrated under reduced pressure and purified by column
chromatography to give tert-butyl N-[(3,S',4)S)-8-[7-(2,3-dichlorophenyl)pyrazolo[l,5- a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (36 mg, 100% yield) as an orange foam that was carried forward to the next step without further purification. LC-MS (ESI): m/z: [M + H] calculated for C26H31CI2N5O3: 532.2; found 532.1.
Step 2.
[00767] A 20 mL vial was charged with fert-butyl N-[(3S,4S)-8-[7-(2,3- dichlorophenyl)pyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl]carbamate (36 mg, 0.06 mmol), DCM (2 mL), and TFA (0.5 mL), sequentially. After stirring for 1 hr, the reaction mixture was concentrated under reduced pressure to give a thick red-orange oil that was purified by preparative HPLC to give (3S,4S)-8-[7-(2,3- dichlorophenyl)pyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (5.54 mg, 18.9% yield). 1H MR (500 MHz, Methanol-^) δ 7.94 (d, J = 2.4 Hz, 1H), 7.74 - 7.69 (m, 1H), 7.47 - 7.44 (m, 2H), 7.38 (s, 1H), 7.04 (d, J = 2.5 Hz, 1H), 4.46 - 4.29 (m, 3H), 4.04 (d, J = 9.2 Hz, 1H), 3.93 (d, J = 9.1 Hz, 1H), 3.48 (d, J = 4.1 Hz, 1H), 3.46 - 3.32 (m, 2H), 2.05 - 1.92 (m, 3H), 1.79 (d, J = 13.1 Hz, 1H), 1.34 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z [M + H] calculated for C21H24CI2N5O: 432.1; found 432.3.
Example 27. Synthesis of [4-(4-amino-4-methylpiperidin-l-yl)-7-(2,3-dichlorophenyl)-6- methylpyrazolo[l,5-a]pyrazin-2-yl]methanol.
Figure imgf000235_0001
Step 1.
[00768] A 40 mL vial was charged with ethyl 4-chloro-6-methylpyrazolo[l,5-a]pyrazine- 2-carboxylate (500 mg, 2.08 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (533 mg, 2.4 mmol), DMA (10 mL), and N,N-diisopropylethylamine (2 mL, 10.4 mmol), sequentially. The flask was then sealed and warmed to 120 °C. After stirring for 16 hrs, the reaction was cooled and diluted with ethyl acetate (40 mL) and water (10 mL). The layers were separated, and the organic phase was washed with water (10 mL) and saturated aqueous sodium chloride (10 mL), sequentially. The washed organic solution was then dried over sodium sulfate. The dried solution was filtered and the filtrate was concentrated to an orange oil. This crude material was purified by column chromatography to give ethyl 4-(4-{[(tert- butoxy)carbonyl]amino}-4-methylpiperidin-l-yl)-6-methylpyrazolo[l,5-a]pyrazine-2- carboxylate (836 mg, 96.3 % yield) as a pale yellow oil. LC-MS (ESI): m/z [M + H] calculated for C21H32N5O4: 418.2; found 418.1.
Step 2.
[00769] An 8 mL vial was charged with ethyl 4-(4-{[(ter/-butoxy)carbonyl]amino}-4- methylpiperidin-l-yl)-6-methylpyrazolo[l,5-a]pyrazine-2-carboxylate (200 mg, 0.4 mmol) and DMF (3 mL). The resulting pale tan solution was cooled to 0 °C. Once cool, a solution of N-bromosuccinimide (76 mg, 0.43 mmol) in DMF (2.0 mL) was added to the reaction in a slow, dropwise fashion. The resulting solution was left to stir for 1 hr at 0 °C. After this time, the reaction mixture was diluted with water (10 mL) and ethyl acetate (10 mL), and the layers were separated. The aqueous phase was extracted with ethyl acetate (10 mL), and the combined organic extracts were washed with water (2 x 5 mL) and saturated aqueous sodium chloride (5 mL), sequentially. The washed organic solution was then dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to a pink oil that was purified by column chromatography to give ethyl 7-bromo-4-(4-{[(tert- butoxy)carbonyl]amino}-4-methylpiperidin-l-yl)-6-methylpyrazolo[l,5-a]pyrazine-2- carboxylate (165.7 mg, 69.6% yield) as a white foam. LC-MS (ESI): m/z [M + H] calculated for CiiftiBrChNsC : 496.11; found 496.0.
Step 3.
[00770] A 20 mL vial was charged with ethyl 7-bromo-4-(4-{ [(tert- butoxy)carbonyl]amino}-4-methylpiperidin-l-yl)-6-methylpyrazolo[l,5-a]pyrazine-2- carboxylate (100 mg, 0.2 mmol), (2,3-dichlorophenyl)boronic acid (46 mg, 0.24 mmol), tripotassium phosphate (128 mg, 0.6 mmol), 4-(anthracen-9-yl)-3-tert-butyl-2,3-dihydro-l,3- benzoxaphosphole (15 mg, 0.04 mmol), and degassed dioxane (2 mL). The resulting slurry was then degassed for 10 min before palladium(II) acetate (4.51 mg, 0.02 mmol) was added, and the orange mixture was degassed for an additional 5 min. After this time, the vial was sealed and warmed to 105 °C. After 2 hrs, the reaction mixture was cooled and filtered through a pad of celite. The filtrate was then concentrated and purified by column
chromatography to give ethyl 4-(4-{[(tert-butoxy)carbonyl]amino}-4-methylpiperidin-l-yl)- 7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazine-2-carboxylate (75.8 mg, 67% yield). LC-MS (ESI): m/z [M + H] calculated for C27H34CI2N5O4: 562.2; found 562.2.
Step 4.
[00771] A 20 mL vial was charged with ethyl 4-(4-{[(ter/-butoxy)carbonyl]amino}-4- methylpiperidin-l-yl)-7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazine-2-carboxylate (76 mg, 0.13 mmol) and DCM (1.3 mL) before it was cooled to -78 °C. Once cool, DIBAL- H (1 M in DCM, 538 μΕ, 0.53 mmol) was added in a dropwise fashion. After complete addition, the reaction was left to stir at -78 °C for 30 min before it was warmed to 0 °C and stirred for an additional 30 min. After this time, the reaction was once again cooled to -78 °C. At this time, the reaction solution was poured into a saturated aqueous solution of Rochelle's salt (10 mL) pre-cooled to 0 °C, and the reaction mixture was allowed to warm to room temperature and left to stir vigorously overnight. The layers were then separated, and the aqueous phase was extracted with DCM. The combined organic extracts were dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated under reduced pressure. The crude residue was then purified by column chromatography to give tert-butyl N-{ l-[7-(2,3-dichlorophenyl)-2-(hydroxymethyl)-6-methylpyrazolo[l,5-a]pyrazin- 4-yl]-4-methylpiperidin-4-yl} carbamate as a clear, colorless glaze that was submitted to the next reaction without further purification.
Step 5.
[00772] A 20 mL vial was charged with fert-butyl N-{ l-[7-(2,3-dichlorophenyl)-2- (hydroxymethyl)-6-methylpyrazolo[l,5-a]pyrazin-4-yl]-4-methylpiperidin-4-yl}carbamate (46 mg, 0.09 mmol), DCM (2 mL), and TFA (0.5 mL), sequentially. The resulting pale yellow solution was left to stir for 1 hr. After this time, the reaction mixture was concentrated under reduced pressure, and the crude residue was purified by preparative HPLC to give [4- (4-amino-4-methylpiperidin-l-yl)-7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-2- yljmethanol (20.6 mg, 56% yield) as a fluffy white solid. [4-(4-amino-4-methylpiperidin-l- yl)-7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-2-yl]methanol was isolated as its formate salt. ¾ MR (500 MHz, Methanol-^) δ 8.50 (s, 1H), 7.70 (dd, J = 8.1, 1.5 Hz, 1H), 7.46 (t, 1H), 7.35 (dd, J = 7.6, 1.5 Hz, 1H), 6.90 (s, 1H), 4.67 (s, 2H), 4.37 - 4.27 (m, 2H), 3.63 - 3.51 (m, 2H), 2.12 (s, 3H), 2.05 - 1.90 (m, 4H), 1.54 (s, 3H); LC-MS (ESI): m/z [M + H] calculated for C20H24CI2N5O: 420.13; found 420.1.
Example 28. Synthesis of {4-[(3,S', )S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]- 7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-2-yl}methanol.
[00773] {4-[(3^,45)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-7-(2,3- dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-2-yl}methanol was synthesized in the manner similar to Example 27, except tert-butyl (4-methylpiperidin-4-yl)carbamate was substituted for (3 4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine ¾ NMR (500 MHz, methanol-^) δ 8.53 (s, 1H), 7.70 (dd, J = 8.1, 1.6 Hz, 1H), 7.48 - 7.43 (m, 1H), 7.35 (dd, J = 7.7, 1.5 Hz, 1H), 6.88 (s, 1H), 4.66 (s, 2H), 4.37 - 4.25 (m, 3H), 3.97 (d, J = 9.0 Hz, 1H), 3.85 (d, J = 9.0 Hz, 1H), 3.49 - 3.34 (m, 2H), 3.27 (d, J = 4.5 Hz, 1H), 2.11 (s, 3H), 2.02 - 1.90 (m, 2H), 1.90 - 1.82 (m, 1H), 1.79 - 1.72 (m, 1H), 1.29 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z [M + H] calculated for C23H28CI2N5O2: 476.2; found 476.4.
Example 29. Synthesis of {7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-4-[(3,S', )S)-4-amino- 3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-methylpyrazolo[l,5-a]pyrazin-2-yl}methanol.
Figure imgf000238_0001
Step 1.
[00774] A 5 mL microwave vial was charged with ethyl 7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]-4-[(3,S',4)S)-4-{ [(tert-butoxy)carbonyl]amino}-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-6-methylpyrazolo[l,5-a]pyrazine-2-carboxylate (200 mg, 0.36 mmol), 3-chloro-4-(potassiosulfanyl)pyridin-2-amine (86 mg, 0.4 mmol), Xantphos (42 mg, 0.07 mmol), degassed dioxane (3.6 mL), and N,N-diisopropylethylamine (187 μΐ^, 1.08 mmol), sequentially. The resulting mixture was degassed by bubbling nitrogen gas through the solution for 10 min, and then tris(dibenzylideneacetone) dipalladium (33.1 mg, 0.0362 mmol) was added to the vial in one portion. The mixture was then degassed for an additional 5 min before it was sealed. The mixture was then warmed to 120 °C via microwave radiation and stirred for 1.5 hrs. After this time, the reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated under reduced pressure to an orange oil. This oil was purified by column chromatography to give ethyl 7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- 4-[(3,S',4)S)-4-{ [(tert-butoxy)carbonyl]amino}-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- methylpyrazolo[l,5-a]pyrazine-2-carboxylate (197 mg, 86% yield) as an orange foam. LC- MS (ESI): m/z [M + H] calculated for C29H39CIN7O5S: 632.2; found 632.5.
Step 2.
[00775] A 20 mL vial was charged with ethyl 7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- 4-[(3,S',4)S)-4-{ [(tert-butoxy)carbonyl]amino}-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- methylpyrazolo[l,5-a]pyrazine-2-carboxylate (197 mg, 0.31 mmol) and DCM (3 mL). The resulting orange solution was then cooled to -78 °C. Once cool, DIBAL-H (1 M in DCM, 1.2 mL, 1.2 mmol) was added to the solution in a dropwise manner, and the resulting mixture was left to stir at -78 °C for 30 min. After this time, the reaction mixture was warmed to 0 °C and stirred for an additional 30 min. The reaction mixture was then cooled to -78 °C once again. The reaction mixture was then poured into saturated aqueous Rochelle's salt solution (10 mL) pre-cooled to 0 °C, and the biphasic mixture was stirred vigorously overnight while letting the mixture warm to room temperature. After this time, the biphasic mixture was transferred to a separatory funnel, and the layers were separated. The aqueous phase was then extracted with DCM, and the combined organic extracts were dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated under reduced pressure. The crude residue so obtained was then purified by column chromatography to give tert-butyl N- [(3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-2-(hydroxymethyl)-6- methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (93 mg, 51% yield) as a tan solid. LC-MS (ESI): m/z [M + H] calculated for C27H37CIN7O4S : 590.2; found 590.6.
Step 3.
[00776] A 20 mL vial at room temperature was charged with tert-butyl N-[(3 S,4S)-8-{7- [(2-amino-3-chloropyridin-4-yl)sulfanyl]-2-(hydroxymethyl)-6-methylpyrazolo[l,5- a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (93 mg, 0.158 mmol), DCM (2 mL), and TFA (0.5 mL), sequentially. The resulting yellow solution was left to stir for 1 hr before the reaction mixture was concentrated under reduced to give a thick golden oil that was purified by preparative HPLC to give {7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- 4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-methylpyrazolo[l,5- a]pyrazin-2-yl}methanol (40.2 mg, 52% yield) as its formate salt. ¾ MR (500 MHz, Methanol-^) δ 8.11 (s, 1H), 7.47 (d, J = 5.6 Hz, 1H), 6.99 (s, 1H), 5.65 (d, J = 5.6 Hz, 1H), 4.70 (s, 2H), 4.58 (ddt, J = 13.5, 5.4, 2.6 Hz, 1H), 4.55 - 4.48 (m, 1H), 4.33 (qd, J = 6.5, 4.1 Hz, 1H), 4.04 (d, J = 9.2 Hz, 1H), 3.93 (d, J = 9.2, 0.8 Hz, 1H), 3.48 - 3.42 (m, 2H), 3.37 (ddd, J = 14.0, 11.3, 2.9 Hz, 1H), 2.51 (s, 3H), 1.99 - 1.89 (m, J = 4.2 Hz, 3H), 1.82 - 1.74 (m, 1H), 1.33 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z [M + H] calculated for C22H29CIN7O2S: 490.2; found 490.4.
Example 30. Synthesis of (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-6- methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000239_0001
Step 1.
[00777] An 8 mL microwave vial was charged with tert-butyl N-[(3S,4S)-8-{7-bromo-6- methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (200 mg, 0.4163 mmol), 3-chloro-4-(potassiosulfanyl)pyridin-2-amine (99.2 mg, 0.49 mmol), Xantphos (48 mg, 0.08 mmol), degassed dioxane (4.16 mL), and N,N-diisopropylethylamine (215 μΐ., 1.24 mmol), sequentially. The resulting mixture was degassed by bubbling nitrogen gas through the solution for 10 min, and then tris(dibenzylideneacetone) dipalladium (38.1 mg, 0.04163 mmol) was added to the vial in one portion. The mixture was then degassed for an additional 5 min before it was sealed. The mixture was then warmed to 120 °C via microwave radiation and stirred for 1.5 hrs. After this time, the reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to an orange oil. Purification by column chromatography resulted in tert-butyl N-[(3,S', )S)-8-{7-[(2-amino- 3-chloropyridin-4-yl)sulfanyl]-6-methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (233 mg, 100% yield) as an orange oil. LC-MS (ESI): m/z [M + H] calculated for C26H34CIN7O3S: 560.2; found 560.3.
Step 2.
[00778] A 20 mL vial at room temperature was charged with tert-butyl N-[(3S, 5)-8-{7- [(2-amino-3-chloropyridin-4-yl)sulfanyl]-6-methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-yl]carbamate (233 mg, 0.41 mmol), DCM (2 mL), and TFA (1 mL), sequentially. The resulting red-orange solution was left to stir for 1 h before the reaction mixture was concentrated under reduced to give a thick red oil that was purified by preparative HPLC to give (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-6- methylpyrazolo[l,5-a]pyrazin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (54 mg, 26% yield) as formate salt. 1H MR (500 MHz, methanol-^) δ 8.21 (s, 1H), 7.86 (d, J = 2.5 Hz, 1H), 7.46 (d, J = 5.5 Hz, 1H), 7.03 (d, J = 2.5 Hz, 1H), 5.61 (d, J = 5.6 Hz, 1H), 4.62 - 4.56 (m, 1H), 4.56 - 4.49 (m, 1H), 4.32 (qd, J = 6.5, 4.2 Hz, 1H), 4.04 (d, J = 9.2 Hz, 1H), 3.93 (d, J = 9.3, 0.9 Hz, 1H), 3.50 - 3.42 (m, 2H), 3.38 (ddd, J = 14.0, 11.3, 2.9 Hz, 1H), 2.53 (s, 3H), 1.99 - 1.91 (m, J = 4.2 Hz, 4H), 1.81 - 1.75 (m, 1H), 1.33 (d, J = 6.6 Hz, 3H); LC- MS (ESI): m/z [M + H] calculated for C21H27CIN7OS: 460.2; found 460.4. Example 31. Synthesis of (3,S', )S)-8-{5-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- [l,2,4]triazolo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000241_0001
Step 1.
[00779] tert-Butyl N-[(3^^-8-{5-bromo-[l,2,4]triazolo[l,5-a]pyrazin-8-yl}-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-yl]carbamate (50 mg, 106 μηιοΐ), 3-chloro-4- (potassiosulfanyl)pyridin-2-amine (31.5 mg, 159 μmol), [5-(diphenylphosphanyl)-9,9- dimethyl-9H-xanthen-4-yl]diphenylphosphane (known as XantPhos) (12.2 mg, 21.2 μιηοΐ), tris(dibenzylideneacetone) dipalladium (10 mg, 10.6 μmol) and a Teflon coated magnetic stir bar were sequentially added to a 2.5 mL microwave vial. The vial was capped, and then purged with nitrogen gas for 3 min. To this vial was then added dioxane (1.1 mL), which had been purged with nitrogen gas for 30 minutes, followed by the addition of N,N- diisopropylethylamine (36.7 μΐ., 212 μιηοΐ). This heterogeneous mixture was then heated in a microwave to 120 °C for 1.5 hrs. The reaction was filtered over a pad of celite, washed with EtOAc. The filtrate was concentrated under reduced pressure and the resulting residue was purified via silica gel chromatography. LCMS (ESI): m/z: [M + H] calculated for
C24H32CIN8O3S: 547.2; found 547.2.
Step 2.
[00780] To a solution of fert-butyl N-[(3^ 5)-8-{5-[(2-amino-3-chloropyridin-4- yl)sulfanyl]-[l,2,4]triazolo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl]carbamate (58 mg, 106 μπιοΐ) in DCM (3 mL) was added TFA (706 μΐ.). The reaction mixture was stirred at 25 °C for 1 hr. The resulting solution was concentrated under reduced pressure and the residue was purified by prep HPLC to yield (3,S', )S)-8-{5-[(2-amino-3- chloropyridin-4-yl)sulfanyl]-[l,2,4]triazolo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine (20 mg, 38.6%) as formic acid salt. ¾ MR (500 MHz, Methanol-^) δ 8.38 (s, 1H), 7.99 (s, 1H), 7.52 (d, J = 5.5 Hz, 1H), 5.79 (d, J = 5.5 Hz, 1H), 5.39 - 5.20 (m, 2H), 4.35 (qd, J = 6.5, 4.2 Hz, 1H), 4.06 (d, J = 9.2 Hz, 1H), 3.95 (d, J = 9.2 Hz, 1H), 3.70 - 3.51 (m, 2H), 3.46 (d, J = 4.2 Hz, 1H), 2.00 - 1.89 (m, 3H), 1.81 (dt, J = 14.1, 3.6 Hz, 2H), 1.35 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M + H] calculated for
C19H24CIN8OS: 447.1; found 447.4.
Example 32. Synthesis of (3,S', )S)-8-[5-(2,3-dichlorophenyl)-[l,2,4]triazolo[l,5-a]pyrazin-8- yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000242_0001
Step 1.
[00781] To a reaction vial was added fert-butyl N-[(3 4S 8-{5-bromo-[l,2,4]triazolo[l,5- a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (100 mg, 213 μηιοΐ), (2,3-dichlorophenyl)boronic acid (60.8 mg, 319 μιηοΐ), Pd(dppf)Cl2 CH2Cl2 (34.7 mg, 42.6 μπιοΐ), and K2CO3 (117 mg, 852 μιηοΐ). The mixture was sparged with N2 for 10 minutes before adding in ACN (2.1 mL). The reaction was stirred at 100 °C for 1 hr. The resulting mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated under reduced pressure and purified by column chromatography to yield the desired product. LCMS (ESI): m/z [M +H] calculated for C25H31CI2N6O3: 533.2; found 533.5.
Step 2.
[00782] To a solution of fert-butyl N-[(3 S)-8-[5-(2,3-dichlorophenyl)- [l,2,4]triazolo[l,5-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (56 mg, 104 μπιοΐ) in DCM (1 mL) was added TFA (260 μΕ). The reaction mixture was stirred at 25 °C for 1.5 hrs. The resulting solution was concentrated under reduced pressure and the residue was purified by prep HPLC to yield (3,S', )S)-8-[5-(2,3-dichlorophenyl)- [l,2,4]triazolo[l,5-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (18.5 mg, 38.5 μιηοΐ, 37%) as the formic acid salt. 1H MR (500 MHz, Methanol-^) δ 8.36 (s, 1H), 7.74 (dd, J = 7.7, 2.0 Hz, 1H), 7.65 (s, 1H), 7.54 - 7.44 (m, 2H), 5.15 (ddt, J = 28.2, 13.7, 3.2 Hz, 2H), 4.33 (qd, J = 6.5, 4.4 Hz, 1H), 4.04 (d, J = 9.1 Hz, 1H), 3.92 (d, J = 9.1 Hz, 1H), 3.62 (ddd, J = 14.1, 9.9, 4.3 Hz, 1H), 3.55 (ddd, J = 13.8, 11.0, 2.9 Hz, 1H), 3.38 (d, J = 4.4 Hz, 1H), 2.00 - 1.89 (m, 3H), 1.83 - 1.75 (m, 1H), 1.33 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M +H] calculated for C20H23CI2N6O: 433.1; found 433.2. Example 33. Synthesis of (3,S',4)S)-8-{7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- [l,2,5]thiadiazolo[3,4-c]pyridin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000243_0001
Step 1.
[00783] To a solution of 4-chloro-[l,2,5]thiadiazolo[3,4-c]pyridine (230 mg, 1.34 mmol) and N-[(3S,4S)-8-chloro-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]chloranamine (454 mg, 1.87 mmol) in DMA (7 mL) was added DIPEA (1 mL, 6.70 mmol) at 25 °C. The mixture was capped and heated to 110 °C for 2 hrs. After this time, the reaction was cooled to 25 °C and concentrated under reduced pressure. The crude product was submitted to the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for C14H20N5OS: 306.14; found 306.1.
Step 2.
[00784] To a solution of (3^,45)-3-methyl-8-{[l,2,5]thiadiazolo[3,4-c]pyridin-7-yl}-2- oxa-8-azaspiro[4.5]decan-4-amine (409 mg, 1.34 mmol) in ACN (3.94 mL) was added N- bromosuccinimide (261 mg, 1.47 mmol) and the reaction mixture was stirred at room temperature for 1 hr, concentrated under reduced pressure. The residue was diluted with EtOAc (6 mL), washed with saturated NaHCCb (2 x 3 mL), dried over Na2S04, filtered, and concentrated under reduced pressure. The crude material submitted to the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for CwHigBrNsOS: 384.04; found 384.2.
Step 3.
[00785] To a microwave vial was added (3,S', )S)-8-{7-bromo-[l,2,5]thiadiazolo[3,4- c]pyridin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (80 mg, 208 μπιοΐ), 3-chloro- 4-(potassiosulfanyl)pyridin-2-amine (82.6 mg, 416 μπιοΐ) , Pd2dba3 (19.0mg, 20.8
μπιοΐ) , Xantphos (24 mg, 41.6 μπιοΐ) , and DIEPA (53 mg, 416 μπιοΐ), and
degassed dioxane (1 mL). The mixture was purged with N2 and evacuated three times. The reaction mixture was stirred under microwave conditions at 130 °C for 2 hrs. The resulting mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]- [l,2,5]thiadiazolo[3,4-c]pyridin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (78.0 mg, 168 μιηοΐ, 80.8 %) as a yellow solid. ¾ NMR (500 MHz, Methanol-^) δ 8.41 (s, 1H), 8.22 (s, 1H), 7.42 (d, J = 5.6 Hz, 1H), 5.78 (d, J = 5.6 Hz, 1H), 4.33 (dd, J = 6.6, 4.2 Hz, 1H), 4.06 (d, J = 9.2 Hz, 1H), 3.94 (dd, J = 9.2, 0.8 Hz, 1H), δ 3.73 - 3.56 (m, 2H), 3.45 (d, J = 4.2 Hz, 1H), 2.01 - 1.91 (m, 3H), 1.85 - 1.78 (m, 1H), 1.33 (d, J = 6.5 Hz, 3H). LC-MS (ESI): m/z [M + H] calculated for C19H23CIN7OS2: 464.10; found 464.3.
Example 34. Synthesis of 4-{[4-(4-amino-4-methylpiperidin-l-yl)-[l,2,5]oxadiazolo[3,4- c]pyridin-7-yl]sulfanyl}-3-chloropyridin-2-amine.
Figure imgf000244_0001
Step 1.
[00786] To a solution of 5-bromo-2-chloro-3-nitropyridin-4-amine (0.50 g, 1.98 mmol) in DMA (9.90 mL) was added tert-butyl N-(4-methylpiperidin-4-yl)carbamate (0.63 g, 2.96 mmol) and N,N-diisopropylethylamine (1.7 mL, 9.89 mmol) at room temperature. The reaction was heated to 100 °C for 1 hr, concentrated under reduced pressure and the resulting residue was submitted to next step without purification. LC-MS (ESI): m/z [M + H]+ calculated for CieHisBrNsC : 430.1; found 430.1.
Step 2.
[00787] tert-Butyl N-[l-(4-amino-5-bromo-3-nitropyridin-2-yl)-4-methylpiperidin-4- yl]carbamate (650 mg, 1.51 μπιοΐ) was in benzene (7.55 mL, 0.2 M). (acetyloxy)(phenyl)- 3- iodanyl acetate (0.53 g, 1.66 mmol) was added. The resulting mixture was stirred at 85 °C for 4 hrs. The mixture was concentrated under reduced pressure and diluted with DCM, washed with NaHCCb until pH 8, and dried over Na2S04. The solvent was removed under reduced pressure, and the residue was subjected to next step. LC-MS (ESI): m/z [M + H]+ calculated for Ci6H23BrN504: 428.1; found 427.9. Step 3.
[00788] A solution of triphenylphosphine (0.12 g, 0.46 mmol) in PhMe (0.5 mL) was added to a solution of tert-butyl 7-bromo-4-(4-((tert-butoxycarbonyl)amino)-4- methylpiperidin-l-yl)-[l,2,5]oxadiazolo[3,4-c]pyridine 3-oxide (0.15 g, 0.35
mmol) in PhMe (1.24 mL). The reaction mixture was stirred for 4 hrs at 110 °C, fitered through a silica-gel pad, and the filtrate was concentrated under reduced pressure. The resulting product was subjected to next step without further purification. LC-MS (ESI): m/z: [M + H] calculated for CieHzsBrNsOs: 412.1; found 412.0.
Step 4.
[00789] A microwave vial was charged with tert-butyl N-(l-{7-bromo- [l,2,5]oxadiazolo[3,4-c]pyridin-4-yl}-4-methylpiperidin-4- yl)carbamate (0.075g, 0.181mmol), 3-chloro-4-(potassiosulfanyl)pyridin-2-amine (0.072 g, 0.362 mmol), tris(dibenzylideneacetone) dipalladium (0.016 g, 0.0181
mmol), xantphos (0.02 g, 0.0362 mmol), and N,N-diisopropylethylamine (0.0944 mL, 0.543 mmol). The mixture was degassed before adding in degassed dioxane (1.80 mL 0.1 M). The reaction vial was evacuated and purged with N2 three times before stirring under microwave conditions at 130 °C for 2 hrs. After 1.5 hrs, LCMS showed full conversion. The reaction mixture was filtered through a celite pad and then concentrated under reduced pressure. The residue was dissolved in DCM (3 mL), and TFA (1 mL) was added at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 hr at that temperature. The reaction mixture was concentrated under reduced pressure and subjected to column.
Purification by reverse phase column chromatography afforded 4-{[4-(4-amino-4- methylpiperidin-l-yl)-[l,2,5]oxadiazolo[3,4-c]pyridin-7-yl]sulfanyl}-3-chloropyridin-2- amine (52.7 mg, 61% yield). ¾ MR (500 MHz, OMSO-d6) δ 8.11 (s, 1H), 7.59 (d, J = 5.4 Hz, 1H), 6.37 (s, 2H), 5.97 (d, J = 5.4 Hz, 1H), 3.33 (s, 4H), 1.89 (s, 4H), 1.42 (s, 3H). LCMS (ESI): m/z [M + H]+ calculated for C16H19CIN7OS: 392.1; found 392.3. Example 35. Synthesis of (3,S', )S)-8-{5-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-6-methyl- [l,2,4]triazolo[4,3-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000246_0001
Step 1.
[00790] To a mixture of 5-methylpyrazin-2-amine (10 g, 92 mmol) in DCM (300 mL) was added BS (16 g, 91.63 mmol) in one portion at 0 °C under N2. The mixture was stirred at 30 °C for 1 hr. The resulting mixture was poured into saturated aq. Na2S03 (100 mL) and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to afford 3-bromo-5-methyl-pyrazin-2-amine (12 g, 69% yield,) as a light yellow solid. ¾ MR (400 MHz, CDCh-d) δ ppm 7.82 (s, 1 H) 4.79 - 5.03 (m, 2 H) 2.39 (s, 3 H).
Step 2.
[00791] To a mixture of 3-bromo-5-methyl-pyrazin-2-amine (31 g, 164.87 mmol) in MeOH (150 mL) was added NaOMe (14 g, 263.79 mmol) in one portion at 30 °C under N2. The mixture was stirred at 100 °C for 6 hrs. The mixture was concentrated under reduced pressure and the resulting residue was dissolved in water (100 mL). The mixture was extracted with EtOAc and the combined organic layers were washed with brine (20 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (to afford 3-methoxy-5-methyl-pyrazin-2-amine (21 g, 92% yield) as a white solid. 1H MR (400 MHz, CDCh-d) δ ppm 7.39 (s, 1 H) 4.59 (br s, 2 H) 3.97 (s, 3 H) 2.29 (s, 3 H)
Step 3.
[00792] To a solution of 3-methoxy-5-methyl-pyrazin-2-amine (21 g, 150.91 mmol) in CH2I2 (40 mL) was added isopentyl nitrite (35.36 g, 301.82 mmol, 40.64 mL) and I2 (45.96 g, 181.09 mmol, 36.48 mL) at 0 °C. The mixture was warmed to 30 °C and stirred at 30 °C for 3 hrs. The reaction mixture was poured into 300 mL of saturated aq. Na2S03 and the aqueous phase was extracted with DCM. The combined organic layers were washed with brine, dried with anhydrous Na2S04, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford 2-iodo-3-methoxy-5-methyl- pyrazine (21 g, 55.65% yield) as a yellow solid. ¾ NMR (400 MHz, CDCh-d) δ ppm 7.81 (s, 1 H) 3.99 (s, 3 H) 2.40 (s, 3 H)
Step 4.
[00793] To a mixture of 2-iodo-3-methoxy-5-methyl-pyrazine (5 g, 20 mmol) in EtOH (50 mL) at 70 °C under N2 was added hydrazine monohydrate (5.01 g, 100 mmol, 4.9 mL) in one portion. The mixture was stirred at 70 °C for 48 hrs The mixture was concentrated under reduced pressure and purified by column chromatography to afford (3-methoxy-5-methyl- pyrazin-2-yl)hydrazine (2.16 g, 14.01 mmol, 70% yield) as a light yellow solid. LCMS (ESI): m/z [M +H] calculated for C6HnN40: 155.1; found 155.2.
Step 5.
[00794] A mixture of (3-methoxy-5-methyl-pyrazin-2-yl)hydrazine (2 g, 12.97 mmol) and triethyl orthoformate (17.8 g, 120.24 mmol, 20 mL) was heated at 140 °C under N2 for 1 hr. The reaction solution was filtered and the filter cake was dried under reduced pressure to give 8-methoxy-6-methyl-[l,2,4]triazolo[4,3-a]pyrazine (1.5 g, 70.4% yield) as a light yellow solid. LCMS (ESI): m/z [M +H] calculated for C7H9N40: 165.1; found 165.1.
Step 6.
[00795] To a mixture of 8-methoxy-6-methyl-[l,2,4]triazolo[4,3-a]pyrazine (740 mg, 4.51 mmol) in CH3COOH (18 mL) was added HC1 (IN, 6 mL) in one portion. The mixture was stirred at 105 °C for 1 hr. The resulting mixture was concentrated under reduced pressure to give 6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-ol (740 mg) as a brown solid. LCMS (ESI): m/z [M +H] calculated for C6H7N40: 151.1; found 151.1.
Step 7.
[00796] A mixture of 6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-ol (900 mg, 5.99 mmol ) in POCh (29.70 g, 193.70 mmol, 18.00 mL) was heated at 120 °C for 1 hr. The excess POCh was removed under reduced pressure. The mixture was then quenched with saturated aq.NaHCCb (100 mL) to remove any remaining POCh. The resulting mixture was poured into water (300 mL) and stirred for 2 min. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with water and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford 8-chloro-6- methyl-[l,2,4]triazolo[4,3-a]pyrazine (900 mg, 84.61% yield,) as a black brown solid.
Step 8.
[00797] To a mixture of 8-chloro-6-methyl-[l,2,4]triazolo[4,3-a]pyrazine (400 mg, 2.37 mmol) and (3,S',4)S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (403.49 mg, 2.37 mmol) in i-PrOH (20 mL) was added DIEA (1.53 g, 11.85 mmol, 2.06 mL). The mixture was heated to 80 °C and stirred for 1 hr. After 1 hr, Boc20 (517.25 mg, 2.37 mmol, 544.47 μί) was added and the reaction mixture was stirred at 20 °C for 2 hrs. The reaction mixture was
concentrated under reduced pressure and purified by column chromatography (S1O2, petroleum ether/ethyl acetate=5/l to 0: 1) to afford tert-butyl N-[(3 4S)-3-methyl-8-(6- methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl)-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (800 mg, 1.95 mmol, 82.1% yield) as a white solid. 1H MR (400 MHz, CDC13-d) δ ppm 8.61 (s, 1 H) 7.23 (s, 1 H) 4.63 (br d, J=10.80 Hz, 2 H) 4.17 - 4.24 (m, 1 H) 4.01 (br dd, 7=10.69, 4.30 Hz, 1 H) 3.68 - 3.77 (m, 2 H) 2.26 (s, 2 H) 1.82 - 1.96 (m, 2 H) 1.53 - 1.59 (m, 4 H) 1.52 (s, 1 H) 1.49 (s, 1 H) 1.45 (s, 9 H) 1.18 - 1.25 (m, 4 H).
Step 9.
[00798] To a mixture of tert-butyl N-[(3^ 5)-3-methyl-8-(6-methyl-[l,2,4]triazolo[4,3- a]pyrazin-8-yl)-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (700 mg, 1.74 mmol) in DMF (7 mL) was added BS (309 mg, 1.74 mmol). The mixture was stirred at 0 °C for 5 min. The resulting mixture was quenched by addition saturated aq. Na2S03 (10 mL) and concentrated under reduced pressure. The remaining residue was purified by column chromatography to afford tert-butyl N-[(3S,4S)-8-(5-bromo-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl)-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (500 mg, 59.7% yield) as a red solid. LCMS (ESI): m/z [M +H] calculated for C2oH3oBrN603: 481.15; found 481.3.
Step 10.
[00799] To a solution of tert-butyl N-[(3S,4S)-8-(5-bromo-6-methyl-[l,2,4]triazolo[4,3- a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (200 mg, 415 μπιοΐ) in dioxane (3 mL) was added 2-amino-3-chloro-pyridine-4-thiol (166 mg, 1.04 mmol), K3PO4 (176 mg, 830 μιηοΐ), 1, 10-phenanthroline (14.9 mg, 83.1 μιηοΐ) and Cul (7.91 mg, 41.5 μπιοΐ). The reaction mixture was stirred at 130 °C for 4 hrs. The reaction was monitored by LCMS. The reaction was filtered and concentrated, the residue was purified by silica gel chromatography (petroleum ethenethyl acetate=5: 1, 0: 1) to give tert-butyl N-[(3,S',4)S)-8-[5- [(2-amino-3-chloro-4-pyridyl)sulfanyl]-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (80 mg, 32.7% yield) as white solid. LCMS (ESI): m/z [M +H] calculated for C25H34CIN8O3S : 561.2; found 561.3.
Step 11
[00800] A mixture of tert-butyl N-[(3^,45)-8-[5-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-6- methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl]carbamate (20 mg, 35.6 μιηοΐ) in HCI/MeOH (1 mL) was stirred at 25 °C for 2 hrs. The reaction was monitored by LCMS and HPLC. The reaction mixture was concentrated to dryness, and adjusted to pH = 7 with NaOH in MeOH at -78 °C, then filtered and
concentrated. The residue was purified by pre-HPLC to give (3,S',4)S)-8-[5-[(2-amino-3- chloro-4-pyridyl)sulfanyl]-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine (10 mg, 60% yield,) as white solid. LCMS (ESI): m/z [M +H] calculated for CioHieClNsOS: 461.16; found 461.2. ¾ NMR (400 MHz, Methanol-^) δ ppm 8.99 (s, 1 H) 7.60 (d, J = 5.50 Hz, 1 H) 5.88 (d, J = 5.50 Hz, 1 H) 5.26 - 4.96 (m, 1 H) 4.57 (s, 1 H) 4.34 - 4.21 (m, 1 H) 4.05 - 3.71 (m, 4 H) 3.07 (d, J = 5.01 Hz, 1 H) 2.48 (s, 3 H) 2.03 - 1.67 (m, 4 H) 1.25 (d, J = 6.48 Hz, 3 H).
Example 36. Synthesis of 4-[[8-(4-amino-4-methyl-l-piperidyl)-6-methyl- [l,2,4]triazolo[4,3-a]pyrazin-5-yl]sulfanyl]-3-chloro-pyridin-2-amine.
Figure imgf000249_0001
Step 1.
[00801] To a solution of 2-amino-3-chloro-pyridine-4-thiol (122 mg, 764 μπιοΐ) in dioxane (2 mL) was added tert-butyl N-[l-(5-bromo-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl)-4- methyl-4-piperidyl]carbamate (130 mg, 305 μιηοΐ), Κ3Ρ04 (129 mg, 611 μιηοΐ), 1, 10- phenanthroline (11.0 mg, 61.1 μπιοΐ) and Cul (6 mg, 30.5 μπιοΐ). The reaction mixture was stirred at 130 °C for 4 hrs. The reaction mixture was filtered and concentrated under reduced pressure. The remaining residue was purified by column chromatography to afford tert-butyl N-[l-[5-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]- 4-methyl-4-piperidyl]carbamate (60 mg, 37% yield) as a white solid. LCMS (ESI): m/z [M +H] calculated for C22H30CIN8O2S: 505.18; found 505.3.
Step 2.
[00802] A mixture of tert-butyl N-[l-[5-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-6-methyl- [l,2,4]triazolo[4,3-a]pyrazin-8-yl]-4-methyl-4-piperidyl]carbamate (30 mg, 59 μιηοΐ) in HCI/MeOH (2 mL) was stirred at 25 °C for 2 hrs. The reaction mixture was concentrated under reduced pressure. The remaining residue was dissolved in MeOH (2 mL) and the pH of the solution was adjusted to pH 7 by the addition of NaOH in MeOH at -78 °C. The mixture was filtered and the filtrate was concentrated under reduced pressure to afford 4-[[8-(4- amino-4-methyl-l-piperidyl)-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-5-yl]sulfanyl]-3-chloro- pyridin-2-amine (10 mg, 40% yield) as a white solid; found 405.3. ¾ NMR (400 MHz, methanol-^) δ ppm 8.96 (s, 1 H) 7.57 (d, J = 5.50 Hz, 1 H) 5.85 (d, J = 5.50 Hz, 1 H) 4.47 (s, 2 H) 3.34 (s, 2 H) 2.45 (s, 3 H) 1.79 - 1.59 (m, 4 H) 1.25 (s, 2 H); LCMS (ESI): m/z [M +H] calculated for C17H22CIN8S: 405.1; found 405.1.
Example 37. Synthesis of l-[5-(2,3-dichlorophenyl)-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin- 8-yl]-4-methyl-piperidin-4-amine.
Figure imgf000250_0001
Step 1.
[00803] A mixture of 6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-ol (120 mg, 799.27 μιηοΐ) and POCh (3.30 g, 21.52 mmol, 2.00 mL) was heated to 120 °C and stirred for 1 hr. The excess POCh was removed under reduced pressure. The mixture was then quenched with saturated aq.NaHC03 (100 mL) to remove any remaining POCh. The resulting mixture was poured into water (300 mL) and stirred for 2 min. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with water and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford 8- chloro-6-methyl-[l,2,4]triazolo[4,3-a]pyrazine (120 mg, 80.2% yield) as a black brown solid. ¾ NMR (400 MHz, OMSO-d6) δ ppm 9.05 (s, 1 H) 7.32 (s, 1 H) 2.09 (s, 3 H).
Step 2.
[00804] To a mixture of 8-chloro-6-methyl-[l,2,4]triazolo[4,3-a]pyrazine (120 mg, 711.81 μπιοΐ) and tert-butyl N-(4-methyl-4-piperidyl)carbamate (198 mg, 925.36 μιηοΐ) in z'-PrOH (2 mL) was added DIEA (460 mg, 3.56 mmol, 619.93 μΐ.). The mixture was heated to 80 °C and stirred for 1 hr. The reaction mixture was concentrated under reduced pressure and the remaining residue was purified by column chromatography to afford tert-butyl N-[4-methyl- l-(6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl)-4-piperidyl]carbamate (160 mg, 55% yield) as a red solid. ¾ NMR (400 MHz, methanol-^) δ ppm 8.99 (s, 1 H) 7.55 (d, J=0.98 Hz, 1 H) 3.68 (br t, J=11.13 Hz, 2 H) 2.26 (d, J=0.98 Hz, 3 H) 2.21 (br d, J=13.08 Hz, 2 H) 2.02 (s, 1 H) 1.58 - 1.67 (m, 2 H) 1.43 - 1.51 (m, 9 H) 1.37 (s, 3 H).
Step 3.
[00805] To a mixture of fert-butyl N-[4-methyl-l-(6-methyl-[l,2,4]triazolo[4,3-a]pyrazin- 8-yl)-4-piperidyl]carbamate (160 mg, 461.86 μιηοΐ) in DMF (2 mL) was added BS (82.20 mg, 461.86 μπιοΐ) in one portion at 0 °C. The mixture was stirred at 0 °C for 10 min. The mixture was quenched by addition sat.aq.Na2S03 (10 mL) and concentrated under reduced pressure. The remaining residue was purified by column chromatography to afford tert-butyl N-[l-(5-bromo-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl)-4-methyl-4-piperidyl]carbamate (180 mg, 91.6% yield) as a red solid. ¾ NMR (400 MHz, CDC13-d) δ ppm 8.82 (s, 1 H) 4.83 (br s, 2 H) 4.46 (br s, 1 H) 3.82 (br s, 2 H) 2.41 (s, 3 H) 2.16 (br d, J=15.21 Hz, 2 H) 2.06 (s, 1 H) 1.70 (ddd, J=14.22, 10.47, 3.97 Hz, 2 H) 1.46 (s, 9 H) 1.42 (s, 3 H)
Step 4.
[00806] To a mixture of tert-butyl N-[l-(5-bromo-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin- 8-yl)-4-methyl-4-piperidyl]carbamate (180 mg,423.21 μιηοΐ) and (2,3- dichlorophenyl)boronic acid (121 mg, 634.81 μπιοΐ) in DME (2 mL) and H20 (1 mL) was added Pd(PPh3 (63.58 mg, 55.02 μιηοΐ) and Na2C03 (112 mg, 1.06 mmol). The reaction mixture was heated to 80 °C and stirred for 5 hrs. The reaction mixture was concentrated under reduced pressure and the remaining residue was purified by column chromatography to afford tert-butyl N-[l-[5-(2,3-dichlorophenyl)-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-4- methyl-4-piperidyl]carbamate (100 mg, 47.6 % yield) as a light yellow solid. LCMS (ESI): m/z [M +H] calculated for C23H29C12N602: 491.2; found 491.2. Step 5.
[00807] A mixture of tert-butyl N-[l-[5-(2,3-dichlorophenyl)-6-methyl-[l,2,4]triazolo[4,3- a]pyrazin-8-yl]-4-methyl-4-piperidyl]carbamate (100 mg, 203.5 μιηοΐ) in HCI/MeOH (6 mL) was stirred at 20 °C for 1 hr. The reaction mixture was concentrated under reduced pressure to afford l-[5-(2,3-dichlorophenyl)-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-4-methyl- piperidin-4-amine (66 mg, 160.24 μηιοΐ, 78% yield) as a light yellow solid. ¾ MR (400 MHz, methanol-^) δ ppm 8.86 (s, 1 H) 7.84 (dd, J=7.89, 1.75 Hz, 1 H) 7.55 - 7.60 (m, 1 H) 7.50 - 7.55 (m, 1 H) 5.10 (br s, 2 H) 3.99 (br s, 2 H) 2.17 (s, 3 H) 2.05 (br t, J=5.26 Hz, 5 H) 1.59 (s, 3 H). LCMS (ESI): m/z [M +H] calculated for CiuHziCkNe: 391.11; found 391.1.
Example 38. Synthesis of (3^ 5)-8-[5-(2,3-dichlorophenyl)-6-methyl-[l,2,4]triazolo[4,3- a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000252_0001
Step 1.
[00808] To a mixture of fert-butyl N-[(3^ 5)-8-(5-bromo-6-methyl-[l,2,4]triazolo[4,3- a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (150 mg, 311.60 μιηοΐ) and (2,3-dichlorophenyl)boronic acid (89.19 mg, 467.40 μιηοΐ) in DME (2 mL) was added Pd(PPh3 (46.81 mg, 40.51 μιηοΐ) and Na2C03 (82.57 mg, 779.00 μιηοΐ). The mixture was heated and stirred at 80 °C for 2 hrs. The reaction was concentrated under reduced pressure and the residue was purified by column chromatography to afford tert-butyl N-[(3,S', )S)-8-[5- (2,3-dichlorophenyl)-6-methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (90 mg, 51.70% yield) as a white solid. LCMS (ESI): m/z [M +H] calculated for C26H32C12N603: 547.19; found 547.3.
Step 2.
[00809] A solution of fert-butyl N-[(3^, 5)-8-[5-(2,3-dichlorophenyl)-6-methyl- [l,2,4]triazolo[4,3-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (40 mg, 73.06 μπιοΐ) in HCI/MeOH (3 mL) was stirred at 25 °C for 1.5 hrs. The reaction mixture was concentrated under reduced pressure to afford (3,S', )S)-8-[5-(2,3-dichlorophenyl)-6- methyl-[l,2,4]triazolo[4,3-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (29 mg, 77.94% yield HC1 salt) as a white solid. ¾ NMR (400 MHz, Methanol-^) δ ppm 8.92 (s, 1 H) 7.86 (dd, J=7.64, 1.65 Hz, 1 H) 7.57 - 7.61 (m, 1 H) 7.56 (d, J=3.30 Hz, 1 H) 5.36 (br s, 1 H) 5.17 (br s, 1 H) 4.36 (dd, J=6.42, 4.10 Hz, 1 H) 4.08 (d, J=9.29 Hz, 1 H) 3.96 (d, J=9.17 Hz, 1 H) 3.80 (br s, 2 H) 3.55 (d, J=4.16 Hz, 1 H) 2.20 (s, 3 H) 2.07 - 2.17 (m, 3 H) 1.91 (br d, J= 12.47 Hz, 1 H) 1.32 - 1.39 (m, 3 H). LMS (ESI): m/z [M +H] calculated for C21H25CI2N6O: 447.1; found 447.1.
Example 39. Synthesis of l-[7-(2,3-dichlorophenyl)-6-methyl-lH-pyrazolo[4,3-c]pyridin-4- yl]-4-methyl-piperidin-4-amine.
Figure imgf000253_0001
Step 1.
[00810] To a solution of 4-chloro-6-methyl-lH-pyrazolo[4,3-c]pyridine (0.5 g, 2.98 mmol) in DCM (3 mL) was added SEM-C1 (1.24 g, 7.46 mmol, 1.32 mL) and DIEA (3.86 g, 29.8 mmol, 5.20 mL) at 0 °C and the mixture was stirred at 0 °C for 4 hrs. The reaction was poured into ice-water and stirred for 5 min. The aqueous phase was extracted with EtOAc and the combined organic phases were washed with brine, dried with anhydrous Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give 2-[(4-chloro-6-methyl-pyrazolo[4,3-c]pyridin-l-yl)methoxy]ethyl- trimethyl-silane (365 mg, 41.1% yield). ¾ NMR (400 MHz, CDC13-d) δ ppm 8.22 (s, 1 H), 7.24 (s, 1 H), 5.69 (s, 2 H) 3.66 - 3.60 (m, 2 H), 2.57 (s, 3 H), 0.98 - 0.91 (m, 2 H), 0.01 -0.05 (m, 9 H); LCMS (ESI): m/z [M +H] calculated for Ci3H2iClN3OSi: 298.1; found 298.3;
Step 2.
[00811] To a solution of 2-[(4-chloro-6-methyl-pyrazolo[4,3-c]pyridin-l- yl)methoxy]ethyl-trimethyl-silane (350 mg, 1.18 mmol) in z'-PrOH (1 mL) was added DIEA (911 mg, 7.05 mmol, 1.23 mL) and tert-butyl N-(4-methyl-4-piperidyl)carbamate (755 mg, 3.53 mmol) and the mixture was stirred at 90 °C for 24 hrs. The mixture was cooled to room temperature and concentrated under reduced pressure. The crude residue was purified by column chromatography to give tert-butyl N-[4-methyl-l-[6-methyl-l-(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-piperidyl]carbamate (384 mg, 68.7% yield). ¾ NMR (400 MHz, Methanol-^) δ ppm 8.52 (s, 1 H) 6.51 (s, 1 H) 5.54 - 5.49 (m, 2 H) 4.01 - 3.96 (m, 1 H) 3.53 ( t, J = 8.11 Hz, 1 H) 3.48 - 3.30 (m, 3 H) 2.25 (s, 2 H) 2.09 ( d, J = 12.72 Hz, 2 H) 1.91 (s, 1 H) 1.59 - 1.49 (m, 2 H) 1.34 (s, 9 H) 1.26 (s, 3 H) 0.85 - 0.72 (m, 2 H) -0.12 (s, 9 H); LCMS (ESI): m/z [M +H] calculated for: C24H42N5O3S1 476.3; found 476.3.
Step 3.
[00812] To a solution of fert-butyl N-[4-methyl-l-[6-methyl-l-(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-piperidyl]carbamate (250 mg, 525 μπιοΐ) in DMF (3 mL) was added BS (112 mg, 630 μπιοΐ) at 0 °C and the mixture was stirred at 0 °C for 0.5 h. and then poured into sat.aq. Na2S03 (9 mL) and filtered. The aqueous phase was extracted with EtOAc and the combined organic phases were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography to give tert-butyl N-[l-[7-bromo-6-methyl- l-(2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4- piperidyl]carbamate (160 mg, 54.9% yield). ¾ NMR (400 MHz, CDC13-d) δ ppm 8.19 (s, 1 H) 5.68 (s, 2 H) 4.43 ( s, 1 H) 4.04 ( d, J = 12.96 Hz, 2 H) 3.71 - 3.63 (m, 2 H) 3.45 - 3.55 (m, 2 H) 2.51 (s, 3 H) 2.19 - 2.07 (m, 2 H) 1.78 - 1.66 (m, 2 H) 1.44 (s, 9 H) 1.41 (s, 3 H) 0.99 - 0.80 (m, 2 H) 0.09 - 0.01 (m, 9 H); LCMS (ESI): m/z [M +H] calculated for C24H4iBrN503Si: 556.2; found 556.0.
Step 4.
[00813] To a solution of fert-butyl N-[l-[7-bromo-6-methyl-l-(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4-piperidyl]carbamate (50 mg, 90.2 μπιοΐ) in H2O (0.2 mL) and DME (1 mL) was added (2,3-dichlorophenyl)boronic acid (18.9 mg, 99.2 μιηοΐ), Na2C03 (19.1 mg, 180 μιηοΐ) and Pd(PPh3)4 (10.4 mg, 9.02 μπιοΐ). The mixture was stirred under under N2 at 80 °C for 6 hrs, cooled to room temperature and filtered. The solvent was removed under reduced pressure and the crude residue was purified by column chromatography to give tert-butyl N-[l-[7-(2,3-dichlorophenyl)-6- methyl-l-(2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4- piperidyl]carbamate (20.0 mg, 32.2 μιηοΐ, 35.7% yield). LCMS (ESI): m/z [M +H] calculated for C30H43CI2N5O3S1 : 620.3; found 620.3.
Step 5.
[00814] A mixture of tert-butyl-N-[l-[7-(2,3-dichlorophenyl)-6-methyl-l-(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4-piperidyl]carbamate (40 mg, 64.5 μπιοΐ) in HCl/MeOH (2 mL each) was stirred at 25 °C for 0.5 hr. The mixture was concentrated under reduced pressure and the crude residue was purified by preparative HPLC to give l-[7-(2,3-dichlorophenyl)-6-methyl-lH-pyrazolo[4,3-c]pyridin-4-yl]-4-methyl- piperidin-4-amine (2.7 mg, 10.70% yield,). 1H MR (400 MHz, methanol-^) δ ppm 8.37 ( s, 1 H) 8.10 (s, 1 H) 7.53 ( J =8.07, 1.34 Hz, 1 H) 7.30 (t, J = 7.89 Hz, 1 H) 7.16 ( J = 7.58, 1.47 Hz, 1 H) 4.31 (t, J =14.12 Hz, 2 H) 3.58 - 3.33 (m, 2 H) 2.06 (s, 3 H) 1.92 - 1.75 (m, 4 H) 1.42 (s, 3 H); LCMS (ESI): m/z [M +H] calculated for C19H22CI2N5 : 390.1; found 390.3.
Example 40. Synthesis of (3^ 5)-8-[7-(2,3-dichlorophenyl)-[l,2,5]thiadiazolo[3,4-c]pyridin- 4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000255_0001
Step 1.
[00815] To a solution of 4-chloro-[l,2,5]thiadiazolo[3,4-c]pyridine (230 mg, 1.34 mmol) and (3,S', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (454 mg, 1.87 mmol) in DMA (6.7 mL) was added DIPEA (1.19 mL, 6.70 mmol) at 25 °C. The mixture was capped and heated to 110 °C for 2 hrs, cooled to 25 °C, and concentrated under reduced pressure. The crude product was submitted to the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for C14H20N5OS: 306.14; found 306.1.
Step 2.
[00816] To a solution of (3^ 5)-3-methyl-8-{[l,2,5]thiadiazolo[3,4-c]pyridin-7-yl}-2- oxa-8-azaspiro[4.5]decan-4-amine (409 mg, 1.34 mmol) in acetonitrile (3.94 mL) was added N-bromosuccinimide (261 mg, 1.47 mmol) and the reaction mixture was stirred at room temperature for 1 hr. After concentration under reduced pressure, the crude residue was diluted with EtOAc (6 mL), washed with saturated NaHCCb (2 x 3 mL), dried over Na2S04, filtered, and concentrated under reduced pressure. The crude material so obtained was used into the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for Ci4Hi9BrN5OS: 384.04; found 384.2.
Step 3.
[00817] To a 20 mL vial containing (3^,45)-8-{7-bromo-[l,2,5]thiadiazolo[3,4-c]pyridin- 4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (166 mg, 431 μπιοΐ) was added (2,3- dichlorophenyl)boronic acid (123 mg, 646 μπιοΐ), palladium(2+) bis(cyclopenta-l,3-dien-l- yldiphenylphosphane) methylene chloride iron dichloride (70.3 mg, 86.2 μπιοΐ), and potassium carbonate (237 mg, 1.72 mmol). The vial was flushed with N2, ACN (4.31 mL) was added and the vial was sealed and heated to 100 °C. After 1 hr, the reaction was cooled to 25 °C, filtered through celite, eluted with EtOAc and concentrated under reduced pressure. The crude residue was purified by prep-HPLC to give (3,S', )S)-8-[7-(2,3-dichlorophenyl)- [l,2,5]thiadiazolo[3,4-c]pyridin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (12.1 mg, 5.7% yield) as a white solid. ¾ MR (500 MHz, Methanol-^) δ 8.55 (s, 1H), 7.97 (s, 1H), 7.62 (dd, J = 7.6, 2.0 Hz, 1H), 7.51 - 7.33 (m, 2H), 5.19 - 5.08 (m, 2H), 4.38 - 4.25 (m, 1H), 4.03 (d, J = 8.9 Hz, 1H), 3.90 (d, J = 9.0 Hz, 1H), 3.77 (ddd, J = 13.9, 10.4, 3.4 Hz, 1H), 3.69 (ddd, J = 13.9, 10.5, 2.9 Hz, 1H), 3.29 (d, J = 4.6 Hz, 1H), 2.68 (s, 3H), 2.06 - 1.86 (m, 3H), 1.80 (d, J = 13.8 Hz, 1H), 1.31 (d, J = 6.5 Hz, 3H); LC-MS (ESI): m/z [M + H] calculated for C20H22CI2N5OS : 450.1; found 450.3.
Example 41. Synthesis of 4-{[4-(4-amino-4-methylpiperidin-l-yl)-3H-[l,2,3]triazolo[4,5- c]pyridin-7-yl]sulfanyl}-3-chloropyridin-2-amine.
Figure imgf000256_0001
Step 1.
[00818] To a suspension of 2,5-dibromopyridine-3,4-diamine (2.5 g, 9.36 mmol) in aqueous 2 N HCI (12.4 mL) at 0 °C was added an aqueous solution of sodium nitrite (3.7 mL water, 965 mg). Upon completion of addition, the solution was vigorously stirred for 2 hrs while maintaining the reaction temperature at 0 °C. After this time, the reaction mixture was filtered, and the collected solid was washed with ice cold water and dried under reduced pressure to afford 4,7-dibromo-3H-[l,2,3]triazolo[4,5-c]pyridine (2.38 g, 91% yield) as a light tan solid. LC-MS (ESI): m/z [M + H] calculated for C5H2Br2N4 : 276.9; found 277.0.
Step 2.
[00819] A vial was charged with 4,7-dibromo-3H-[l,2,3]triazolo[4,5-c]pyridine (753 mg, 2.70 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (867 mg, 4.05
mmol), copper iodide (51.4 mg, 0.27 mmol), tripotassium phosphate (573 mg, 2.70 mmol), N,N-bis(2,4,6-trimethoxyphenyl)oxalamide (BTMPO, 113 mg, 0.27 mmol), and degassed DMSO (5 mL), sequentially. The vial was then sealed, and the reaction headspace was evacuated and filled with N2. This procedure was repeated two times and the vial was then placed in a preheated reaction block at 120 °C. After stirring for 16 hrs, the reaction mixture was diluted with ethyl acetate and filtered through a pad of celite. The filtrate was further diluted with ethyl acetate and washed with water (4 x 50 ml) and saturated aqueous sodium chloride (1 x 25 mL), sequentially. The washed solution was dried over magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified column chromatography to give tert-butyl (l-(7- bromo-3H-[l,2,3]triazolo[4,5-c]pyridin-4-yl)-4-methylpiperidin-4-yl)carbamate (213 mg, 19% yield) as a yellow solid. LC-MS (ESI): m/z: [M + H] calculated for Ci6H23BrN602: 411.1; found 410.9.
Step 3.
[00820] A 5 mL microwave vial was charged with tert-butyl N-(l-{7-bromopyrazolo[l,5- a]pyrazin-4-yl}-4-methylpiperidin-4-yl)carbamate (37.3 mg, 0.09 mmol), 3-chloro-4- (potassiosulfanyl)pyridin-2-amine (21.6 mg, 0.10 mmol), Xantphos (10.5 mg, 0.018 mmol), degassed dioxane (909 μΕ), and N,N-diisopropylethylamine (47.4 μΕ, 0.27 mmol), sequentially. The resulting mixture was degassed by bubbling nitrogen gas through the solution for 10 min, and then tris(dibenzylideneacetone) dipalladium (8.32 mg, 0.01 mmol) was added to the vial in one portion. The mixture was then degassed for an additional 5 min before it was sealed, and the mixture was warmed to 120 °C via microwave radiation and stirred for 1.5 hrs. After this time, the reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to an orange oil. This oil was purified by column chromatography to give tert-butyl N-(l-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]-3H-[l,2,3]triazolo[4,5-c]pyridin-4-yl}-4-methylpiperidin-4-yl)carbamate as an impure orange oil that was submitted to the next step without further purification. LC-MS (ESI): m/z [M + H] calculated for C21H27CIN8O2S: 491.2; found 491.4.
Step 4.
[00821] A 20 mL vial was charged with tert-butyl N-(l-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]-3H-[l,2,3]triazolo[4,5-c]pyridin-4-yl}-4-methylpiperidin-4-yl)carbamate (33 mg, 0.07 mmol), DCM (2 mL), and TFA (0.5 mL), sequentially, at room temperature. The resulting yellow solution was left to stir for 1 hr. After this time, the reaction mixture was concentrated under reduced pressure to give an orange residue. This crude residue was purified by preparative HPLC to give 4-{[4-(4-amino-4-methylpiperidin-l-yl)-3H- [l,2,3]triazolo[4,5-c]pyridin-7-yl]sulfanyl}-3-chloropyridin-2-amine (7.7 mg, 29% yield) as a fluffy white solid. 4-{[4-(4-amino-4-methylpiperidin-l-yl)-3H-[l,2,3]triazolo[4,5-c]pyridin- 7-yl]sulfanyl}-3-chloropyridin-2-amine was isolated as its formate salt. ¾ NMR (500 MHz, Methanol-^) δ 8.34 (s, 1H), 8.08 (s, 1H), 7.50 (d, J = 5.5 Hz, 1H), 5.70 (d, J = 5.6 Hz, 1H), 5.13 (d, J = 14.1 Hz, 2H), 3.88 (ddd, J = 14.0, 9.5, 4.0 Hz, 2H), 2.01 - 1.88 (m, 4H), 1.57 (s, 3H); LC-MS (ESI): m/z [M + H] calculated for CieHioClNsS: 391.1; found 391.2.
Example 42. Synthesis of l-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl]-4- methylpiperidin-4-amine.
Figure imgf000258_0001
Step 1.
[00822] To a solution of 5-bromo-8-chloro-6-methylimidazo[l,2-a]pyrazine (800 mg, 3.24 mmol) in DMA (16.2 mL) was added tert-butyl N-(4-methylpiperidin-4-yl)carbamate (762 mg, 3.56 mmol) and DIPEA (16.2 mmol). The reaction mixture was stirred in a capped vial at 100 °C for 1 hr. The resulting reaction mixture was concentrated under reduced pressure, removing as much of the DMA as possible. The residue was purified by column chromatography to yield tert-butyl N-(l-{5-bromo-6-methylimidazo[l,2-a]pyrazin-8-yl}-4- methylpiperidin-4-yl)carbamate (1.10 g, 80 %). LCMS (ESI): m/z [M +H] calculated for CisHivBrNsOi: 424.13; found 424.4.
Step 2.
[00823] To a vial was added tert-butyl N-(l-{5-bromo-6-methylimidazo[l,2-a]pyrazin-8- yl}-4-methylpiperidin-4-yl)carbamate (100 mg, 235 μηιοΐ), (2,3-dichlorophenyl)boronic acid (53.8 mg, 282 μιηοΐ), Antphos (17.4 mg, 47.0 μιηοΐ), K3P04 (149 mg, 705 μmol), and Pd(OAc)2 (5.27 mg, 23.5 μιηοΐ). The mixture was evacuated under house vacuum for 10 min before adding in degassed dioxane (2.34 mL). The resulting mixture was filled with N2 and degassed three times before stirring at 105 °C for 2 hrs. The resulting reaction mixture was filtered through a pad of celite washing with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography to yield tert- butyl N-{ l-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl]-4-methylpiperidin- 4-yl} carbamate (95.0 mg, 82.6 %). LCMS (ESI): m/z [M+H] calculated for C24H3oCl2N502: 490.2; found 490.4.
Step 3.
[00824] To a solution of fert-butyl N-{ l-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,2- a]pyrazin-8-yl]-4-methylpiperidin-4-yl}carbamate (115 mg, 234 μπιοΐ) in methanol (1.9 mL) was added 4 M hydrogen chloride in dioxane (482 μΕ, 1.93 mmol). The reaction was stirred in capped vial for 4 hrs. The resulting reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (Biotage) to yield the desired product l-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,2-a]pyrazin-8-yl]-4-methylpiperidin-4- amine (10.0 mg, 25.6 μιηοΐ, 13.2 %) as the formic acid salt. ¾ NMR (500 MHz, methanol- i«) 5 8.56 (s, 1H), 7.79 (dd, J = 8.1, 1.5 Hz, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.50 (d, J = 1.2 Hz, 1H), 7.44 (dd, J = 7.7, 1.6 Hz, 1H), 7.04 (d, J = 1.3 Hz, 1H), 3.92 - 3.77 (m, 2H), 2.11 (s, 3H), 1.90 (dt, J = 11.7, 4.8 Hz, 6H), 1.49 (s, 3H). LCMS (ESI): m/z [M +H] calculated for C19H22CI2N5: 390.1; found 390.1. Example 43. Synthesis of (3^ 5)-8-[7-(2,3-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl]- 3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000260_0001
Step 1.
[00825] To a reaction vial was added 7-bromo-4-chloro-lH-imidazo[4,5-c]pyridine (130 mg, 559 μηιοΐ), 2-methyl-N-[(3,S', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]propane-2- sulfinamide (153 mg, 559 μιηοΐ), Cul (106 mg, 559 μιηοΐ), K3P04 (118 mg, 559 μιηοΐ), and BTMPO (235 mg, 559 μιηοΐ). The vial was evacuated and filled with N2 three times before adding in dimethyl sulfoxide (1 mL). The reaction was stirred in the capped vial at 120 °C for 24 hrs. The resulting reaction mixture was diluted with EtOAc and H2O. The aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine. The resulting organic layer was dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by column chromatographyto yield the desired product, N-[(3,S', )S)-8-{7-bromo-lH-imidazo[4,5-c]pyridin-4-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide (60 mg, 22.9 %). LCMS (ESI): m/z [M +H] calculated for CifeBrNsChS: 470.1; found 470.2.
Step 2.
[00826] To a reaction vial was added N-[(3,S', )S)-8-{7-bromo-lH-imidazo[4,5-c]pyridin-4- yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide (50 mg, 106 μιηοΐ), (2,3-dichlorophenyl)boronic acid (30.3 mg, 159 μιηοΐ), Pd(dppf)Cl2 DCM (17.3 mg, 21.2 μπιοΐ), and K2C03 (43.9 mg, 318 μπιοΐ). The mixture was evacuated and filled with N2 three times before adding in acetonitrile (1.05 mL). The reaction was stirred at 100 °C for 2 hrs. The resulting reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography to yield N-[(3^ 5)-8-[7-(2,3-dichlorophenyl)-lH-imidazo[4,5-c]pyridin-4-yl]-3-methyl-2- oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide (25.0 mg, 44.0 %). LCMS (ESI): m/z [M +H] calculated for C25H32CI2N5O2S : 536.1; found 536.3.
Step 3.
[00827] To a solution of N-((3^ 5)-8-(7-(2,3-dichlorophenyl)-lH-imidazo[4,5-c]pyridin- 4-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2-methylpropane-2-sulfinamide (25 mg, 46.5 μπιοΐ) in methanol (1 mL) was added a 4 M solution of hydrogen chloride (34.7 μΐ., 139 μπιοΐ) in dioxane. The reaction mixture was stirred in a capped vial at room temperature for 2 hrs. The resulting reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC to yield (3,S', )S)-8-[7-(2,3-dichlorophenyl)-3H- imidazo[4,5-c]pyridin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (5.00 mg, 24.8 %). 1H MR (500 MHz, Methanol-^) δ 8.57 (s, 1H), 8.05 (s, 1H), 7.75 (s, 1H), 7.64 (dd, J = 7.6, 2.0 Hz, 1H), 7.50 - 7.32 (m, 2H), 4.30 (dd, J = 6.5, 4.8 Hz, 1H), 3.96 (d, J = 8.7 Hz, 1H), 3.83 (d, J = 8.8 Hz, 1H), 3.54 (d, J = 41.6 Hz, 2H), 3.16 (d, J = 4.9 Hz, 2H), 1.96 (dd, J = 16.0, 10.6 Hz, 2H), 1.82 (s, 1H), 1.76 (s, 1H), 1.28 (d, J = 6.5 Hz, 4H). LCMS (ESI): m/z [M +H] calculated for C21H24CI2N5O: 432.1; found 432.2.
Example 44. Synthesis of (3,S', )S)-8-{5-[(2,3-dichlorophenyl)sulfanyl]imidazo[l,5-a]pyrazin- 8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000261_0001
Step 1.
[00828] To a solution of 5-bromo-8-chloroimidazo[l,5-a]pyrazine (30 mg, 129 μπιοΐ) in DMA (1 mL) was added 2-methyl-N-((3^ 5)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- yl)propane-2-sulfinamide (38.6 mg, 141 μπιοΐ) and DIPEA (112 μΐ., 645 μπιοΐ). The mixture was capped and stirred at 80 °C for 2 hrs. The resulting mixture was diluted with EtOAc and H2O. The organic layer was separated and then washed 3 more times with H2O. The combined organic layer was separated, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to yield N-((3S,4S)-&- (5-bromoimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2- methylpropane-2-sulfinamide (30.0 mg, 49.5 %). LCMS (ESI): m/z [M +H] calculated for Ci9H29BrN502S: 470.1; found 470.3.
Step 2.
[00829] In a microwave vial was added N-((3,S', )S)-8-(5-bromoimidazo[l,5-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2-methylpropane-2-sulfinamide (30 mg, 63.7 μπιοΐ), 2,3-dichlorobenzenethiol (22.7 mg, 127 μιηοΐ), Xantphos (7.34 mg, 12.7 μιηοΐ), Pd2(dba)3 (2.84 mg, 6.37 μmol) and DIPEA (16.4 mg, 127 μιηοΐ). The vial was evacuated for 10 min before adding in degassed dioxane (637 μΐ.). The mixture was purged and evacuated with N2 gas three times. The reaction was subjected to microwave conditions for 2 hrs at 110 °C. The resulting reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and residue was purified by column
chromatographyto yield N-((3,S', )S)-8-(5-((2,3-dichlorophenyl)thio)imidazo[l,5-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2-methylpropane-2-sulfinamide (23.0 mg, 63.5 %). LCMS (ESI): m/z [M +H] calculated for C25H32Cl2N502S2: 568.1; found 568.3.
Step 3.
[00830] To a solution of N-((3,S', )S)-8-(5-((2,3-dichlorophenyl)thio)imidazo[l,5-a]pyrazin- 8-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl)-2-methylpropane-2-sulfinamide (23 mg, 40.4 μπιοΐ), in methanol (2 mL) was added 4 M HC1 in dioxane (1 mL, 4.00 mmol). The reaction mixture was stirred in a capped vial at room temperature for 1 hr. The resulting reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase HPLC to yield (3S, S)-8-{5-[(2,3-dichlorophenyl)sulfanyl]imidazo[l,5- a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (7.00 mg, 37.4 %). 1H MR (500 MHz, Methanol-^) δ 8.53 (s, 1H), 8.21 (s, 1H), 7.99 (s, 1H), 7.61 (s, 1H), 7.40 (dd, J = 8.0, 1.4 Hz, 1H), 7.11 (t, J = 8.1 Hz, 1H), 6.69 (dd, J = 8.1, 1.4 Hz, 1H), 4.53 - 4.41 (m, 2H), 4.37 - 4.25 (m, 1H), 3.99 (d, J = 9.0 Hz, 1H), 3.86 (d, J = 8.9 Hz, 1H), 3.70 - 3.50 (m, 2H), 2.04 - 1.84 (m, 4H), 1.78 (d, J = 13.2 Hz, 1H), 1.30 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M +H] calculated for C21H24CI2N5OS: 464.1; found 464.2. Example 45. Synthesis of (3,S', )S)-8-[5-(2,3-dichlorophenyl)imidazo[l,5-a]pyrazin-8-yl]-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000263_0001
Step 1.
[00831] To a solution of 5-bromo-8-chloroimidazo[l,5-a]pyrazine (120 mg, 516 μηιοΐ) in DMA (2 mL) was added (3,S', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (135 mg, 567 μπιοΐ) and DIPEA (447 μΐ., 2.57 mmol). The mixture was capped and stirred at 80 °C for 2 hrs. The resulting reaction mixture was diluted with EtOAc and H4OH. The organic layer was separated and then washed three more times with H2O. The resulting organic layer was separated, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by column chromatographyto yield (3S, S)-8-(5-bromoimidazo[l,5-a]pyrazin-8- yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (113 mg, 60.1 %). LCMS (ESI): m/z [M + H] calculated for CisHiiBrNsO: 366.09; found 366.2.
Step 2.
[00832] (3^ 5)-8-(5-Bromoimidazo[l,5-a]pyrazin-8-yl)-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine (113 mg, 308 μπιοΐ), (2,3-dichlorophenyl)boronic acid (88.1 mg, 462 μπιοΐ), tetrakis (21.2 mg, 18.4 μπιοΐ), and potassium carbonate (127 mg, 924 μπιοΐ) were added to a microwave vial. The vial was flashed with N2 before adding in degassed EtOH (3.94 mL). The mixture was purged and evacuated with N2 three times. The reaction was heated under microwave irradiation for 2 h at 110 °C. The resulting reaction mixture was filtered through a pad of celite, concentrated under reduced pressure and residue was purified by reverse phase to yield the (3,S', )S)-8-[5-(2,3-dichlorophenyl)imidazo[l,5-a]pyrazin-8-yl]-3- methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (35.0 mg, 26.3 %) as formic acid salt. 1H MR (500 MHz, Methanol-^) δ 8.40 (s, 2H), 7.91 (s, 1H), 7.83 (s, 1H), 7.81 - 7.74 (m, 1H), 7.56 - 7.49 (m, 2H), 7.12 (s, 1H), 4.58 - 4.39 (m, 2H), 4.33 (qd, J = 6.5, 4.1 Hz, 1H), 4.04 (d, J = 9.2 Hz, 1H), 3.99 - 3.87 (m, 1H), 3.49 - 3.45 (m, 2H), 1.95 (s, 4H), 1.79 (d, J = 13.5 Hz, 1H), 1.34 (d, J = 6.5 Hz, 3H). LCMS (ESI): m/z [M +H] calculated for C21H24CI2N5O: 432.1; found 432.2. Example 46. Synthesis of (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4-yl)sulfanyl]furo[3,2- c]pyridin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000264_0001
Step 1.
[00833] To a solution of 7-bromo-4-chlorofuro[3,2-c]pyri dine (250 mg, 1.07 mmol) and (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (311 mg, 1.28 mmol, HC1 salt) in dimethylacetamide (5.35 mL) was added N,N-diisopropylethylamine (931 μΐ., 5.35 mmol) at room temperature. The solution was then heated at 140 °C for 18 hrs. The resulting solution was concentrated under reduced pressure and purified via flash column chromatography to yield (3,S', )S)-8-{7-bromofuro[3,2-c]pyridin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- amine (390 mg, 100%) as a viscous yellow oil. LC-MS (ESI): m/z [M + H]+ calculated for Ci6H2iBrN302: 366.1; found 366.2.
Step 2.
[00834] To a 5 mL microwave vial was added (3,S', )S)-8-{7-bromofuro[3,2-c]pyridin-4- yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (100 mg, 273 μπιοΐ), 3-chloro-4- (potassiosulfanyl)pyridin-2-amine (81 mg, 409 μπιοΐ), XantPhos (32 mg, 54.6 μπιοΐ), and tris(dibenzylideneacetone) dipalladium (25 mg, 27.3 μπιοΐ). The vial was then capped and purged with N2, followed by addition of degassed dioxane (3 mL) and DIPEA (95 μΐ., 546 μπιοΐ). The mixture was heated to 120 °C for 2 hrs under microwave irradiation. The resulting mixture was filtered through a pad of celite, washed with 20% MeOH/DCM, and concentrated under reduced pressure. Purification by silica gel chromatography, followed by purification by preparatory HPLC yielded (3,S', )S)-8-{7-[(2-amino-3-chloropyridin-4- yl)sulfanyl]furo[3,2-c]pyridin-4-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (7.9 mg, 7% yield) as a formic acid salt. ¾ MR (500 MHz, methanol-^) δ 8.49 (s, 1H), 8.08 (s, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.49 (d, J = 5.6 Hz, 1H), 7.13 (d, J = 2.3 Hz, 1H), 5.71 (d, J = 5.6 Hz, 1H), 4.39 (dt, J = 14.2, 4.5 Hz, 1H), 4.36 - 4.26 (m, 2H), 4.00 (d, J = 9.1 Hz, 1H), 3.88 (d, J = 9.0 Hz, 1H), 3.44 (ddd, J = 14.0, 10.0, 4.1 Hz, 1H), 3.41 - 3.33 (m, 2H), 2.02 - 1.87 (m, 3H), 1.75 (d, J = 13.3 Hz, 1H), 1.31 (d, J = 6.5 Hz, 3H). LC-MS (ESI): m/z [M + H]+ calculated for C21H25CIN5O2S: 446.1; found 446.3.
Example 47. Synthesis of (3,S', )S)-8-[5-(2H-indazol-6-yl)-6-methylimidazo[l,5-a]pyrazin-8- yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000265_0001
[00835] To a 40 mL scintillation vial was added (3S,4S)-8-{5-bromo-6- methylimidazo[l,5-a]pyrazin-8-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (0.1 g, 262 μιηοΐ), (lH-indazol-6-yl)boronic acid (50.8 mg, 314 μιηοΐ), Pd(dppf)ClrDCM (21.3 mg, 26.2 μηιοΐ) and potassium carbonate (143 mg, 1.04 mmol). The vial was capped and the headspace was then purged with nitrogen gas for 3 min. To the mixture of solids was then added ACN (3.61 mL) that had been sparged with nitrogen gas for 45 minutes. The heterogeneous solution was then heated to 100 °C for 1 hr. Dimethylacetamide (0.5 mL), ACN (0.5 mL), Pd(dppf)ClrDCM (21.3 mg, 26.2 μιηοΐ), and (lH-indazol-6-yl)boronic acid (20 mg, 123 μπιοΐ) were added to the solution. The solution was then sparged with nitrogen gas for 10 minutes. The reaction was then allowed to stir at 115 °C for additional 16 hrs. The resulting mixture was filtered through a pad of celite, which was washed with 20%
MeOH/DCM and the filtrate was concentrated under reduced pressure. The residue was purified via preparatory HPLC to afford (3,S', )S)-8-[5-(lH-indazol-6-yl)-6- methylimidazo[l,5-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (8.0 mg, 7% yield) as formic acid salt. ¾ NMR (500 MHz, methanol-^) δ 8.55 (s, 2H), 8.17 (s, 1H), 8.00 (dt, J = 8.3, 0.9 Hz, 1H), 7.79 (d, J = 0.9 Hz, 1H), 7.65 (dd, J = 2.7, 1.0 Hz, 2H), 7.19 (dt, J = 8.3, 1.2 Hz, 1H), 4.43 - 4.21 (m, 3H), 3.95 (d, J = 8.7 Hz, 1H), 3.81 (d, J = 8.8 Hz, 1H), 3.54 (dd, J = 14.4, 9.3 Hz, 1H), 3.50 - 3.38 (m, 1H), 3.24 - 3.09 (m, 1H), 2.13 (d, J = 0.8 Hz, 3H), 2.06 - 1.87 (m, 2H), 1.86 - 1.79 (m, 1H), 1.78 - 1.70 (m, 1H), 1.27 (d, J = 6.5 Hz, 3H). LC-MS (ESI): m/z [M + H] calculated for C23H28N7O: 418.2; found 418.4. Example 48. Synthesis of 4-((7-(4-amino-4-methylpiperidin-l-yl)-lH-pyrazolo[3,4- c]pyridin-4-yl)thio)-3-chloropyridin-2-amine.
Figure imgf000266_0001
Step 1.
[00836] To a vial charged with 4-bromo-7-chloro-lH-pyrazolo[3,4-c]pyridine (200 mg, 0.860 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (276 mg, 1.29 mmol), copper iodide (16.3 mg, 0.08603 mmol), tripotassium phosphate (182 mg, 0.860 mmol), and N,N- bis(2,4,6-trimethoxyphenyl)oxalamide (BTMPO) (36.1 mg, 0.08603 mmol), was added degassed DMSO (860 μΐ.). The vial was capped and reaction headspace was evacuated and filled with N2 and mixture was allowed to stir at 120 °C overnight. The resulting mixture was diluted with ethyl acetate, filtered through a pad of celite, and the filtrate concentrated under reduced pressure. The crude material was purified via column chromatography to afford tert- butyl (l-(4-bromo-lH-pyrazolo[3,4-c]pyridin-7-yl)-4-methylpiperidin-4-yl)carbamate (240 mg, 68%). LC-MS (ESI): m/z [M + H] calculated for CnHwBrNsCh: 410.1; found 409.9.
Step 2.
[00837] To a microwave vial charged with tert-butyl (l-(4-bromo-lH-pyrazolo[3,4- c]pyridin-7-yl)-4-methylpiperidin-4-yl)carbamate (47 mg, 0.115 mmol), potassium 2-amino-
3- chloropyridine-4-thiolate (34.1 mg, 0.1717 mmol), Pd2(dba)3 (6.29 mg, 0.0069 mmol), and xantphos (6.62 mg, 0.0115 mmol), was added degassed dioxane (1.14 mL) followed by DIPEA (60 μΐ., 0.343 mmol). The vial was capped and the reaction headspace evacuated and filled with N2. The vial was capped and reaction headspace was evacuated and filled with N2 and mixture was allowed to stir at 125 °C for 1.5 hrs. The resulting mixture was then diluted with ethyl acetate, filtered through a celite pad and concentrated under reduced pressure. The crude product was purified by column chromatography to afford tert-butyl (1- (4-((2-amino-3-chloropyridin-4-yl)thio)-lH-pyrazolo[3,4-c]pyridin-7-yl)-4-methylpiperidin-
4- yl)carbamate, 19 mg (33%) as a light yellow film. LC-MS (ESI): m/z [M + H] calculated for C22H28CIN7O2S : 490.2; found 490.5. Step 3.
[00838] To a dichloromethane (3 mL) solution of tert-butyl (l-(4-((2-amino-3- chloropyridin-4-yl)thio)-lH-pyrazolo[3,4-c]pyridin-7-yl)-4-methylpiperidin-4-yl)carbamate (19 mg, 0.038 mmol) was added trifluoroacetic acid (500 μΐ.). The resulting homogenous solution was stirred at room temperature for 1.5 hrs. The reaction mixture was concentrated and the crude product was purified by preparative HPLC to afford 4-((7-(4-amino-4- methylpiperidin-l-yl)-lH-pyrazolo[3,4-c]pyridin-4-yl)thio)-3-chloropyridin-2-amine, (10.7 mg, 71 %) as formate salt. ¾ NMR (500 MHz, methanol-***) δ 8.26 (br s, 1H), 7.83 (br s, 1H), 7.48 (d, J = 5.6 Hz, 1H), 5.83 (d, J = 5.6 Hz, 1H), 5.06 (br s, 1H), 3.77 (m, 2H), 1.96 (m, 4H), 1.58 (s, 3H). LC-MS (ESI): m/z [M + H] calculated for C17H21CIN7S: 390.1; found 390.4.
Example 49. Synthesis of (3^,45)-8-[6-amino-5-(2,3-dichlorophenyl)-[l,2,4]triazolo[l,5- a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000267_0001
Step 1.
[00839] To a mixture of methyl 4H-l,2,4-triazole-3-carboxylate (15 g, 118.02 mmol ) and 2-chloroacetonitrile (13 g, 177.02 mmol, 11.23 mL) in ACN (200 mL) was added K2CO3 (32 g, 236 mmol). The mixture was heated to 80 °C for 24 hrs. After cooling to room
temperature the mixture was filtered and the solvent was removed under reduced pressure. The crude residue was purified by silica gel chromatography to give methyl 2-(cyanomethyl)- l,2,4-triazole-3-carboxylate (5 g, 25.50% yield). LCMS (ESI): m/z [M +H] calculated for C6H7N4O2: 167.1; found 167.0. 1H MR (400 MHz, OMSO-d6) δ ppm 8.30 (s, 1 H) 5.79 (s, 2 H) 3.94 (s, 3 H).
Step 2.
[00840] A mixture of methyl 2-(cyanomethyl)- 1,2,4- triazole-3-carboxylate (5 g, 30.10 mmol) in H3/MeOH (100 mL, 30%) was stirred at 25 °C for 24 hr. MTBE (100 mL) was added dropwise into the reaction mixture and the forming precipitate was isolated by filtration to give 6-amino-[l,2,4]triazolo[l,5-a]pyrazin-8-ol (3.4 g, 22.5 mmol, 74 % yield). LCMS (ESI): m/z: [M +H] calculated for CsHeNsO: 152.1; found 152.3. 1H MR (400 MHz, OMSO-d6) δ ppm 11.24 (br s, 1 H) 8.17 (s, 1 H) 6.94 (s, 1 H) 5.35 (s, 2 H).
Step 3.
[00841] To a mixture of 6-amino-[l,2,4]triazolo[l,5-a]pyrazin-8-ol (3 g, 19.8 mmol ) in THF (60 mL) was added TEA (6.03 g, 59.55 mmol, 8.3 mL), B0C2O (13.00 g, 59.55 mmol, 13.68 mL) and DMAP (242.52 mg, 1.99 mmol). The mixture was stirred at 30 °C for 3 hrs and then concentrated under reduced pressure. The crude residue was purified by silica gel chromatography to give tert-butyl-N-tert-butoxycarbonyl-N-(8-hydroxy-[l,2,4]triazolo[l,5- a]pyrazin-6-yl)carbamate (700 mg, 10.04% yield). LCMS (ESI): m/z [M +H] calculated for C15H22N5O5: 352.1; found 352.2; ¾ MR (400 MHz, DMSO- d6) δ ppm 12.51 (br s, 1 H) 8.55 (s, 1 H) 8.34 (s, 1 H) 1.41 (s, 18 H).
Step 4.
[00842] To a mixture of tert-butyl N-/er/-butoxycarbonyl-N-(8-hydroxy- [l,2,4]triazolo[l,5-a]pyrazin-6-yl)carbamate (400 mg, 1.14 mmol ) in DMF (4 mL) was added BS (222.88 mg, 1.25 mmol) at 0 °C under N2. The mixture was stirred at 0 °C for 5 min and then quenched with Na2S03 (aq. sat.). A yellow precipitate formed and was isolated by filtration to give tert-butyl N-(5-bromo-8-hydroxy-[l,2,4]triazolo[l,5-a]pyrazin-6-yl)-N- tert-butoxycarbonyl-carbamate (430 mg, 83.40% yield). ¾ NMR (400 MHz, DMSO-<f<5) δ ppm 13.01 (br s, 1 H) 8.64 (s, 1 H) 1.41 (s, 18 H).
Step 5.
[00843] To a mixture of tert-butyl N-(5-bromo-8-hydroxy-[l,2,4]triazolo[l,5-a]pyrazin-6- yl)-N-tert-butoxycarbonyl-carbamate (430 mg, 999.41 μπιοΐ) in dioxane (17 mL) was added PPh3 (521.65 mg, 1.99 mmol) and NCS (272.25 mg, 2.04 mmol). The mixture was stirred at 100 °C for 8 h and then cooled to room temperature. TEA (5 mL) was added over 15 min, followed by MTBE (10 mL). The forming precipitate was isolated by filtration and purified by column chromatography to give tert-butyl N-(5-bromo-8-chloro-[l,2,4]triazolo[l,5- a]pyrazin-6-yl)carbamate (100 mg, 28.70% yield) as a yellow solid. 1H MR (400 MHz, OMSO-d6) δ ppm 8.99 - 9.04 (m, 1 H) 1.40 (s, 9 H).
Step 6.
[00844] To a mixture of tert-butyl N-(5-bromo-8-chloro-[l,2,4]triazolo[l,5-a]pyrazin-6- yl)carbamate (50 mg, 143.44 μπιοΐ) and (3,S',4)S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4- amine hydrochloride (29mg, 143.4 μιηοΐ, HC1) in z-PrOH (3 mL) was added DIEA (92 mg, 717 μπιοΐ, 124 μΕ). The mixture was stirred at 80 °C for 2 h and then concentrated under reduced pressure. The crude residue was purified by silica gel chromatography to give tert- butyl N-[8-[(3,S',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-bromo- [l,2,4]triazolo[l,5-a]pyrazin-6-yl]carbamate (20 mg, 28.91% yield). LCMS (ESI): m/z [M +H] calculated for Ci9H29BrN703: 482.1, found 482.2.
Step 7.
[00845] To a solution of fert-butyl N-[8-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-bromo-[l,2,4]triazolo[l,5-a]pyrazin-6-yl]carbamate (22 mg, 45.6 μπιοΐ) in DME (1 mL) was added (2,3-dichlorophenyl)boronic acid (13.0 mg, 68.4 μπιοΐ), Na2C03 (9.67 mg, 91.2 μιηοΐ, 3.11 μί) in H20 (0.2 mL) and Pd(PPh3)4 (5.27 mg, 4.56 μιηοΐ). The reaction mixture was stirred at 85°C for 0.5 hrs. The reaction mixture was cooled to room temperature and filtered. The solvent was removed under reduced pressure and the residue was purified by column chromatography to give tert-butyl-N-[8-[(3,S', )S)-4-amino-3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-[l,2,4]triazolo[l,5- a]pyrazin-6-yl]carbamate (12 mg, 47.9% yield). LCMS (ESI): m/z [M +H] calculated for C25H32C12N703: 548.2; found 548.2.
Step 8.
[00846] To a solution of fert-butyl Ν-[8-[(3 4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-[l,2,4]triazolo[l,5-a]pyrazin-6-yl]carbamate (10 mg, 18.2 μπιοΐ) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at 25 °C for 48 hrs. The reaction mixture was then concentrated to dryness and redissolved in MeOH. The solution was adjusted to pH 7 with NaOH/MeOH (0.5 N) at - 78°C. The mixture was then concentrated and any solids were removed by filtration. The final filtrate was dissolved with MeOH and stirred with anion exchange resin for 4 hrs. The resin was then filtered and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give (3,S',4)S)-8-[6-amino-5-(2,3-dichlorophenyl)- [l,2,4]triazolo[l,5-a]pyrazin-8-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (1 mg, 12.2% yield). ¾ MR (400 MHz, methanol-^) δ ppm 8.66 - 8.36 (m, 1 H) 8.07 (s, 1 H) 7.68 ( d, J = 7.02 Hz, 1 H) 7.51 - 7.37 (m, 1 H) 5.23 - 5.00 (m, 1 H) 4.61 (s, 1 H) 4.35 - 4.24 (m, 1 H) 4.04 - 3.99 (m, 1 H) 3.89 (d, J = 9.65 Hz, 1 H) 3.60 - 3.53 (m, 2 H) 1.93 - 1.88 (m, 2 H) 1.74 -1.71 (m, 1 H) 1.30 (d, J = 6.14 Hz, 3 H); LCMS (ESI): m/z [M +H] calculated for: C20H24CI2N7O: 448.1; found 448.2.
Example 50. Synthesis of 4-[[4-(4-amino-4-methyl-l-piperidyl)-6-methyl-lH-pyrazolo[4,3- c]pyridin-7-yl]sulfanyl]-3-chloro-pyridin-2-amine.
Figure imgf000270_0001
Step 1.
[00847] Degassed dioxane (4.00 mL) was added to a mixture of tert-butyl N-[l-[7-bromo- 6-methyl-l-(2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4- piperidyl]carbamate (60 mg, 108 μπιοΐ), 2-amino-3-chloro-pyridine-4-thiol (34.8 mg, 216 μιηοΐ), 1, 10-phenanthroline (5.85 mg, 32.5 μιηοΐ), K3P04 (45.9 mg, 216 μιηοΐ) and Cul (4.12 mg, 21.6 μπιοΐ) under N2 and the mixture was stirred at 130 °C for 12 hrs. The solvent was removed under reduced pressure and the crude residue was purified by preparative HPLC to give tert-butyl N-[l-[7-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-6-methyl-l- (2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4-piperidyl]carbamate (15.0 mg, 15.8 μιηοΐ, 21.9% yield). LCMS (ESI): m/z: [M +H] calculated for
C29H45ClN703SSi 634.27; found 634.4.
Step 2.
[00848] A solution of fert-butyl N-[l-[7-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-6-methyl- l-(2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-4-methyl-4- piperidyl]carbamate (15 mg, 23.7 μπιοΐ) in HCI/MeOH (2 mL) was stirred at 25 °C for 1 hr. The solvent was removed under reduced pressure the residue was dissolved in MeOH (0.5 mL). The resulting mixture was adjusted to pH ~8 with NaOH/MeOH (0.5 M). The solvent was removed under reduced pressure and the residue was suspended in DCM/MeOH (2 mL). The mixture was filtered and the filtrate was to give 4-[[4-(4-amino-4-methyl-l-piperidyl)-6- methyl-lH-pyrazolo[4,3-c]pyridin-7-yl]sulfanyl]-3-chloro-pyridin-2-amine (3.30 mg, 7.86 μιηοΐ, 33.2% yield). 1H MR (400 MHz, methanol-^) δ ppm 8.25 (s, 1 H) 7.49 (d, J = 5.26 Hz, 1 H) 5.68 (d, J=5.70 Hz, 1 H) 4.40 ( d, J = 13.15 Hz, 2 H) 3.75 ( s, 2 H) 2.51 (s, 3 H) 1.87 ( s, 4 H) 1.46 (s, 3 H); LCMS (ESI): m/z [M +H] calculated for C18H23CIN7S 404.13; found 404.3.
Example 51. Synthesis of (3,S', )S)-8-(7-((2-amino-3-chloropyridin-4-yl)thio)-lH- pyrazolo[4,3-c]pyridin-4-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
Figure imgf000271_0001
Step 1.
[00849] To a solution of 4-chloro-lH-pyrazolo[4,3-c]pyridine (2 g, 13.02 mmol) in anhydrous THF (25 mL) was added NaH (625 mg, 15.6 mmol, 60% ) at 0° C. After stirring at 25 °C for 20 min SEM-C1 (2.82 g, 16.93 mmol, 3 mL) was added dropwise at 0 °C. The reaction was stirred at 25 °C for 2 hrs and then quenched by slowly adding H2O. After extraction with EtOAc the combined organic phases were washed with brine, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography to give 4-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrazolo[4,3-c]pyridine (1.7 g, 5.99 mmol, 46% yield). LCMS (ESI): m/z [M +H] calculated for C12H19CIN3OS1: 284.1; found 284.1.
Step 2.
[00850] To a solution of 4-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazolo[4,3- c]pyridine (400 mg, 1.41 mmol) in z-PrOH (8 mL) was added (3^, 5)-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine bis-hydrochloride (377 mg, 1.55 mmol) and DIEA (1.27 g, 9.87 mmol, 1.72 mL). The reaction mixture was stirred at 85 °C for 16 hrs and then concentrated to give (3,S', )S)-3-methyl-8-(l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazolo[4,3-c]pyridin- 4-yl)-2-oxa-8-azaspiro[4.5]decan-4-amine (600 mg, crude) as yellow solid which was used for the next step without further purification. LCMS (ESI): m/z [M +H] calculated for C21H36N5O2S1: 418.3; found 418.3.
Step 3.
[00851] To a solution of (3S,4S)-3-methyl-8-[l-(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine (600 mg, 1.44 mmol ) in DCM (10 mL) was added TEA (290 mg, 2.87 mmol, 399 μί) and B0C2O (627 mg, 2.87 mmol, 660 μΐ.). The reaction mixture was stirred at 40 °C for 1 hr and then concentrated under reduced pressure. The crude residue was purified by silica gel chromatography to give tert-butyl ((3,S', )S)-3-methyl-8-(l-((2-(trimethylsilyl)ethoxy)methyl)- lH-pyrazolo[4,3-c]pyridin-4-yl)-2-oxa-8-azaspiro[4.5]decan-4-yl)carbamate (300 mg, 40% yield). 1H MR (400 MHz, CDC13-d) δ ppm 8.06 (s, 1 H) 8.01 (d, J = 5.99 Hz, 1 H) 6.86 (d, J = 5.87 Hz, 1 H) 5.69 (s, 2 H) 4.67 (d, J = 10.64 Hz, 1 H) 4.20 - 4.04 (m, 3 H) 3.81 - 3.74 (m, 3 H) 3.70 - 3.56 (m, 3 H) 2.22 (s, 1 H) 2.03 - 1.82 (m, 3 H) 1.77 - 1.68 (m, 1 H) 1.50 (s, 9 H) 1.26 (d, J = 6.36 Hz, 3 H) 0.00 (s, 9 H); LCMS (ESI): m/z: [M +H] calculated for C26H44N5O4S1: 518.3; found 518.4.
Step 4.
[00852] To a solution of fert-butyl N-[(3^,45)-3-methyl-8-[l-(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-2-oxa-8-azaspiro[4.5]decan-4- yl]carbamate (300 mg, 579 μιηοΐ) in DMF (5 mL) was added BS (123 mg, 695 μιηοΐ) at -20 °C. The reaction mixture was stirred at -20 °C for 30 min and then quenched by adding
Na2SCb (sa. aq.). The mixture was filtered and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography to give tert-butyl N-[(3,S', )S)-8-[7- bromo-l-(2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (250 mg, 72% yield). ¾ NMR (400 MHz, CDC13-d) δ ppm 8.06 (d, J = 1.34 Hz, 1 H) 6.05 (s, 1 H) 4.66 (d, J = 10.64 Hz, 1 H) 4.27 - 4.20 (m, 1 H) 4.09 - 3.94 (m, 3 H) 3.79 - 3.71 (m, 3 H) 3.69 - 3.61 (m, 3 H) 2.01 - 1.81 (m, 3 H) 1.76 - 1.67(m, 1 H) 1.50 (s, 9 H) 1.26 (d, J = 6.36 Hz, 3 H) 1.02 - 0.892 (m, 2 H) -0.02 - 0.05 (m, 8 H); LCMS (ESI): m/z [M +H] calculated for C26H43BrN504Si: 598.2; found 598.4. Step 5.
[00853] To a solution of fert-butyl N-[(3 S)-8-[7-bromo- 1 -(2- trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (250 mg, 419 μηιοΐ) in dioxane (3.5 mL) was added 2- amino-3-chloro-pyridine-4-thiol (134 mg, 838 μιηοΐ), K3P04 (177 mg, 838 μιηοΐ), 1,10- phenanthroline (15.1 mg, 83.8 μιηοΐ) and Cul (7.98 mg, 41.9 μιηοΐ). The reaction mixture was stirred at 130 °C for 48 hrs under N2. After cooling to room temperature the reaction mixture was filtered and concentrated under vacuum. The crude residue was purified by preparative TLC to give tert-butyl N-[(3,S', )S)-8-[7-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-l- (2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (50 mg, 73.9 μιηοΐ, 17% yield). LCMS (ESI): m/z [M +H] calculated for C3iH47ClN704SSi: 676.3; found 676.1.
Step 6.
[00854] A solution of fert-butyl N-[(3^ 5)-8-[7-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-l- (2-trimethylsilylethoxymethyl)pyrazolo[4,3-c]pyridin-4-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-yl]carbamate (40 mg, 59.1 μπιοΐ) in HCl/MeOH (2 mL) was stirred at 25 °C for 1 hr and then concentrated under reduced pressure. The crude residue was purified by preparative HPLC to give (3,S', )S)-8-(7-((2-amino-3-chloropyridin-4-yl)thio)-lH- pyrazolo[4,3-c]pyridin-4-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (16 mg, 60% yield). 1H MR (400 MHz, Methanol-^) δ ppm 8.61 - 8.42 (m, 1 H) 8.33 (s, 1 H) 7.97 (s, 1 H) 7.48 (d, J = 5.50 Hz, 1 H) 5.72 (d, J = 5.62 Hz, 1 H) 4.61 - 4.42 (m, 2 H) 4.36 - 4.25 (m, 1 H) 4.00 (d, J = 9.05 Hz, 1 H) 3.88 (d, J = 9.05 Hz, 1 H) 3.60 - 3.37 (m, 2 H) 3.34 (d, J = 4.40 Hz, 1 H) 1.97 - 1.84 (m, 3 H) 1.76 (d, J = 13.08 Hz, 1 H) 1.30 (d, J = 6.48 Hz, 3 H); LCMS (ESI): m/z [M +H] calculated for C20H25CIN7OS: 446.2; found 446.0.
Example 52: Synthesis of 3-{4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl]-6-methylpyrazolo[l,5-a]pyrazin-7-yl}-2-chlorobenzonitrile.
[00855] 3-{4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- methylpyrazolo[l,5-a]pyrazin-7-yl}-2-chlorobenzonitrile was synthesized in the manner similar to Example 22, except (2-chloro-3-cyanophenyl)boronic acid was used instead of (2,3-dichlorophenyl)boronic acid.¾ MR (500 MHz, Methanol-i/4) δ 7.99 (dd, J= 7.8, 1.7 Hz, 1H), 7.82 (d, J= 2.5 Hz, 1H), 7.76 (dd, J= 7.8, 1.6 Hz, 1H), 7.67 (t, J= 7.7 Hz, 1H), 6.96 (d, J= 2.5 Hz, 1H), 4.37 - 4.20 (m, 1H), 3.94 (d, J= 8.7 Hz, 1H), 3.81 (d, J= 8.7 Hz, 1H), 3.63 - 3.42 (m, 2H), 3.12 (d, J= 4.8 Hz, 1H), 2.14 (s, 3H), 1.95 (dtd, J= 28.8, 9.9, 5.0 Hz, 2H), 1.79 (dd, J= 27.2, 13.3 Hz, 2H), 1.27 (d, J= 6.5 Hz, 3H). LC-MS (ESI): m/z [M + H] calcd for CisHieClNeO: 437.2; found 437.4.
Biological Examples - SHP2 Allosteric Inhibition Assay
[00856] Without wishing to be bound by theory, SHP is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation step leads to the release of the auto-inhibitory interface of SHP2, which in turn renders the SHP2 protein tyrosine phosphatase (PTP) active and available for substrate recognition and reaction catalysis. The catalytic activity of SHP2 was monitored using the surrogate substrate DiFMUP in a prompt fluorescence assay format.
[00857] The phosphatase reactions were performed at room temperature in 96-well black polystyrene plate, flat bottom, non-binding surface (Corning, Cat # 3650) using a final reaction volume of 100 μΙ_, and the following assay buffer conditions: 50 mM HEPES, pH 7.2, 100 mM NaCl, 0.5 mM EDTA, 0.05% P-20, 1 mM DTT.
[00858] The inhibition of SHP2 by compounds of the disclosure (concentrations varying from 0.00005-10 μΜ) was monitored using an assay in which 0.2 nM of SHP2 was incubated with 0.5 μΜ of Activating Peptide 1 (sequence: H2N-
LN(p Y)IDLDL V(dPEG8)L S T(p Y) ASINF QK-ami de) or Activating Peptide 2 (sequence: H2N-LN(pY)AQLWHA(dPEG8)LTI(pY)ATIRRF-amide). After 30-60- minutes incubation at 25 °C, the surrogate substrate DiFMUP (Invitrogen, Cat # D6567) was added to the reaction and activity was determined by a kinetic read using a microplate reader (Envision, Perkin-Elmer or Spectramax M5, Molecular Devices). The excitation and emission wavelengths were 340 nm and 450 nm, respectively. Initial rates were determined from a linear fit of the data, and the inhibitor dose response curves were analyzed using normalized IC50 regression curve fitting with control based normalization.
[00859] Using the above-protocol, SHP2 inhibition measured as set forth in Table 1. Table 1 : SHP2 Inhibition of Tested Compounds
Figure imgf000275_0001
[00860] In some embodiments, compounds of the disclosure can have an activity of less than 1000 nM. In some embodiments, compounds of the disclosure can have an activity of about 1 nM to about 10 nM. In some embodiments, compounds of the disclosure can have an activity of less than about 1 nM. In some embodiments, compounds of the disclosure can have an activity of about 10 nM to about 100 nM. In some embodiments, compounds of the disclosure can have an activity of about 100 nM to about 10 μΜ.
Equivalents
[00861] While the present disclosure has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present disclosure.

Claims

Claims:
1. A compound of the Formula IV:
Figure imgf000276_0001
IV or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof wherein:
Figure imgf000276_0002
A is a 5- to 12-membered monocyclic or olycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, provided that the heteroaryl is not
Figure imgf000276_0003
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -Ci-Cealkynyl, -Cs-Csc cloalkyl, -OH, -OR5, halogen, -NO2, -CN, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, - R5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, -C(0)R5, or -C02R5, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
Y1 is -S-, a direct bond, -NH-, -S(0)2-, -S(0)2-NH-, -C(=CH2)-, -CH-, or -S(O)-; X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3,
Figure imgf000276_0004
R2 is -H, -OH, - R5R6, -Ci-Cealkyl, -Ci-Cealkenyl, -C4-C8cycloalkenyl,
-C2-C6alkynyl, - H2, halogen, -C3-C8cycloalkyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, - R5R6, -SR5, -S(0)2 R5R6, -S(0)2R5, -NR5S(0)2 R5R6, - R5S(0)2R6, -S(0) R5R6, -S(0)R5, - R5S(0) R5R6, - R5S(0)R6, heterocycle, aryl, or heteroaryl; and wherein the heterocyclyl is not attached via a nitrogen atom;
Y2 is - Ra- -(CR¾)m-, -C(O)-, -C(Ra)2 H-, -(CRa 2)mO-, -C(0)N(Ra)-,
-N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2-, -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -C(0)0- -OC(O)-, -OC(0)N(Ra)-, -N(Ra)C(0)0-, -C(0)N(Ra)0-, -N(Ra)C(S)-, -C(S)N(Ra)-, or -OC(0)0-; wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
Ra is independently, at each occurrence, -H, -D, -OH, -C3-C8cycloalkyl, or
-Ci-C6alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more - H2, wherein 2 Ra, together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
Rb is independently, at each occurrence, -H, -D,-Ci-C6alkyl, -C3-C8cycloalkyl, -C2-C6alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, -CF3,
Figure imgf000277_0001
R3 is -H, -Ci-C6alkyl, a 3- to 12-membered monocyclic or poly cyclic heterocycle, -C3-C8cycloalkyl, or -(CH2)n-Rb, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -ORb, -NHRb, -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl; R5 and R6 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, a monocyclic or poly cyclic 3- to 12- membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, or -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, or a monocyclic or poly cyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
2. The compound of claim 1, wherein Y2 is -NRa-
3. The compound of claim 1, wherein Y2 is -(CR¾)m-.
4. The compound of claim 1, wherein Y2 is -C(O)-.
5. The compound of claim 1 , wherein Y2 is -C(Ra)2NH- or -(CRa 2)mO-.
6. The compound of claim 1, wherein Y2 is -C(0)N(Ra)-, -N(Ra)C(0)-, -S(0)2N(Ra)-, -N(Ra)S(0)2- -N(Ra)C(S)-, or -C(S)N(Ra)-.
7. The compound of claim 1 , wherein Y2 is -N(Ra)C(0)N(Ra)-, -N(Ra)C(S)N(Ra)-, -OC(0)N(Ra)-, -N(Ra)C(0)0- or -C(0)N(Ra)0-.
8. The compound of claim 1, wherein Y2 is -C(0)0- -OC(O)-, or -OC(0)0-.
9. The compound of any one of claims 1-8, wherein Ra is -H.
10. The compound of any one of claims 1-8, wherein Ra is -OH.
1 1. The compound of any one of claims 1-8, wherein Ra is an optionally substituted -C3-C8cycloalkyl.
12. The compound of any one of claims 1-8, wherein Ra is an optionally substituted -Ci-C6alkyl.
13. The compound of any one of claims 1-12, wherein Rb is -H.
14. The compound of any one of claims 1-12, wherein Rb is an optionally substituted -Ci-C6alkyl.
15. The compound of any one of claims 1-12, wherein Rb is an optionally substituted -C3-C8cycloalkyl.
16. The compound of any one of claims 1-12, wherein Rb is an optionally substituted -C2-C6alkenyl.
17. The compound of any one of claims 1-12, wherein Rb is an optionally substituted heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O.
18. The compound of any one of claims 1-17, wherein R3 is an optionally substituted -Ci-C6alkyl.
19. The compound of any one of claims 1-17, wherein R3 is an optionally substituted 3- to 12-membered monocyclic or poly cyclic heterocycle.
20. The compound of any one of claims 1-17, wherein R3 is an optionally substituted 3- to 12-membered monocyclic heterocycle.
21. The compound of any one of claims 1-17, wherein R3 is an optionally substituted 5- to 12-membered polycyclic heterocycle.
22. The compound of any one of claims 1-8, wherein R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
23. The compound of any one of claims 1-8, wherein R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered polycyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
24. The compound of any one of claims 1-8, wherein R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
25. The compound of claim 22 or 23, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl.
26. The compound of any one of claims 22, 23, or 25, wherein the heterocycle is optionally substituted with one or more -(CH2)nNH2, wherein n is 1.
27. The compound of any one of claims 22, 23, 25, or 26, wherein the heterocycle is optionally substituted with one or more -NH2.
28. The compound of claim 24, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl.
29. The compound of claim 24 or 28, wherein the spiroheterocycle is optionally substituted with one or more -(CH2)n H2, wherein n is 1.
30. The compound of any one of claims 24, 28, or 29, wherein the spiroheterocycle is optionally substituted with one or more -NH2.
31. The compound of claim 1, wherein the compound of Formula IV is a compound of Formula IV-Q:
Figure imgf000280_0001
IV-Q
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof wherein:
Figure imgf000280_0002
A is a 5- to 12-membered monocyclic or polycyclic aryl or heteroaryl, provided that
Figure imgf000280_0003
R1 is independently, at each occurrence, -H, -OR5, halogen, -Ci-C6alkyl, -CN, or - R5R6;
Y1 is -S- or a direct bond;
X1 is N or C;
X2 is N or CH;
B, including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl, wherein each heterocycle or heteroaryl is optionally substituted with one or more
-Ci-Cealkyl, -OH, - H2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F; R2 is -H, -OH, - R5R6, -Ci-Cealkyl, or - H2; wherein each alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6;
Y2 is - Ra- wherein the bond on the left side of Y2, as drawn, is bound to the ring and the bond on the right side of the Y2 moiety, as drawn, is bound to R3;
R3 is combined with Ra to form a 3- to 12-membered monocyclic or poly cyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F, provided that the heterocycle formed by the combination of R3 and Rais not an optionally substituted piperazinyl;
R5 and R6 are independently, at each occurrence, -H or -Ci-C6alkyl;
m is independently, at each occurrence, 1, 2, 3, 4, 5 or 6; and
n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
32. The compound of claim 31, wherein R3 and Ra together with the atom to which they are attached combine to form a 3- to 12-membered monocyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2.
33. The compound of claim 31, wherein R3 and Ra together with the atoms to which they are attached combine to form a 3- to 12-membered poly cyclic heterocycle, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -(CH2)nNH2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
34. The compound of claim 31, wherein R3 and Ra together with the atoms to which they are attached combine to form a 5- to 12-membered spiroheterocycle, wherein the
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, - H2, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
35. The compound of claim 32 or 33, wherein the heterocycle is optionally substituted with one or more -Ci-C6alkyl.
36. The compound of any one of claims 32, 33, or 35, wherein the heterocycle is optionally substituted with one or more -(CH2)nNH2, wherein n is 1.
37. The compound of any one of claims 32, 33, 35, or 36, wherein the heterocycle is optionally substituted with one or more -NH2.
38. The compound of claim 34, wherein the spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl.
39. The compound of claim 34 or 38, wherein the spiroheterocycle is optionally substituted with one or more -(CH2)n H2, wherein n is 1.
40. The compound of any one of claims 34, 38, or 39, wherein the spiroheterocycle is optionally substituted with one or more -NH2.
41. The compound any one of claims 1-40, wherein R4 is
Figure imgf000282_0001
42. The compound of any one of claims 1-41, wherein A is monocyclic or polycyclic aryl.
43. The compound of claim 42, wherein A is phenyl.
44. The compound of any one of claims 1-41, wherein A is monocyclic or polycyclic heteroaryl.
45. The compound of claim 44, wherein A is pyridinyl.
46. The compound of any one of claims 1-45, wherein Y1 is -S-.
47. The compound of any one of claims 1-45, wherein Y1 is a direct bond.
48. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H, -OR5 or halogen.
49. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H, -OR5 or - R5R6.
50. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H, halogen or -NR5R6.
51. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H or -OR5.
52. The compound of claim 48 or 51, wherein R5 is -H or -Ci-C6alkyl.
53. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H or halogen.
54. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H or - R5R6.
55. The compound of any one of claims 1-47, wherein R1 is independently, at each occurrence, -H, methyl, fluoro, chloro, or -NH2.
56. The compound of any one of claims 49, 50, or 54, wherein R5 and R6 are
independently, at each occurrence, -H or -Ci-C6alkyl.
57. The compound of claim 56, wherein R5 and R6 are independently, at each occurrence, -H.
58. The compound of claim 56, wherein R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
59. The compound any one of claims 1-40, wherein R4 is -H.
60. The compound of any one of claims 1-59, wherein R2 is -OH.
61. The compound of any one of claims 1-59, wherein R2 is -Ci-C6alkyl, wherein the alkyl is optionally substituted with one or more -OH, halogen, -OR5, or - R5R6.
62. The compound of any one of claims 1-59, wherein R2 is methyl.
63. The compound of any one of claims 1-59, wherein R2 is - R5R6.
64. The compound of claim 63, wherein R5 and R6 are independently, at each occurrence, -H.
65. The compound of claim 63, wherein R5 and R6 are independently, at each occurrence, -Ci-C6alkyl.
66. The compound of any one of claims 1-59, wherein R2 is -H.
67. The compound of any one of claims 1-59, wherein R2 is - H2.
68. The compound of any one of claims 1-67, wherein X1 is N and X2 is N.
69. The compound of any one of claims 1-67, wherein X1 is N and X2 is CH.
70. The compound of any one of claims 1-67, wherein X1 is C and X2 is N.
71. The compound of any one of claims 1-67, wherein X1 is C and X2 is CH.
72. The compound of any one of claims 1-71, wherein B, including the atoms at the points of attachment, is a monocyclic 5- to 12-membered heterocycle, wherein each heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
73. The compound of any one of claims 1-71, wherein B, including the atoms at the points of attachment, is a polycyclic 5- to 12-membered heterocycle, wherein each heterocycle is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
74. The compound of claim 72 or 73, wherein the B heterocycle is substituted with one or more oxo.
75. The compound of any one of claims 1-71, wherein B, including the atoms at the points of attachment, is a monocyclic 5- to 12-membered heteroaryl, wherein each heteroaryl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
76. The compound of any one of claims 1-71, wherein B, including the atoms at the points of attachment, is a polycyclic 5- to 12-membered heteroaryl, wherein each heteroaryl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, oxo, -(CH2)n H2, -(CH2)nOH, -CF3, -CHF2, or -CH2F.
77. The compound of claim 75 or 76, wherein the B heteroaryl is substituted with one or more -Ci-C6alkyl.
78. The compound of any one of claims 75-77, wherein the B heteroaryl is substituted with one or more -OH.
79. The compound of any one of claims 75-78, wherein the B heteroaryl is substituted with one or more -NH2.
80. The compound of any one of claims 75-79, wherein the B heteroaryl is substituted with one or more -(CH2)n H2.
81. The compound of any one of claims 75-80, wherein the B heteroaryl is substituted with one or more -(CH2)nOH.
82. The compound of claim 80 or 81, wherein n is 1.
83. The compound of any one of claims 75-82, wherein the B heteroaryl is substituted
Figure imgf000284_0001
84. The compound of any one of claims 75-83, wherein the B heteroaryl is substituted
Figure imgf000285_0001
85. The compound of any one of claims 75-84, wherein the B heteroaryl is substituted
Figure imgf000285_0002
86. A compound selected from the group consisting of:
Figure imgf000285_0003
Figure imgf000286_0001
Figure imgf000287_0001
Figure imgf000288_0001
Figure imgf000289_0001
Figure imgf000290_0001
Figure imgf000291_0001
290
Figure imgf000292_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer of any of the foregoing.
87. A pharmaceutical composition comprising a compound of any one of claims 1-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
88. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
89. The method of claim 88, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
90. A compound of any one of claims 1-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
91. A compound of any one of claims 1-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
92. Use of a compound of any one of claims 1-86, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
93. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of claim 87.
94. The method of claim 93, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
95. A pharmaceutical composition of claim 87 for use as a medicament.
96. A pharmaceutical composition of claim 87 for use in treating or preventing a disease associated with SHP2 modulation.
97. Use of a pharmaceutical composition of claim 87 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
PCT/US2018/013023 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors WO2018136265A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP18701883.3A EP3571199A1 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors
KR1020197024604A KR102665763B1 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric SHP2 inhibitors
MX2019008695A MX2019008695A (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors.
RU2019126456A RU2776846C2 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors
BR112019015075-7A BR112019015075A2 (en) 2017-01-23 2018-01-09 BICYCLIC COMPOUNDS AS ALLOSTIC SHP2 INHIBITORS
CN201880018606.4A CN110446709B (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric SHP2 inhibitors
CN202311080113.2A CN117327075A (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric SHP2 inhibitors
IL296456A IL296456A (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors
SG11201906209SA SG11201906209SA (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors
AU2018210770A AU2018210770B2 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric SHP2 inhibitors
CA3051206A CA3051206A1 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors
JP2019539774A JP7240319B2 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric SHP2 inhibitors
IL268030A IL268030B2 (en) 2017-01-23 2019-07-14 Bicyclic compounds as allosteric shp2 inhibitors
US16/518,798 US11739093B2 (en) 2017-01-23 2019-07-22 Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
AU2022204275A AU2022204275A1 (en) 2017-01-23 2022-06-17 Bicyclic compounds as allosteric SHP2 inhibitors
JP2022187881A JP2023018095A (en) 2017-01-23 2022-11-25 Bicyclic compounds as allosteric SHP2 inhibitors
US18/220,196 US20240199616A1 (en) 2017-01-23 2023-07-10 Bicyclic compounds as allosteric shp2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449530P 2017-01-23 2017-01-23
US62/449,530 2017-01-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/518,798 Continuation US11739093B2 (en) 2017-01-23 2019-07-22 Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

Publications (1)

Publication Number Publication Date
WO2018136265A1 true WO2018136265A1 (en) 2018-07-26

Family

ID=61054566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/013023 WO2018136265A1 (en) 2017-01-23 2018-01-09 Bicyclic compounds as allosteric shp2 inhibitors

Country Status (14)

Country Link
US (2) US11739093B2 (en)
EP (1) EP3571199A1 (en)
JP (2) JP7240319B2 (en)
KR (1) KR102665763B1 (en)
CN (2) CN110446709B (en)
AR (1) AR110740A1 (en)
AU (2) AU2018210770B2 (en)
BR (1) BR112019015075A2 (en)
CA (1) CA3051206A1 (en)
IL (2) IL296456A (en)
MX (2) MX2019008695A (en)
SG (1) SG11201906209SA (en)
TW (1) TWI820013B (en)
WO (1) WO2018136265A1 (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118909A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
US10561655B2 (en) 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
US10590090B2 (en) 2016-07-12 2020-03-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
WO2020065452A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
WO2020065453A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
WO2020072656A1 (en) * 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020076723A1 (en) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
WO2020081848A1 (en) 2018-10-17 2020-04-23 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
CN111138412A (en) * 2018-11-06 2020-05-12 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
WO2020094104A1 (en) * 2018-11-07 2020-05-14 如东凌达生物医药科技有限公司 Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
CN111153899A (en) * 2018-11-08 2020-05-15 四川科伦博泰生物医药股份有限公司 Substituted pyridine compound, preparation method and application thereof
WO2020108590A1 (en) 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
WO2020181283A1 (en) 2019-03-07 2020-09-10 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN111704611A (en) * 2019-07-25 2020-09-25 上海凌达生物医药有限公司 Aryl spiro SHP2 inhibitor compound, preparation method and application
WO2020201991A1 (en) 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
WO2020210384A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
US10851110B2 (en) 2016-05-31 2020-12-01 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2020259679A1 (en) 2019-06-28 2020-12-30 上海拓界生物医药科技有限公司 Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
WO2021018287A1 (en) * 2019-08-01 2021-02-04 上海奕拓医药科技有限责任公司 Spiroaromatic compound, preparation and application thereof
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10954243B2 (en) 2018-05-02 2021-03-23 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021143680A1 (en) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 Heteroaryl derivative, preparation method therefor, and use thereof
US11104675B2 (en) 2018-08-10 2021-08-31 Navire Pharma, Inc. PTPN11 inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
WO2021244659A1 (en) 2020-06-05 2021-12-09 上海奕拓医药科技有限责任公司 Isotope-substituted spiro aromatic ring compound and application thereof
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
WO2022269525A1 (en) 2021-06-23 2022-12-29 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
US11596633B2 (en) 2017-09-07 2023-03-07 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
US11673896B2 (en) 2017-01-23 2023-06-13 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US11702411B2 (en) 2017-10-12 2023-07-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
US11739093B2 (en) 2017-01-23 2023-08-29 Revolution Medicines, Inc. Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US11780845B2 (en) 2019-05-13 2023-10-10 Relay Therapeutics, Inc. FGFR inhibitors and methods of use thereof
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024035830A1 (en) 2022-08-11 2024-02-15 Relay Therapeutics, Inc. Solid forms of a cdk inhibitor
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
US11952386B2 (en) 2014-01-17 2024-04-09 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2018081091A1 (en) 2016-10-24 2018-05-03 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
JP7418395B2 (en) 2018-03-21 2024-01-19 リレー セラピューティクス， インコーポレイテッド SHP2 phosphatase inhibitors and methods of using them
CN114450287A (en) 2019-09-24 2022-05-06 传达治疗有限公司 SHP2 phosphatase inhibitors and methods of making and using the same
CN114829362A (en) * 2019-12-10 2022-07-29 成都倍特药业股份有限公司 Six-membered and five-membered aromatic ring derivative containing nitrogen heteroatom and used as SHP2 inhibitor
CN111393459B (en) * 2020-04-16 2022-07-22 南京安纳康生物科技有限公司 SHP2 inhibitor and application thereof
CA3181898A1 (en) * 2020-06-11 2021-12-16 Bang Fu Shp2 inhibitors, compositions and uses thereof
CN111925333A (en) * 2020-09-01 2020-11-13 济南悟通生物科技有限公司 Preparation method, product and application of 2-amino-5-methylpyrazine
AU2021370660A1 (en) 2020-10-27 2023-06-08 Amgen Inc. Heterocyclic spiro compounds and methods of use
CN112194652B (en) * 2020-11-30 2021-03-05 北京华氏开元医药科技有限公司 4-hydroxymethyl-1H-indole compound, preparation method and application
CN112402385B (en) * 2020-11-30 2022-04-01 北京华氏开元医药科技有限公司 4-hydroxymethyl-1H-indole compound pharmaceutical preparation and preparation method thereof
WO2022135568A1 (en) * 2020-12-25 2022-06-30 江苏恒瑞医药股份有限公司 Crystal form of pyrimido five-membered nitrogen heterocyclic derivative and preparation method therefor
EP4301756A1 (en) * 2021-03-05 2024-01-10 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117651700A (en) 2021-04-29 2024-03-05 安进公司 2-aminobenzothiazole compounds and methods of use
WO2023109761A1 (en) * 2021-12-15 2023-06-22 贝达药业股份有限公司 Crystal of pyrazolopyrimidinone compound and salt thereof
KR102681872B1 (en) * 2022-01-11 2024-07-04 서울대학교산학협력단 New spiro-macrolide compounds, preparing method and use thereof
AU2023222076A1 (en) 2022-02-16 2024-08-15 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
AU2023221732A1 (en) 2022-02-16 2024-08-15 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2023160577A1 (en) * 2022-02-23 2023-08-31 正大天晴药业集团股份有限公司 Fused bicyclic compound containing pyrrolinone
CN114685301A (en) * 2022-03-31 2022-07-01 山东省药学科学院 Production improvement method of 2-amino malonamide
WO2024040131A1 (en) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO2001016097A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
WO2010011666A2 (en) * 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
WO2016203404A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2572728A (en) 1949-01-07 1951-10-23 American Cyanamid Co Hydroxybenzenesulfonamidopyra-zines and preparation of same
US2636882A (en) 1950-08-11 1953-04-28 Quaker Oats Co Preparation of 3-pyridols from 2-acylfurans
BE758503A (en) 1969-11-07 1971-05-05 Shell Int Research PESTICIDE COMPOSITIONS
GB1459571A (en) 1974-09-12 1976-12-22 Pfizer Ltd Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
JPS5762269A (en) 1980-10-03 1982-04-15 Ogawa Koryo Kk 2,3,5-trisubstituted pyrazine derivative
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
DE3242195A1 (en) 1982-11-15 1984-05-17 Basf Ag, 6700 Ludwigshafen NEW 2-AMINOPYRAZINE AND METHOD FOR PRODUCING 2-AMINOPYRAZINE AND PYRAZINE
JPH0249775A (en) 1988-05-19 1990-02-20 Nippon Soda Co Ltd Heterocyclic compound having 6-membered or 7-membered ring and production thereof
JPH04112877A (en) 1990-09-04 1992-04-14 Nippon Soda Co Ltd New cyanopyrazine derivative and production thereof
EP0579835A4 (en) 1991-11-12 1994-06-01 Nippon Soda Co Wavelength conversion material for agriculture
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
WO1997029109A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists
AU8071698A (en) 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
ES2247070T3 (en) 2000-02-16 2006-03-01 Neurogen Corporation SUBSTITUTED ARILPIRAZINS.
EP1448587B1 (en) 2001-10-01 2009-09-02 Mount Sinai School of Medicine Noonan syndrome gene
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
AU2002343557A1 (en) 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
WO2004024719A1 (en) 2002-09-12 2004-03-25 Pharmacia & Upjohn Company Llc Substituted 1,4-pyrazine derivatives
ATE514713T1 (en) 2002-12-23 2011-07-15 Wyeth Llc ANTIBODIES TO PD-1 AND THEIR USE
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
BRPI0409505A (en) 2003-05-09 2006-04-18 Pharmacia & Upjohn Co Llc compounds as crf1 receptor antagonists
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2856684B1 (en) 2003-06-26 2008-04-11 Sanofi Synthelabo DIPHENYLPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
MXPA06004043A (en) * 2003-10-10 2006-06-28 Pfizer Prod Inc Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors.
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
DE102004015954A1 (en) 2004-04-01 2005-11-10 Ina-Schaeffler Kg belt drive
CN1938296A (en) 2004-04-01 2007-03-28 安斯泰来制药有限公司 Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CA2592021A1 (en) 2004-12-23 2006-07-06 Raghavan Rajagopalan Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
JP2008536950A (en) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション Substituted heteroaryl CB1 antagonists
HUE027370T2 (en) 2005-06-22 2016-10-28 Plexxikon Inc Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
NZ598088A (en) 2005-10-21 2013-09-27 Univ California C-kit oncogene mutations in melanoma
AU2006340061A1 (en) 2006-02-24 2007-09-20 Mallinckrodt Llc Process for using optical agents
JP2007277097A (en) 2006-04-03 2007-10-25 Mie Univ Luminous compound, method for emitting light, and method for producing luminous compound
US8987474B2 (en) 2006-04-07 2015-03-24 University Of South Florida Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
BRPI0710938A2 (en) 2006-04-28 2012-06-26 Univ Northwestern Formulations containing pyridazine compounds for the treatment of neuroinflammatory diseases
EP2015751A2 (en) 2006-04-28 2009-01-21 Northwestern University Salts of pyridazine compounds
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
MX2008015057A (en) * 2006-05-31 2008-12-10 Galapagos Nv Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases.
MX2008015747A (en) * 2006-06-06 2008-12-19 Schering Corp Imidazopyrazines as protein kinase inhibitors.
JP2010520238A (en) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド Integrated photoactive small molecule and integrated photoactive small molecule use
CA2682340A1 (en) 2007-04-06 2008-10-16 Novartis Ag [2 , 6] naphthyridines useful as protein kinase inhibitors
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
US8133895B2 (en) * 2007-05-10 2012-03-13 Janssen Pharmaceutica N.V. Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
JPWO2008156174A1 (en) 2007-06-21 2010-08-26 大正製薬株式会社 Pyrazineamide compound
US8003797B2 (en) 2007-08-09 2011-08-23 Merck Sharp & Dohme Corp. Pyridine carboxamide orexin receptor antagonists
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
AU2009308982A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
WO2010085684A1 (en) 2009-01-23 2010-07-29 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
US20120065205A1 (en) 2009-06-01 2012-03-15 Mercer Swati P Pyrazine carboxamide orexin receptor antagonists
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US8163283B2 (en) 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
EP2569304A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
PT2593452T (en) 2010-07-14 2017-04-24 Novartis Ag Ip receptor agonist heterocyclic compounds
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
US9127000B2 (en) * 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012149280A2 (en) 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
CN103181918B (en) 2011-05-04 2014-10-29 厦门大学 Application of fatty acid compound in preparation of medicines for preventing and treating liver cancer
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
JP6374384B2 (en) * 2012-08-07 2018-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Pyridopyrimidine derivatives as protein kinase inhibitors
CA2890009C (en) * 2012-11-08 2017-11-28 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
JP6272897B2 (en) 2012-11-29 2018-01-31 ケモセントリックス，インコーポレイティド CXCR7 antagonist
US20150352131A1 (en) 2013-01-16 2015-12-10 Rhode Island Hospital Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
US20150374687A1 (en) 2013-02-07 2015-12-31 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
ES2760023T3 (en) 2013-02-20 2020-05-12 Univ Pennsylvania Cancer treatment using humanized anti-EGFRvIII chimeric antigen receptor
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
CN103554038B (en) 2013-06-19 2015-10-14 云南大学 Phenyl polyhalide nitrile quinazolinones and its production and use
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
CA2946759A1 (en) 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
US9695168B2 (en) * 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016016316A1 (en) 2014-08-01 2016-02-04 Nuevolution A/S Compounds active towards bromodomains
WO2016081290A1 (en) 2014-11-18 2016-05-26 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
ES2881305T3 (en) 2014-12-17 2021-11-29 Siemens Healthcare Diagnostics Inc Sandwich Assay Design for Small Molecules
PT3237418T (en) 2014-12-23 2019-05-23 Novartis Ag Triazolopyrimidine compounds and uses thereof
EP3247378B8 (en) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
CA2975673A1 (en) 2015-02-05 2016-08-11 Tyrnovo Ltd. Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
MA51438A (en) 2015-04-03 2021-04-14 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS LSD1 INHIBITORS
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN107922388B (en) 2015-06-19 2020-12-29 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
WO2017011618A1 (en) 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of sirna and drug
AU2016329064B2 (en) 2015-10-01 2023-10-19 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
MA45189A (en) 2016-06-07 2019-04-10 Jacobio Pharmaceuticals Co Ltd NEW HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
RU2021106500A (en) 2016-06-14 2021-04-16 Новартис Аг COMPOUNDS AND COMPOSITIONS FOR SUPPRESSING SHP2 ACTIVITY
TWI806832B (en) 2016-07-12 2023-07-01 美商銳新醫藥公司 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2018081091A1 (en) 2016-10-24 2018-05-03 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
RU2769132C2 (en) 2017-01-10 2022-03-28 Новартис Аг Pharmaceutical combination containing alk inhibitor and shp2 inhibitor
TWI820013B (en) 2017-01-23 2023-11-01 美商銳新醫藥公司 Bicyclic compounds as allosteric shp2 inhibitors
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
KR20240026521A (en) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Novel heterocyclic derivatives useful as shp2 inhibitors
BR112019020967A2 (en) 2017-04-05 2020-05-05 Revolution Medicines Inc methods and reagents to analyze protein-protein interfaces
AU2018248417A1 (en) 2017-04-05 2019-11-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
CA3078565A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN111433205B (en) 2017-12-15 2024-01-19 锐新医药公司 Polycyclic compounds as allosteric SHP2 inhibitors
SG11202007740TA (en) 2018-02-13 2020-09-29 Shanghai Blueray Biopharma Co Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CN110156786B (en) 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 Pyrimido-cyclic compounds, process for their preparation and their use
KR20200144102A (en) 2018-03-21 2020-12-28 신블리아 테라퓨틱스 인코포레이티드 SHP2 inhibitors and uses thereof
EP3773590A1 (en) 2018-04-10 2021-02-17 Revolution Medicines, Inc. Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
CR20230103A (en) 2018-05-01 2023-04-11 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
JP7381492B2 (en) 2018-05-01 2023-11-15 レヴォリューション・メディスンズ，インコーポレイテッド C26-linked rapamycin analogs as MTOR inhibitors
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
BR112021005082A2 (en) 2018-09-18 2021-06-08 Nikang Therapeutics, Inc. fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
WO2020076723A1 (en) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
US20220127271A1 (en) 2018-11-07 2022-04-28 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
KR20210097144A (en) 2018-11-30 2021-08-06 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 Pyrimidine and 5-membered nitrogen heterocycle derivatives, methods for their preparation, and medical uses thereof
US20220073521A1 (en) 2018-11-30 2022-03-10 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
JP2022520154A (en) 2018-12-21 2022-03-29 レボリューション メディシンズ インコーポレイテッド Compounds involved in cooperative binding and their use
CN114901366A (en) 2019-11-04 2022-08-12 锐新医药公司 RAS inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO2001016097A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
WO2010011666A2 (en) * 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
WO2016203404A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. L. ELIEL; S. H. WILEN; L. N. MANDER: "Stereochemistry of Organic Compounds", 1994, WILEY-LNTERSCIENCE
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis, 3rd ed.", 1999, WILEY

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US11952386B2 (en) 2014-01-17 2024-04-09 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US11840536B2 (en) 2016-05-31 2023-12-12 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US10851110B2 (en) 2016-05-31 2020-12-01 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US11905283B2 (en) 2016-06-14 2024-02-20 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10590090B2 (en) 2016-07-12 2020-03-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
US11661401B2 (en) 2016-07-12 2023-05-30 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
US11739093B2 (en) 2017-01-23 2023-08-29 Revolution Medicines, Inc. Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
US11673896B2 (en) 2017-01-23 2023-06-13 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
US11596633B2 (en) 2017-09-07 2023-03-07 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
US11702411B2 (en) 2017-10-12 2023-07-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
WO2019118909A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
US11673901B2 (en) 2017-12-15 2023-06-13 Revolution Medicines, Inc. Polycyclic compounds as allosteric SHP2 inhibitors
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US10561655B2 (en) 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
US11932643B2 (en) 2018-05-02 2024-03-19 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
US10954243B2 (en) 2018-05-02 2021-03-23 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11104675B2 (en) 2018-08-10 2021-08-31 Navire Pharma, Inc. PTPN11 inhibitors
US11945815B2 (en) 2018-08-10 2024-04-02 Navire Pharma, Inc. PTPN11 inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11873307B2 (en) 2018-09-29 2024-01-16 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of SHP2
WO2020065452A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
CN112867718A (en) * 2018-09-29 2021-05-28 诺华股份有限公司 Manufacture of Compounds and compositions for inhibiting SHP2 Activity
WO2020065453A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
WO2020072656A1 (en) * 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020076723A1 (en) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
WO2020081848A1 (en) 2018-10-17 2020-04-23 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
CN114341124A (en) * 2018-10-17 2022-04-12 Array生物制药公司 Protein tyrosine phosphatase inhibitors
CN111138412A (en) * 2018-11-06 2020-05-12 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
CN111138412B (en) * 2018-11-06 2023-09-15 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
CN111592525A (en) * 2018-11-06 2020-08-28 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
WO2020094018A1 (en) 2018-11-06 2020-05-14 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
US10844079B2 (en) 2018-11-06 2020-11-24 Etern Biopharma (Shanghai) Co., Ltd. Spiro aromatic ring compound and application thereof
EP4074713A1 (en) 2018-11-06 2022-10-19 Etern Biopharma (Shanghai) Co., Ltd. 1'-(imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine derivatives and related compounds as shp2 inhibitors for the treatment of cancer
CN111592525B (en) * 2018-11-06 2020-12-08 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
US11685748B2 (en) 2018-11-06 2023-06-27 Etern Biopharma (Shanghai) Co., Ltd. Spiro aromatic ring compound and application thereof
JP2022506887A (en) * 2018-11-07 2022-01-17 シャンハイ リンジーン バイオファーマ カンパニー リミテッド Nitrogen-containing condensed heterocyclic SHP2 inhibitor compound, production method and use
CN114751903A (en) * 2018-11-07 2022-07-15 上海凌达生物医药有限公司 Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application
WO2020094104A1 (en) * 2018-11-07 2020-05-14 如东凌达生物医药科技有限公司 Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
CN114751903B (en) * 2018-11-07 2023-09-15 上海凌达生物医药有限公司 Nitrogen-containing fused heterocycle SHP2 inhibitor compound, preparation method and application
CN111153899A (en) * 2018-11-08 2020-05-15 四川科伦博泰生物医药股份有限公司 Substituted pyridine compound, preparation method and application thereof
CN111153899B (en) * 2018-11-08 2023-12-01 四川科伦博泰生物医药股份有限公司 Substituted pyridine compound, preparation method and application thereof
WO2020108590A1 (en) 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US11033547B2 (en) 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
WO2020181283A1 (en) 2019-03-07 2020-09-10 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
US11696916B2 (en) 2019-03-07 2023-07-11 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
US11884664B2 (en) 2019-04-02 2024-01-30 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
WO2020201991A1 (en) 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
US11634417B2 (en) 2019-04-02 2023-04-25 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
WO2020210384A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
US11001561B2 (en) 2019-04-08 2021-05-11 Merck Patent Gmbh Pyrimidinone derivatives as SHP2 antagonists
US11702392B2 (en) 2019-04-08 2023-07-18 Merck Patent Gmbh Pyrimidinone derivatives as SHP2 antagonists
US11780845B2 (en) 2019-05-13 2023-10-10 Relay Therapeutics, Inc. FGFR inhibitors and methods of use thereof
WO2020259679A1 (en) 2019-06-28 2020-12-30 上海拓界生物医药科技有限公司 Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
CN113840603A (en) * 2019-06-28 2021-12-24 上海拓界生物医药科技有限公司 Pyrimido five-membered nitrogen heterocyclic derivative, preparation method and application thereof in medicine
CN111704611A (en) * 2019-07-25 2020-09-25 上海凌达生物医药有限公司 Aryl spiro SHP2 inhibitor compound, preparation method and application
WO2021018287A1 (en) * 2019-08-01 2021-02-04 上海奕拓医药科技有限责任公司 Spiroaromatic compound, preparation and application thereof
CN114269746A (en) * 2019-08-01 2022-04-01 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound, preparation and application thereof
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
WO2021028362A1 (en) 2019-08-09 2021-02-18 Irbm S.P.A. Shp2 inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US11168102B1 (en) 2019-11-08 2021-11-09 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021143680A1 (en) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 Heteroaryl derivative, preparation method therefor, and use thereof
WO2021244659A1 (en) 2020-06-05 2021-12-09 上海奕拓医药科技有限责任公司 Isotope-substituted spiro aromatic ring compound and application thereof
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022167682A1 (en) 2021-02-08 2022-08-11 Irbm S.P.A. Azabicyclic shp2 inhibitors
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
WO2022207924A1 (en) 2021-04-02 2022-10-06 C.N.C.C.S. S.C.A.R.L. Collezione Nazionale Dei Composti Chimici E Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
WO2022269525A1 (en) 2021-06-23 2022-12-29 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024035830A1 (en) 2022-08-11 2024-02-15 Relay Therapeutics, Inc. Solid forms of a cdk inhibitor
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
WO2024068976A1 (en) 2022-09-29 2024-04-04 Irbm S.P.A. Azole derivatives as shp2 inhibitors

Also Published As

Publication number Publication date
BR112019015075A2 (en) 2020-03-10
US20240199616A1 (en) 2024-06-20
IL296456A (en) 2022-11-01
CN117327075A (en) 2024-01-02
AU2018210770A1 (en) 2019-08-15
EP3571199A1 (en) 2019-11-27
CN110446709B (en) 2023-09-12
CA3051206A1 (en) 2018-07-26
TWI820013B (en) 2023-11-01
KR102665763B1 (en) 2024-05-10
IL268030A (en) 2019-09-26
JP2020506178A (en) 2020-02-27
JP7240319B2 (en) 2023-03-15
AU2022204275A1 (en) 2022-07-07
CN110446709A (en) 2019-11-12
MX2023004037A (en) 2023-04-27
US20200017511A1 (en) 2020-01-16
JP2023018095A (en) 2023-02-07
RU2019126456A3 (en) 2021-02-26
US11739093B2 (en) 2023-08-29
SG11201906209SA (en) 2019-08-27
IL268030B (en) 2022-10-01
RU2019126456A (en) 2021-02-24
AR110740A1 (en) 2019-05-02
MX2019008695A (en) 2019-09-11
KR20190111079A (en) 2019-10-01
TW201827435A (en) 2018-08-01
AU2018210770B2 (en) 2022-03-24
IL268030B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AU2018210770B2 (en) Bicyclic compounds as allosteric SHP2 inhibitors
AU2018210196B2 (en) Pyridine compounds as allosteric SHP2 inhibitors
EP3724189B1 (en) Polycyclic compounds as allosteric shp2 inhibitors
WO2018013597A1 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR20170023145A (en) Mnk inhibitors and methods related thereto
CA2998802A1 (en) Fused pyrazole derivatives as kinase inhibitors
AU2015266492A1 (en) Certain protein kinase inhibitors
JP2021506977A (en) Chromenopyridine derivative as a phosphatidylinositol phosphate kinase inhibitor
RU2776846C2 (en) Bicyclic compounds as allosteric shp2 inhibitors
WO2017055306A1 (en) Fused pyridine derivatives as kinase inhibitors
WO2023064164A1 (en) Chimeric compounds useful in treating diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18701883

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3051206

Country of ref document: CA

Ref document number: 2019539774

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122022024764

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019015075

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018210770

Country of ref document: AU

Date of ref document: 20180109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197024604

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018701883

Country of ref document: EP

Effective date: 20190823

ENP Entry into the national phase

Ref document number: 112019015075

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190722